-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UNen1yD3HcR5dfcAkscPSrcarz5tgefIjBq929uRuFhvb377ihtsClDoeMUxgx52
 8j4TAs+ZfbXf8r0crc+LfA==

<SEC-DOCUMENT>0000950123-08-012018.txt : 20081003
<SEC-HEADER>0000950123-08-012018.hdr.sgml : 20081003
<ACCEPTANCE-DATETIME>20081003172115
ACCESSION NUMBER:		0000950123-08-012018
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20081109
FILED AS OF DATE:		20081003
DATE AS OF CHANGE:		20081003
EFFECTIVENESS DATE:		20081003

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		081107500

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			21000
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			21000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>y00215def14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 89%; margin-left: 5%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>UNITED STATES<BR>
    SECURITIES AND EXCHANGE COMMISSION<BR>
    Washington,&#160;D.C. 20549</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>SCHEDULE&#160;14A</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Proxy Statement Pursuant to Section&#160;14(a) of the<BR>
    Securities Exchange Act of 1934</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Filed by the Registrant
    <FONT style="font-family: Wingdings; font-variant: normal">&#120;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Filed by a Party other than the Registrant
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Check the appropriate box:
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;Preliminary
    Proxy Statement
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;<B>Confidential,
    for Use of the Commission Only (as permitted by
    <FONT style="white-space: nowrap">Rule&#160;14a-6(e)(2))</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-family: Wingdings; font-variant: normal">&#120;</FONT>&#160;&#160;Definitive
    Proxy Statement
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;Definitive
    Additional Materials
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;Soliciting
    Material Pursuant to
    <FONT style="white-space: nowrap">&#167;&#160;240.14a-12</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 12pt">Protalix BioTherapeutics,
    Inc.</FONT></B>
</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt">(Name of Registrant as Specified
    In Its Charter)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 8pt">(Name of Person(s) Filing Proxy
    Statement, if other than the Registrant)</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Payment of Filing Fee (Check the appropriate box):
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-family: Wingdings; font-variant: normal">&#120;</FONT>&#160;&#160;No
    fee required.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;</TD>
    <TD align="left">
    Fee computed on table below per Exchange Act
    <FONT style="white-space: nowrap">Rules&#160;14a-6(i)(1)</FONT>
    and 0-11.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    1)&#160;&#160;
</TD>
    <TD align="left">
    Title of each class of securities to which transaction applies:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    2)&#160;&#160;
</TD>
    <TD align="left">
    Aggregate number of securities to which transaction applies:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    3)&#160;&#160;
</TD>
    <TD align="left">
    Per unit price or other underlying value of transaction computed
    pursuant to Exchange Act
    <FONT style="white-space: nowrap">Rule&#160;0-11</FONT>
    (set&#160;forth the amount on which the filing fee is calculated
    and state how it was determined):
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    4)&#160;&#160;
</TD>
    <TD align="left">
    Proposed maximum aggregate value of transaction:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    5)&#160;&#160;
</TD>
    <TD align="left">
    Total fee paid:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;Fee
    paid previously with preliminary materials.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    <FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;</TD>
    <TD align="left">
    Check box if any part of the fee is offset as provided by
    Exchange Act
    <FONT style="white-space: nowrap">Rule&#160;0-11(a)(2)</FONT>
    and identify the filing for which the offsetting fee was paid
    previously. Identify the previous filing by registration
    statement number, or the form or schedule and the date of its
    filing:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    1)&#160;&#160;
</TD>
    <TD align="left">
    Amount Previously Paid:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    2)&#160;&#160;
</TD>
    <TD align="left">
    Form, Schedule or Registration Statement No:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    3)&#160;&#160;
</TD>
    <TD align="left">
    Filing Party:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="4%"></TD>
    <TD width="93%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    4)&#160;&#160;
</TD>
    <TD align="left">
    Date Filed:
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 8pt; margin-left: 3%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=480 length=0 -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="y00215y0021500.gif" alt="(LOGO)">
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 3%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">2&#160;Snunit
    Street<BR>
    Science Park<BR>
    POB 455<BR>
    Carmiel, Israel 20100</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    October&#160;2, 2008
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Dear Shareholder,
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We cordially invite you to attend the 2008 Annual Meeting of
    Shareholders of Protalix BioTherapeutics, Inc. to be held at
    4:00&#160;p.m., Israel time, on November&#160;9, 2008 at the
    offices of our Israeli counsel, Baratz, Horn&#160;&#038; Co., 1
    Azrieli Center, Round Tower, 18th&#160;Floor, Tel Aviv, Israel
    67021. The attached notice of annual meeting and proxy statement
    describe the business we will conduct at the meeting and provide
    information about us that you should consider when you vote your
    shares. As set forth in the attached proxy statement, the
    meeting will be held to consider the election of directors and
    the ratification of the appointment of our independent
    registered public accounting firm for the fiscal year ending
    2008. Please take the time to carefully read each of the
    proposals shareholders are being asked to consider and vote on.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When you have finished reading the proxy statement, please
    promptly vote your shares either via the Internet, by telephone
    or by marking, signing, dating and returning the proxy card in
    the enclosed envelope. Your vote is important, whether or not
    you attend the meeting in person. We encourage you to vote by
    proxy so that your shares will be represented and voted at the
    meeting. If you decide to attend the meeting and vote in person,
    your proxy may be revoked at your request.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 3%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We appreciate your support and look forward to seeing you at the
    meeting.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Sincerely,
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    &#160;<DIV style="display:inline; text-align:center; width:90%">&#160;&#160;&#160;<FONT style="font-variant: SMALL-CAPS">&#160;</FONT></DIV>
</DIV>

<DIV align="left" style="margin-left: 50%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    David Aviezer,&#160;Ph.D.
</DIV>

<DIV align="left" style="margin-left: 50%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>President and Chief Executive Officer</I>
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    2 Snunit Street<BR>
    Science Park<BR>
    POB 455<BR>
    Carmiel, Israel 20100</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTICE OF
    2008 ANNUAL MEETING OF SHAREHOLDERS<BR>
    TO BE HELD NOVEMBER 9, 2008</FONT></B>
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To the Shareholders of Protalix BioTherapeutics, Inc.:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Annual Meeting of Shareholders of Protalix BioTherapeutics,
    Inc. will be held at the following time, date and place for the
    following purposes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    TIME: &#160;&#160;&#160;&#160;&#160;&#160;&#160;4:00&#160;p.m.,
    Israel time
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    DATE: &#160;&#160;&#160;&#160;&#160;&#160;&#160;November&#160;9,
    2008
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="14%"></TD>
    <TD width="86%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    PLACE:&#160;&#160;&#160;&#160;&#160;&#160;</TD>
    <TD align="left">
    Baratz, Horn&#160;&#038; Co.<BR>
    1 Azrieli Center<BR>
    Round Tower<BR>
    18th Floor<BR>
    Tel Aviv, Israel 67021
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    PURPOSES:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    1.&#160;&#160;&#160;&#160;</TD>
    <TD align="left">
    To elect ten members to the Board of Directors to serve for the
    ensuing year or until their respective successors have been duly
    elected.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="5%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    2.&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">    To ratify the appointment of Kesselman&#160;&#038; Kesselman,
    Certified Public Accountant (Isr.), a member of
    PricewaterhouseCoopers International Limited, as our independent
    registered public accounting firm for the fiscal year ending
    December&#160;31, 2008.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    3.&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">    To transact such other business that is properly presented at
    the meeting or any adjournment.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All of these proposals are more fully described in the proxy
    statement that follows. You may vote at the meeting and any
    adjournments if you were the record owner of our common stock at
    the close of business on October&#160;2, 2008. A list of
    shareholders of record will be available at the meeting and,
    during the 10&#160;days prior to the meeting, at the office of
    our Corporate Secretary at the above address.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Please sign, date and promptly return the enclosed proxy card
    in the enclosed envelope, or vote by telephone or Internet
    (instructions are on your proxy card), so that your shares will
    be represented whether or not you attend the annual meeting.</B>
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BY ORDER OF THE BOARD OF DIRECTORS
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Yossi Maimon
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vice President and Chief Financial Officer</I>
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>and Corporate Secretary</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Carmiel, Israel
</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    October&#160;2, 2008
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">PROXY STATEMENT FOR PROTALIX BIOTHERAPEUTICS, INC.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">GENERAL INFORMATION ABOUT THE ANNUAL MEETING</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">PROPOSAL 1: ELECTION OF DIRECTORS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#004">MANAGEMENT</A></TD></TR>
<TR><TD colspan="9"><A HREF="#005">GRANTS OF PLAN-BASED AWARDS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#006">OPTION EXERCISES AND STOCK VESTED</A></TD></TR>
<TR><TD colspan="9"><A HREF="#007">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#008">AUDIT COMMITTEE REPORT</A></TD></TR>
<TR><TD colspan="9"><A HREF="#009">PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></TD></TR>
<TR><TD colspan="9"><A HREF="#010">SHAREHOLDER PROPOSALS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#011">ANNUAL REPORT TO SHAREHOLDERS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#012">HOUSEHOLDING OF PROXY MATERIALS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#013">OTHER MATTERS</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Protalix
    BioTherapeutics, Inc.<BR>
    2 Snunit Street<BR>
    Science Park<BR>
    POB 455<BR>
    Carmiel, Israel 20100<BR>
    <FONT style="white-space: nowrap">972-4-988-9488</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>


<!-- link1 "PROXY STATEMENT FOR PROTALIX BIOTHERAPEUTICS, INC." -->
<DIV align="left"><A NAME="000"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROXY
    STATEMENT FOR PROTALIX BIOTHERAPEUTICS, INC.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">2008
    ANNUAL MEETING OF SHAREHOLDERS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TO BE
    HELD ON</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">NOVEMBER
    9, 2008</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 21%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=96 -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>


<!-- link1 "GENERAL INFORMATION ABOUT THE ANNUAL MEETING" -->
<DIV align="left"><A NAME="001"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">GENERAL
    INFORMATION ABOUT THE ANNUAL MEETING</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Why Did
    You Send Me this Proxy Statement?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We sent you this proxy statement and the enclosed proxy card
    because the Board of Directors of Protalix BioTherapeutics, Inc.
    is soliciting your proxy to vote at the 2008 annual meeting of
    shareholders and any adjournments of the meeting to be held at
    4:00&#160;p.m., Israel time, on November&#160;9, 2008 at the
    offices of our Israeli counsel, Baratz, Horn&#160;&#038; Co., 1
    Azrieli Center, Round Tower, 18th&#160;Floor, Tel Aviv, Israel
    67021. This proxy statement along with the accompanying Notice
    of Annual Meeting of Shareholders summarizes the purposes of the
    meeting and the information you need to know to vote at the
    annual meeting.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We anticipate that on or before October&#160;9, 2008, we will
    begin sending this proxy statement, the attached Notice of
    Annual Meeting and the form of proxy enclosed to all
    shareholders entitled to vote at the meeting. Although not part
    of this proxy statement, we are also sending along with this
    proxy statement our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    which includes financial statements for the fiscal year ended
    December&#160;31, 2007. <B>You can also find a copy of our
    Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2007, as amended, on
    the Internet through the electronic data system called EDGAR
    provided by the Securities and Exchange Commission at
    <U><FONT style="white-space: nowrap">http://www.sec.gov</FONT></U>
    or through the Investor Relations section of our website at
    <U><FONT style="white-space: nowrap">http://www.protalix.com.</FONT></U>
    Additional copies of the Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ending December&#160;31, 2007, as amended,
    are available upon request.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Who Can
    Vote?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Only holders of our common stock, par value $0.001 per share, of
    record, at the close of business on October&#160;2, 2008 are
    entitled to vote at the annual meeting. On the record date,
    there were 75,930,235&#160;shares of common stock outstanding
    and entitled to vote. The common stock is currently our only
    outstanding class of voting stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You do not need to attend the annual meeting to vote your
    shares. Shares represented by valid proxies, received in time
    for the meeting and not revoked prior to the meeting, will be
    voted at the meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How Many
    Votes Do I Have?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each share of common stock that you own entitles you to one vote.
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How Do I
    Vote?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Whether you plan to attend the annual meeting or not, we urge
    you to vote by proxy. Voting by proxy will not affect your right
    to attend the annual meeting. If your shares are registered
    directly in your name through our stock transfer agent, American
    Stock Transfer&#160;&#038; Trust&#160;Company, or you have stock
    certificates, you may vote:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    <B>By mail.&#160;&#160;</B>Complete, date, sign and mail the
    enclosed proxy card in the enclosed postage prepaid envelope.
    Your proxy will be voted in accordance with your instructions.
    If you sign the proxy card but do not specify how you want your
    shares voted, they will be voted as recommended by our Board of
    Directors.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    <B>By Internet or by telephone.</B>&#160;&#160;Follow the
    instructions attached to the proxy card to vote by Internet or
    telephone.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    <B>In person at the meeting.</B>&#160;&#160;If you attend the
    meeting, you may deliver your completed proxy card in person or
    you may vote by completing a ballot, which will be available at
    the meeting.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If your shares are held in &#147;street name&#148; (held in the
    name of a bank, broker or other nominee), you must provide the
    bank, broker or other nominee with instructions on how to vote
    your shares and can generally do so as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    <B>By mail.</B>&#160;&#160;You will receive instructions from
    your broker or other nominee explaining how to vote your shares.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    <B>By Internet or by telephone.</B>&#160;&#160;Follow the
    instructions you receive from your broker to vote by Internet or
    telephone.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    <B>In person at the meeting.</B>&#160;&#160;Contact the broker
    or other nominee who holds your shares to obtain a broker&#146;s
    proxy card and bring it with you to the meeting. You will not be
    able to vote at the meeting unless you have a proxy card from
    your broker.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What am I
    Voting On?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You are voting on:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    The election of ten members to our Board of Directors to serve
    for the ensuing year or until their respective successors have
    been duly elected (Eli Hurvitz, David Aviezer,&#160;Ph.D.,
    Yoseph Shaaltiel,&#160;Ph.D., Alfred Akirov, Amos Bar-Shalev,
    Zeev Bronfeld, Yodfat Harel Gross, Roger D.
    Kornberg,&#160;Ph.D., Eyal&#160;Sheratzky and Sharon
    Toussia-Cohen).
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    The ratification of the appointment of Kesselman and Kesselman,
    Certified Public Accountant (Isr.), A Member of
    PricewaterhouseCoopers International Limited, as our independent
    registered public accounting firm for the fiscal year ending
    December&#160;31, 2008.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How Does
    the Board of Directors Recommend that I Vote at the
    Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Board of Directors recommends that you vote as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    &#147;<B>FOR</B>&#148; the election or re-election of all
    director nominees named in the &#147;Proposal&#160;1: Election
    of Directors&#148; section in this proxy statement.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    &#147;<B>FOR</B>&#148; the ratification of Kesselman and
    Kesselman as our independent registered public accounting firm
    for the 2008 fiscal year, as named in the &#147;Proposal&#160;2:
    Ratification of Independent Registered Public Accounting
    Firm&#148; section in this proxy statement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If any other matter is properly presented at the meeting or any
    adjournment, the proxy card provides that your shares will be
    voted by the proxy holder listed on the proxy card in accordance
    with his or her best judgment. At the time this proxy statement
    was printed, we knew of no matters that needed to be acted on at
    the annual meeting, other than those discussed in this proxy
    statement.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What
    Constitutes a Quorum for the Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The holders of a majority of all of the shares of common stock
    entitled to vote at the annual meeting, present in person or by
    proxy, shall constitute a quorum at the annual meeting. Of the
    75,930,235&#160;shares of common stock outstanding as of the
    record date, a majority, or more than 37,965,118&#160;shares,
    must be present at the meeting in person or represented by proxy
    to hold the meeting and conduct business. Once a quorum is
    established at a meeting, it shall not be broken by the
    withdrawal of enough votes to leave less than a quorum. Votes of
    shareholders of record who are present at the meeting in person
    or by proxy, abstentions, and broker non-votes are counted for
    purposes of determining whether a quorum exists. If a quorum is
    not present, the meeting will be adjourned until a quorum is
    obtained.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What are
    the Voting Requirements to Approve a Proposal?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Assuming a quorum is present at the annual meeting, nominees for
    director must receive a plurality of the votes cast to be
    elected. This means that the 10 nominees receiving the highest
    number of votes will be elected. The ratification of the
    appointment of our independent registered public accountant and
    any other proposal that may properly be brought before the
    meeting must receive the affirmative vote of a majority of the
    votes cast by the shareholders. Neither abstentions nor withheld
    votes will have any effect on the outcome of the vote, but both
    abstentions and withheld votes will be counted for the purposes
    of determining whether a quorum is present.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">How are
    My Votes Cast when I Sign and Return a Proxy Card?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    When you sign the proxy card or submit your proxy by telephone
    or over the Internet, you appoint
    David&#160;Aviezer,&#160;Ph.D., our president and chief
    executive officer, and Yossi Maimon, our Vice President and
    chief financial officer, as your representatives at the meeting.
    Either David Aviezer or Yossi Maimon will vote your shares at
    the meeting as you have instructed them on the proxy card. Each
    of such persons may appoint a substitute for himself.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Even if you plan to attend the meeting, it is a good idea to
    complete, sign and return your proxy card or submit your proxy
    by telephone or over the Internet in advance of the meeting in
    case your plans change. This way, your shares will be voted by
    you whether or not you actually attend the meeting.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">May I
    Revoke My Proxy?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you give us your proxy, you may revoke it at any time before
    it is voted at the meeting. There will be no double counting of
    votes. You may revoke your proxy in any one of the following
    ways:
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    entering a new vote or by granting a new proxy card or new
    voting instruction bearing a later date (which automatically
    revokes the earlier instructions);
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    if your shares are held in street name, re-voting by Internet or
    by telephone as instructed above. Only your latest Internet or
    telephone vote will be counted;
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    notifying our Corporate Secretary, Yossi Maimon, in writing
    before the annual meeting that you have revoked your
    proxy;&#160;or
</TD>
</TR>


<TR style="line-height: 4pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    attending the meeting in person and voting in person. Attending
    the meeting in person will not in and of itself revoke a
    previously submitted proxy unless you specifically
    request&#160;it.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What if I
    Receive More than One Proxy Card?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may receive more than one proxy card or voting instruction
    form if you hold shares of our common stock in more than one
    account, which may be in registered form or held in street name.
    Please vote in the manner described under &#147;How Do I
    Vote?&#148; for each account to ensure that all of your shares
    are voted.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What if I
    do not Vote for Some of the Matters Listed on My Proxy
    Card?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If you return your proxy card without indicating your vote, your
    shares will be voted <I>for </I>the nominees listed on the card
    and <I>for </I>the ratification of the appointment of
    Kesselman&#160;&#038; Kesselman.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What if I
    Vote &#147;Abstain&#148;?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A vote to &#147;abstain&#148; on any matter will have the effect
    of a vote <I>against</I> the matter.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Will My
    Shares be Voted if I do not Return My Proxy Card and do not
    Attend the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If your shares are registered in your name or if you have stock
    certificates, they will not be voted if you do not return your
    proxy card by mail or vote at the meeting as described above
    under &#147;How Do I Vote?&#148;.
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    If your shares are held in street name and you do not provide
    voting instructions to the bank, broker or other nominee that
    holds your shares as described above under &#147;How Do I
    Vote?,&#148; the bank, broker or other nominee has the authority
    to vote your un-voted shares on any of the matters scheduled to
    come before the meeting even if it does not receive instructions
    from you. We encourage you to provide voting instructions. This
    ensures your shares will be voted at the meeting in the manner
    you desire. If your broker cannot vote your shares on a
    particular matter because it has not received instructions from
    you and does not have discretionary voting authority on that
    matter or because your broker chooses not to vote on a matter
    for which it does have discretionary voting authority, this is
    referred to as a &#147;broker non-vote.&#148; A broker non-vote
    will have no effect on the vote for any matter scheduled to be
    considered at the meeting but is counted as present for purposes
    of determining the presence or absence of a quorum for the
    annual meeting.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Is Voting
    Confidential?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Yes. Only the inspector of elections and our employees that have
    been assigned the responsibility for overseeing the legal
    aspects of the annual meeting will have access to your proxy
    card. The inspector of elections will tabulate and certify the
    vote. Any comments written on the proxy card will remain
    confidential unless you ask that your name be disclosed.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What are
    the Costs of Soliciting these Proxies?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will pay all of the costs of soliciting these proxies. Our
    directors and employees may solicit proxies in person or by
    telephone, fax or email. We will pay these employees and
    directors no additional compensation for these services. We will
    ask banks, brokers and other institutions, nominees and
    fiduciaries to forward these proxy materials to their principals
    and to obtain authority to execute proxies. We will then
    reimburse them for their expenses.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Could
    other Matters be Decided at the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not know of any other matters that will be considered at
    the annual meeting. If any other matters arise at the annual
    meeting, the proxies will be voted at the discretion of the
    proxy holders.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">What
    Happens if the Annual Meeting is Postponed or
    Adjourned?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Your proxy will still be valid and may be voted at the postponed
    or adjourned meeting. You will still be able to change or revoke
    your proxy until it is voted.
</DIV>

<DIV style="margin-top: 8pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Do I Need
    a Ticket to Attend the Annual Meeting?</FONT></B>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Yes, you will need an admission ticket or proof of ownership of
    common stock to enter the annual meeting. If you are a
    shareholder of record, your admission ticket is the bottom half
    of the proxy card sent to you. If you plan to attend the annual
    meeting, please so indicate when you vote and bring the ticket
    with you to the annual meeting. If your shares are held in the
    name of a bank, broker or other holder of record, your admission
    ticket is the left side of your voting information form. If you
    do not bring your admission ticket, you will need proof of
    ownership to be admitted to the annual meeting. A recent
    brokerage statement or letter from a bank or broker is an
    example of proof of ownership. If you arrive at the annual
    meeting without an admission ticket, we will admit you only if
    we are able to verify that you are a shareholder of our company.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT" -->
<DIV align="left"><A NAME="002"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information, as of
    September&#160;30, 2008, regarding beneficial ownership of our
    common stock:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    each person who is known by us to own beneficially more than 5%
    of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    each director;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    each of our Chief Executive Officer, our Executive Vice
    President, Research and Development, our Vice President, Product
    Development, our Vice President of Operations and our Chief
    Financial Officer;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    all of our directors and executive officers collectively.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless otherwise noted, we believe that all persons named in the
    table have sole voting and investment power with respect to all
    shares of our common stock beneficially owned by them. For
    purposes of these tables, a person is deemed to be the
    beneficial owner of securities that can be acquired by such
    person within 60&#160;days from September&#160;30, 2008 upon
    exercise of options, warrants and convertible securities. Each
    beneficial owner&#146;s percentage ownership is determined by
    assuming that options, warrants and convertible securities that
    are held by such person (but not those held by any other person)
    and that are exercisable within such 60&#160;days from such date
    have been exercised.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The address for all directors and officers is
    <FONT style="white-space: nowrap">c/o&#160;Protalix</FONT>
    BioTherapeutics, Inc., 2 Snunit Street, Science Park, POB 455,
    Carmiel, Israel, 20100.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="73%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Amount and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Nature of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Beneficial<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Percentage of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Name and Address of Beneficial Owner</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Ownership</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Class</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Board of Directors and Executive Officers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eli Hurvitz(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,270,949
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer,&#160;Ph.D., MBA(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,407,589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel,&#160;Ph.D.(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,646,194
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred Akirov(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,186,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amos Bar Shalev(5)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zeev Bronfeld(6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,466,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yodfat Harel Gross
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger D. Kornberg,&#160;Ph.D.(7)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eyal Sheratzky
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sharon Toussia-Cohen(8)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,556,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon,&#160;Ph.D.(9)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347,320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon(10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    265,093
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All executive officers and directors as a group
    (12&#160;persons)(11)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,145,891
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>5% Holders</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Biocell Ltd.(12)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,466,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Pontifax G.P. Ltd.(13)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,270,949
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Techno-Rov Holdings 1993)&#160;Ltd.(14)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,186,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Marathon Investments Ltd.(15)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,556,381
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Frost Gamma Investment Trust(16)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,776,273
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12.9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="left" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    less than 1%.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 2,994,378&#160;shares of our common stock held by
    Pontifax (Cayman) L.P., 1,378,278 of which shares are owned of
    record and 1,616,100 of which shares are issuable upon exercise
    of </TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    options that are exercisable within 60&#160;days of
    September&#160;30, 2008, and 3,276,571&#160;shares of our common
    stock held by Pontifax (Israel) L.P., 1,508,169 of which shares
    are owned of record and 1,768,402 of which shares are issuable
    upon exercise of options that are exercisable within
    60&#160;days of September&#160;30, 2008. Mr.&#160;Hurvitz is the
    chairman of Pontifax G.P. Ltd.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 1,407,589&#160;shares of our common stock issuable
    upon exercise of outstanding options within 60&#160;days of
    September&#160;30, 2008. Does not include 927,565&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of September&#160;30,
    2008.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 144,140&#160;shares of our common stock issuable
    upon exercise of outstanding options within 60&#160;days of
    September&#160;30, 2008. Does not include 241,750&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of September&#160;30,
    2008, and 1,472,053&#160;shares of our common stock transferred
    by Dr.&#160;Shaaltiel with other assets pursuant to a court
    order.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 6,186,046&#160;shares of our common stock held by
    Techno-Rov Holdings (1993)&#160;Ltd. Mr.&#160;Akirov is the
    chief executive officer of Techno-Rov Holdings and has the power
    to control its investment decisions.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Bar-Shalev is the manager of Techno-Rov Holdings.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 14,466,319&#160;shares of our common stock held by
    Biocell Ltd. Mr.&#160;Bronfeld is a director and Chief Executive
    Officer of Biocell. Mr.&#160;Bronfeld disclaims beneficial
    ownership of these shares.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (7) </TD>
    <TD></TD>
    <TD valign="bottom">
    Does not include 50,000&#160;shares of common stock issuable
    upon exercise of outstanding options that are not exercisable
    within 60&#160;days of September&#160;30, 2008.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (8) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 6,556,381&#160;shares of our common stock held by
    Marathon Investments Ltd. Mr.&#160;Toussia-Cohen is a director
    and Chief Executive Officer of Marathon Investments Ltd.
    Mr.&#160;Toussia-Cohen disclaims beneficial ownership of these
    shares.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (9) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 347,320&#160;shares of our common stock issuable
    upon exercise of outstanding options within 60&#160;days of
    September&#160;30, 2008. Does not include 421,715&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of September&#160;30,
    2008.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (10) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 238,393&#160;shares of our common stock issuable
    upon exercise of options within 60&#160;days of
    September&#160;30, 2008. Does not include 455,820&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of September&#160;30,
    2008.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (11) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 5,521,944&#160;shares of our common stock issuable
    upon exercise of options within 60&#160;days of
    September&#160;30, 2008. Does not include 2,046,850&#160;shares
    of common stock issuable upon exercise of outstanding options
    that are not exercisable within 60&#160;days of
    September&#160;30, 2008.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (12) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address is Moshe Aviv Tower, 7 Jabotinsky Street, Ramat Gan,
    Israel. Biocell Ltd.&#146;s investment and voting decisions are
    made collectively by its Board of Directors.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (13) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address of Pontifax (Israel) L.P. and Pontifax (Cayman) L.P.
    is 8 Hamenofim Street, Herzliya Pituach 46725, Israel. Consists
    of 2,994,378&#160;shares of our common stock held by Pontifax
    (Cayman) L.P., 1,378,278 of which shares are owned of record and
    1,616,100 of which shares are issuable upon exercise of options
    that are exercisable within 60&#160;days of September&#160;30,
    2008, and 3,276,571&#160;shares of our common stock held by
    Pontifax (Israel) L.P., 1,508,169 of which shares are owned of
    record and 1,768,402 of which shares are issuable upon exercise
    of options that are exercisable within 60&#160;days of
    September&#160;30, 2008. Pontifax (Cayman) L.P. and Pontifax
    (Israel) L.P. are governed by Pontifax Management L.P. Pontifax
    G.P. Ltd. is the general partner of Pontifax Management L.P.
    Pontifax G.P. Ltd.&#146;s investment and voting decisions are
    made collectively by its Board of Directors.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (14) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address is Alrov Tower, 46 Rothschild Blvd., Tel Aviv,
    Israel. Mr.&#160;Akirov is the Chief Executive Officer of
    Techno-Rov Holdings (1993)&#160;Ltd. and Mr.&#160;Bar-Shalev is
    the manager of Techno-</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD valign="top">
</TD>
    <TD></TD>
    <TD valign="bottom">
    Rov Holdings. Mr.&#160;Akirov has the power to control the
    investment decisions of Techno-Rov Holdings.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (15) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address is 7 Hanagar Street, Holon, Israel. Marathon
    Investments Ltd.&#146;s investment and voting decisions are made
    collectively by its board of directors.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="left" valign="top">
    (16) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address is 4400 Biscayne Blvd., Miami, Florida 33137. Frost
    Gamma, L.P. is the sole and exclusive beneficiary of Frost Gamma
    Investments Trust. Dr.&#160;Phillip Frost is the sole limited
    partner of Frost Gamma, L.P. The general partner of Frost Gamma,
    L.P. is Frost Gamma, Inc. and the sole shareholder of Frost
    Gamma, Inc. is Frost-Nevada Corporation. Dr.&#160;Frost is also
    the sole shareholder of Frost-Nevada Corporation.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Section&#160;16(a)
    Beneficial Ownership Reporting Compliance</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Section&#160;16(a) of the Securities Exchange Act of 1934, or
    the Exchange Act, requires our directors, executive officers and
    holders of more than 10% of our common stock to file with the
    Securities and Exchange Commission reports regarding their
    ownership and changes in ownership of our equity securities. All
    of our officers, directors and 10% shareholders failed to file
    Form&#160;3s and Form&#160;4s on a timely basis upon the closing
    of the merger of our subsidiary with Protalix Ltd. on
    December&#160;31, 2006, their receipt of interests in our
    company in connection therewith and, to the extent applicable,
    their appointment as officers
    <FONT style="white-space: nowrap">and/or</FONT>
    directors of our company. In addition, Dr.&#160;Shaaltiel failed
    to file a Form&#160;4 on a timely basis on two subsequent
    occasions during 2007. Otherwise, we believe that all
    Section&#160;16 filings requirements were met during 2007. In
    making this statement, we have relied solely upon examination of
    the copies of Forms&#160;3, 4 and 5 provided to us and the
    written representations of our former and current directors,
    officers and 10% shareholders.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "PROPOSAL 1: ELECTION OF DIRECTORS" -->
<DIV align="left"><A NAME="003"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;1:
    ELECTION OF DIRECTORS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    At the annual meeting, our shareholders will be asked to elect
    ten directors for a one-year term expiring at the next annual
    meeting of shareholders. Each director will hold office until
    his or her successor has been elected and qualified or until the
    director&#146;s earlier resignation or removal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors recommends that the persons named below
    be elected as directors of our company and it is intended that
    the accompanying proxy will be voted for their election as
    directors, unless the proxy contains contrary instructions.
    Shares of common stock represented by all proxies received by
    the Board of Directors and not so marked as to withhold
    authority to vote for any individual nominee or for all nominees
    will be voted (unless one or more nominees are unable to serve)
    for the election of the nominees named below. The Board of
    Directors knows of no reason why any such nominee should be
    unable or unwilling to serve, but if such should be the case,
    proxies will be voted for the election of some other person or
    the size of the Board of Directors will be fixed at a lower
    number.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Each of the nominees currently serves as a member of our Board
    of Directors. The directors are elected by a plurality of the
    votes cast by the shareholders present or represented by proxy
    and entitled to vote at the annual meeting.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Nominees
    for Election to the Board of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The names of the nominees for election to the Board of Directors
    and certain information about such nominees are set forth below.
    For information concerning the number of shares of common stock
    beneficially owned by each nominee, see &#147;Security Ownership
    of Certain Beneficial Owners and Management&#148; above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Name</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Age</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Position</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eli Hurvitz
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    76
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Chairman of the Board
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    43
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director, President and Chief Executive Officer
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    55
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and Executive VP, Research and Development
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred Akirov
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    66
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amos Bar-Shalev
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    55
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zeev Bronfeld
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    57
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yodfat Harel Gross
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    36
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger D. Kornberg,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    61
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eyal Sheratzky
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    39
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sharon Toussia-Cohen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    49
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Eli Hurvitz.</B>&#160;&#160;Mr.&#160;Hurvitz serves as
    Chairman of our Board of Directors and has served as a director
    of Protalix Ltd., our wholly-owned subsidiary since 2005 and as
    our director since December&#160;31, 2006. Mr.&#160;Hurvitz has
    served as chairman of the board of directors of Teva
    Pharmaceutical Industries Ltd. since April 2002. Previously, he
    served as Teva&#146;s president and chief executive officer for
    over 25&#160;years and has been employed at Teva in various
    capacities for over 40&#160;years. He serves as chairman of the
    board of directors of The Israel Democracy Institute (IDI),
    chairman of the board of directors of NeuroSurvival Technologies
    Ltd. (a private company) and a director of Vishay
    Intertechnology. He served as chairman of the Israel Export
    Institute from 1974 through 1977 and as the president of the
    Israel Manufacturers Association from 1981 through 1986. He
    served as chairman of the board of directors of Bank Leumi Ltd.
    from 1986 through 1987. He was a director of Koor Industries
    Ltd. from 1997 through 2004 and a member of the Belfer Center
    for Science and International Affairs at the John F. Kennedy
    School of Government at Harvard University from 2002 through
    2005. He received a B.A. in Economics and Business
    Administration from the Hebrew University of Jerusalem in 1957.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>David Aviezer,&#160;Ph.D.,
    MBA.</B>&#160;&#160;Dr.&#160;Aviezer has served as Chief
    Executive Officer of Protalix Ltd. since 2002 and its director
    since 2005, and as our director since December&#160;31, 2006. On
    December&#160;31, 2006, he became our President and Chief
    Executive Officer. Dr.&#160;Aviezer has over a decade of
    experience in biotechnology management, advancing products from
    early-stage research up to their regulatory approval and
    commercialization. Prior to joining Protalix Ltd., from 1996 to
    2002, he served as general manager of ProChon Biotech Ltd., an
    Israeli company focused on orthopedic disorders. Previously,
    Dr.&#160;Aviezer was a visiting scientist at the Medical
    Research Division of American Cyanamid, a subsidiary of Wyeth
    (NYSE:WEY), in New York. Since 1996, Dr.&#160;Aviezer has served
    as an adjunct lecturer at Bar Ilan University. Dr.&#160;Aviezer
    is the recipient of the Clore Foundation Award and the J.F.
    Kennedy Scientific Award. He received a Ph.D. in Molecular
    Biology and Biochemistry from the Weizmann Institute of Science
    and an M.B.A. from the Bar Ilan University Business School.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Yoseph
    Shaaltiel,&#160;Ph.D.</B>&#160;&#160;Dr.&#160;Shaaltiel founded
    Protalix Ltd. in 1993 and has served as a member of our Board of
    Directors and as our Vice President, Research and Development
    since December&#160;31, 2006. Prior to establishing Protalix
    Ltd., from 1988 to 1993, Dr.&#160;Shaaltiel was a research
    associate at the MIGAL Technological Center. He also served as
    deputy head of the Biology Department of the Biological and
    Chemical Center of the Israeli Defense Forces and as a
    Biochemist at Makor Chemicals Ltd. Dr.&#160;Shaaltiel was a
    postdoctoral fellow at the University of California at Berkeley
    and at Rutgers University in New Jersey. He has co-authored over
    40 articles and abstracts on plant biochemistry and holds seven
    patents. Dr.&#160;Shaaltiel received a Ph.D. in Plant
    Biochemistry from the Weizmann Institute of Science, an M.Sc. in
    Biochemistry from the Hebrew University and a B.Sc. in Biology
    from the Ben Gurion University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Alfred Akirov.</B>&#160;&#160;Mr.&#160;Akirov has served as
    our director since January 2008. Mr.&#160;Akirov is the founder,
    chairman of the board of directors and chief executive officer
    of the Alrov Group (TASE: ALRO), an Israeli publicly-traded
    company that is listed on the Tel Aviv Stock Exchange.
    Mr.&#160;Akirov founded the Alrov Group in 1978 and it is
    currently one of Israel&#146;s largest real-estate companies.
    The Alrov Group holds 80% of the capital stock of Techno-Rov
    Holdings (1993)&#160;Ltd., one of our shareholders.
    Mr.&#160;Akirov serves in different capacities, including
    chairman, chief executive officer and director, for a number of
    private companies in the Alrov Group and Techno-Rov portfolios.
    Mr.&#160;Akirov serves on the Executive Council and the Board of
    Governors of the Tel Aviv University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Amos Bar-Shalev.</B>&#160;&#160;Mr.&#160;Bar-Shalev has
    served as our director and as a director of Protalix Ltd. since
    July&#160;14, 2008. Previously, Mr.&#160;Bar-Shalev served as a
    director of Protalix Ltd. from 2005, and of our company from
    December&#160;31, 2006, until our 2007 annual meeting of
    shareholders. Mr.&#160;Bar Shalev brings to us extensive
    experience in managing technology companies. Currently,
    Mr.&#160;Bar Shalev is the president of 1andOne Technology, and
    manages the Technorov portfolio. Until recently he was the
    managing director of TDA Israel, a management company of the TGF
    (Templeton Tadiran) Fund. Mr.&#160;Bar-Shalev was vice president
    of Eurofund and a senior analyst at Teuza. He has served on the
    board of directors of many companies, such as Schema,
    ScitexVision, MessageVine, Objet, Idanit and ART. Mr.&#160;Bar
    Shalev holds a B.Sc. in Electrical Engineering from the
    Technion, Israel and an M.B.A. from the Tel Aviv University. He
    holds the highest award from the Israeli Air Force for
    technological achievements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Zeev Bronfeld.</B>&#160;&#160;Mr.&#160;Bronfeld has served as
    a director of Protalix Ltd. since 1996 and as our director since
    December&#160;31, 2006. Mr.&#160;Bronfeld brings to us vast
    experience in management and value building of biotechnology
    companies. Mr.&#160;Bronfeld is an experienced businessman who
    is involved in a number of biotechnology companies. He is a
    co-founder of Biocell Ltd., an Israeli publicly traded holding
    company specializing in biotechnology companies and has served
    as its chief executive officer since 1986. Mr.&#160;Bronfeld
    currently serves as a director of Biocell Ltd., Nasvax Ltd., D.
    Medical Industries Ltd., and Biomedix Incubator Ltd., all of
    which are public companies traded on the Tel Aviv Stock
    Exchange. Mr.&#160;Bronfeld is also a director of each of the
    following privately-held companies: Meitav Technological
    Incubator Ltd., Innovetica Ltd., Ecocycle Israel Ltd., Contipi
    Ltd., Nilimedix Ltd., G-Sense Ltd. and L.N. Innovative
    Technologies. Mr.&#160;Bronfeld holds a B.A. in Economics from
    the Hebrew University.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Yodfat Harel Gross.</B>&#160;&#160;Ms.&#160;Harel Gross has
    served as our director since June 2007. Since 2006,
    Ms.&#160;Harel Gross has served as the business development
    director and the head of the Israel office of Tamares Capital
    Ltd., a private investment group with interests in real estate,
    technology, manufacturing, leisure and media. Prior to joining
    Tamares Capital, from 2004 to 2006, she was the corporate
    director, medical imaging, of Orbotech, Ltd., a company
    providing high-tech inspection and imaging solutions for bare
    printed circuit board (PCB), flat panel display (FPD) and PCB
    assembly manufacturing worldwide. Prior to that, from 1994 to
    2003, she was a managing director of Harel-Hertz Investment
    House Ltd., a business investment company with offices in Tel
    Aviv and Tokyo. In 2002, Harel-Hertz Investment House became the
    Israeli representative office for ITX Corporation, a
    publicly-traded company in Japan. Ms.&#160;Harel Gross currently
    serves on the board of directors of Tamares Capital, Tamares
    Hotels, Tamares Real Estate, Storewiz and Halman-Aldubi
    Provident Funds, Ltd. Ms.&#160;Harel Gross holds a B.A. in
    Communication and Political Science from Bar Ilan University and
    an executive M.B.A. from Bradford University, Great Britain. She
    has also completed programs in Directors&#146; Studies and
    Advanced Advertising and Marketing at the Israel Management
    Center.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Roger D. Kornberg,&#160;Ph.D.</B>&#160;&#160;Professor
    Kornberg has served as our director since February 2008.
    Professor Kornberg is a member of the U.S.&#160;National Academy
    of Sciences and the Winzer Professor of Medicine in the
    Department of Structural Biology at Stanford University,
    Stanford, California. He has been a member of the faculty of
    Stanford University since 1972. Prior to that, Dr.&#160;Kornberg
    was a professor at Harvard Medical School. In 2006, Professor
    Kornberg was awarded the Nobel Prize in Chemistry in recognition
    for his studies of the molecular basis of eukaryotic
    transcription, the process by which DNA is copied to RNA.
    Professor Kornberg is also the recipient of several awards,
    including the 2001 Welch Prize, the highest award granted in the
    field of chemistry in the United States, and the 2002 Leopold
    Mayer Prize, the highest award granted in the field of
    biomedical sciences from the French Academy of Sciences. He
    received a B.S. in Chemistry from Harvard University in 1967 and
    a Ph.D. in Chemistry from Stanford University in 1972. He holds
    honorary degrees from universities in Europe and Israel,
    including the Hebrew University in Jerusalem, where he currently
    is a visiting professor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Eyal Sheratzky.</B>&#160;&#160;Mr.&#160;Sheratzky has served
    as a director of Protalix Ltd. since 2005 and as our director
    since December&#160;31, 2006. Mr.&#160;Sheratzky has served as a
    director of Ituran Location&#160;&#038; Control, a
    publicly-traded company quoted on the Nasdaq, since 1995 and as
    a co-chief executive officer since 2003. Prior to such date, he
    served as an alternate chief executive officer of Ituran from
    2002 through 2003 and as vice president of business development
    from 1999 through 2002. Mr.&#160;Sheratzky serves as a director
    of Moked Ituran Ltd. and of Ituran&#146;s subsidiaries. From
    2004 to 2007, Mr.&#160;Sheratzky served as the chairman of the
    board of directors of Biocell. From 1994 to 1999 he served as
    the chief executive officer of Moked Services, Information and
    Investments Ltd. and as legal advisor to several of
    Ituran&#146;s affiliated companies. Mr.&#160;Sheratzky holds
    LL.B and LL.M degrees from Tel Aviv University School of Law and
    an Executive M.B.A. degree from Kellogg University.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Sharon Toussia-Cohen.</B>&#160;&#160;Mr.&#160;Toussia-Cohen
    has served as a director of Protalix Ltd. since 2004 and as our
    director since December&#160;31, 2006. Mr.&#160;Toussia-Cohen is
    the president, chief executive officer and a director of
    Marathon Investments, an Israeli publicly-traded company since
    2004. During the period from 1996 to 2002, he served as the
    chief executive officer of the Aleppo Group and also as managing
    director of Israel&#146;s Airport City Project. From the years
    2002 through 2004, Mr.&#160;Toussia-Cohen was a partner and
    managing director of the Tiv Taam Group and from the years 2004
    through 2006 he was the chief executive officer and a director
    of ISRI Investments Ltd. Mr.&#160;Toussia-Cohen currently serves
    on the board of directors of Bioview, an Israeli company traded
    on the Tel Aviv Stock Exchange, and several privately-held
    companies including Nanomotion, Margan Business Development
    Ltd., Pegasus, Chromat Ltd., and Yeulit. Mr.&#160;Toussia-Cohen
    is certified in Bank Management by the First International Bank
    of Israel and the Republic National Bank of New York. He was
    also the co-owner and director of a strategic consulting firm in
    Israel. Mr.&#160;Toussia-Cohen holds a Bachelor&#146;s degree in
    Economics and Political Science and an M.B.A. from the Hebrew
    University.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Independent
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We believe a majority of the members of our Board of Directors
    are independent from management. When making determinations from
    time to time regarding independence, the Board of Directors will
    reference the listing standards adopted by the American Stock
    Exchange as well as the independence standards set forth in the
    Sarbanes-Oxley Act of 2002 and the rules and regulations
    promulgated by the Securities and Exchange Commission under that
    Act. In particular, our Audit Committee periodically evaluates
    and reports to the Board of Directors on the independence of
    each member of the Board of Directors. We anticipate that the
    Audit Committee will analyze whether a director is independent
    by evaluating, among other factors, the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors has any material
    relationship with us, either directly, or as a partner,
    shareholder or officer of an organization that has a
    relationship with us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors is a current
    employee of our company or our subsidiaries or was an employee
    of our company or our subsidiaries within three years preceding
    the date of determination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors is, or in the three
    years preceding the date of determination has been, affiliated
    with or employed by (i)&#160;a present internal or external
    auditor of our company or any affiliate of such auditor or
    (ii)&#160;any former internal or external auditor of our company
    or any affiliate of such auditor, which performed services for
    us within three years preceding the date of determination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors is, or in the three
    years preceding the date of determination has been, part of an
    interlocking directorate, in which any of our executive officers
    serve on the Compensation Committee of another company that
    concurrently employs the member as an executive officer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors receives any
    compensation from us, other than fees or compensation for
    service as a member of the Board of Directors and any committee
    of the Board of Directors and reimbursement for reasonable
    expenses incurred in connection with such service and for
    reasonable educational expenses associated with Board of
    Directors or committee membership matters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether an immediate family member of the member of the Board of
    Directors is a current executive officer of our company or was
    an executive officer of our company within three years preceding
    the date of determination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether an immediate family member of the member of the Board of
    Directors is, or in the three years preceding the date of
    determination has been, affiliated with or employed in a
    professional capacity by (i)&#160;a present internal or external
    auditor of ours or any of our affiliates or (ii)&#160;any former
    internal or external auditor of our company or any affiliate of
    ours which performed services for us within three years
    preceding the date of determination;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    Whether an immediate family member of the member of the Board of
    Directors is, or in the three years preceding the date of
    determination has been, part of an interlocking directorate, in
    which any of our executive officers serve on the Compensation
    Committee of another company that concurrently employs the
    immediate family member of the member of the Board of Directors
    as an executive officer.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The above list is not exhaustive and we anticipate that the
    Audit Committee will consider all other factors which could
    assist it in its determination that a director will have no
    material relationship with us that could compromise that
    director&#146;s independence.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under these standards, our Board of Directors has determined
    that Messrs.&#160;Sheratzky, Bar Shalev and Toussia-Cohen and
    Ms.&#160;Harel Gross are considered &#147;independent&#148;
    pursuant to the rules of the
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    American Stock Exchange and Section&#160;10A(m)(3) of the
    Securities Exchange Act of 1934, as amended. In addition, our
    Board has determined that these members of the Board of
    Directors are able to read and understand fundamental financial
    statements and have substantial business experience that results
    in their financial sophistication, qualifying them for
    membership on our Audit Committee. Our Board of Directors has
    also determined that Messrs.&#160;Akirov, Bronfeld, Bar Shalev,
    Sheratzky and Toussia-Cohen, Ms.&#160;Harel Gross and
    Dr.&#160;Kornberg are &#147;independent&#148; pursuant to the
    rules of the American Stock Exchange.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our non-management directors hold formal meetings, separate from
    management, at least twice per year. We have no formal policy
    regarding attendance by our directors at annual meetings of
    shareholders, although we encourage such attendance and
    anticipate most of our directors will attend these meetings.
    Mr.&#160;Hurvitz, Dr.&#160;Aviezer, Dr.&#160;Shaaltiel,
    Ms.&#160;Harel Gross and Mr.&#160;Bar-Shalev attended our 2007
    annual meeting of shareholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Board and
    Committee Meetings</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors has an Audit Committee, a Compensation
    Committee and a Nominating Committee. The following indicates
    the members of each committee and provides a description of the
    committees&#146; primary functions:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Audit
    Committee</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We require that all Audit Committee members possess the required
    level of financial literacy and at least one member of the Audit
    Committee meet the current standard of requisite financial
    management expertise as required by the American Stock Exchange
    and applicable rules and regulations of the Securities and
    Exchange Commission. Messrs.&#160;Bar Shalev and Toussia-Cohen
    and Ms.&#160;Harel Gross have been appointed by the Board of
    Directors to serve on the Audit Committee until their respective
    successors have been duly elected. Mr.&#160;Sheratzky served as
    a member of the Audit Committee for part of 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Audit Committee operates under a formal charter that governs
    its duties and conduct. A current copy of the Audit Committee
    Charter is available on our website at
    <U><FONT style="white-space: nowrap">http://www.protalix.com.</FONT></U>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All members of the Audit Committee are independent from our
    executive officers and management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our independent registered public accounting firm reports
    directly to the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Audit Committee meets with management and representatives of
    our registered public accounting firm prior to the filing of
    officers&#146; certifications with the Securities and Exchange
    Commission to receive information concerning, among other
    things, effectiveness of the design or operation of our internal
    controls over financial reporting, as required by
    Section&#160;404 of the Sarbanes-Oxley Act of 2002.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Audit Committee has adopted a Policy for Reporting
    Questionable Accounting and Auditing Practices and Policy
    Prohibiting Retaliation against Reporting Employees to enable
    confidential and anonymous reporting of improper activities to
    the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Messrs.&#160;Bar Shalev and Toussia-Cohen qualify as &#147;audit
    committee financial experts&#148; under the applicable rules of
    the Securities and Exchange Commission. In making the
    determination as to these individuals&#146; status as audit
    committee financial experts, our Board of Directors determined
    they have accounting and related financial management expertise
    within the meaning of the aforementioned rules, as well as the
    listing standards of the American Stock Exchange.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee is currently comprised of
    Messrs.&#160;Bar Shalev and Sheratzky and Ms.&#160;Harel Gross.
    Messrs.&#160;Bronfeld and Toussia-Cohen served as members of the
    Compensation Committee for part of 2008. The Compensation
    Committee reviews and approves the compensation of executive
    officers and key employees and administers our stock incentive
    plan. A current copy of the Compensation Committee Charter is
    available on our website at
    <U><FONT style="white-space: nowrap">http://www.protalix.com.</FONT></U>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <I><FONT style="font-family: 'Times New Roman', Times">Nominating
    Committee</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nominating Committee, currently comprised of
    Messrs.&#160;Bar Shalev, Sheratzky and Toussia-Cohen, is
    responsible for assisting our Board of Directors in selecting
    nominees for election to the Board of Directors and monitoring
    the composition of the Board of Directors. Mr.&#160;Bronfeld
    served as a member of the Nominating Committee for part of 2008.
    A current copy of the Nominating Committee Charter is available
    on our website at
    <U><FONT style="white-space: nowrap">http://www.protalix.com.</FONT></U>
    In considering potential new directors, the Nominating Committee
    will review individuals from various disciplines and
    backgrounds, and consider the following qualifications: broad
    experience in business, finance or administration; familiarity
    with national business matters; familiarity with our industry;
    independence; and prominence and reputation. After making such a
    review, the Nominating Committee submits the nomination to the
    full Board of Directors for approval.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Nominating Committee will consider any nominees submitted by
    shareholders of record at the time of any such nomination in
    compliance with applicable rules of the Securities and Exchange
    Commission and our Amended and Restated By-Laws, or the By-Laws.
    The Nominating Committee will determine whether any shareholder
    nominee meets the qualifications for candidacy described above
    and in the Nominating Committee Charter. Shareholders&#146;
    nominations for election at the 2009 Annual Meeting of
    Shareholders must be submitted in writing to Yossi Maimon,
    Corporate Secretary, not less than 45&#160;days nor more than
    75&#160;days prior to the date on which we first mailed this
    proxy statement. Such written notice must include the following
    information: (i)&#160;name, age, business address and residence
    address of the nominee, (ii)&#160;the principal occupation or
    employment of the nominee, (iii)&#160;the class and number of
    shares of our company beneficially owned by the nominee and
    (iv)&#160;any other information relating to the nominee that
    would be required to be disclosed in solicitations for proxies
    for elections of directors pursuant to Regulation&#160;14A of
    the Exchange Act. The written notice must also include the
    following information with respect to each shareholder
    delivering such notice: (i)&#160;the name and record address of
    such shareholder and (ii)&#160;the class and number of shares of
    our company beneficially owned by the shareholder. Lastly, the
    written notice must include certain information relating to any
    derivative or hedging transactions by the shareholder delivering
    such notice and its Shareholder Associated Persons, as defined
    in our By-Laws, and other arrangements with other parties
    regarding our securities, as presented in detail in our By-Laws.
    Shareholders can mail any such recommendations, including the
    criteria outlined above, to Yossi Maimon, Corporate Secretary,
    Protalix BioTherapeutics, Inc., 2 Snunit Street, Science Park,
    POB 455, Carmiel, Israel 20100.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During the year ended December&#160;31, 2007, there were seven
    meetings of the Board of Directors of Protalix Ltd., six
    meetings of the Audit Committee of Protalix Ltd. and one meeting
    of the Compensation Committee of Protalix Ltd. Our
    non-management directors hold meetings separate from management
    at least twice per year. All directors attended at least 75% of
    the aggregate number of meetings of the Board of Directors and
    the committees of the Board of Directors on which they served.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the rules of the American Stock Exchange, a director of
    our company will only qualify as an &#147;independent
    director&#148; if, among other things, in the opinion of our
    Board of Directors, that person does not have a material
    relationship that would interfere with the exercise of
    independent judgment in carrying out the responsibilities of a
    director. The Board of Directors has determined that none of the
    directors has a relationship that would interfere with the
    exercise of independent judgment in carrying out the
    responsibilities of a director and that each of these directors
    is an &#147;independent director&#148; as defined under rules of
    the American Stock Exchange. In addition, the Board of Directors
    has determined that all members of the Audit Committee meet the
    independence requirements set forth in
    <FONT style="white-space: nowrap">Rule&#160;10A-3</FONT>
    under the Exchange Act.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Contacting
    the Board of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Shareholders who wish to communicate with the Board of Directors
    may do so by mailing any such communications to Yossi Maimon,
    Corporate Secretary, Protalix BioTherapeutics, Inc., 2 Snunit
    Street,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Science Park, POB 455, Carmiel, Israel 20100. All communications
    are distributed to the Board of Directors, as appropriate,
    depending upon the facts and circumstances outlined in the
    communications received. For example, if any complaints
    regarding accounting
    <FONT style="white-space: nowrap">and/or</FONT>
    auditing matters are received, they may be forwarded by our
    Corporate Secretary to the Audit Committee for review.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Policy
    Governing Director Attendance at Annual Meetings of
    Shareholders</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have no formal policy regarding attendance by our directors
    at annual shareholders meetings, although we encourage such
    attendance and anticipate most of our directors will attend
    these meetings. Mr.&#160;Hurvitz, Dr.&#160;Aviezer,
    Dr.&#160;Shaaltiel, Ms.&#160;Harel Gross and Mr.&#160;Bar-Shalev
    attended our 2007 annual meeting of shareholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information with respect to
    compensation of our directors during fiscal year 2007. The fees
    to our current directors were paid by Protalix Ltd. Prior to our
    merger with Protalix Ltd., Protalix Ltd. compensated only
    certain of its directors, which compensation was limited to the
    granting of options under its employee stock option plan. The
    &#147;former directors&#148; were our directors who resigned
    during fiscal year 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="35%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Nonqualified<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fees Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Deferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Paid in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Cash<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Award<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Name</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Current Directors</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Eli Hurvitz(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,289,086
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,325,086
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Amos Bar-Shalev
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Zeev Bronfeld
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Eyal Sheratzky
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Sharon Toussia-Cohen
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Former Directors</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Phillip Frost,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Pinhas Barel Buchris
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Jane H. Hsiao,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents amounts paid to Pontifax Management Company, Ltd.
    pursuant to a management consulting agreement.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors will review director compensation
    annually and adjust it according to then current market
    conditions and corporate governance guidelines.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On August&#160;14, 2007, our Board of Directors resolved to pay
    a director&#146;s fee equal to $33,000 per year to all
    non-executive directors. The director&#146;s fee is payable
    commencing upon calendar year 2008. Except as set forth above,
    no fees were paid to directors for fiscal year 2007.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Compensation Committee currently consists of
    Messrs.&#160;Bar Shalev and Sherazky and Ms.&#160;Harel Gross,
    who were appointed to the Committee on various dates during
    2008. In addition, for certain periods during 2007 and 2008,
    Messrs Bronfeld and Toussia-Cohen and former directors Pinhas
    Barel Buchris and Jane H. Hsiao, served on our Compensation
    Committee. No member of our Compensation Committee or any
    executive officer of our company or of Protalix Ltd. has a
    relationship that would constitute an interlocking relationship
    with executive officers or directors of another entity. No
    Compensation Committee member is or was an officer or employee
    of ours or of Protalix Ltd. Further, none of our executive
    officers serves on the board of directors or compensation
    committee of any entity that has one or more executive officers
    serving as a member of our Board of Directors or Compensation
    Committee.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "MANAGEMENT" -->
<DIV align="left"><A NAME="004"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">MANAGEMENT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our executive officers, their ages and positions as of
    September&#160;30, 2008, are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="40%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=quadright -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="51%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Name</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Age</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Position</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    43
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    President, Chief Executive Officer and Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    55
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Executive VP, Research and Development and Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    49
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Vice President, Product Development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon, CPA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    38
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Chief Financial Officer, Treasurer and Secretary
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Biographical information follows for the executive officers
    named in the above chart who do not also serve as our directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Einat Brill Almon,&#160;Ph.D.</B>&#160;&#160;Dr.&#160;Almon
    joined Protalix Ltd. in December 2004 as its Vice President,
    Product Development and became our Vice President, Product
    Development on December&#160;31, 2006. Dr.&#160;Almon has many
    years of experience in the management of life science projects
    and companies, including biotechnology and agrobiotech, with
    direct experience in clinical, device and scientific software
    development, as well as a strong background and work experience
    in Intellectual Property. Prior to joining Protalix, from 2001
    to 2004, she served as a director of R&#038;D and IP of
    Biogenics Ltd., a company that developed an autologous platform
    for tissue based protein drug delivery. Biogenics, based in
    Israel, is a wholly-owned subsidiary of Medgenics Inc.
    Dr.&#160;Almon has trained as a biotechnology patent agent at
    leading IP firms in Israel. Dr.&#160;Almon holds a Ph.D. and an
    M.Sc. in molecular biology of cancer research from the Weizmann
    Institute of Science, a B.Sc. from the Hebrew University and has
    carried out Post-Doctoral research at the Hebrew University in
    the area of plant molecular biology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Yossi Maimon, CPA.</B>&#160;&#160;Mr.&#160;Maimon joined
    Protalix Ltd. on October&#160;15, 2006 as its Chief Financial
    Officer and became our Vice President and Chief Financial
    Officer on December&#160;31, 2006. Prior to joining Protalix
    Ltd., from 2002 to 2006, he served as the chief financial
    officer of Colbar LifeScience Ltd., a biomaterial company
    focusing on aesthetics, where he led all of the corporate
    finance activities, fund raisings, and legal aspects of Colbar
    including the sale of Colbar to Johnson and Johnson. Prior to
    that, from 2000 to 2002, he served as the chief financial
    officer of Way2Call Communications, Ltd., an Israeli start up
    company in the telecommunications field, where he led the fund
    raising efforts, accounting issues and business development
    activities. Prior to that, from 1998 to 2000, he served as the
    controller of PEC, a United States company publicly traded on
    the New York Stock Exchange, where he was responsible for
    reporting and compliance with the Securities and Exchange
    Commission and led the process of delisting and merging PEC into
    Discount Investment Bank. Mr.&#160;Maimon has a B.A. in
    accounting from the City University of New York and an M.B.A.
    from Tel Aviv University, and he is a Certified Public
    Accountant in the United States (New York State) and Israel.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Family
    Relationships</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There are no family relationships among directors or executive
    officers of our company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have adopted a Code of Business Conduct and Ethics that
    includes provisions ranging from restrictions on gifts to
    conflicts of interest. All of our employees and directors are
    bound by this Code of Business Conduct and Ethics. Violations of
    our Code of Business Conduct and Ethics may be reported to the
    Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Code of Business Conduct and Ethics includes provisions
    applicable to all of our employees, including senior financial
    officers and members of our Board of Directors and is posted on
    our website
    (<U><FONT style="white-space: nowrap">http://www.protalix.com</FONT></U>).
    We intend to post amendments to or waivers from any such Code of
    Business Conduct and Ethics.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Discussion and Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The primary goals of the Compensation Committee of our Board of
    Directors with respect to executive compensation are to attract
    and retain the most talented and dedicated executives possible,
    to tie annual and long-term cash and stock incentives to
    achievement of specified performance objectives, and to align
    executives&#146; incentives with shareholder value creation. To
    achieve these goals, the Compensation Committee intends to
    implement and maintain compensation plans that tie a portion of
    executives&#146; overall compensation to key strategic goals
    such as developments in our clinical path, the establishment of
    key strategic collaborations, the
    <FONT style="white-space: nowrap">build-up</FONT> of
    our pipeline and the strengthening of our financial position.
    The Compensation Committee evaluates individual executive
    performance with a goal of setting compensation at levels the
    committee believes are comparable with executives in other
    companies of similar size and stage of development operating in
    the biotechnology industry while taking into account our
    relative performance and our own strategic goals.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Elements
    of Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Executive compensation consists of following elements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Base Salary.</I></B>&#160;&#160;Base salaries for our
    executives are established based on the scope of their
    responsibilities taking into account competitive market
    compensation paid by other companies for similar positions.
    Generally, we believe that executive base salaries should be
    targeted near the median of the range of salaries for executives
    in similar positions with similar responsibilities at comparable
    companies. Base salaries are reviewed annually, and adjusted
    from time to time to realign salaries with market levels after
    taking into account individual responsibilities, performance and
    experience. The review for 2007 took place in February 2008 and
    the base salaries are set forth above under &#147;Employment
    Agreements and Change in Control Arrangements.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, our Board of Directors, acting upon the
    resolution of a majority of our independent directors, approved
    increases to the monthly salaries of our Chief Executive
    Officer, our Executive Vice President, Research and Development,
    our Vice President, Product Development, and our Vice President
    and Chief Financial Officer. The amended monthly salaries are
    NIS 136,000 (approximately $37,559), NIS 60,500 (approximately
    $16,727), NIS 55,000 (approximately $15,206) and NIS 55,000
    (approximately $15,206), respectively. Our intention was to
    provide general raises of between 10% and 15%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Annual Bonus.</I></B>&#160;&#160;The Compensation
    Committee has the authority to award discretionary annual
    bonuses to our executive officers. It has not established a
    formal bonus plan. These awards are intended to compensate
    officers for achieving financial, clinical and operational goals
    and for achieving individual annual performance objectives.
    These objectives vary depending on the individual executive, but
    relate generally to strategic factors such as developments in
    our clinical path, the establishment of key strategic
    collaborations, the
    <FONT style="white-space: nowrap">build-up</FONT> of
    our pipeline and to financial factors such as raising capital.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    For each year, the Compensation Committee will select, in its
    discretion, the executive officers of our company or our
    subsidiary who are eligible to receive bonuses. Any bonus
    granted by the Compensation Committee will generally be paid in
    the first quarter following completion of a given year. Similar
    to bonuses paid in the past, the actual amount of discretionary
    bonus will be determined following a review of each
    executive&#146;s individual performance and contribution to our
    goals. The Compensation Committee has not fixed a minimum or
    maximum payout for any officer&#146;s annual discretionary
    bonus, unless specified in an executive&#146;s employment
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Pursuant to each officer&#146;s employment agreement, the
    executive officer is eligible for a discretionary annual bonus.
    The Compensation Committee determines the discretionary annual
    bonus paid to our executive officers, and the discretionary
    bonus awarded to certain officers in 2008 for performance in
    2007. The actual amount of discretionary bonus is determined
    following a review of each executive&#146;s individual
    performance and contribution to our strategic goals conducted
    during the first quarter of each fiscal year. The Compensation
    Committee has not fixed a minimum or a maximum amount for any
    officer&#146;s annual discretionary bonus.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, our Board of Directors, acting upon the
    resolution of a majority of our independent directors, awarded a
    total of approximately $438,000 to our Chief Executive Officer,
    our Executive Vice President, Research and Development, our Vice
    President, Product Development, and our Vice President and Chief
    Financial Officer for their performance during the year 2007.
    The amount of the bonuses were NIS 920,000 (approximately
    $256,131), $50,000, $50,000 and NIS 297,000 (approximately
    $82,061), respectively. The bonuses paid to our Chief Executive
    Officer and our Vice President and Chief Financial Officer were
    multiples of eight and six times their salary in 2007,
    respectively, in recognition of the time and effort expended by
    them from the end of 2006 through 2007 in connection with the
    merger, the American Stock Exchange Listing and our underwritten
    public offering. In addition, the bonuses to the officers were
    awarded in recognition of their ongoing efforts in achieving our
    milestones regarding clinical developments, financial
    developments and other factors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Options.</I></B>&#160;&#160;Our 2006 Stock Option Plan
    authorizes us to grant options to purchase shares of common
    stock to our employees, directors and consultants. Our
    Compensation Committee is the administrator of the stock option
    plan. Stock option grants are generally made at the commencement
    of employment and following a significant change in job
    responsibilities or to meet other special retention or
    performance objectives. The Compensation Committee reviews and
    approves stock option awards to executive officers based upon a
    review of competitive compensation data, its assessment of
    individual performance, a review of each executive&#146;s
    existing long-term incentives, and retention considerations. In
    2007, we awarded stock options to one of the Named Executive
    Officers in the amount indicated under &#147;Grants of Plan
    Based Awards&#148;. This grant was made in May 2007 as the first
    grant to the Named Executive Officer upon commencement of his
    employment by our company. The exercise price of stock options
    granted under the 2006 Stock Incentive Plan must be equal to at
    least 100% of the fair market value of our common stock on the
    date of grant; however, in certain circumstances, grants may be
    made at a lower price to Israeli grantees who are residents of
    the State of Israel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In February 2008, our Board of Directors, acting upon a
    resolution of a majority of our independent directors, granted
    stock options to our Chief Executive Officer, our Executive Vice
    President, Research and Development, our Vice President, Product
    Development, and our Vice President and Chief Financial Officer.
    The number of shares of Common Stock underlying the option
    grants was 600,000; 263,728; 311,272; and 175,000, respectively.
    As was the case with respect to the annual bonuses, the grants
    of stock options to our Chief Executive Officer and our Vice
    President and Chief Financial Officer were in recognition of the
    time and effort expended by them from the end of 2006 through
    2007 in connection with the merger, the American Stock Exchange
    Listing and our underwritten public offering. In addition, the
    grants of stock options to the other officers were awarded in
    recognition of their ongoing efforts in achieving our milestones
    regarding clinical developments, research and development,
    financial developments and other factors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Severance and Change in Control
    Benefits.</I></B>&#160;&#160;Pursuant to the employments
    agreements entered into with each of our executive officers, the
    executive officer is entitled to be insured by Protalix Ltd.
    under a Manager&#146;s Policy in lieu of severance. The
    intention of such Manager&#146;s Policies is to provide the
    officers with severance protection of one month&#146;s salary
    for each year of employment. In addition, the stock option
    agreements provide for the acceleration of the vesting periods
    of options in the event of a termination without cause following
    a change in control of our company. In February 2008, our Board
    of Directors, acting upon the resolution of a majority of our
    independent directors, agreed to amend the outstanding option
    agreements of the Named Executive Officers. The amendments
    provide that all of the outstanding options of each Named
    Executive Officer shall be subject to accelerated vesting
    immediately upon a change in control of our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Other Compensation.</I></B>&#160;&#160;Consistent with our
    compensation philosophy, we intend to continue to maintain our
    current benefits for our executive officers; however, the
    Compensation Committee in its discretion may revise, amend, or
    add to the officer&#146;s executive benefits if it deems it
    advisable. As an additional benefit to all of our Named
    Executive Officers and for most of our employees, we contribute
    to certain funds amounts equaling a total of approximately 15%
    of their gross salaries for certain pension and other savings
    plans. In addition, in accordance with customary practice in
    Israel, our
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    executives&#146; agreements require us to contribute towards
    their vocational studies, and to provide annual recreational
    allowances, a company car and a company phone. We believe these
    benefits are currently equivalent with median competitive levels
    for comparable companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I>Executive Compensation.</I></B>&#160;&#160;We refer to the
    &#147;Summary Compensation Table&#148; set forth below for
    information regarding the compensation earned during the fiscal
    year ended December&#160;31, 2007 by our Chief Executive
    Officer, our Executive Vice President, Research and Development,
    our Vice President, Product Development, Vice President and
    Chief Financial Officer and our Vice President of Operations.
    There are no other executive officers for 2007 whose total
    compensation exceeded $100,000 during that fiscal year other
    than those set forth below. We refer to our Chief Executive
    Officer, our Executive Vice President, Research and Development,
    our Vice President, Product Development, Vice President and
    Chief Financial Officer and our Vice President of Operations as
    our &#147;Named Executive Officers.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Report</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The above report of the Compensation Committee does not
    constitute soliciting material and shall not be deemed filed or
    incorporated by reference into any other filing by us under the
    Securities Act of 1933 or the Securities Exchange Act of
    1934.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Compensation Committee has reviewed and discussed the
    Compensation Discussion and Analysis set forth below with our
    management. Based on this review and discussion, the
    Compensation Committee has recommended to our Board of Directors
    that the Compensation Discussion and Analysis be included in our
    Annual Report on Form&#160;10-K and our annual proxy statement
    on Schedule&#160;14A.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Respectfully submitted on March&#160;13, 2008, by the members of
    the Compensation Committee of the Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 5%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Yodfat Harel Gross<BR>
    Sharon Toussia-Cohen<BR>
    Zeev Bronfeld</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth a summary for the fiscal years
    ended December&#160;31, 2007 and 2006 respectively, of the cash
    and non-cash compensation awarded, paid or accrued by Protalix
    Ltd. to our Named Executive Officers. There were no restricted
    stock awards, long-term incentive plan payouts or other
    compensation paid during fiscal years 2007 and 2006 by Protalix
    Ltd. to the Named Executive Officers, except as set forth below.
    The Named Executive Officers are employees of our subsidiary,
    Protalix Ltd. As a result of the merger, all of the directors
    and officers at the time resigned and appointed our current
    directors and officers in their stead. All currency amounts are
    expressed in U.S.&#160;dollars.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Nonqualified<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Deferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Name and Principal<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Bonus<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Award(s)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Award(s)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Position</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    David Aviezer,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    341,074
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    239,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    351,343
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    999,617
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <I>President and CEO </I>(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    237,845
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    202,895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    717,666
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    23,202
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,181,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Yoseph Shaaltiel,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    177,297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,339
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    277,056
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <I>Executive Vice President</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    177,658
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,684
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,521
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Einat Brill Almon,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    153,254
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,171
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,482
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    355,189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <I>VP, Product Development</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    102,468
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,420
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    107,782
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,174
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    301,844
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Yossi Maimon, CPA(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    156,444
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    77,223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    247,815
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,975
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    523,457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <I>Chief Financial Officer</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,746
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    96,712
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,077
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    164,488
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Iftah Katz(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    114,087
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,254,567
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,117
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,404,771
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    <I>Vice President of Operations</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 06 -->

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes employer contributions to pension and/or insurance
    plans and other miscellaneous payments.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 06 -->

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Dr.&#160;Aviezer served as Protalix Ltd.&#146;s Chief Executive
    Officer on a consultancy basis until September 2006 pursuant to
    a Consulting Services Agreement between Protalix Ltd. and Agenda
    Biotechnology Ltd., a company wholly-owned by Dr.&#160;Aviezer.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes payments from October&#160;15, 2006 only.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Iftah Katz joined our company as our Vice President of
    Operations on February&#160;28, 2007. Mr.&#160;Katz ceased to be
    employed by the Company as of May&#160;6, 2008.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to the merger, Glenn L. Halpryn served as the
    Company&#146;s Chief Executive Officer and Alan J. Weisberg
    served as the Company&#146;s Chief Financial Officer and
    Treasurer. Messrs.&#160;Halpryn and Weisberg received no salary
    in 2006 and are not included in the above table.
    Mr.&#160;Weisberg is a shareholder of Weisberg Brause, which
    firm we paid $11,600 and $5,800 for accounting services during
    the years ended December&#160;31, 2006 and 2005, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table summarizes the grant of awards made to Named
    Executive Officers during 2007 as of December&#160;31, 2007.
</DIV>


<!-- link1 "GRANTS OF PLAN-BASED AWARDS" -->
<DIV align="left"><A NAME="005"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">GRANTS OF
    PLAN-BASED AWARDS</FONT></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 01 -->
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="24%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=11 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>	<!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=11 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=12 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=12 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=12 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=12 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Estimated Future Payouts<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Estimated Future Payouts<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Under Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Under Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Incentive Plan Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Incentive Plan Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Awards:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Awards:</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant Date<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Base<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Threshold<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Target<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Maximum<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Threshold<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Target<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Maximum<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Units<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Name</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)(2)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($/Sh)(3)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(4)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>(a)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(b)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(c)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(d)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(e)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(f)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(g)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(h)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(i)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(j)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(k)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(l)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    David Aviezer(1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    Yoseph Shaaltiel
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
    Einat Brill Almon(5)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    126,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
    Yossi Maimon Iftah Katz(6)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,784,132
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF"><!-- TABLE 06 -->

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents bonuses to be paid according to
    Dr.&#160;Aviezer&#146;s employment agreement upon achieving
    certain clinical milestones. In addition, non-defined bonuses
    may be granted to all of the above officers at the discretion of
    the Board of Directors.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents outstanding options at December&#160;31, 2007.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents the range of the exercise price of the stock options.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents the fair value as recorded on the grant date of the
    stock options.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents specific bonuses to be paid to Dr.&#160;Brill Almon
    upon the achievement of certain clinical milestones.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Katz ceased to be employed by the Company as of
    May&#160;6, 2008.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth information with respect to the
    Named Executive Officers concerning equity awards assumed by us
    as of December&#160;31, 2007.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="26%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=08 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=09 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=10 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>	<!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=10 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Market or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payout<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Market<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Units or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Units or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Units of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Units of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Rights That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Rights That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Have Not<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Have Not<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Have Not<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Have Not<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Name</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Exercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Unexercisable</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options (#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price ($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Vested (#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Vested ($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Vested (#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Vested&#160;($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    David Aviezer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    807,858
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/1/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    366,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    610,810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/10/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Yoseph Shaaltiel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    244,324
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/30/2011
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Einat Brill Almon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    188,695
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,898
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/23/2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    189,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Yossi Maimon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    193,742
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    426,230
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/19/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Iftah Katz(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204,351
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5/30/2017
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Katz ceased to be employed by the Company as of
    May&#160;6, 2008.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Option exercises during 2007 and vested stock awards for Named
    Executive Officers as of December&#160;31, 2007 were as follows:
</DIV>


<!-- link1 "OPTION EXERCISES AND STOCK VESTED" -->
<DIV align="left"><A NAME="006"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OPTION
    EXERCISES AND STOCK VESTED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="28%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="16%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value Received<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value Received<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Name</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Acquired on Exercise&#160;(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>on Exercise ($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Acquired on Vesting (#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>on Vesting ($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>(a)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(b)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(c)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(d)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(e)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Iftah Katz(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Katz ceased to be employed by the Company as of
    May&#160;6, 2008.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Agreements and
    <FONT style="white-space: nowrap">Change-in-Control</FONT>
    Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>David Aviezer,&#160;Ph.D.,
    MBA.</B>&#160;&#160;Dr.&#160;Aviezer originally served as
    Protalix Ltd.&#146;s Chief Executive Officer on a consultancy
    basis pursuant to a Consulting Services Agreement between
    Protalix Ltd. and Agenda Biotechnology Ltd., a company
    wholly-owned by Dr.&#160;Aviezer. On September&#160;11, 2006,
    Protalix Ltd. entered into an employment agreement with
    Dr.&#160;Aviezer pursuant to which he agreed to be employed as
    Protalix Ltd.&#146;s President and Chief Executive Officer,
    which agreement supersedes the Consultancy Services Agreement.
    Dr.&#160;Aviezer currently serves as our President and Chief
    Executive Officer. Protalix Ltd. agreed to pay Dr.&#160;Aviezer
    a monthly base salary equal to NIS 80,000 (approximately
    $19,000) and an annual bonus at the Board&#146;s discretion. The
    monthly salary is subject to cost of living adjustments from
    time to time and is currently NIS 136,000 (approximately
    $37,700). Dr.&#160;Aviezer is eligible to receive a substantial
    bonus in the event of certain public offerings or acquisition
    transactions,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    which bonus shall be at the discretion of the Board, and certain
    specified bonuses in the event Protalix achieves certain
    specified milestones. In connection with the employment
    agreement, in addition to other options already held by
    Dr.&#160;Aviezer, Protalix Ltd. granted to Dr.&#160;Aviezer
    options to purchase 16,000 ordinary shares of Protalix Ltd. at
    an exercise price equal to $59.40 per share, which we assumed as
    options to purchase 977,297&#160;shares of our common stock at
    $0.97 per share. Such options vest quarterly retroactively from
    June&#160;1, 2006, over a four-year period. The employment
    agreement is terminable by either party on 90&#160;days&#146;
    written notice for any reason and we may terminate the agreement
    for cause without notice. Dr.&#160;Aviezer is entitled to be
    insured by Protalix Ltd. under a Manager&#146;s Policy in lieu
    of severance, company contributions towards vocational studies,
    annual recreational allowances, a company car and a company
    phone. Dr.&#160;Aviezer is entitled to 24 working days of
    vacation. All stock options that have not vested as of the date
    of termination shall be deemed to have expired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Yoseph
    Shaaltiel,&#160;Ph.D.</B>&#160;&#160;Dr.&#160;Shaaltiel founded
    Protalix Ltd. in 1993 and currently serves as our Executive Vice
    President, Research and Development. Dr.&#160;Shaaltiel entered
    into an employment agreement with Protalix Ltd. on
    September&#160;1, 2001. Pursuant to the employment agreement,
    Protalix Ltd. agreed to pay Dr.&#160;Shaaltiel a monthly base
    salary equal to $7,000, subject to annual cost of living
    adjustments. His current salary is $10,600 (approximately
    $16,800) per month. The employment agreement is terminable by
    Protalix Ltd. on 90&#160;days&#146; written notice for any
    reason and we may terminate the agreement for cause without
    notice. Dr.&#160;Shaaltiel is entitled to be insured by Protalix
    Ltd. under a Manager&#146;s Policy in lieu of severance, company
    contributions towards vocational studies, annual recreational
    allowances, a company car and a company phone.
    Dr.&#160;Shaaltiel is entitled to 24 working days of vacation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Einat Brill Almon,&#160;Ph.D.</B>&#160;&#160;Dr.&#160;Brill
    Almon joined Protalix Ltd. on December&#160;19, 2004 as its Vice
    President, Product Development, pursuant to an employment
    agreement effective on December&#160;19, 2004 by and between
    Protalix Ltd. and Dr.&#160;Brill Almon, and currently serves as
    our Vice President, Product Development. Pursuant to the
    employment agreement, Protalix Ltd. agreed to pay Dr.&#160;Brill
    Almon a monthly base salary equal to NIS 28,000 (approximately
    $6,575), subject to cost of living adjustments from time to
    time. Her current salary is NIS 55,000 per month (approximately
    $15,300). She is also entitled to certain specified bonuses in
    the event that Protalix achieves certain specified clinical
    development milestones within specified timelines. In connection
    with the employment agreement, Protalix Ltd. agreed to grant to
    Dr.&#160;Brill Almon options to purchase 7,919 ordinary shares
    of Protalix Ltd. at exercise prices equal to $24.36 and $59.40
    per share, which we assumed as options to purchase
    483,701&#160;shares of our common stock at $0.40 and $0.97 per
    share. The options vest over four years. The employment
    agreement is terminable by either party on 60&#160;days&#146;
    written notice for any reason and we may terminate the agreement
    for cause without notice. Dr.&#160;Brill Almon is entitled to be
    insured by Protalix Ltd. under a Manager&#146;s Policy in lieu
    of severance, company contributions towards vocational studies,
    annual recreational allowances, a company car and a company
    phone at up to NIS 1,000 per month. Dr.&#160;Brill Almon is
    entitled to 22 working days of vacation. All stock options that
    have not vested as of the date of termination shall be deemed to
    have expired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Yossi Maimon, CPA.</B>&#160;&#160;Mr.&#160;Maimon joined
    Protalix Ltd. as its Chief Financial Officer pursuant to an
    employment agreement effective as of October&#160;15, 2006 by
    and between Protalix Ltd. and Mr.&#160;Maimon and currently
    serves as our Chief Financial Officer. Pursuant to the
    employment agreement, Protalix Ltd. agreed to pay
    Mr.&#160;Maimon a monthly base salary equal to NIS 45,000
    (approximately $10,600) and an annual discretionary bonus and
    additional discretionary bonuses in the event Protalix Ltd.
    achieves significant financial milestones, subject to the
    Board&#146;s sole discretion. The monthly salary is subject to
    cost of living adjustments from time to time. His current salary
    is NIS 55,000 (approximately $15,300) per month. In connection
    with the employment agreement, Protalix agreed to grant to
    Mr.&#160;Maimon options to purchase 10,150 ordinary shares of
    Protalix Ltd. at an exercise price equal to $59.40 per share,
    which we assumed as options to purchase 619,972&#160;shares of
    our common stock at $0.97 per share. The first 25% of such
    options shall vest on the first anniversary of the grant date
    and the remainder shall vest quarterly in 12 equal increments.
    The employment agreement is terminable by
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    either party on 60&#160;days&#146; written notice for any reason
    and we may terminate the agreement for cause without notice.
    Mr.&#160;Maimon is entitled to be insured by Protalix Ltd. under
    a Manager&#146;s Policy in lieu of severance, company
    contributions towards vocational studies, annual recreational
    allowances, a company car and a company phone. Mr.&#160;Maimon
    is entitled to 24 working days of vacation. All stock options
    that have not vested as of the date of termination shall be
    deemed to have expired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We do not provide any change in control benefits to our
    executive officers except that their stock option agreements
    provide for the acceleration of the vesting periods of options
    in the event of a termination without cause following a change
    in control of our company. In February 2008, our Board of
    Directors, acting upon the resolution of a majority of our
    independent directors, agreed to amend the outstanding option
    agreements of the Named Executive Officers. The amendments
    provide that all of the outstanding options of each Named
    Executive Officer shall be subject to accelerated vesting
    immediately upon a change in control of our company.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">2006
    Stock Incentive Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors and a majority of our shareholders
    approved our 2006 Stock Incentive Plan on December&#160;14, 2006
    and cancelled our 1998 stock option plan (no options were
    outstanding under the 1998 plan at that time). We have reserved
    9,741,655&#160;shares of our common stock for issuance, in the
    aggregate, under the 2006 Stock Incentive Plan, subject to
    adjustment for a stock split or any future stock dividend or
    other similar change in our common stock or our capital
    structure. Immediately prior to the closing of the merger,
    Protalix Ltd. had outstanding options to purchase 88,001
    ordinary shares under its employee stock option plan. Pursuant
    to the terms of the merger agreement, we assumed all of the
    outstanding obligations under such plan and, accordingly,
    approximately 5,375,174&#160;shares of our common stock under
    our 2006 Stock Incentive Plan. As of March&#160;15, 2007,
    options to acquire 4,366,481&#160;shares of common stock remain
    available to be granted under our 2006 Stock Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our 2006 Stock Incentive Plan provides for the grant of stock
    options, restricted stock, restricted stock units, stock
    appreciation rights and dividend equivalent rights, collectively
    referred to as &#147;awards.&#148; Stock options granted under
    the 2006 Stock Incentive Plan may be either incentive stock
    options under the provisions of Section&#160;422 of the Internal
    Revenue Code, or non-qualified stock options. Incentive stock
    options may be granted only to employees. Awards other than
    incentive stock options may be granted to employees, directors
    and consultants. The 2006 Stock Incentive Plan is also in
    compliance with the provisions of the Israeli Income Tax
    Ordinance New Version, 1961 (including as amended pursuant to
    Amendment 132 thereto) and is intended to enable us to grant
    awards to grantees who are Israeli residents as follows:
    (i)&#160;awards to employees pursuant to Section&#160;102 of the
    Tax Ordinance (definition refers only to employees, office
    holders and directors of our company or a related entity
    excluding those who are considered &#147;Controlling
    Shareholders&#148; pursuant to the Tax Ordinance); and
    (ii)&#160;awards to non-employees pursuant to Section&#160;3(I)
    of the Tax Ordinance. In accordance with the terms and
    conditions imposed by the Tax Ordinance, grantees who receive
    awards under the 2006 Stock Incentive Plan may be afforded
    certain tax benefits in Israel as described below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors or the Compensation Committee, referred
    to as the &#147;plan administrator,&#148; will administer our
    2006 Stock Incentive Plan, including selecting the grantees,
    determining the number of shares to be subject to each award,
    determining the exercise or purchase price of each award, and
    determining the vesting and exercise periods of each award.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The exercise price of stock options granted under the 2006 Stock
    Incentive Plan must be equal to at least 100% of the fair market
    value of our common stock on the date of grant; however, in
    certain circumstances, grants may be made at a lower price to
    Israeli grantees who are residents of the State of Israel. If,
    however, incentive stock options are granted to an employee who
    owns stock possessing more than 10% of the voting power of all
    classes of our stock or the stock of any parent or subsidiary of
    our company, the exercise price of any incentive stock option
    granted must equal at least 110% of the fair market value on the
    grant date and the maximum term of these incentive stock options
    must not exceed five years. The maximum term of all other awards
    must not exceed 10&#160;years. The plan
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    administrator will determine the exercise or purchase price (if
    any) of all other awards granted under the 2006 Stock Incentive
    Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the 2006 Stock Incentive Plan, incentive stock options and
    options to Israeli grantees may not be sold, pledged, assigned,
    hypothecated, transferred or disposed of in any manner other
    than by will or by the laws of descent or distribution and may
    be exercised during the lifetime of the participant only by the
    participant. Other awards shall be transferable by will or by
    the laws of descent or distribution and to the extent and in the
    manner authorized by the plan administrator by gift or pursuant
    to a domestic relations order to members of the
    participant&#146;s immediate family. The 2006 Stock Incentive
    Plan permits the designation of beneficiaries by holders of
    awards, including incentive stock options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event the service of a participant in the 2006 Stock
    Incentive Plan is terminated for any reason other than cause,
    disability or death, the participant may exercise awards that
    were vested as of the termination date for a period ending upon
    the earlier of 12&#160;months or the expiration date of the
    awards unless otherwise determined by the plan administrator.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a corporate transaction or a change of control,
    all awards will terminate unless assumed by the successor
    corporation. Unless otherwise provided in a participant&#146;s
    award agreement, in the event of a corporate transaction for the
    portion of each award that is assumed or replaced, then such
    award will automatically become fully vested and exercisable
    immediately upon termination of a participant&#146;s service if
    the participant is terminated by the successor company or us
    without cause within 12&#160;months after the corporate
    transaction. For the portion of each award that is not assumed
    or replaced, such portion of the award will automatically become
    fully vested and exercisable immediately prior to the effective
    date of the corporate transaction so long as the
    participant&#146;s service has not been terminated prior to such
    date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In the event of a change in control, except as otherwise
    provided in a participant&#146;s award agreement, following a
    change in control (other than a change in control that also is a
    corporate transaction) and upon the termination of a
    participant&#146;s service without cause within 12&#160;months
    after a change in control, each award of such participant that
    is outstanding at such time will automatically become fully
    vested and exercisable immediately upon the participant&#146;s
    termination.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under our 2006 Stock Incentive Plan, a corporate transaction is
    generally defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    a merger or consolidation in which we are not the surviving
    entity, except for the principal purpose of changing our
    company&#146;s state of incorporation;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    the sale, transfer or other disposition of all or substantially
    all of our assets;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    the complete liquidation or dissolution of our company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    any reverse merger in which we are the surviving entity but our
    shares of common stock outstanding immediately prior to such
    merger are converted or exchanged by virtue of the merger into
    other property, whether in the form of securities, cash or
    otherwise, or in which securities possessing more than forty
    percent (40%) of the total combined voting power of our
    outstanding securities are transferred to a person or persons
    different from those who held such securities immediately prior
    to such merger;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    acquisition in a single or series of related transactions by any
    person or related group of persons of beneficial ownership of
    securities possessing more than fifty percent (50%) of the total
    combined voting power of our outstanding securities but
    excluding any such transaction or series of related transactions
    that the plan administrator determines not to be a corporate
    transaction (provided however that the plan administrator shall
    have no discretion in connection with a corporate transaction
    for the purchase of all or substantially all of our shares
    unless the principal purpose of such transaction is changing our
    company&#146;s state of incorporation).
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under our 2006 Stock Incentive Plan, a change of control is
    defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="4%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    the direct or indirect acquisition by any person or related
    group of persons of beneficial ownership of securities
    possessing more than fifty percent (50%) of the total combined
    voting power of our outstanding securities pursuant to a tender
    or exchange offer made directly to our shareholders and which a
    majority of the members of our board (who have generally been on
    our board for at least 12&#160;months) who are not affiliates or
    associates of the offeror do not recommend shareholders accept
    the offer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;&#160;&#160;
</TD>
    <TD align="left">
    a change in the composition of our board over a period of
    12&#160;months or less, such that a majority of our board
    members ceases, by reason of one or more contested elections for
    board membership, to be comprised of individuals who were
    previously directors of our company.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless terminated sooner, the 2006 Stock Incentive Plan will
    automatically terminate in 2016. Our Board of Directors has the
    authority to amend, suspend or terminate our 2006 Stock
    Incentive Plan. No amendment, suspension or termination of the
    2006 Stock Incentive Plan shall adversely affect any rights
    under awards already granted to a participant. To the extent
    necessary to comply with applicable provisions of federal
    securities laws, state corporate and securities laws, the
    Internal Revenue Code, the rules of any applicable stock
    exchange or national market system, and the rules of any
    <FONT style="white-space: nowrap">non-U.S.&#160;jurisdiction</FONT>
    applicable to awards granted to residents therein (including the
    Tax Ordinance), we shall obtain shareholder approval of any such
    amendment to the 2006 Stock Incentive Plan in such a manner and
    to such a degree as required.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Impact
    of Israeli Tax Law</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The awards granted to employees pursuant to Section&#160;102 of
    the Tax Ordinance under the 2006 Stock Incentive Plan may be
    designated by us as approved options under the capital gains
    alternative, or as approved options under the ordinary income
    tax alternative.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    To qualify for these benefits, certain requirements must be met,
    including registration of the options in the name of a trustee.
    Each option, and any shares of common stock acquired upon the
    exercise of the option, must be held by the trustee for a period
    commencing on the date of grant and deposit into trust with the
    trustee and ending 24&#160;months thereafter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the terms of the capital gains alternative, we may not
    deduct expenses pertaining to the options for tax purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Under the 2006 Stock Incentive Plan, we may also grant to
    employees options pursuant to Section&#160;102(c) of the Tax
    Ordinance that are not required to be held in trust by a
    trustee. This alternative, while facilitating immediate exercise
    of vested options and sale of the underlying shares, will
    subject the optionee to the marginal income tax rate of up to
    50% as well as payments to the National Insurance Institute and
    health tax on the date of the sale of the shares or options.
    Under the 2006 Stock Incentive Plan, we may also grant to
    non-employees options pursuant to Section&#160;3(I) of the Tax
    Ordinance. Under that section, the income tax on the benefit
    arising to the optionee upon the exercise of options and the
    issuance of common stock is generally due at the time of
    exercise of the options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    These options shall be further subject to the terms of the tax
    ruling that has been obtained by Protalix Ltd. from the Israeli
    tax authorities in connection with the merger. Under the tax
    ruling, the options issued by us in connection with the
    assumption of Section&#160;102 options previously issued by
    Protalix Ltd. under the capital gains alternative shall be
    issued to a trustee, shall be designated under the capital gains
    alternative and the issuance date of the original options shall
    be deemed the issuance date for the assumed options for the
    calculation of the respective holding period.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS" -->
<DIV align="left"><A NAME="007"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On March&#160;17, 2005, Protalix Ltd. entered into a Management
    Services Agreement with Pontifax Management Company, Ltd. in
    connection with the purchase of Protalix&#146;s Series&#160;B
    Preferred Shares by the Pontifax Funds. Pursuant to the
    Management Services Agreement, Mr.&#160;Hurvitz serves as a
    member of the Board of Directors. Further, Protalix agreed not
    to designate a permanent chairman of the Board of Directors
    until Pontifax Management Company chose to nominate
    Mr.&#160;Hurvitz as the Chairman of the Board in 2006. In
    consideration for Mr.&#160;Hurvitz&#146;s services, Protalix is
    required to pay Pontifax Management Company a fee equal to
    $3,000 per month plus required taxes on such payment. In
    addition, in connection with the execution of the Management
    Services Agreement, Protalix issued to Pontifax options to
    purchase a number of its Series&#160;B Preferred Shares equal to
    3.5% of the then outstanding share capital with an exercise
    price equal to the par value of the shares. Lastly, upon the
    appointment of Mr.&#160;Hurvitz as Chairman of the Board of
    Directors, Protalix issued to Pontifax additional warrants for
    Series&#160;B Preferred Shares equal to 3.76% of the then
    outstanding share capital of Protalix. In connection with the
    merger, we assumed the Management Services Agreement and all
    options granted under the Management Services Agreement have
    been converted into options to purchase 3,384,502&#160;shares of
    our common stock. Under the terms of the assumed Management
    Services Agreement, we are obligated only to use our best
    efforts to nominate Mr.&#160;Hurvitz for election to our Board
    of Directors, which remains subject to the review and approval
    of the Nominating Committee of the Board of Directors and the
    entire Board of Directors, as applicable. For 2008, the fee
    payable under this agreement will be $33,000, which is the same
    fee payable to the other non-executive directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On September&#160;14, 2006, Protalix Ltd. entered into a
    collaboration and licensing agreement with Teva for the
    development and manufacture of two proteins using ProCellEx.
    Mr.&#160;Hurvitz, the Chairman of our Board of Directors, is the
    Chairman of Teva&#146;s Board of Directors, and Phillip Frost
    M.D., a former director and a major shareholder of our company,
    is the Vice Chairman of Teva&#146;s Board of Directors. Pursuant
    to the agreement, we will collaborate on the research and
    development of two proteins using ProCellEx. Protalix Ltd. has
    granted to Teva an exclusive license to commercialize the
    products developed under the collaboration in return for royalty
    and milestone payments payable upon the achievement of certain
    pre-defined goals. Protalix Ltd. will retain certain exclusive
    manufacturing rights with respect to the active pharmaceutical
    ingredient of the proteins following the first commercial sale
    of a licensed product under the agreement and other rights
    thereafter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All related party transactions are reviewed and approved by the
    Audit Committee, as required by the audit committee charter.
</DIV>


<!-- link1 "AUDIT COMMITTEE REPORT" -->
<DIV align="left"><A NAME="008"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">AUDIT
    COMMITTEE REPORT</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>The information contained in this report shall not be deemed
    to be &#147;soliciting material&#148; or to be &#147;filed&#148;
    with the Securities and Exchange Commission, nor shall such
    information be incorporated by reference into any future filings
    with the Securities and Exchange Commission, or subject to the
    liabilities of Section&#160;18 of the Securities Exchange Act of
    1934, as amended, except to the extent that the Company
    specifically incorporates it by reference into a document filed
    under the Securities Act of 1933, as amended, or Securities
    Exchange Act of 1934, as amended.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee of our Board of Directors operates under a
    written charter adopted by our Board of Directors, and currently
    consists of Amos Bar-Shalev, Yodfat Harel Gross and Sharon
    Toussia-Cohen. Mr.&#160;Sheratzky served as a member of the
    Audit Committee for part of 2008. All members of the committee
    fall under the safe harbor provision of the independence
    requirements contemplated by
    <FONT style="white-space: nowrap">Rule&#160;10A-3</FONT>
    under the Exchange Act.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    As described more fully in its charter, the audit committee
    provides oversight of the quality and integrity of our
    consolidated financial statements, internal controls and
    financial reporting process, and our process to manage business
    and financial risks and compliance with legal, ethical and
    regulatory
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    requirements. In addition, the audit committee interacts
    directly with and evaluates the qualifications, independence and
    performance of the independent auditors, Kesselman&#160;&#038;
    Kesselman, and is responsible for the appointment, compensation,
    retention and oversight of the work of the auditors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Management is responsible for the preparation, presentation and
    integrity of the consolidated financial statements, and
    evaluation of and assessment of the effectiveness of our
    internal control over financial reporting. The independent
    auditors are responsible for performing an independent audit of
    the consolidated financial statements in accordance with the
    standards of the Public Company Accounting Oversight Board. The
    Audit Committee&#146;s responsibility is to monitor and oversee
    these processes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee has reviewed and discussed the audited
    consolidated financial statements with our Board of Directors
    and management. Management has represented to the audit
    committee that our consolidated financial statements were
    prepared in accordance with U.S.&#160;generally accepted
    accounting principles. The Audit Committee discussed with
    Kesselman&#160;&#038; Kesselman the matters required to be
    discussed by Statement of Auditing Standards No.&#160;61,
    <I>Communications with Audit Committees</I>. In addition, the
    independent auditors provided the Audit Committee with the
    written disclosures and letter required by Independence
    Standards Board Standard No.&#160;1, <I>Independence Discussions
    with Audit Committees</I>, and the audit committee has discussed
    with Kesselman&#160;&#038; Kesselman that firm&#146;s
    independence from our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Based on the review and discussions of the audited consolidated
    financial statements and discussions with management and
    Kesselman&#160;&#038; Kesselman, the Audit Committee recommended
    to Board of Directors that the audited consolidated financial
    statements be included in our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2007, as amended,
    for filing with the Securities and Exchange Commission.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Respectfully submitted,
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Members of the Protalix BioTherapeutics, Inc.
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Audit Committee
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Amos Bar-Shalev</I>
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Yodfat Harel Gross</I>
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Sharon Toussia-Cohen</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Our Board of Directors recommends that shareholders vote
    &#147;FOR&#148; the election or re-election of all director
    nominees named in this &#147;Proposal&#160;1: Election of
    Directors.&#148;</B>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "PROPOSAL 2: RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM" -->
<DIV align="left"><A NAME="009"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">PROPOSAL&#160;2:
    RATIFICATION OF APPOINTMENT OF<BR>
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors, upon the recommendation of its Audit
    Committee, has ratified the selection of Kesselman&#160;&#038;
    Kesselman to serve as our independent registered public
    accounting firm for the fiscal year ending December&#160;31,
    2008. The Audit Committee of our Board of Directors is solely
    responsible for selecting our independent public accountants.
    Although shareholder approval is not required to appoint
    Kesselman&#160;&#038; Kesselman as our independent public
    accountants, we believe that submitting the appointment of
    Kesselman&#160;&#038; Kesselman to our shareholders for
    ratification is a matter of good corporate governance. If our
    shareholders do not ratify the appointment, then the appointment
    will be reconsidered by the Audit Committee. Even if the
    appointment is ratified, the Audit Committee may engage a
    different independent registered public accounting firm at any
    time during the year if it determines that such a change would
    be in the best interest of our company and our shareholder. The
    proxy will be voted as specified, and if no specification is
    made, the proxy will be cast &#147;FOR&#148; this proposal.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    During our fiscal year ended December&#160;31, 2007, there were
    no disagreements with Kesselman&#160;&#038; Kesselman on any
    matter of accounting principles or practices, financial
    statement disclosure, or auditing scope or procedures, which if
    not resolve to their satisfaction would have caused them to make
    reference to the subject matter of the disagreements in
    connection with their opinion.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The audit report of Kesselman&#160;&#038; Kesselman on our
    consolidated financial statements for the years ended
    December&#160;31, 2007, 2006 and 2005 did not contain any
    adverse opinion or disclaimer of opinion, nor was it qualified
    or modified as to uncertainty, audit scope or accounting
    principles.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Audit Committee will consider whether the provision of any
    other services by Kesselman&#160;&#038; Kesselman is compatible
    with maintaining the independence of Kesselman&#160;&#038;
    Kesselman. The Audit Committee has concluded that
    Kesselman&#160;&#038; Kesselman is independent.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Representatives of Kesselman&#160;&#038; Kesselman will be
    present at the annual meeting and available to answer
    shareholders questions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Our Board of Directors recommends that shareholders vote
    &#147;FOR&#148; the ratification of the appointment of
    Kesselman&#160;&#038; Kesselman for fiscal year ending
    December&#160;31, 2008.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The following table sets forth fees billed to us by our
    independent registered public accounting firm during the fiscal
    years ended December&#160;31, 2007 and 2006 for:
    (i)&#160;services rendered for the audit of our annual financial
    statements and the review of our quarterly financial statements;
    (ii)&#160;services by our independent registered public
    accounting firm that are reasonably related to the performance
    of the audit or review of our financial statements and that are
    not reported as Audit Fees; (iii)&#160;services rendered in
    connection with tax compliance, tax advice and tax planning; and
    (iv)&#160;all other fees for services rendered.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="72%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Audit Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    393,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    456,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Audit Related Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    77,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    76,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    22,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All Other Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    70,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Policy on Audit Committee Pre-Approval of Audit and
    Permissible Non-Audit Services of Independent&#160;Auditors</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Prior to entering into the engagement letter with our
    independent registered accountants, our Audit Committee approved
    the 2007 audit fees. For fiscal year 2008, our Audit Committee
    has approved fees for certain services to be rendered by the
    independent registered accountants.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->


<!-- link1 "SHAREHOLDER PROPOSALS" -->
<DIV align="left"><A NAME="010"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">SHAREHOLDER
    PROPOSALS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    All shareholder proposals intended to be presented at our 2009
    Annual Meeting of Shareholders must be submitted in writing to
    Yossi Maimon, Corporate Secretary, Protalix BioTherapeutics,
    Inc., 2 Snunit Street, Science Park, P.O.&#160;Box&#160;455,
    Carmiel, Israel 20100 and received by us no later than
    June&#160;4, 2009, and must comply in all other respects with
    applicable rules and regulations of the Securities and Exchange
    Commission relating to such inclusion. Such notice must include,
    with respect to each matter the shareholder proposes to bring
    before the annual meeting: (i)&#160;a brief description of the
    business desired to be brought before the annual meeting and the
    reasons for conducting such business at the annual meeting,
    (ii)&#160;the name and record address of the shareholder
    proposing such business, (iii)&#160;the class and number of
    shares of our company which are beneficially owned by the
    shareholder and (iv)&#160;any material interest of the
    shareholder in such business. In addition, the notice must
    include certain information relating to any derivative or
    hedging transactions by the shareholder delivering such notice
    and its Shareholder Associated Persons, as defined in our
    By-Laws, and other arrangements with other parties regarding our
    securities, as presented in detail in our By-Laws.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Any such proposal submitted with respect to our 2009 Annual
    Meeting of Shareholders which is submitted outside the
    requirements of
    <FONT style="white-space: nowrap">Rule&#160;14a-8</FONT>
    under the Exchange Act will be considered timely if we receive
    written notice of that proposal not less than 45&#160;days nor
    more than 75&#160;days prior to the date on which we first
    mailed this proxy statement; however, if the date of the annual
    meeting is changed by more than 30&#160;days from the date of
    the prior year&#146;s annual meeting, the notice will be
    considered untimely if it is not received at least 90&#160;days
    prior to the newly announced date that the Company will mail its
    proxy statement.
</DIV>


<!-- link1 "ANNUAL REPORT TO SHAREHOLDERS" -->
<DIV align="left"><A NAME="011"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">ANNUAL
    REPORT TO SHAREHOLDERS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2007, as amended,
    filed with the Securities and Exchange Commission, which
    provides additional information about us, will be distributed to
    all shareholders entitled to vote along with the proxy
    materials. <B>Additional copies of our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2007, as amended,
    are available on the Internet at
    <U><FONT style="white-space: nowrap">http://www.sec.gov</FONT></U>
    and
    <U><FONT style="white-space: nowrap">http://www.protalix.com</FONT></U>
    and are also available in paper form without charge upon written
    request to Investor Relations, Protalix BioTherapeutics, Inc., 2
    Snunit Street, Science Park, P.O.&#160;Box&#160;455, Carmiel,
    Israel 20100</B>. The Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;31, 2007, as amended,
    and information on the website other than the proxy statement,
    are not part of our proxy soliciting materials.
</DIV>


<!-- link1 "HOUSEHOLDING OF PROXY MATERIALS" -->
<DIV align="left"><A NAME="012"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">HOUSEHOLDING
    OF PROXY MATERIALS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The Securities and Exchange Commission has adopted rules that
    permit companies and intermediaries (e.g., brokers) to satisfy
    the delivery requirements for proxy statements and annual
    reports with respect to two or more shareholders sharing the
    same address by delivering a single proxy statement addressed to
    those shareholders. This process, which is commonly referred to
    as &#147;householding,&#148; potentially means extra convenience
    for shareholders and cost savings for companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This year, a number of brokers with account holders who are
    shareholders of our company will be &#147;householding&#148; our
    proxy materials. A single proxy statement may be delivered to
    multiple shareholders sharing an address unless contrary
    instructions have been received from the affected shareholders.
    Once a shareholder has received notice from its broker that it
    will be &#147;householding&#148; communications to such
    shareholder&#146;s address, &#147;householding&#148; will
    continue until such shareholder is notified otherwise or until
    such shareholder notifies its broker or us that it no longer
    wishes to participate in &#147;householding.&#148; If, at any
    time, a shareholder no longer wishes to participate in
    &#147;householding&#148; and would prefer to receive a separate
    proxy statement and annual report in the future such shareholder
    may (1)&#160;notify its broker or (2)&#160;direct its written
    request to: Yossi Maimon, Corporate Secretary, Protalix
    BioTherapeutics, Inc., 2 Snunit Street, Science Park,
    P.O.&#160;Box&#160;455, Carmiel, Israel 20100, +972
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <FONT style="white-space: nowrap">(4)&#160;988-9488,</FONT>
    ext. 143. Shareholders who currently receive multiple copies of
    the proxy statement at their address and would like to request
    &#147;householding&#148; of their communications should contact
    their broker. In addition, we will promptly deliver, upon
    written or oral request to the address or telephone number
    above, a separate copy of the annual report and proxy statement
    to such shareholders at a shared address to which a single copy
    of the documents was delivered.
</DIV>


<!-- link1 "OTHER MATTERS" -->
<DIV align="left"><A NAME="013"></A></DIV>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">OTHER
    MATTERS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our Board of Directors knows of no other business to be acted
    upon at the annual meeting. However, if any other business
    properly comes before the Annual Meeting of Shareholders, it is
    the intension of the persons named in the enclosed proxy to vote
    on such matters in accordance with their best judgment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The prompt return of your proxy is appreciated and will be
    helpful in obtaining the necessary vote. Therefore, whether or
    not you expect to attend the annual meeting please sign the
    proxy and return it in the enclosed envelope or vote by internet
    or telephone.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    BY ORDER OF THE BOARD OF DIRECTORS,
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Yossi Maimon
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Vice President and Chief Financial Officer and<BR>
    Corporate Secretary</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Carmiel, Israel
</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    October&#160;2, 2008
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt"><IMG src="y00215y0021501.gif" alt="(PROXY CARD)"></DIV>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">0
PROTALIX BIOTHERAPEUTICS, INC.
2 Snunit Street Science Park POB 455 Carmiel, Israel 20100
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned hereby appoints David Aviezer and Yossi Maimon as proxies, each with full power of
substitution, to represent and vote as designated on the reverse side, all the shares of Common
Stock of Protalix BioTherapeutics, Inc. held of record by the undersigned on October&nbsp;2, 2008, at
the Annual Meeting of Shareholders to be held at the offices of Baratz, Horn
&#038; Co., 1 Azrieli Center, Round Tower, 18th Floor, Tel Aviv, Israel 67021 on November&nbsp;9, 2008, or
any adjournment or postponement thereof.
(Continued and to be signed on the reverse side)
14475</TD>
</TR>
</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center" style="font-size: 10pt"><IMG src="y00215y0021502.gif" alt="(PROXY CARD)"></DIV>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">ANNUAL MEETING OF SHAREHOLDERS OF
PROTALIX BIOTHERAPEUTICS, INC.
November&nbsp;9, 2008
Please sign,date and mail your proxy card in the envelope provided as soon as possible.
Please detach along perforated line and mail in the envelope provided.
21030000000000000000 0 110908
THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE ELECTION OF THE NOMINEES
FOR DIRECTOR LISTED IN PROPOSAL 1 AND &#147;FOR&#148; PROPOSAL 2.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x
FOR AGAINST ABSTAIN
1. Election of Directors: 2. To ratify the appointment of Kesselman &#038; Kesselman, Certified Public
Accountant (Isr.), a member of PricewaterhouseCoopers
NOMINEES:
International Limited, as our independent registered public
FOR ALL NOMINEES
Eli Hurvitz
accounting firm for the fiscal year ending December&nbsp;31, 2008. O David Aviezer, Ph.D.
WITHHOLD AUTHORITY Yoseph Shaaltiel, Ph.D. 3. In their discretion, the proxies are authorized to
vote upon such other business FOR ALL NOMINEES Alfred Akirov as may properly come before the
meeting.
Amos Bar-Shalev
FOR ALL EXCEPT
Zeev Bronfeld
(See instructions below)
Yodfat Harel Gross Roger D. Kornberg, Ph.D. Eyal Sheratzky Sharon Toussia-Cohen
INSTRUCTIONS: To withhold authority to vote for any individual nominee(s), mark &#147;FOR ALL EXCEPT&#148;
and fill in the circle next to each nominee you wish to withhold, as shown here:
To change the address on your account, please check the box at right and indicate your new address
in the address space above. Please note that changes to the registered name(s) on the account may
not be submitted via this method.
Signature of Shareholder Date: Signature of Shareholder Date:
Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly,
each holder should sign. When signing as executor, administrator, attorney, trustee or guardian,
please give full title as such. If the signer is a corporation, please sign full corporate name by
duly authorized officer, giving full title as such. If signer is a partnership, please sign in
partnership name by authorized person.</TD>
</TR>
</TABLE>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center" style="font-size: 10pt"><IMG src="y00215y0021503.gif" alt="(PROXY CARD)"></DIV>


<TABLE width="90%">
<TR><TD style="font-size: 1pt; color: #FFFFFF">ANNUAL MEETING OF SHAREHOLDERS OF
PROTALIX BIOTHERAPEUTICS, INC.
November&nbsp;9, 2008
PROXY VOTING INSTRUCTIONS
MAIL &#151; Sign, date and mail your proxy card in the envelope provided as soon as possible.
- - OR -
TELEPHONE &#151; Call toll-free 1-800-PROXIES
(1-800-776-9437) in the United States or 1-718-
921-8500 from foreign countries and follow the COMPANY NUMBER instructions. Have your proxy card
available when you call.
- - OR &#151; ACCOUNT NUMBER
INTERNET &#151; Access &#147;www.voteproxy.com&#148; and follow the on-screen instructions. Have your proxy card
available when you access the web page.
- - OR -
IN PERSON &#151; You may vote your shares in person by attending the Annual Meeting.
You may enter your voting instructions at 1-800-PROXIES in the United States or 1-718-921-8500 from
foreign countries or www.voteproxy.com up until 11:59 PM Eastern Time the day before the cut-off or meeting date.
Please detach along perforated line and mail in the envelope provided IF you are not voting via telephone or the Internet.
21030000000000000000 0 110908
THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE ELECTION OF THE NOMINEES
FOR DIRECTOR LISTED IN PROPOSAL 1 AND &#147;FOR&#148; PROPOSAL 2.
PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x
FOR AGAINST ABSTAIN
1. Election of Directors: 2. To ratify the appointment of Kesselman &#038; Kesselman, Certified Public
Accountant (Isr.), a member of PricewaterhouseCoopers
NOMINEES:
International Limited, as our independent registered public
FOR ALL NOMINEES&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eli Hurvitz
accounting firm for the fiscal year ending December&nbsp;31, 2008. David Aviezer, Ph.D.
WITHHOLD AUTHORITY Yoseph Shaaltiel, Ph.D. 3. In their discretion, the proxies are authorized to
vote upon such other business FOR ALL NOMINEES Alfred Akirov as may properly come before the meeting.
Amos Bar-Shalev
FOR ALL EXCEPT
Zeev Bronfeld
(See instructions below)
Yodfat Harel Gross Roger D. Kornberg, Ph.D. Eyal Sheratzky Sharon Toussia-Cohen
INSTRUCTIONS: To withhold authority to vote for any individual nominee(s), mark &#147;FOR ALL EXCEPT&#148;
and fill in the circle next to each nominee you wish to withhold, as shown here:
JOHN SMITH 1234 MAIN STREET APT. 203 NEW YORK, NY 10038
To change the address on your account, please check the box at right and indicate your new address
in the address space above. Please note that changes to the registered name(s) on the account may
not be submitted via this method.
Signature of Shareholder Date: Signature of Shareholder Date:
Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly,
each holder should sign. When signing as executor, administrator, attorney, trustee or guardian,
please give full title as such. If the signer is a corporation, please sign full corporate name by
duly authorized officer, giving full title as such. If signer is a partnership, please sign in
partnership name by authorized person.</TD>
</TR>
</TABLE>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>y00215y0021500.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y00215y0021500.gif
M1TE&.#EA@``K`-4@`%%KG$!`0("`@/#P\"9%@Q`0$&Z$K>#@X-#0T$->E#`P
M,-3;Y_'S][?"UN/G[["PL#12C'!P<*FUSGV0M6!WI*"@H"`@(&!@8)"0D)JI
MQE!04,;.WHN<O<#`P!<Y>P```/___P``````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````"'Y!`$``"``+`````"``"L```;_
M0(]P2"P*$QN0<LEL.I_0J'0ZW0R95@^'"C5ZC0VN>$PN@[(>K'!K!@T-G+A\
MSJ$,"8RV?C]&,Q<``!)Z0TE3$D.#?&4`:XM0?H]+A5P00A228XU:F4V1F914
M!D(`G5R;;*9G5YVA4QQ'JE.HLJM"IJY2L+=*@:4;%)9'''E,#0:;1`D4BDJ`
M``1"$+[430X3R40`$PM.GR#/S1R!%,5-%.1N0H:OL4IO7PE+#`E?RL5H]FE+
MB/I"$YY8*<F2BD$T#YB:[/*0)%<4.QY*O2-"0<XH(1F47/20@`Z'>J24.(@C
M#(#'@@<1TC&0,LR2;P35"''I;`A`=0RY'#0P20@!_W9*=I5R,"3CDWX>NBVA
M%:7!$*5-Z%V2N6^@(R:["#A8`E+>Q)Q3-C8;DNJE-!#]"$@15I8IE%U>C_JD
M*K.L$I`2LV[]"N=D'`/"/$!@XM!6&J%2+O)<>A52G&;>!!JNZ\3!P0QH:.+T
M1X0`5)Q[HTP(&04Q8TY\8$J.Z<2I-"&+>W)^$_HKE4TWWY+NU3C*@G'4`G'8
MH)J75=1.1@])8.XK9N+0HQ/O8CR*VR>F>2.'HMP>R*J3S6YO$OCS5Z!D)$.Y
M[B0["/9-D!(P*0=;$;KB[2Y90$1_83'J/0$?5KN]UYL3736WA`.!X7><?B`P
M$-A,3?S'18!.7"21;A$Q<?_=!H]]I5D3&:QFXGA*0)3`15H1M@XAU7&XX1/*
MS7B=:1:&=QQXK!$HQ`(2NG,>C.!!4:)@4EQWXU0XC6C,B3P>B(91_/TC&WIC
M8-A$E6`YP:5FURG'QD[604G9/`?-N)!+.4ZA91.;$#`!<7D0E\%!@S&A'`$-
M.+"`!`>YM)$!=)ZQ0083.FA+6S[5!@)(+;8IQ9M_I*0/>EP:$9=!_J2D:(]K
M5G:0/))&02D3#K#T!0$&F*=$`Q/"UAP#JAK!JFM15L<:KK'%9U,M7#`@W0:.
M/N%`=%(<&YVKP#;K[+/01BOMM-16:^VUV&:K[;;8?N#MMP$,L,0''>A!+K>+
MG-O_AKH'5*`N"!V(.T4%$3CQ+KI3(!```DW$:VZYXV*PA+]*#/"```(`#,(!
M%RC000<'C%M!!0(\(*\2[0I00<1+('#`P?QVC('&'"L!,<4/-&$PP@J#X/'`
M\F+P`08=A`SOQ2O3S,3*%<O+KLPVOVN!!1%<4$``2E1@P=$!5#!N`1H8C;3)
M'P0@@`;O!O"!`A>H*[,&$2CP0=!0&ZW`$@,48,$%1M>KA-7C`BRV`@&X#<*[
M"A`=0`%V!V!!`'X7H,2WWRIPL;H=?,#Q`Q\L(<#43'S@-`B,+W$!Y`H(L$0`
M&KRM.0CT+E'`YW=/SGC(B<LK@.">QTUURW<#G#C'CX_[__D!G[][`-^NP]LX
MU8Y#WGOBFS.]-^EP-Z$OX'Z3_B[B50-NP>\@)!_[ZTU`#\7>@%^0\O6;0ZX]
M\$K4?D#0LE,?@,,/0[PYZ>$_S+CS``\`??L/OS\\N0,H/#X(_4-;!Q"&M8B]
M:P!$VQ_'W.6XL]5N<.FSW-E:1T$FU*U@'W">VQC'L=0I06:;VR"[R$4\"%(M
M9!A@W=V^E[AR$<Y;!4#?$A3`M`_8+7''VU_'"D`WL7VO>O`K7_0*,+JGT>T#
M%V`"#0''.R4PCHGO4IL%)@@^$"Q1:W83&Q,GB+_\,8%@2D#`PVP6QII]45X!
M%.##+N:RDC'A``\[7\E(:$;EC1VQ"7",%QC[US(PNBR.=O0BOO9PKT$:<EVP
&&V00```[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y00215y0021501.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y00215y0021501.gif
M1TE&.#EA[@+E`?<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````[@+E`0`(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWC;;KC`]P*'K!@B"!Y,F+"%
MO(@3*UY\L8.``0,(""B0U0&`RY@S9U[`N+/GSYXW`.#@P0,&`94UJ\;,&;3K
MU[#?BO[[X73JU:I;Q][-N[?7V0)M8[6,6[-NW\B3*V\*O#;JX<6-+Y].O3K0
MYL*O$H]^^;CU[^##_K/$_EP[=];BTZM?#Y+\[?/>V<N?3W\A!P$&\A<@\)Y[
M_/H`!C@?!A1,4*`&_47WGX`,-NA@4Q$4L)^$$A)`X80./*CAAAQVZ.&'((8H
MXH@DEFCBB2BFJ.**++;HXHLPQBCCC#36:..-..:HXXX\]NCCCT`&*>201!9I
MY)%()JGDDDPVZ>234$8IY9145FGEE5AFJ>667';IY9=@ABGFF&26:>:9:*:I
MYIILMNGFFW#&*>><=-9IYYUXYJGGGGSVZ>>?@`8JZ*"$%FKHH8@FJNBBC#;J
MZ*.01BKII)16:NFEF&:JZ::<=NKIIZ"&*NJHI)9JZJFHIJKJJJRVZNJK_K#&
M*NNLM-9JZZVXYJKKKKSVZNNOP`8K[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16
M:^VUV&:K[;;<=NOMM^"&*^ZXY)9K[KGHIJONNNRVZ^Z[\,8K[[STUFOOO?CF
MJ^^^_/;K[[\`!RSPP`07;/#!"">L<&P;:)"!PQIH0)M`'D3\,,2D'60:!118
M,/$'#5_\L,@(#F2QQ`5M</%!'5C\5P<7ERQ0R"@;Q`')#W\,,L0>%,1!!114
M@$'/%.-\<@9_<0!Q!P,I[3#3%4.,<\]*CQSQ!CH/1/,&!;5,\@9$"W2RU!$S
M#?/3`WF-\MA60RS0R%P3Y$$&0%L0=]<7<.QQ_D0G"^1T!F%7G'/7%G`\],(+
M';!:`17X'<!J`2@PL0</")!9Y'$K7MP`1&>P64$%7"9`V`-Y?AD#'W0PP&4!
M9#"SY0`(<#=!#.!F``8#:1X`TV\CH-D`$O1L>G$0?+#=!0-%@)D$'W`0'8(-
MX$8`!05Y`#L`!9`^P6H"-,`[`<51O_UES`MD`68-?!!Z<=EW@!D"`WDP`?B9
M)7`WY=<#$,`"I"ND^F64^8#R+I.AF6&F>'Y;P.,P(X`(("XAFEL-[CBPP-48
MH&<>2`!N!N`ZWVV.=]N)'>\$LK[1&61XJ/M`!3!S@)XM8'D(J1UN!$";"/(.
M`Q64#@:X4[SC)0\S_A,`60XU`[WH'&8@*\P,[@8ROM6DD'ZK$1\,S8<^]46'
M`!YPWV7@)Y`09H8`M'D`;A9D$.L!L&<#O`SR0';`F4%1,P]XX$%T)Y@(HHZ"
M`)2`!!Y00=RE40`,:``46XB``!CR<H;DW`<\\$8`!'$@)>S?!U`XD!=>9@([
MO,P!$B)#`#Q``A%8W66H]P$;+A**!G"``BI(@0P\[I"8,60`>HB9-0H0ALZ[
M#`$<P,M>,JV3GY1`!!5`$`UF)GU,9(T$HL<ZIHDR`+WLI>N:6+X/G.\RZ3.`
M+!$9`,IH$0!<O$#]'&``S*#.C`!(@`<XH+NLL4R4`83`%YDFFLL4SP,*_L#,
M`!K`@.NY3HX$T5W/-/"^YBV0B\;#C`48R;HE=J"<E\%`!R;:@?4%8`,4I:+^
M-(=0*\9.DI3TFR@'`-$`R,P@G?QG&DEI2@I@1IT"22(`-DE1F3*`HCWSH4#2
MR+Q<IA,AS`3`$GV*4*)>9@`CI*9`/`@`!-%O``A1JD8!D#Z*_B]V')AH:;[)
MQ7R2CV()"``!&+#.!=[.-`Z(@`3<64;89>^6F4$=0>W)1EW&S94".,`1`2H0
MW3%-I@DPJ"8GB@&+1JR@`Y%`&R'9S()X%0'CNRAC/WI"<Q)$IHN-(1`M4`&(
M$H!WINSD7C]`O]T-Y)I4+<AV#'``!!P`BCW5_N<"9CO;\@7U`AW8@#RQ^</8
M#:]Q`E$J!]8'`*Z5EK:S+:!4K5G%^(V4=%P]I>C"QH')051T"5CK0]`93]54
MH)X`*)Y++Q-'DXV0KWW%C(0RT],*PI*WXN3M0.(+@`*2L+%-6^!:,QO)RIZN
M(,:\S`45TDG-$$!FI@SP[!1\VN8.Q(NJB>T8!=+)]P)@`''S`$3Y1[_`!E>?
M!;C>@!N)&?Y\8+FH12;%GGK>Z';`K)(<"`9$F1D!/)(AW$5CB8^:R?#"U9'H
M54@$-8,`J@T1@!/H&7U5_($E$\2BYU7L9;@&T;=ZU(0%":E`.O#&`;"5PK%\
M;P'^F6#,+-C,#9;O_H.Y(V']/68`CTEA4"_'@+OUN'',#`!MFJ@9`:P1BG"&
M#'X^_-6I,MD#SR6(B\VZD`TX@,2V5`AW!;+;`%@`=MJD:QIO'&2#1!`!H%X`
M!8B&1^Q1@'X"(.7PB)E,ND[6M`.!J``>`('K+K&_6;;L0.;<G1B#68W5K<!!
MTWN97V)FB??5WPA3K-H#5N#9G6RS.CM0FM(()*@1Z&0"1AA4!T#`JP`H7Q,+
M`.H$/.!NJ*YVM04R7@`X<*KVE>Z%6UQ01!\U;!=80`5&F,6Y10"*9)2;6W6L
MOPU(.3/%:R("KPT!P'7:KP<I-?QZW+K4B5(`)?,`4T<+Y=)%!YFX)HB6_NE+
M@.L"]R`I7?%T2XD9IC61K&]3+T&831"=_EC:0#WV!Y@*\ZNNIH4GGJ)!GHH0
M^K+Z`V*\S+LIENBT(3;`:\S@43L@@0+`^8C#"^P&,,#U&$_Z`Y4&6X#I.M>9
M=@XS&>H`US'P98()-.+#_D`GN;@=`D`@`@&V<K)AG=`/>A2<H"XWS'1=487B
M\*AL[:0#]&A)`&"1Y<5N'HT5L$<:+YVY:NYB+7L;[N:5F`&@#[WK@HH[5[(.
M>>W&#8*66Y#2AC[TC7.,,AM0P9,R=-Z*1BQJ9RV!``>6O@<@31KC&-23QF_@
M<)7L!FCLXP\$&`$1@`"-#T/?RR<,XC:+>ZD!_D"]A^(F`)'V**SM[?@,F#\#
MC6\<<?NL=EUOAW\?".J""JP:!)KR`ZDG,NEHOF8U<K[-JX%G.A=_+"1U:G1^
MNU5?05=H0U<<!91&JI%"SG5ON;=%%$-_#.0Z'A!!`7`]7D:`EV%\%.-6E,8Z
M<9-Z"*0!S)<9K(9:UH<P;Y=]%EB"NL0T'`!NZH5LK\8[,L5DJ$5,ZU=C-V-9
M/49#?@-%)T<[,^0`1'-_*M1(`0!S,^=@FN=_.X5+T2&`$>4WU\-'FD00/H5%
MK$<0)(9V`P$!1]8`_7-[2%6!X!0_#C!$!&!+&S!D`K9$Q:<QR#=`DB40C;=P
M&7!=K$$TU?=`&&`!_A9P`5YW`8B(;!Z`B(DX,1M``1#P28=C$(>8B$2C`9#X
M,8^(B,C#B)`XBHK8`9"((!EPB@3!B8UX$*Q(BAI`.IFHB')S`7L$`10P.TVC
MBJL(B2.T`9VX2*,XC'OSBB.4BJ#(B_,%B>L$B;JXC,28B"?U,Q%`:[E8=*!8
M/9"H@\U#`=48`0MU0A)0B1)`BV)S::.!C1:P1,"8B"-DBH@X.Z8QCA`@`2<%
MCW;3:9"B/`:@C[[B4@+`C?Z(*QW@`,\XD`B9D`JYD`S9D`[YD!`9D1(YD119
MD19YD1B9D1HY*!RP1]IU$!C``*W5`"*($1G@`*24.D4GD@C@`/?H:Q)Q_EX;
M"207X('_1!!\IC\">1';0TP=T`!'AY-]ACL><&HR.1$;H`#E-9-!4DX-@`'Y
MY&$$L3H.@`$7H#B;Q!%JQS4]6494:96*`S\O!@!'*1&6L91,Z2,:]UFUX7C5
M\SC_E`$*`',00)(-4``*L$1U63)[^0'+=)(&@`!'A`$-,`$9X#L$X#UR<QEQ
M.9<>0!P,<`$:4)BUQCP:P`"!>6,=``$'8``/\!<64$Z>F99$HEA2.1"^$SD2
M`#8#`3X$D`#EI$BALT:SZ7R.UUH%%W0*@(YBI8N*HYJLZ0'K`SSG(TJKN3H)
M`#[WE$^!:781\#B#1II!<AH`,%IB(X@(4#+@_A-'LN<ZM6E%R*-!G"&<`-`X
M7=F5!J$!Q!4`",`U8\DTUR0!;!<]<70?NR-.V8-/W)=0:"F=/4*=_1D_%<``
MZ_-6X/-G0@6>]Q6>0&:;4D1,Z%E&`UJ@6?0X\'EAC$4!$:,X%B!/"Z`!&R!&
MJ'.6_ODCAQ<!DF2*45>3"0H^MY:@WUF;&D1*,ZJ;-NHSB4@Q%_`X0V.AS-6/
M`K&"W`=AQ$2?)=HC&B```<!I4_B!J6,YR..B]X4[Y71$J\.@-+J?+@6A`!"4
M,85[3RI4[\E<6?D!55I=U>4!RL,`:)I5_'FD/.([`I``="J!3(<]$%!KN">E
M5H0[&I0^XX6E`E&C_EWI4BU$.O96`'D:.DAE1AAU/F4J3PK0,@2``$IS81K0
M`;!Y&&*DF'"*(V578@9Q`<PG`,#%IZ&#.Q3P2@2@.(+JH#:J`:]TDP+!H@QT
M1+_I`)":-JGI:O)T2`?P5ROWJ3;"`8QXK.O(,A3P``]``1-SB#=D`3=4CRTC
MK9.T-Y/D%\UC`?^$`0\0`4?9`<O:K"/$`=$G4<DJH-]ZD_[V`$E8`0^09,0Z
MK_1:K_9ZK_B:K_JZK_Q:'^N4J?T:*1100O:C$!Q@(2@Q/Y$1&0D0C@X!`787
ML#T27Q;R.'IG,P50IB6A6-T48OH3?@IA&?$FL3@2/3!G>K8T-[&8$!$C_DD5
MHXMG@Z@9P)H&89I;ICBZH3(K*S>`([(DNR/1<P#_Q(A_X0$2`#MS"#("8&*!
MJ$O`U4__UFL"43D`M$04($H'\(S*(Y5B)):%I$O((ZL)X#L*X+//60`'^;,N
M8GJ.QP![=3[3\YPTM`$=F#K*.0%*RC4O%``2@+?5&72,(T]8A$.I)D8#1A`V
M^P'JF5J6L0`6$#WP8SKX(0$BNZH"0*MJ*R-763],4Z,G1@&Y%3OX]X9(YV,O
MA$P:Q#SEM$82,&JU8W\)2A!IM$"RDSJ`8ZZ.5S%;^)C@9$@@F[DRL@$38$P.
M!#Z82[>H8;C,FD_$]$+OYKQFI#.*HY0/4$[5_B00BB4`Y79N6_9HHNHY6+8=
M%0>\,O*8!7MM`,`9?*HUHBM&KXD`=)HAS@MF*&HYO@D`!C"V=)J2V/M3!I%/
M"-`Q;NDYC]=W&G2:Y/LBY713J:,XZ9-/Y:-*,UNW6RHV#C>_'_!"P:,X3_NA
MM5,^&+"SB>6_!6$Y"")._$'`1&,99`4^UIG`+#)>)&4Y%5><X]B!'"`:J,%E
MGC0!J],X&NR'G;<]!#`![FL:L7/#M8NX)/QDZ3L!C*J[!>RS+G6X,.PB\_-*
M!K!7\P-`R+,!!,"TF38`[]8``_!(9OQ(H:0_M\-N]%,`(.O#_T&JL?,`KQ4Q
M`P!T8#<`]Y0``\"__E?,(A[0,!DC-R`*DPT#D]4#HM6S`30+$153EH$\R91<
MR99\R9B<R9J\R0J)00AAK&Q7/12S2)Q,)DG'.HRC-4S5I7$C>[&4R@EQF!)H
MQZYU`*UQE:UU`%E;RD(B1@-`I_0S0>##G@?P.`3@GI9S`'0*49@;/^64E1J6
M&0%TRHS)RT$BHA3CE'+G>"4#Q@"`.MTY$!KT@E68E2\V`!B0`2$L$/E$`>E\
MB=;L(]@,9OQC.?P+D%ED.?_4`1QZ$#OZS,$!3HPX0@?Z7?%\S>F+-15@.1%0
M3Q]33YEJ.19B=:EE$%Q&`+NZ@#SF>;$$`8I\T#1"S0(V>'I6@1D@>Y$A_AG8
MT\PO=`$[E)5\A``2\$*?E0&/$7V/\[L@;2/N"WJ%V3,0O8I3%LZI4SL:JT*L
M7,6QN$XJ-S03I7E,MM,X,L]RHYP$(4^<0]3,%0`%@8'%I0$54$/5R0'INJ92
MO2-431!BM*2EL:J>%*;_Y`&U$T`#00$-<-?YM$\<H$'U:;_;,V#C?-8ZDM:\
M*CH'93:6(P"*O4"`3!`O347LN3K@##X9ZWB2+-@Q(DP+5ST04*`>33$(P%J=
M:<M)F)X&(($#>V%,*#:%%``)4)*8#236]A&S+3<?'=NXG=NZO=N\W=N^_=O`
MK1X><`$.P``/L).-,0&E71`7,`%INT@%<MD7_E$!$R#=J=/<YB@V'=,_'8!)
MB@8T\H@!WAW<8-$!.$A5MPT1!&5B")%/3%H0<`D2QJL0&H!*<8.&`O8Q+&PR
MI45*^BFUY-T5M2,`N*A`^[D1XKK<!/%"[TT0\?T1\YT0OI,`%("SBMN!$N`[
MR/23_S6HZ:L\1K@]!=#%C1W@5E%/R$:@[X8!JK0`P:.X$8`!,[V.$:`!%*``
M#>#(JO3B5'=C%#!;\IK!#8H0\=T!$;``2ADW,IX!$+``@&,!##"7*4EU<[E7
M$:XQ!&!:^`EVWZRXHGNPL=/E!F5:OD,]-:I87FKB5B'BMAT<AF0`EH,Z(GY)
MEF%UX`,9!?`X<;3>_HL4/9'1I>P\Y`<!EQJ'/8SZ%V*T/LT=.YGF0!OH>):#
M0%>N,;SC4O`SOQ[P.%@S2_*40CMD8M&3(:N#.Y^NYEK1M0AQXX=!P`L(`1/`
M`99A`!UP'_55E/CKY5#UZ:31SPRN$'!)4`/V;;BSUGVKIJ\]NH%EFNLT`"4]
MZ0FQ?/OI.^6CSTQMUD@]S=\L>Z@HNJ:.%:B.$.+J`*$S.BYE93[+4,BS0]G#
MYYUZA1GBWKX.`!/<MJ`[M4W,`1/``."S29[;SJ0E[PSAS:TA[0*ASS^40BN$
M[3=EPI/$[=UN%2Y5P$T&`5R#C@20UT$GE4;Z[ZZC[E[.'[P&Z+V>$/'M_K>B
M,^P5[9<6JT'P8X?NQO$+H8+?3#00O$B/(S/6CL*:QX2KT_$8^O!6D4N/Q,_I
M:Z9`)AI0%:$D"O/JKKM0)48+P'4NC2`C3^0`GT46\`#@$UAB5$"RASSG`S\:
M!`%6R77&!?`)`>9HZ;/.$P!AT^EB0UDU7Z6CVU%`/Q5)A^.A4W'@TSC*PSD1
MNO'S[?%\CI_4!I2X`^\5X`#AE^GR?@$EQS0VV_6.8U)R_8;*HP!9I``+</;-
M3!#Y)`"]5#QPJUM-;.W_/@%):E())3EC?_=603D5-`#`91G=I*1Z5L&:5UZ#
MCSU.+\1_7@!_T>N6L=D"0>B^,P!Y'@`H;U\:_K2TKED:Y40`R"D0SDX0X"6J
M!J@_M`KW,55!R`3F-0C[5\$!%"`!^Q8_$E"VP+B:&B`!>R7C5JM='=E]?4LQ
M%,``"P`!O&,!]@@0'S`<@/#!X$$)$CA\\#"!@8('&@QBD(#A8(<'"R!PF"#!
MPX<.$A8LF/#Q`P6%!U4:W)#0I00*!CV(;)!A908)%U1B8$#2Y`<.#R`N7%G4
MZ%&D294N9=K4Z5.H4:5.I5K5ZE6L6;5NY=K5ZU>P8<6"S4!`YUBT:=6N9=O6
M[5NX<>7.I5O7;MV$/^_NY=O7[U_`@04/)ES8\&'$B14O9MS8\6/(D25/IES9
M\F7,F35OYMS9\V?0_J%%CR9=VO1IU*E5KV;=VO5KV+%ESZ9=V_9MW+EU[^;=
MV_=OX,&%#R=>W/AQY,F5+V?>W/ESZ-&E3U^\@<%U[-<U7&!04&8#!AL^2&!0
M@64#`P001-`KTT'V!Q;<9V<00>)!#>C51^A@D,-UBQB"@`$)(NA.)0H8>$`O
M[B(X+[WUVCOH@@4**$`!\PZ:*0$"#&`@0*`8:*`_E?YC0,,)$.C0`:*L:^`#
M`^D[\#T9/3`1.PCN.\J""B^DP*0.KA//((=`1(B^'`^B,;L13?S)0/GPNXY$
M@RH@L"CK9*12PPH4L%"!*!D"CSXC.QB3/@M<_&E`B[B3,4,-EQ0Q`J+\_H/@
M``(.<&!(!`]4Z0$D;0(IT*1XM#"!'PT*4D8=)V(R)8/(,\]-[!Q(]`.'9!34
M`PHX-*"!(0&540*6'L#S@`?JM(`^!RKX"8,>$X"3NLTP`.!67&^U8`(`#KA(
M``!L4@"`@C88(%<`%"BJ@V.1?8"A9G,-($`+`D"V@"$7`*"`_B@`8-H+K#V+
M`VLG6$D"`!#XP%ADE2VJ`F0!(!4D!)`-P,%UOZW3(`UN5;3>7`F0R-8`/@`8
M65^CQ34`#C:P5EISB_+@@7@5^&B#6]W]@`$`8EHI@7BG-0A8>SO`&``J0<;7
M(([E_3/9HC*(%P`^OXNW@8\\(#E7C_U[&%D(_F06X"<#`#`7W7@=6$GG>`D@
M2@,"D!7@+)FB#J#FJ.V5CUQ[YRV*XG8_XF!F(\>+=P!!ARTH@ID7,&C8>.7S
M`&Y<T?Z@@)F5S4!A``8($(*93_R@6F17IC4S#S;@(`-K,=A@@X9Z_378#X9]
M%O`#')>@\:6!33,_?3TXEH+'-3@@61N!1<#Q"J)&0.QC68R=90`,^(CCU\]-
M]P/,->=\I=,;T$`#C@?XJ`$`!)!`@PQ:U@ECAE?J%P"&'.B;=`NB5I9@H!3G
M>(''%QI=\?#S!4"##3*P/@!!58(7`.$UB,#:8G&-4MN>#P+Y@<<W&-;=T36,
M?.9+&0!6U@&2&>!E_AH[B,P&@+Z&<:`]O`)`1#3P`&N1BFD6$"`'MM2]#41-
M(1OH@-"(9C2S'2!\C_L@TRJ@N`S@38.G(\`++U"O`=3I?<12B0@5IX%ZO8YK
M&=B`!M;7OH-8X%8UV<#\*@B46Z&/?!.LG>(N`+("?,1R,*J=`)%F$VV!JH/]
M`9P`)K"!"^!-70(<EA@E&#4#I.D"12,`&=,5/K:=SV``8,#PD#>TPW6&:WSB
ME:\4!2QA\1!Y"S`)!!I0-J8)J@.WRH#H`!`FMMD.<'5LX*T"Y*T`%(U;_CE6
M!&06@$9%:G>+;.0CEX:WB'&@`2/J0+E4`C)E06]?'Y@>2(`%IPLH@%3<_CL(
M\@1GD&-1[2`.0]E!ZO4BX`'`;0=AF_%.MJW^<"QBM^0AD6!F266RY%8%7!FO
M$``L$%&,@09QH(0TA#>E*6E;'K`D$I&"-SB9\"!%.YKDDL(T$'',01?XEHXZ
M$+65X1(`!/A)U'K&*X:.#0!U`MDQG2G-GZ!+`!V0Z`=74LB#<,!SE>,AVPS)
MD%]^0%O/6EK4MIF!!+#G("L]B+<$P">1=HQWNY.)M>13M'F9J0&[#.1E!GD0
MB$9`J1"P5B*?I<2%,H`"1(46Y3Y`4)I9,DH=J)>R]K>2HB445\JT:=%8JCMU
M094`4J7J!Y!7NP=<P"0$W2B"^I:OZ*FDEP3S_JA`OJ428ZKD6`U0JE+E<S(J
M86YIXE(),XF8O*@5!']%`5E,(P`!`@3@+,`B;&$/>RL(%!9O*RM:@OAX$'7&
M+'D8R$!K=RG11O7K:DRC0&N)B)2HY?-;A8V`2\U&`-[RIW,`<(!2'1``IWV`
M8NI2"<?<Y;"KY?8@#E74L-9HK3IE<KAA`DI3)7H!V];,FR?=8T&V:%*90%4B
MUN6MN:;75H/0U"#(6^>P3@0XYGK@?>*Q7NT<8`%W%M4R1_7FS!)9$`\X\58"
M@$![F':`!"#`6NJR9``$$`!KV0VH*QE6/#\@,P`D8&D@FZ=1V,9<IN**P1+J
M`-T6*A]O$6`EM@)`_N+T)3U_P4L`1R'F?$][$+Y)DX!(7>A*8*L2IET`8P.`
M%RHYEC^#D#A7"!A2D-UVS<*Q,WD>L)4`B)+:F\1KFUK.JZ(HR;1<3=,H^.SD
MS/H9KU2B.5<XVYB05:+8G;J-8B(VB-4N;"T!6(29=?+6`(P<123_4J*Y.BN1
MR=M&DJYMP19>XMN:QF5_)66+EO:P0:PG8L`EC]+$592V<%5#`6^&P)C:E@5<
M78&FDO2L'%$`R:!LR;HQH#^6M-"M&$"4L*ZD7AYNF<CTJJNCG#BD(K'U43(`
M`0GKJ]`K(6@`;%QF?OE+B8`L2H_=^F-D$LO5KK8),ZF$K@*L9))ZO(BX_I9,
MT@1H:\Q1YN.KL?@18$5@W!8H]ZTJ,.Y@?UMP,C0(F%5R2@<\(.%E>V^)SGPL
M!24<RBIA,YG_[6I8FJT`^P;P</6]*[R=B+XK4:P'HB8?V=XG:KU.%E$D6B>(
MJIN2*F'6)27J@(3'IR@@U1^ISYN\`P!K`'*-KS3WK1,0]W6F3RPZ-(L)LS(&
MO6_AU`"TK76U5&=FU3SW)>74Y@$+2(!$<X-9H@%@$;UHE8L!N%_997*LB*FU
M=FE'M%'0];JPC_U_ZJ;`-CD`]U,V"G#IUB6.J7>R]@W$(]X.+)`!$,XA%SS$
M10'6F&FLN+MN0.@Z_5@W0<*Y9&)IG#UW4,VO_O41@W?2>$A!(`!FI<0`=""2
M3*GXA[>\3Q2BB[Q&`6@2OS63A>JEHH.;&4NI"TJ/<:U.^"W*L;QF^_-U-"E<
M_\"&?^XK#D0M`2:1+\T9RR\#R+3H9Z68`C5T.J4Q/X2H`TG?0RK"K&-FZ_[L
MNE/OYOF1(_E8]JQJE(:5PY/XEC"AF.BIN3ZRED;S@+HKBA/S`+SQCF];)]G:
M%)<R.?;CI=DIO&.C'@\((MGCJMUA/'#[@-!;"7-3%/A;"8XA@"'IP%ZQ,4/C
MHEN9MP\`&0AD)HL`%LA#+-)C-0%``"",-IU(/2U;/:0`&0,@B@XH&A&;O:6H
M/7TR"'Y*(:7H/8.P_BD;\[SWD8]A*8`@+)K5HZXZNZEUP2Z9&*VB0!X65!0D
MM)'10PJNPP!K6:^2\B<Y9+KN4XEA24*0V,.?Z#X:*XDK]*2=8BX:<Q`<E(D-
MB[\!LQ9"HK_6.S`95``'(#$HJSG^4SN@.!9&VJ,`H,33X2$/*)Z%8!OVT9`Y
M/(J[F\1*O)6)JQ<!8``'*)KH>9\">`]@2:Z3:0"<PSG6RK0,`!8!D#J1$4&+
MXL1>Q+G'62*<PYM1,L%C&0`1L9KGN2N&*!K.XR8$Z$6\82@2E*9DW!,>I#<'
M.1T()"D]VY9D?(`2ZIL`8R>AFZ5C.44G5`HHO#TIS+V%"L=Y8YH%P+D&_@"6
M:>JO;80;$9.H]FF]F!##@PHQ&[$67FP`9_2HOTL>$<$;MH.B9H+#OL$Y!N`L
M2WL6])*\4]06/4G&YYG'`YC'6<G#EDF`5K0SYO.T;X$<D(G%6:Q)1FQ$FG&T
MR;&_4906.C.[3#R6,/&62^I#:6FPJ_(WF3B=`S`)!60W!MR=H%R8H6PL;%RP
MGJ$`A3F`^\`R7)$`$&N@@]FXB?BKISM&LF&FA4F`MLJ`K5RH#'DW@P@7%.H\
M:2F``-F97'&<-ZQ!`V*<GO0]A@$;:5D<=U2*-`J8`*G'I+A';JL^?8P7YM(0
MO_P6!""*B?D9:;(C\SL(W/D`,22^CEFT6PF`_@00+_R82R;SC\`T"@I2,0<P
M";7AHI/R@**)2E,#&GY)@(<I@%E1*:;[CI\)``9H))YB"#4"BE!<,!K<2<CP
M`.;YB1)JE-:ZF`RH$PWH"`I()?RH)*-@GBUA'C[1``J(@`JHD_1!HL413W:"
MSZ)8G//T3O#4$(J0@`KXH`X(.[+\"0^P+0&5H-8RLMO2D`(-J0/E%P&U+7IJ
M4*7#SX2X`"H)T-C*`(]JS_#2JP;-S@!%HO3QH`R(L^Q\SP8%B1%]1PG-";VH
M3J8@3P35@)^`41,54-9DG@&=3Y3XSF7:3G5+41@-3\B!T"K$@`F(``K5$.91
MBAJ5T<;R4?HLD>S4_M`<55#(P1(?-<$=K9DH55#QY+*$V$_I'%,R+5,S/5,T
M35,U75,V;5,W?5,XC5,YG5,ZK5,[O5,\S5,]W5,^[5,__5-`#51!'51"+51#
M/51$351%751&;51'?51(C51)G51*K51+O51,S51-W51.[51/_510#551'552
M+553/5543=7=8(`$4(`$:-57)14(.$>U:#'^@XH.2(#[Q(JYN54'>+ZL*(^^
MH`"G.PKJ=`H/6(!7=54'*!NGV`"X[+9.Y#T'F-:DN*S!$-:/4@#QXD6L<(#H
MG`"87(E.H=6BT-;/4`!GE8M1',ZHH!"3(*'YFKC;B`"<`QE>;)4:5+.U_I@D
MR,/5/?D*!>2N@SB`8LT*X.J+L%,*2G0*!-I&G#-'J>``!_`H"JBK\;PP=RT*
M"J!7ODA8(QL`/O.F?XT*"2#8^<*P?3$`U50*"%A7S7"`6XT+DS-7J'BVC]``
MK+N;3N,-"MC9*.-7M2"7DJV+@34*@^T*`K#9P=`3AQ4`PZ$8F)6*"L#8KS&`
M!;A,QP#9E8`7C]&\GNV*!EC);=*``4"`D2U3DS,<J["5(2F`1O-9H*U!!6@`
M"TM.F8"`8XFCHW@`\O,.!I@`!;"P!?$/X"0`7AF7P55-HIC5`P@`<ZD`O!$`
M.N,`!!"4#*"A"J"RP0E<U[F/!%LY..&`P1V`_@G(R*(X@`5@``L;RHD!E@,8
ME_4(I8^0@*A!W.ER@'H1SH]PI&7BW*7!K.19`*+XU=*=EPU`@-9)%QT9"(LD
M$8<PB,MR@`M;@/X(R`%PFU$$%@/86`0R'),3'`Y8`*%#,(7##RK;@`,@BCGJ
M%0BP6B1;VFH1%`O('898`/.``);R@(#LE0"1@`-`@``^`,$)$M6YCPEP@-LL
M"@G`R-4TB-`*R`"85@.&6JY="?)="`6P'8:0W+YA2EZJET\<DO:-11)I`&"=
M+X,=V0AP53[K``<X%LJU3?,`HNP),8JU,`C4`."<8**P$@DX%N`MBANR%@,X
M"S/AWHU5J12AR[O\_L<)9@C;7:AYR0`$.`MQ78@K5A36#0`$N(\6P[#,80HK
M3IX1.0CA%0`%R*Z5BPF34^`/MKMC6H`H@:G^M!@-V$WS*(`&6`#"5='8^-F:
M`9D%N`"VP9<8GH`+.*YU=57]F28#$``'6.2D_(`#$,[EU0G=/`!74Y';"8`'
MJ(#M!.4+F``&@R*+^+L$V)5CD0AOZ=[6R9T(4!X,P*`HN>0*\&"4M63XN0#`
M<6,&(``*N`"[E0B,B:,?,>4(P`"F\IC,FF36M0E8:UP.7HE9K@@)D&2#D#`&
MH.28Z!?3M8#TZ`_&48`+\$H^>P#S8UUSWIQG\4H$D%4FHQ!L.R2VK9!M_NY>
M2M:)GR41=;8]\7`8<YYE^$TB5'ICG\D0.12/!5"69*TA"B%#"YA51X(?AD``
M?58``,0@!K``9X67E_5*=V'=0D87P!T`"K"`TV';D,I>6!,46&N`"]B<>"J`
M!+@`"_!"7Y)IKX0FITW#V(T]@S@`"G!DMT)I9@Z`>4E86\%D`9!&8M:CO^-D
MR>7@TZ5JD34*S2MDE5X]O:T`>J8J`I!D[CB[#X"7FS:/^8$`7W89E:HC#8!:
M@]"I#M3G!`!`!MBX&S)"I-CJ"V@==]F<BC!E:%IK#$`>BQ@`4D8>R`N7A7"8
M@12Q"3`>62*N2BJ:2::8)9X-0;ZE+-IFMT$@_CAI5:-0UD>6PI$=@(*PE?NP
M%9VH6A*II9@(9I.P%6JQB;&QB`@8`.C5(V\1E%E&J6UB`'61&4&QE5T^@).Z
MQ>ZB&@+.EVWBVEGL,S5[;F:9%P.PV8Z8*7<18.[SE7Y)O@"8[6HF*)OXYXWQ
M1KH=ZGC*VO[H``KPJ.]501GS@&8%,E)!('-Q0`>1&?%X`/5^@()^&^9Z`-Z.
M,G=I`.9J:%ZRJNKKM`ZPZ8]8Z*IQ$`P*L`J`0/1>`/4F;=GV&9:N*1TN6#7;
M'-F[EX_(@&KLN`L(D)]>B;$5G9C0O%QU%PCHF9]F:M>++V\D%_G06Q+!&//@
ME?O0V_'$6[]:B`4X_H#WCF^C((#J=AMXH4`/<P!O/*BQM=\=IW"&2%C5%1M7
M40I3J6T]VFZ682X"B"?[Q@"3<Q>=26$9'X^5I*<"B(G)[@^W-0@)[W*FY>RY
M)>VWV9YM,0!"'X#/YK"1C3<I]#"XQ90=DXFI4:Y0(G2651KBOH@"""69%1NS
M9G#8=&6,-64;*P!*'P#C$?6W2^YC0H`342)2)_1AS)=Q02Y*SZS^$&8E,3\'
M\!7&84U%";L&R&J#@<`[[Y>Q,X!G>7&=,9?IWIC+-&U+CB=8$X`$@!1UD^OF
MDC&6J(`(\.-YN70*]^\:/*8+F,R0"@"#A>.(@379,]WX4I97IO0?U!",_B:1
M3*+T*`;PI.B`4K;R='/V@U"`[0':`PAQ9SKT#X#<93+K%>SHG-G=22[8L'4K
M7WD(&/&JD>6`L/M(:-+Q(;ET7S(/3[]&I9ELD]AM8\T`"GB`>A&/:J%V:U\)
M7"^X=)MFEM"L"9FHNTP>/M&I>R=TY#2;`5``)U>*<Z)TO/$8?I>`!E"/[B+8
MFITNFVT`K[I8#-#9_C!YOWI;#S.`B:>-SC[M0/<K"'@)>A5XL4?V@VCT(-:0
MH?L`*W^)G`#XBY"`<WJBW%:IC/?M4!^:?GF`ES`7K>_RY'8Z5B>^"##[?`D0
MAT%AEQ#$F5>N?]=9(]):!!$``3"`#>:S]:BI_J%AG)]PVD8_".51KG5^=CY[
M\0R02`L#S_E6"<VOGKXAX-*_*H9A52T3CP0XIF#TJ/EI:('/$TB?``O`6`;W
M%KG/D&0=`#ZYYI>0CP?X=Z.X@`$0`)M&@'_'_;%W;&<R^/@BKVS$&+3K$B'^
MB`X05V`1G!<'+%\I?JZ*"4"?G\P/YHYWD#S?F!?.2+3?IY(WPFP&B`\"!W[@
M<"#`@`0+`&P0F*%!@0`",A`<2*#"0`@%/E`(T$'@!@`4!5X(T/`#!HDG/P#`
M&$&`A)@Q+9!D0````0X5=R(X(#.FA@\5!`@HH.``@@\;`ERHZ($`!(M1=UX0
MP$%`AP4/("@0.&'`_D<,#`46>##0@(.=:M>R;>OV+=RX<M]V7/E!X4`%74/2
M=!ATYX*D`@TL&&R6K%D+`'069/KAY4>2.AD(+MCT0P<&`CQP`(#A`P0"'@16
M`!"4`E:OFSL`H#`P0U#%C#L$Z%OQ0(.!"!B@]#P00\.0GS$+B#!0PTBH>;M^
M\'#@`8$):I\RB*P@@4`$N04Z,.!!@VF!'F!^N#YP*<WN`AE@%[B@_8&T'S0$
M_3[@,,$.Q0F*=9VA]6CC22`>5`.X]L%_#35@P$"H14808011())`#22@0&'N
M=75!>`(!Q]U$$IHTT`4Z/;#16@8D$)D#*+ZWG%(`7/:4<6PM<`!!!.!G_D$`
M&GAPP4<>3"!2!Q>,UL$#`(P6GUH-X"B@57=AQT$`#XSV@0';$6"<6">Q)Y!^
M&+4X4`<##/C5E1$,H-8#`_S%8T/T":3!?6IMF1=V%7@$)GD"2;`99@4$EL"5
MK7$4`&,>8,"!!QDTI&@`TK5U(YE&?D#``I$%UER?'S`PP5-372HJ01X,``&.
M$QQ@`$8?H-G;207(A^6L<]EZ*ZZYZMK@B`/A)9!>S2%0P`:*#L#;3@ZXZ4%I
M&1J`7UG-#9"I!PS(J%0`#73@@00`T$390(I5X$&U&W7VV08",*"!!3>=EIJK
M@"9`@(]T=O64`MM::QM!N.G&FP<&'-!056D)_C<0`P-DX,$&!0A&P+)Z'NCJ
M`/!6I%\#Y'8D&`(!8*#H?N"MZ($#479$@0<=)`#6!P\PZ&EE+WYP`+()&*`3
MG37F)\`#&VR@P5<(C,8A1ATT`(#.;;*,X%AB@;J!`19[>"V9ZGHHT64?+-!5
M!P0@H!./444`P`0^^US0`/EZT)%T)[)5`*$>6%#4>NV5QUQ/C(ZMLUJ4#O2`
M`!]#C2.5#I`[@4G_@>I!FTO6.I"3[@G0GGE+14`N!``@>V>"=8-96V^7&RU`
M0Q(,<.6?30Z`LP$,>6`SS@/P;1$!%.F)D9X/+D!OHYA6F),&?;:$MMH3N@9W
M6`%@Q/"#!"DF0<H,_HRHKL8"X*AU`;$%X)IR`G6_4P,\%P3`TE]]]-]?T0[V
M^*[MN__^K741].O=<QH0P$U?JZ4!`0@)ZBRT#G.!BDU.`)=!C0`&$`#Y@$L\
M"T!(Q9IR+H%8H```$,#1WA69"0"*`_=3X`$8@X&*#0`!`^#70&CV+X=$Y"8K
MBM%P"M(Q!6;/>PI(X`*O1)P,J25S`QA``6PR&@08X(<!R-1\`("`!`J@521#
MB``(<!F7><X][6E``+R3@?[U3V@[T0\`PDB^!B0*`3@1P%&0E40U=LX#8ZO8
M#778G`:<KB*:84P!1#.0K7FH?P,`@`)&<Q,QAO$C%B!A`!@P&K>M!7$)_B2`
M`_8DL_K-)R(#,$`!9E<1OXE'`0C)XDDD(!$%U@B+!&P5D\!WO=(<*`'ML=8/
M$:``+]ZI2U4,DT`B`,4F>J6.'TC=3C)`0@%DCB9;Q%\`O+@3`AP`A]O)W4`,
M@DP$?$1/?7D)10SU@4/B4)$?J$HW1T.E`>W$`Q#8I:3>"$0ZBO,@-\E-J*2R
M%@X-QP!J?-55]J,^6L&OG_[\YW08$\T'=>!!/Z)`#-7"`0M8(&61X<"#(!I-
M"QB)41.MP%\PTSP$4<`"D>',:#3P,8CR*$@"[8!`%850.7:@`A65(YDB:M`+
M4&`DS;'H0%1J*8$P:@,4R"A/!8#"BF1@I9P1_@AN.%#3UX@$`Q40*$@Z2M#9
M$/2C##T231>V%@YPE:LP/6A04$H0G-Y4AQJHP,*@RM.-EA5,S1,KF&CJ(YYV
MM:M7ZH`%,'I7M5;$IT`"J49C2B:&%I2M^=EHHU9*D`U4H`)V.>M3!?O%1.&T
MH.+!@%$9(]&C@DF@9.5`!2R0TI/RE:=YU4EELPI3J?@THYS-*69C"->VDA6O
M/QVK!7ZJPYBPA;&B)8@&*&`DP#8'LW,MB`XENM6[&E2@C`V*<@MB6(!2M[K6
MO6YU.22!#%30;MC];@<RP(`"K/8MN]D)>&SZW?6RM[WN?2]\J_N]^!*$`0FE
M+W[SJ]_]NE=-%UQ`_FGY>RL-X.^^<3EO1=(KX`4SN,$.WN]\\2NW!U.XPA86
M,+G*>V&WD"M7'?[BAD,LXA&/^,,D/C&*4ZSB%;.XQ2Y^,8QC+.,9T[C&-KXQ
MCG.LXQWSN,<^_C&0@RSD(1.YR$8^,I*3K.0E,[G)3GXRE*,LY2E3N<I6OC*6
MLZSE+7.YRU[^LI`UX(!UK859([EMBCL``0:T:E?!G<N5A)32MUR)`Z"JKH9A
MG.?VV7G/<-:OG&^5@3;WT\\50;-UK^34(`=WM18P\/L&[:&AE@I,$PBPCP-&
M`#)/YT[CF=B)L<AF][T*+A<03`<*,)P&2(HM$T`6!@HPW?9)8#LUUL`!_F:]
MJY)@>BZXUC5XJ387"7C7?2J#-%L$T&KJ?HH[+_MQ!0ZPVE3^DXHP8XL%VG.P
M(M.&T.7TM`!`36)_O<]TAA:(1M1B)K=@Z+OMMC%JSGTK7K_/0?EE3=;P.T&Y
M*/NZ_?Z`>I),;7\RL@&5V8FUMSUD-2?2-:$=B$N;`VYQ1S,"''"``BY'I@@H
M8-0(:O6CP20!G0AI`0N86%$IH`"*DX@!"H!`D";@->BM1<P*:,!P-J!QI4C@
M(Z83[P+:7/(%:!P#*XO`MBS^2S1B!`.MINDV#6"``6V@YV#B.`-LXU0,,&`!
M=WY+!:<N\HZ/BRW!K8`")'4!ER/]ZAO`^,Z!_F:!M'O(Y3`_3@-N'L.AH_RG
M+J>Y!AX(`;M4I`(NQ[EX)*#SFZ^D`QQ_@&S6LMWCT'SHDM*`]")PDK5G7-<E
M5X`#,OJ0!(2^+25O0`8<TQP*F/SKVW3Y`T2(\KQ/8-$<*>H"LK[QK4&`Y$E"
M_'PP[H"5,"OWP5OV3BS`]LAT0/%<<0"F11ET@!N`ZU[7X=M)3_A#8V#,895`
MQ_M2=8$R%$Q<L2_$+P"!!7R&ZZ!O/-;S74[69YPQ&B#G-[N.`6J[_^YQV0!7
M=)Y`6)O!K04&F%#/@8<%/%]*28#)>1N-00T`",I=\-!YT0BGL%P2P8UFM$<'
M%%'>50FL-`?<4!#+_BC`L6C&=JA)`32`)N42(#4``10`HR0`0N2:0@D``CA`
MQWP&AS`&C^@$XAR+`B`-B#2`9G3%5P3`P'1&4R0`3N1&P'U`Y`".#OX(H@3*
M`(0@!"P2`6Q:$>)?6Y2,#C9',S7``['/0'!0"YJ%],F@`7Q$2,`-%A$*1Q1%
M`Y@%XMQ<`<B:4N@@#P8`17@`"C*`],B'Z6S:0IC%!?1/]:W%`QQ1=W3(!&H'
MQ`3)$EF(`@78A2`,=A!B(DE/830B`#SB'L+AK-U0`\@@RZ0>Z47-]D%.(NT.
MU6B&(0I`ANC)`CC`%WY$NJ$$$_(B,V5''SJ)QV"&`1``$@H`@WS@!`Y(_@8`
M8C.-Q-CD7O\@'T&<T\U=$FI-8`*$#WFM!11"$L!%D<L9(4I(8XBD2$(H@`9T
MP`$HXP,9AWY(BJD,2*JUH"<="`HBP`(\6@"`7@&L#C+*(]FPQ4LP`!U=SZOH
MR3?^D'QT!!_2(%QPP`R.64`.((H4H%J8#A-R`'@0P$.&X^MLX0+PC+RI&&WT
M!?U<X,35'`!LAU@T!020CI^,"`$,")VDAB%N4Z^4!$6,C7I5!)5H'`?4R<RH
MH4#$6W/HW@]24!9V2U_4Y$?<R>N-QB\ZH4"L&\"A"!5>S[L])00,P$GHDDY$
MTD@DP,&UQ;O]R5],"%`1Q)!<1CV"B>S$B$QZ_@M'Z"5F<&771,6K5`M-P`E)
M".(OU2**V-MTB%U?DA,`9,A,"D6/K$<6J@4TZ8?#'>,W78N]U25F1%@T#<!E
M@,=G:$2`*`"RA<3R=$M3I,1(I%Y3?(E2*$!#_"("V*%%7@\"$$"0U,D(G82>
M=.-P^&,G88=^U(AB8"-(!$"-7$54A(1\*$9<$L2_.0"%W`7'9`@A%AN$/)L$
MY(17[$D#!6'+A"-HU!$*LLC+<,`"!"5O^HG4$(1V>`@2O4H0.<0"24N-I!I^
MM`4%O.?2+=++<"2;O$Q(;(=T"H5-^N1TRMA*"D1+`LQ+[L]8(,8'(!AQ2(<#
M8`<$0`20B";`G<I6_D2B<:A)G@4GY+S,P!$5`!P`!-C44_JD3GQGG5V+)['9
M@V0EU7`E(WTEL&3(4V(H;;A&CT8.7/Q*L(@'5^X$!T6&8CS`B)9@2&046AP*
M8W"(`T#`5CA,;[CH<<G@B$;B@/Q)FJS)'>[9:##6?K#$@5`)31@I,`;8>$@'
M!;`,G'J`K-SA1V"IEFK$6CK%=\SE-BF1YOEG`-R58]3DB)Z3V`#2R&7$1F#F
M0#B`;O(0N05(!B1)0TP0;6B%EB;`9I3$2@R`<A[*@S``X5"-@JU%=7JEVW3J
MB(*JAF6)KSR+EEHG38BJUC"'P/2IM5"$>2PE`"2`XNF&`?3IT<B?+)Z<_D"A
MR5)DS0[VA@.,J,#,10=@0/A\1,']Z:0:*-4<C$WT:225*HP]:`6N$`9^6LWM
M27;DQK,0Q%VF1`<@@/(Y0"..AF8@@+[JJVN8J*OY$F@0`%(I)6D<0!@5`$7$
M*'E.P+-YP/!P0/@`0'Z6)YCL*#F-286`)9!FX;L.!'E8&_7%Q;O-ISRI19,*
MZ[[JJ\%4YH7RAF*61LJ2;`7<SP12Q`*44,JZ!HWFDL#J*;89+/DPIT`,3V/0
M!!\M)Z858`(@R]%FA\NF!LRFK*TQJ061#U\R;!@=0(,^1L]*7'KH8,H.B#D-
MT@N]JK"A2KNF$#R%1AC=Q*;Z!I480,JNR%`\_H@!E.K.:B0,S<EUJD5U/IO;
M+(7<[NL+J465(I77I&Q3T(A^],4,QBRP,D=S2$#5(D!#)&/,(EL'*(O$+L!H
MH`EX9-0N#FK,JI'IT9'$5HRV#BBW#N#+D.9R-D4_IBP$.BCHG.M@P-.$HE>%
MCLJ%\I!G1@=65$`+;L>"5-HO`6SR+4:*#JSI%<1_"DV,=L2,FN?!!`BV7HN.
M7@:/>B6J_BA),*^0;D_+/!NEQ@622NX]-A*\1)YX@$3O1DM'1`:'$)]XB%/T
M4N&S-8>?^)*:+"6@J,52+$")I"O1NJF/XB>FI00#9ZP.R6]J*(;]SA,`/,"B
MF&N:?@4/'=JA\DE3_D`'\O*O!NA25*2;@"",;MJ:OR!.!&3`M8X%IY+O^WY3
MKUQ*J4+3>J3J<*RJWTK*%*K'D.946QSNA4HN_[ING5X)K0HQ);WO_6'0[X9P
M.35'IAJ*LZK>7:2%6+A67)3,!+BPO6TK6P3<MCVKIUS/#-^8N2[`ZR:2Q!F'
MNE)H%V[F9[Q$6?9*BR3%50S`<"A&7PQ04_CK5A&3.`V`?*PH05!N9!SO?RSN
M`\THU2A+RF32<M+$]FXE.5'E9VHL5.I$3=YQ0X#L%+);AHC27PS)4*XAO%R%
M?'!`M(2$`/D&#F,,F.1I!/CA&0L%U53%9YC.0/ROSZH%AXR$8M3(`8,._H^L
M&LN64P%@TI7HR64H1E-TI@"T\CY5A"A%QMC0Q`-(&X0:\6)%2G,(:G\XQ`",
MR]'B:5K\XG@Q2C2FL-I2(4D>S=L.QP%X,R$F19D<1G)NE=#^X7/Z1A*ELL=>
M+."BR#V?9NOR4RZMXU><!($M<8B6)7@F*14JDPK5Y"F3Y5JD4EV^B@$$TGR(
M8)EXTP=.+5NHI7B`ZNI6R$);&^QBRS0+]-P@6[G>[H3L!@'8TQMG($RFS0,A
M"SRJ2Q&*BEC42#SJD"?E7C*-AB"OA2XM+3<Z[UJDBSZ*\U,<2T]D(0=M&A0>
M"!;=W$Z/AB@Q`%=1#2891^IE"3-=3_@8SE-^_N"QV.!4B/++6(`!Q&*%5#.Y
M+)'+3:S)!O!A6B)'AT1"G"2RS.\:)M-X"4!0!,]5M](1G:07Y6T$]"R'M*="
M#8`R*L`7;L<QTP0AJLN\+/-.9(ZHC+;))=+0/"9%#`EA;^U:&UP!]%M*9(D-
M*FM&!.3NJ)[T=!PSCL;&.(EC@P:*N')11)%@D-O,Y`;,+HC!?H9^((!K8``>
M'D2K((Y4DRI"#FO"Q.'>#O3;3!W)'+2'7+?RL`41#_5?JY%S]*TK$R$`R(=%
MEP1N+)%T1TU[=_<WYI$0UE%5T,P71B030L0ZHF%W=UP!&*R);.1"ZQ(9Q;09
MOPXN/I!(WYB0K(3A_C%`!ES``8W$!&RM`C[`R>6'`S9`OF6XAZ0XZS$`S7&4
MGUT`&K8=:=BT4CS`S64-!Y#XR$W`1P27>*%X3E%`U]$XR2R`CSPJ2C"`E:`$
M$EJ`I!4$&C+,US7?`@BYA[29[>&:7BL%$@:)`^J>V;F>D[\<8_#%`S``RH`$
MF6.K5JR$!I`XEJ]>UWU=45U)48E'!+!?S3G``O3>!;1*L8[S291<S[SX5BFY
M>+3XQ+@1`7L(&L9>6UA?SU7`<&2`GZ.>Z5G`E0--HAC>`E@=243Z7V"66U5`
MB,NFI4/<9\B-(8)*B)-&J(.$G-O4CQAB46WMJ(<Z\REY\RVP5J"$ED_,_@;4
M>ENL.IF$^9K_QK)?7>[91OG]AO#9E)6SV9Z!>N_-2:L]1-:%G(=@7,]`W$)S
M1.Y50`>4#4=E.5ML[@)LP*];6J),0.Z1>93Q,)C!#S7%E\+=.X4M+;G0":GP
M^XD%GL"WE[T7?*YD@!BZU[XC_()5!6<'0.$Z_(A%@*Y3//QT``4`&\8_F,9S
M?,>[5TLM5<B7O,F?/,JGO,JO/,NWO,N_/,S'O,S//,W7O,W?/,[GO,[O/,_W
MO,__/-`'O=`//=$7O=$?/=*[5\HP&%XUE%H4B5Z)V$(Y5DJN>]4O%EI=3&%!
MU-7'Q;;P5%PX%$I]/9GLV=87EF4M_8:I_?N0_OW[I$Q*LGVI@/Q$Z79[R;UX
MT'U;6-9[X3VN^'VAN?V4N>]^I1K^J)4Y$84`9-'%\U>UC-*P,D;MX<K2XDI)
MH-$F$5(`%(`&NIJ-3]#!5S4A3>#$O%N*C'X8=<4D.=CD>PIWZDJ$]-,UN\5E
MK];YQH5%;G[7]U.I05Q\QH5PK<>X5U?G[!KS4E?H6AGAZU=*Z#86^3B"Q&.O
M[==+6,H6W0M?VDKEWPHOKI8"&`!]B-0#$?1:X%M;3-!WG)OET(=X&69!=+E2
MT(=4TH=.;,J#.6Q?<`#\VTKLPT^>`L0'@0,)$I1`P$/!#PX.*'0HL`*`#0\I
M5K1(<<*`A`0K".AP_M$A@`H"&2``>1)E!HDH'WK0L)'E20T`-,2T>1-GSHH=
M+$S(L-$"``X8*/P<Z"'#!`H3!6[P8,'"1@X4*G`@R*%"T98:J'[\T*%"``Q>
M!V(`,(&@!@%H!2:U0)9#!ZQO/V2@@&%@7*P5$MK%>Q3#!`PP]79UF$`!00H(
M9T[PZB'P!9@?/%SPN3$!`X$=G"IT.8'N!PX,#G0FN,``P0X!('SEP-7J5PM:
M!<ZD$)M#3\D".0#`ZZ'S!K+""VX0.;"#@`B\8W_-6K-@4.@"%R0`6Y5@9<$$
MG5;879EJ\[@;*.Q&WG,Z\(WJ/S3^R*$YSPG3ZQJV:&#!YKBSFU.^<'<R_H<*
M>&"JT#9#;R`)-!((/`X8>LBMC3J(0``-R.*M@PNBXHTJIAB,#":D)C!/M`XP
MJ,`KHC3(*,".<KN-0=-<*PX`":PJZ;K^M/NK(`_B&HBX#YS:8,3)N,+`+`\C
MS,M$%/TK[S$/1?R)J<*</&^^@HY4R<.K*%CJ**?^RT"G,LU$20,"!"`@@`42
M"BJ!`08`H+6O$`B`@`$"H(`R`A`80``R)\`34#[KDI/-_'IL`$\!!L!K`@`D
M;:"@!P((D(.$/%B@40+(_*`D`MA$(`(Y:Z0N`5$#(-54MC@X`,\`#HBM@`4&
M8+.`"TEZ5"%)`=",@SO9G+6I`F)E(*',1#,`_@%=-^V4S`1\O:`@U+(3X(&%
M#)`S6PS49!-9#WREM*-;`\A5--_:`R#:`A(*RX+B]LQ+`$,54-0"0-E\8#+I
M3BN@`#4#Y<V`-0-00--5`>5@@P+6%$``:C]`0`&#$8@M@V\#H%1(==<ETU?-
M&$A`(`ST#2#;#QA5D]>*\!/H@0.VA5CB5V-%N*("_L0U-F\-YO>#@S05=H`#
M&NI1@4YK@L#7.@?R$U`R*2"TWLV$7?6C#I+&E2D$$'"4+P8:_;-%A0&-=S6V
M/E"6H)`_6`!@@?_BH&`V<2[(``<&&E"@`!A8$P`$-HH@`#FEG>A9-0U@ZH"O
M!WCK:@.LND`HRL16_C/ICR@VEP"F,C:8XP\(5U-:^@2:P%$V)1#(`@%LG7.Y
M,V6?G:`&#OBHHYJ"6J`##QKPZ`,(!JBI@P2.)B!7JS0(8`(//*!PHI*<IT"`
M+C\8E"^M-?(@K`QT52"UAPBG-E@#$N(TWHB:]0!\Z@)(/_#>VW^;@)K25+2`
M`<C$@'F%&@:@``VXDG$H\!$&>*H]!4C,Q"3W`7BMC0$=:)RN1!<`\B'`?*.9
M58"LM1FFX<4!`)!,[PJ0`*M8(`"KLTWO!M"`A)AE)+W!BW'(Q($!.,"&H0/2
MKR0@@0@<(`$;N9=H!!!!#U```/$:2$3HPRD*^(@`FEG;Q>I"@-9X0%8^_@)5
M`:Q"-T7=*5X9P!9E\/.1"U3-.']1"9D(:$"2>:"$O9-``#2P@??928H4>=D'
M'G`6'RF0.IW[P`7FU9*"X85_JX-C!#^`PG@)+7@#PX``CD80"`A@,*\R7P<D
M4#U=(2\N+DFA\Z"W$/W513E\Q*20F)60KPF'>W=,TX(X\BL/=&`!!#"@241C
MP8+T9@(W`L`3.1!%RBC@8BZQ8H_RMK>4G6LB$:'6\B)PRP.LI%0U1`#)/G"`
M`<"R(Q/9P`#00CFK3"U>&B@``%PI%E0NQP-E'"0:67-+!*PD+2AS'M/(%)1P
MV2I`M!,H3APP`#!YQ5^-#$`7/[60`O1);P*!_H"G,I"!2:+E@+=QGD(0LT-J
M$;(_`O&:'D.W1E"%+VT"B0`!J'.`A'1@F"IE:7+4-JB$%""/RU1(!RB@@#D9
ME#))_(H`5B<0)'9@-2,IV4<08S0*?L``)667RGA9+0``2D^L$4A!RT*3@2R@
M(3!58@9B0]-TX64FGPK+`=SE/SP5P`#&,J%`AC@ULB!`4:SSZE?#]S:2P=0G
M%;46%F,G).ALBIMX'<@#'JH2"U0T`Q3KV%_2&E0E5J<N>X6,C_PVF*?B35$/
M&,!`;$<9HI;ELP+!J3,'*4+('B`_"DI(,P52VH(4(*(?,$M-J!=0`H1NI9"=
MI`0\H-.Z6(4`*6OD_DJV^55N!HV62UQH4WR9I.LAI%=*9<!#26*2U4@`LMM5
M"&T_P+</:)4R\UKI1B@W$0,P`+*$L\H!%NA`UKQDH^;\P!!/%P#-U;>9CH6L
M9&5;LKT.I%0P(8#>$AJ6U`X4PA=Y%0!D5=2@Q*:]$"'-G%CZ`>,RP%>^RM8&
M#$#A`ZAM;T[SP%H&.=V"'-`S`CGM9@(P$LQ^Y8[0I<X"Q2K3R79U(@5PFG$=
M`ID[.46HO9&8;B6B$M.M#0!K>NJ,<3R2!E25(`HH0`6X?('F.*"OU"/+2K\B
M0MY`(`'&.LM9.]90:2V9.\<I%B^'.-':57*Y37QN2=85XJLZKY"4F0!8_@4`
M@,065LP1\7-JTMB6J8I+B2-S(#L50KBK,L!ZXPUM7TNK9)3@=B#-1**?30+)
M`10U:'CNF]HX<,?>]LB\*O,S`!Z0'$,=)="-1D`>#Y#;"T07(ATV+5K@N)P#
M*+=MVJUJ:6?BYP'HBKSF97%Z^73EO`3`*7/R<TT.$#H/@!B`M6ZM50R@7/YI
M+G3=GO2B%U+)U9C.V@,9(@ICX^`(W]LF2/GAFB\L$$).!`('@T`%'M!AX]H.
MJ;?L'8,R`(%K*C74N<4BGT"J$`E4[BC']G!A>Q,O2>-8B61^&X^%*CJ6>MK?
ME8LUD7NI1-[L"=(M!S(-@92L6;70(03@N%#C_EVMOA8$S-(E2\'+C#91.4`P
M+);AQYH",3>Y]=:J_,@0%400/@\DH:@:")]G,I;>]0[0AOIV$2-@@1L?H+`L
M"@HLP;XN-3ZZY)*.R'`D1(&_M56/FR9M0UKM<AD)2+FB7NC7%VYJ5/]0(:?.
MBYE?79"#;_+KSJM:4R2OMJY/+(^[QCJP'3C:S4P>`HNC8TB4NH!EFV0F%R!\
M0&D+QV>R9>+M7GRV(Y!PI`KD`'ELR@22IAG]JIMU_IU8NBFU]L@GY`%];;7I
M@CX0S=,;(L+']_0O$@%41W6Y&%9YZ'(I$./.L4H,P`L$U);<%YM/KS6I>$&2
MHWLDCB0!59U:]+BY_IJ0=W@!)+\_1`?"U?(.V6D8Q`#N)K,D0ZC@*'0>0`!,
M*W8Z8`"60UF0",X$(OX&8OZHRB$Z2"&:KSUJ;"#HJ\RH)2*8PCC08NEHS@,0
MX``R(-!V".+8IZV&B'+^HKAR*\].8\],8L64*P+@J7_2*W8\`(A$JJH4@&26
MY]:0KF.4"(G().;\2D@\,`HK0`,8(#:.RF7TKK:.)Z+@R`85`M0$HIEF`N(:
M@$\*#)GD3=4FYKD&Y9P$($"*RVD&A2EP"2]@ZP/S`P15"G@T#V:PRY1:9*\2
MJM5((Z`^0,ZN3F4:8@<1+`#%4(HX8(P^8-IB;VJND+FJR@)<J)M"IP)R_JL!
M4D._"LXK.`7=/I!2[$AME#`LF(*)"N("B6@Y4,@K[(WZ;O$A+"4"+B#@XJ7?
M6FPB4H4"S*YP^L1I.@!YJ,*;)N)W).`"^F@"65`!>D(`<,8L0LJH#&T8':!-
M$H*0%L`"YDB*;LS^?&SD-J/D1&Z.'.`"N+&H5NX1%0H!RF.E!`>+&J`F(H4=
M=1%FE,,"*L8J$D!1%$"7"N(;P]%O:@O+^.HA./!MB.H?W0F+'$`#5((!+(--
MEF/I*NN2EJ9ZY$4!'D`D[XDMAB@%#:H"OH8^L@X*NTNB:.T9`<`'Q0ZNN"P!
M9$6D`*`!-M&70"4`R@[$1J*X#*`")H``'FUC_FKBXVP%-`X`(20Q`;C,:(P*
MU0ABCY)O[P1BCB#@`CBE)C;@`3(MUFBK8B2`&!\)N_CG(AEE#2F'`2R`0J2H
M\0C"N#H`8)3QF^R+'1M`7<+B+0DGHOQ02`0@`2S@DC@O(H@R(_(*RJJ2()+R
M;4Y/HE#&`BPE'INQ`@Y``.KD!V,/CA1S3B:"<L"QDQ8H][!.)RWCAL9--)#G
M`>[D4CH1%4GB)R\@*,E(,8_2=."H`*C"``H2^NSKP7`1WSR@H,Z%+2++*S)@
MKC;@3FX(`^9J`:)N`Q8`8A#@4SJ@`?3$`**N+)[3`39"`ZSC(2X@`00@``R@
MFK`.5JQH<%+&`Q+@_B\J0%$B(&6*1ZWR:@*,I0#4I@'4A@&\T]_BY%P<P"L<
MH!I/AS_5Q@,F2E8^Y0%BAP,20$`MH#TA8",DX`LE:D.U4H>,<U26['=B:U@J
M4R,30)LV@`,40.P6X!$G=)NVJ0&6#`+JI`,80$\2P'2BLTOL$\'@\R#.)0@3
M8,DPX$+ITY7N)3U?L.#2\]8PP`!DY0(4@"D0-#%\E#*.,P&8X@(TTW68(O0<
MH@'J9`)"1P+,U%@,0&*8LZ&VSC_9H@..DR@AXND:R5@40$,=P@*BU#W]C0"W
MCCHK1@"PTP+3%.(J@$\+RP$*JRY@Y0`HH$[+@D4!I0$NQ`US\6!$)[?R_I0R
M@E3G'((#K).<'L!0B)1!%$!B-B!IMHR*&BE*6^A`JU("C.6&^H(\1:,!$L`!
M.BDA=I6T8*])>S,O5I4"YJHXK+,:F2(Z4^16B=-9GQ5:HU5:IY5:J_4D!)-:
M4]!:MY5;=ZQ;J6\"E"L4#_%;R]5<SQ5=TU5=UQ5;IU4"4&Q=X]5,)(!3VE1>
M=8)_$"!76_!>^]5?_Q5@`U9>(<`QI74X!19A(=7E$#8F,J`!%J`!>(1A)Y9B
M*]9B+Q9C,U9C-Y9C.]9C/Q9D0U9D1Y9D2]9D3Q9E4U9E5Y9E6]9E7Q9F8U9F
M9Y9F:]9F;Q9G<U9G=Y9G>]9G?Q9H@U9HAY9H_HO6:(\6:9-6:9>6:9O6:2'L
MB)!)`9H')(83-&1G`R2`5`]VD&IT`I]1`KJ$DQZ`+[@C`B!@86WBJ6ZI*<0-
M)S+@`>QU^IS1XAY@`L-58EEBX40G;VF'`K9)5QS6:\)R("Z`464G`OJ6(L`R
MH!J.7'.":[5R`F4"`B+7@02T09]L)QQB;R%`<76B`N(//DA#,`YW^C(`F>!,
M`T12)!/W<=7V)N`R.@HV9FV&`2#@;QJH(A[5(O3U3,+"3P2`BRKBVV3EFD(G
MA!!`3>8F3^XDB$I&>.]$AUC"`KBK("1@@?0+)SBEOFY1R,!P5:ZBT$P7)#(`
M7?8K;6=')19@/;$N_@`2``*2;V#XR'IE1PY1XAH5@@*>C79X]R2^UR;"`ALI
M(O\\0PI!0@%,-V,^P@,>D'9:+0%JSU8\ESZ=-:X@@#[4)_ZBM$-OPD5OH@'J
M5V5$6&8)<CHVP$\L0LXH`OAT`HX4Q88ZV,"4"HG0R@/CDY<<`%U84*D2X'E9
M$B5$KEJX*<-N0A(998`C#(`)0F=<S($*AGPOPD6H;_VL,J^$D)N(CG;N]R2T
M5S'X=W96^")BC7HQ#B0*N$=R#"0<.#J$KX&C^&WWJM>D==H4PXP))]-N@N5.
M(H0+HH]K5B4@3J_^8D*,QD`70ALI`P-0HS"=[W8-P%09Y&^CJDH<P$(C_M4X
M&TH1'2(#PG,@U`L0:7'C!H)MS*O'*J(*#8"2!TDS&Z`_*"!@PI-RNA(_/(0#
M0A$!J-;B!L"&CM$!,H`!!O!35A=UWRLV#!,HG*98F:5]E]B9R.FK1*L!8^8`
M,#0O<+FHF--OR.0!9NB7P0?3!J*8([9#-0"7V6)*?V5A:Y`@`@-F"L`"5/"0
MOP(",*B1O\*282LA-N"<&22Y0@\!7O"'>JUG,*XZHXI7_70`>>0!+"#^)F*2
M%V!R0XA"%9F1T[>\1'*ACV("9`:'%"(LIO2]/(2?F>6)O)4R0H](#Q@Y'&X`
ME>B2#J`JQW.;&SA^F<7E/$`"//JI2AH!B*LN_A;@5\)U`/*F,JRYD1(`/QH*
M`\`'50M7RZ*RR!RNU[*&41#@$9&H.2Y/2,#LO3ZEX2;``%JC`^H9DF&:DI8#
M`AJ`K=D:HTE+A/^X+K9+JK6R`DCC`H@9G)/X8BG$62:Q8AY`>$A&J&6ZQ1*`
M7F.JFP8U`I+F+RYI49U2>0!`YV38"_%773ZNS9Y0]H*'`#"`GPMR<0=5`H2G
M(?;T8+KD(`8@@BCGADHE?(H)[2P%V4*-4AH`$'OCMR(@?[P13P2[:"0*$!FK
MOQI``D#L'>-Q0')U,_3'@5-0YX0'9SB@`&9[C#(`5A0`+Q3/+'#+M!-"+7[Z
M/!=02XHZ`A@E6^(9_@!8U(\#P`'&HE+.)7[=FSH&``(BX)YJ0K<A0&]0&.T0
M](I(1P*DY5,">Z701;^*23U%]2-0B`&P5R*YI5)1:%=OTGH*>W4(";&%6D`=
MYJ=5LK8&($+C2E>"8L&$1W!$8P!(!<!1^F\$^RC3-CZMZ(>P3672,P"Q>[T'
M`U#P]$YJXMOLF[?1[RJ0)P(05#,PX)X0&T=KA9,\;U`68*?S\AOIU9>6Y\$Y
M90+C4\0GR@"0JK"G-R)B`T2S!JYZ4%028FK4<W52Y;Y_?"'2,UL>]EY*#%[]
MF`#@0\_%2[<86VQBYSP9X)=1Z)\']6-Q.Z!62R4DY@*:!1$-90AK"[L0_J"M
M4C`Q)%&I7*]C:)<@%#"/.1>2Z:J^6LW+/"9XN$N")(6E]33%KP<.3<XA/HYR
MV.(23WTC!+@@5`(O'(LW:,W`R(1R#*63/F*B-H*X%T*Y!%*UE-MNA0]15VPY
MIK@#J04"\&[,'4@`8H.[U^QZILL0*9"\K0[OYNB$I$\U$#3*HM+8]RJ8[42)
M8J\WG(8A-L*NBBO%DV,YS")5'3A_2\4K_F:V<LOT*&,`\@K,7NH!GDRQ(UUE
M`'%O4CR>-,..)`89#S<HA!UXYOUT@*>`ET>I@B)M)8CB2^Y3"\+>&OAY4XH%
M/T42X;7@ZLVKN`3W(@J2?LMJXJ6%2</5O:*;_MOX+U11QNX\(I`G3WH2N[4/
MHCVF`Q!`B9+*^QYQG'1/3&<-@"BPDD2+J80M*)1JV#T6MW-.,PJL(([#UKJ*
MVYQFO79G`1@@EU#/U#U#`=]:(33)*_BKETJ=1ZJ=,E00`S3@DC[W*C*@`BKF
M(X08!U-.69DKBM9>`4J.M-9B`E"'FU#N\K07UXO]G8]B*&9U@9Q9M?@%J%ST
MC1>BB-:>4UI#>=F>`1H_?8#G`[:=2Z=KB:<&#)4+ID:B=9*8)W18)_]P(.R,
M032`%_NGXSZP5MB^\:G%_)Y>=#Q/U%G3[EN'LW9M[0O&>=AXN7"+1))MJ)[T
MP%0+U8@;B4P?1[LW_OM2;KZ./__410$2H_%6#*-=PC`+J>0)0I1'7R`<>([(
MOX@*0C`!PH.`"1\R`-CPX<.!!PDC$/#``<"%A!0["$"P@,&"`P$Z:`A`@(&%
M#A0I0B!0,L&"#P(IE$Q(`4"$"10B(!B0H6*&"@T.?J`0@$-)#QHL0`C@\@,!
M""4Y%$C@X:74!@0V6-6P@4&!A`,B4-0``,.'!`HH6@B:L$)'J6S;NGT+-ZY<
MJ1+0#@W`-,(`M@!<=@!@X2N`G`B\)IPPH$,%``P:-V:Z(6Q;#PP$3)2;H<`!
MH0D9)*`8.8,'P!0='"@XF"+&MQT4!`!I0`!)AU%?>DYX`0!G##X/%'#<_CAG
MQ0$#"A`H,"``PHAB/T06FYOS6:$G:S_8^N&"`0`"C)?]4(#IRP(,&2CP@!.]
M5P8A@5=0:``X@YP5!'`>(.$#;\[1/W2E6)]4!!C&$E(?3/?2!A/4QM(#RGWP
M`$H)G920!`,`,`!'!$5T&7CQ`:>!!TM1-.)U)3&`@'ZZ?8!``Q1AD%AD"@#7
M@`?JE61!`@$`4(!P)?7UP5^!)026CPD5D-0'M$T0@'SYX;AB=BL6\*%C&GRP
M0%F(U2;BD!1Y`,&%&0;PGG\$`KC6C5QY%4&3P!%4D@$,4?2?00@IY$"%>Q7Y
M$@<!)$`C21@L(`"&'29D6DD*?"=`DA3%Q!E+_@6419D``60(P)44R$:17AAR
ME-2("76`@`$DP>6`A!0U@)V!"7$XUDH)(?B!6J?.A6NNNNZZ00!G?B!!IA],
MP.D''#@@%`#O=8"?62L>D&=")N9VY:M1@=7<2QT<0("1;UT@P`*W*JDJ@@-2
MI,!*_766HEL.#'`!!QYL.INJ)2WPF91W\H8065]&"M.#HP;`$'-$!@!=E`A6
MEQ"K+!&0@`8D+7JD>"61=V"C!MCX7X0,RCM6OBQQ5M^IS>Z'VX,(,&"2`%(9
MX&)"D4UD@7TO&90M:CF9."%*!D&P@8T!;"B1:K*._+#%(TH@`(.K]8<O@(EU
M,'1%)*F)=`<6A"25_K)!-CMKE!2%M^IIBT4*,I3\/<MR0A`EE.6!`)PJ4)DO
MRA0TU66>^])95_^WYK#%&LM@0OX.[)*="2W4T$-_V0W!!18]&>350GF@W6DE
MZ<7@`6T/)-797R*08ET5R,OO3VNI&$'0'KA*-DL*5"67PR793L"<.L=JUNJV
M[@I\\,*_Y&"2];7=JP1106`SD%@6(!2I!BQ.^P8$Y,GL`E%M,$">S[&5`.UR
M<<]`X1]\])X'"K3+*DD9-&JL`.)Q;S'XFG/`4;WF?W";E+OY5)?+'.5."2'=
M2Q0P`(A(QCF2N8!=$,2DY1S'6`%X$KB^$[N+,40@(Q*(5W@#)[4$ADD"_GS0
M[\RDHK4)A4F!@9'+7L*\*U6*)'Y[B0<,8(`[>6`!#X&0JBBTF&I%```$F5FG
M$"8M^XA(:9#!RZP,A#*UB(54B1E+`4A"JM.(B$`,V!A+XM.UI"P`>D$JE50*
M<,7S"<`K'!!`C=18OP/9I3]MRHD''F"SN%DD6D/TTF%6!";GB0I':,':?WKU
M@*A@0`"4.PP2/^``M"@.3Q7J(>FBD@$#*8",'C!CF#BS@'91))-/6DQ@6B(5
M2+E-+4Q)U=44("QZP<0G@0P54SS0`)S,Q7:KP@Y5$**^'JJD=R1;W?".B<RX
M>""23RE`DQC4I@-P1'E*&=$&"B"`\.F21088_D`"!&"JM`2@``CHCE"P)17>
M!,!2ELI7%Z<"@'7*$TX,"``""""`YG#/FW^J#9,,4,X#G"H!(GL4``R0@`'`
M$B&+04"U*.*@!'1@7:GS@(Y*!8#Z?01.%,D-!0QVO@8J#"UM]*8WL>,:!!Q@
M`&8$3QS!,R<&I$9-#@#``1```.W)+@#2!,"<#'*`B9PL2@X$IDPM54ZID.I/
MSAQ2#5^B`0+8\R;PDA9V/D`A#N`S`53*G;&*YC8$V',[7EDBB<33)H`&0*?]
MV:$]"7"`IIUOJ_B<"-;>=](!/)1$UL2F-KT%GI5>]%1,(B<XQR4W%;)$K!@U
M3-Q49P#?","/\3OI_DH-<Y.8C=*F%S"D8>I"3IZ:SZ)CK1IJ[L0X<F%R`!#K
MIW/H:AEC;=4``3C4A&S*D3=^`'XOB8D\7W,>_8`DH;`,S*8XPP'B<)5;<_IF
M`\#R&G:FB%F_^@`O&X8=#L0F?+'EW1-/=<)DBG>\4)6``R2PUX1D``(/R)8&
M'@"G#E#@O+?"P`8N`-_";2`"#Z``W48B%0Y88,`$;DX&-%>2#!"8P#JTP`-:
M]S$)]+=P&HB``RS`H`L4]$4/@(!HXL62"3P@O1V0<`>T5AL4N\W!$,B9L3!L
M0PN$",`L`;"*C=795_$7`QQHC@=$+`$."#@A&$BO?JIUW]I<@(`88*\?_CW`
MXIQ5H+W90<B-51RTHG```E<=RI1;5Q$82\4#%8"``_S[E6S=5\</J(`',F!'
M&J^RPSY:<D<)N-X'=.C&4.XO!_8\@?-&RLZ@D7"0V?+>^,Y7`HC%C8`G7)(*
M0[I/.0Z2F,E,YU'Z:+T1^#/`7L7>]V!`.!N``#5+,F7H$)#0!>&OF]G29P@\
M],9%EEF'."!A"C"H`R(&\Z@"#6&V-#ER)6$U101,8!"/$@+$MO.?/V9A-\-9
M9A"(`)07;`&Q>"`"+]6`B[W-I45':MJO$O.SR8ON=*M[W:_:,+M+@@'-OGO>
M]*[W2QQ0`(1D@`#RMK>__PWP@`M\X`3?%03L_E;PA"L\X10@H+\/O?"(1QQ_
M`*BX1"6.\8QK?.,<7_>V]]?QD(M\Y"0ON7B][7"3JWSE+&^YRU\.\YC+?.8T
MK[G-;X[SG.M\YSSON<]_#O2@"WWH1"^ZT8^.]*0K?>E,;[K3GP[UJ$M]ZE2O
MNM6OCO6L:WWK7.^ZU[\.]K"+?>QD+[O&R2P!P+)E`S6I0*.3&:*WO/G3<N&`
MVK^D`<YD@.X)GD`$*IWP#<`Y`Z-.>;K?W.C!$W[PA@?X!A`K^+<'231QT<#@
M1[UW8QEYO&^^_.#Y?C[0&RL#DB])!RBO*\1[G/1N.7W0Y/)F(Y]^\P51]YM3
MGG=_;X#VP"-*W.=B_GG$WMZ&D;=A!GX?=(MVATQR;P!(.#(`RB)3EF[)S0%`
M_A;JMX5OH&,+!W1$I7'R'BY&$6]/*HY^`XS_F'ZRK7_0#_]^.[Z[+%G`CGS5
MT3E90&QNV0[\`9`?#S`]Z]8K_U=Q'#4>N@-/U14Z@X,K$>$HY/4Z$4@1B%%Q
M"$`2;11=KS&`,%)Q.>0V#O*!Z54RAT<``^!P!1`M]2:`XH4!!#""<8$!!5!Q
M\@,@A0(`%U=_-4@Y+QB#0>=`.:$`",86E0%C'6!_ZY<K3!(`V`<W.'5W;F$C
M<,$W4SAFOD%YVM5#NY(NYO<0-H(Y+,5N[3=F-E(7KN.$]+9OI%$AM?5C_K65
M$%V86'$1'V`(AA`R@!YG(^QAAVTA)Y-Q$5LH=VG8%A#H<;SU$AB`%Z?7/35F
M`1=@`4QB;2*R`!RP`0@5,!/@$0?@10%C3)QW(=]Q)"M(;RV(3,R2`(_'AW)'
M``CP>'T4/P[`B'QD&1UP%#)$``K0`1N@4D*7&SF!+]A'2J8'-@51;2X&>]^D
M``[8)V0"1J-R`=$HC9C$=IW68^'67[?"-SS&%A.0&J/479BFB:.T>]5V)QIP
M4QA0&TT6`0\E>$T6A=9E+Q`B5S7V`!!W/IM6+3RV7OBH'Q`P`;WB?A5H%T16
M;<)Q;L[Q4-Q(%-R6+3U6:@-9$D=A?U[R6&:E_@&D0S.Z00$'AWW/2#QY."_P
M-2Z\-FG9@6NG]A94X64D21%_V(T"D$E>8E\5T5G7B#FWL@'(V!3.`V75]E#Q
M,A-189+M:'HB]FH%0H%8(DJ1:$,(D"_KXD!"\0"B>!;`M(RN47H'8H[DV(^-
M)R('X#S@L8(5UF)$*3F@T1P<@)3'A@&\UF+G8VJ<(8`<$`&^IF,0X"6"MUXN
MIA9W8A$()Q7<\U`&D"<64AL6\D6Z0S;?\Q/,R',W)"?YY!9'47H/<%#;H8"P
M]P!LUX1NP30>4!>GXD#QM".]80#'<0&RY!0LQ5J7PWV-A"YYZ#85$1OWI%<%
M5$XW(0!7L@`5MQ?+_L13M`4G)Y$AF_D2+/DELT.4''%/W44QAB,KAE5.`\`9
M0X1#V\&3;1@I-<6)&>4<C[0``]@K.?%/8ADM-0-7HM@6$<!C`>`E)W%.\(DE
MP`EE!Z49`"!_"0&2)6&*3G$1Q"$<&4`<Y<1)X)2:HK<JJJ)=`4H`U0*34K$:
M4(DN(@-$2C1(P^06AH@E]N1,+C$:.'1%[].*,#@D4<52AZ648S8@F(-Z)4$L
M=^(0%0%6J)8FG1E>-G114E4F-Y6BN6E#`P`!#&"=H]B&^<DRS/(DG>0B,-**
M%T%#`L")SA0F!AH5#T`<W$*9&1-:P64A<-4V%(&8)(*<4C@B_7-:H^$E_K<A
M$+=T73X72#+Y%NSA%HH()S&QG7"A?2_C(GXBFP4A`'.R4E,H2Z%T-0>P$EO$
M%7\*'D<C%0Y@`)>3`.T25\MA@Q\@AP[4'$R#$!`@&6G8``+@`*-J&@"(*"@H
M.ST4G=YE'$*1/!1D&#TAD<,R1\H2%<&2$W^('F@A`=.S`=VGJ;5"1"Q1=_3I
M-LO($8D4A[*R?]'B`)#Y`0:@@J2:%*8X1E;64@"5@5PC$"E"B`VC*@T03A:5
M+Q@C%6`Q$1'T1'?RAR4(J5%!AAL*)+"")7DR&I3"E%'A`8A:0,&E72Z"2MHB
MJE)E4R4Y`+K3``@6L!51`(Y:*Y]8$DS3')5!_A(KA1"_6EU+I%48Y#U.)$?O
MP0":TROJ6(>OQ13[MT'8A!"_"$G,UTFGT0%>I48N$2RGU#<!@&1-@BMU<24:
MRD#VM4!XB!O%81SQ>',[U#UX`66--T9NX3%C0XJX`A38QQLCT0%<E2`#$*;\
M"A.R(1`-4`%A6QE1P7T(.#8.^R4A$;85$$D5>S2&N:S8M;9`X1+,4SL!L"@T
MF`#9HH*;E1.'PZJ:-2)3^RIPV!9,PAF0FK9,`0'7=P$JY1((P!3$0@%K>SUR
MTWB%:*RU(@`,$`&S(QQRN']W0BLOD9J+0A:&T8)8DQM64:.<XT&XHIPBP@!K
M6U-1$:'^:9V[&*AN_M,L!G$E]2$4F903BOD6AF@1"/!17#*LHW(YWU<6$7%P
M8<M#*]J,DW4^#0NC-M,PHL0LCD(J9&2CDK<:A?L>GC,VR(D>3*$6+M&WH6DT
M*M*I6P$6$K"V"7`:9U$M"I`O!J.X3_1G?;&V!E`63/-V-U0`$S`!L1&F>FI:
M@')L81$:$#4]%A4>$5(^0%<7.>&I3,*H6&H^((.FWJ4K>WH[!GAK3]$YFD4O
M?B(``_#"Q-$!BKI;9JN;`<82`J##Q/'""-$B%'$`,2.'K@'#19P?%!(7L[L`
M`Y`MW1<DI+&J&FJN2I$7JH(>LXJX<<B>07P^RM$`[%6)#^*I/`S#+K)__@K:
MC$."'KJS/G$[A_[#%OU)P4_L)462.N(TPXPDNQ)B$3O\PC8SQ5]R(?!'`*>2
M*`[0+B48K7F26O*:%!4`@_:D;6/9`0_`+?'T&6#QQ\11`$)#@1:A64SS)5R+
M*`@6F*#A&W27HQ=3/U4#M_P9M4D#-]8),Q#292B2$"-"-KD1PR\\/;0BAV18
ME8*1`3%1Q"_\&18B>1RPQ`90`=`B%VU".7+(0'L7M(F2Q5T\JS>W$<?*'6^W
M?RYF`"OQOXNSGW%!N$K5/1K`SOOV'=(S+ES<M2?&?`)B&$X\D=P[*FN$'HPJ
MSY3D7:'$%D@,%\H9)&AD,@1B1*NZ,A5S5L#R_D)!LJ5L41><@<M0RY\34``8
ML$@3H#F<(Q5G_(#&2J_`DD"8RJQ$)3"FV\!S+!`<!;Q\,L\"P:AMH9P68</1
MBIQJ<0&6IP&+42;`2P"EQ+T2T"T!8+0<RA+KA1PV,I;W='`:$#6..12(F+:Z
M$Q/'5L^'L1<RLT`$BH%L`122]\\3"-"+/&9"^BH$,$9Y0AOH\AU<EDD(P1M&
M!LRRXK\BPR]J07=C"A<X#1>5@G")@AMSL[!=2-@/PX`Y]ZPD`P`$P'<>0$ZW
M$A/O`13"L5'`8\(!LU<.(B^SDW+_+$N8*"VR4K9KU[D,XGQ7HE*)&5P_;,YN
M?(;J=0`</(\V;2\._A0M"M")$9!'FF,1TZD[(X*N88/%=J&N!5'/C?N%W?$D
M53LJ"/`>(CT7?J+&:T01W8RIWT'=117'+2TM`W@`^;),"80>T6)16E2,2:PJ
ME]00E)*[<7A]7T).+ZDCX%4L?L+;<6&(&>"*:6'8SD,U3](!3\$26KLJ#N#)
M1=B)(8LF`(-.)DT2&C``.L46J]Q+IQ(35P+-L,RB%K,8`9`GN7$9R34_`-#&
M$CTGE,$0=UVX$X%'B?L0KRH[^:',:U<`U<+7<E<9+G:5B%+!*D&4`T`0!NS5
M@KESW&,`YH6W`Q"IPM8=IB93;;.O2^$07H1+29$!"Y"Y`0-R!E02D5%M_C:U
M`&6^`&(AVIQR%@DP`?4D'J?=C3P5`1*0`*8J7`C`Y`K.(IK5X3Q$$`4^(`Z1
M1@1M`0SP=@;=,$CT/GCN?.(1+`T@`=PRG4P$-_)S$H8;YYS1`:G);2Q5&Q\A
M*Z[!&>H3J+TJ``A!*U+=Y13D)6W2`&U>S^Q!$-V]TG$"WD*;'7@K`?7T)'7!
M`!.@(W:EQ\9RYBNI*@Z4`.8%`-$2WS1^1,(Q1$<CO.ABYQNP`&J'O,<A`1&@
MPF;]18'>39K#)`LP`;])$`L;:1<Q`<X7G_-H45V!1\V%XF;.``Z'X3*3(>;5
MN8NS@J\\%&J=W<L>A_+#[>++(F-Y%+]>7'+$_AG!+!G/NN0]D121=%YB)19^
M_90%(&&]2^S(Z$`-:^;GCD82X'QP<A8+$.F%;"Q4<I>:@4E<WG-234X$D0&Z
M-9@)^Q2Z5A&0:IATXP!!;0#QB`%ZKBT-('W,QA,,T`!*SP!B$0%),O1*QE4(
M`"=W=!D.D*<8T$4->RB#HAFG]O0F$=2<"*_B"C/2H3L6D$:IM)D<`.GJ-4;*
MRR41$%DT49QV\P!J#`$`90$.P'OQ=BO'@D,/,"YZAAOU8XN^P0#54O.GH@$&
MD*=!\EPE00$(\!0=XM]7I`$-X/B</]!+668=M4G2C6J6KP#9X@`E?@!(3OD*
MB`&;=`!+JI>)R`"?_N;V0\(!33]*LO@BM?\JJ\\6'=``S:$!6M'S+#'\7Q'W
M%'`!1%\!4U\FR[2=,H\`?E032F7VUH8H2\_]OC]*-G^N6A'[M7%P8L\6%]84
M8#LJC5L`#0`P%N#Y%6CY"7"BNB4!\=4`#"4!O:J\7Q+I`%%``88/'RXX\%!0
MH4(.#0H<F)#P`X<#%186M-"`@4:-%`IN8/!PPD(*"`HLT,"P@0$##CH4U&"`
MX$6:-6W>Q)E3YTZ>/7<NV.!3Z%"B18W61"#QZ%*F32\R2.E4JM,'%Z9>O>A@
M)E:N7;U^!:NS:EB:0,F>17M30X.T;<E:B.!6KD^02N=V[;#`[EV='/3R_@4<
M6/#0O'O#KAV<F*EAQ8UM,G8<6;).R)$K3\:<6>IEKYPU?P8=6O1HTJ5-GT:=
M6O5JUJU=OX8=6_9LVK5MW\:=6_=NWKU]_P8>7/APXL6-'T>>7/ERYLV=/X<>
M7?ITZM6M7\>>7?MVPAM><@<?7GQ-"`H*&ACYV8/'P1DRD.Y@L2:&J!K19A@`
M8,%X_OVW.SB@H`JBTDP"`CP[*P#V1&L`@9H\",""@A1(`*T&"-B``_\VY%`Q
M#S+88"\."+QH`Q!IZB`##7WR0(,,OF,H`P\`K"G%H'9J$<8482RHQ1`_V+'$
M%VGB8,B")!C@IB)77$@#)B\*<B$;H011*0`6_OS@PR>SU$`#P[K<"\R+/-@@
MJA2W+)+'@M)4B($*401`P@\6J%#,A=A<B$PFEQP3SX(6,*]#00>5:X+\`#C@
M1@08""#"BR@*``!$-=Q`@`@$`""`N"JUZD^V+JJ``$D#>$"B!B(5*,`/"I"@
M(`@P#0`!#3U@5:$!1JJ@@`0`2$"#`5[-M-4/'*!3T@4NR$\`]CI0(%)+$[J`
M``B<]6@"9]_+\]1,_^I``$8%4%,`8`40]H,(#D7@Q@DP!<"`E/(+@($/#G!`
MU``<4"A420O`E@$&#I#T@!5CDI0`.<M30-($,+`W/0\6B)34A#2PU-E6'8AT
M`!X]@!5?!0Y`0%(#_E;,RUD($N*X`0`$X,"#:;>5B%E)!2CU`P2N)31GG;NZ
M@-01#R@@H0,"H$]-!0R0T0)+/]B@7149`."E1=<,H%.&!&B`@PXP#LI:"CJP
M5M4!6K56@@XP*,!!#P:(JR`!1J(`@*R[=)K9`!)2&0*P`>"7`Y/^E*D#"@*P
MZ`(`$'`2@0-!&L`"-1\0H((.+!B@`0\Z0-3$O59V_`&B/Z@@`+TS>`A(33O0
MX*0/+`#@@?<,",!L:T?2(%X.-DA`XSD!B*"#GA_(D@"@./`\J`<`<*D"``BX
M@-D!\"8`@_C>_B"#=IU40(`/$S#`@KV4A^"]A/7&X-Z"0I*>`F6S;'<#_H(D
MB/QL`CY5@'FP8_\``P0.<'QG__]?R@)4]0$-`,`J!P@432JP%02PI6GLL5Y*
MU/>2"1P(2F;[R.>F]B>QQ>4`^\%(`+S$-H60ZP.#BTH!Y8,!`*3D0@GI5MO@
M-Y&JM<E!AIM)Z#2$I+UX@`#`.]+=,%>NBXBN1P9@2P+>E#\`J`@`>F/:=ZYT
M'GEE:0$.<D#0J.:1HRDD`?M1VG=H!8$/0`YE`P!BZ#S`,?D,RP#5BU-!#!<4
M-STHCG/2X@<48)X...I\:N.=0@Q`QH*LRP,<`$`;'?*G!`+0D8_<24L68L(#
M?*HF%X```PR`/*8!8"8%?$^W/((`?*&(`@ZH_I\G/S`VA4A`;*TR84$PYST"
MM.T#)AS<=PH8E0A^H$&R7-\'UL5$2163``8!P(HL$(`=6O!.!E1(!&=I$U7^
M\0/24@B$*.`!E07@`+TKR!0_@!Z%1.!`7UQ(`8`'*"_N)P+%+.9^'E"`'A%`
M6&HL(#P!H+%=%J1\*6&`@VCB@3ON42%T@J,^#T10]G!,GP!P'T05,L$Y-1*2
M%\6H0N@UR595TB90.P`#(H#$3F(+E`5I0`(V$`!LW8D``TA``R+P.58>J8.K
M+!<'(K0V6P8`5P'090L+TLM?`BF8PV0A!3"`@0M@0$8]4R8S/\##1_F1B=ZY
M(TV:V*8*8;-'XLS`_@,`EI0/*.@\Z3'7@10`PH*HLZ(*,>BYFLI4^I3QC<&[
MY]V:-H&ESA6.46$A0)<HI8(N,:!P5.I<"<)08#Z@KTOU``MO=$)PO36CE\6H
M`*,)38_29*4.*X`#MTK`T6)```ZXZT4NM2(6$@0!;/U705CY08FP+D2_6A,`
MX`94F`CUK[X4J"@+*0`:HK4"A4MF")O9PQ^64WO3K`D`A.4!22I1(2Q4$3B%
MF5QQDG1"%:J71'3*Q00:-'0$D@!!YEE/8;%NC9I2B`4JT"+?_O,#AQWH'1%Z
MO@KIM%S'S9)9VUK%_$4$<PO29$+8B5D&.Y*%#C`12Q+BW:K.;0$`D%?3_DPZ
M6NHNC282(!P'+E``:"I/`AP(FVSC,K@(B)@`"4B(2;J4`/R%+JB\%&I1A2M,
MXLYI`!7@P."`!U7E3E4`/UK(JR;`@0I@#4A9O<@^+[`!C*6$=1#@`,,"M-(&
M;&`#"["@Z%X".PIP8*82JAT#RH0`W2U8CWPL`-*H#$T(T!.O`KJ;+Y7%9"?W
M\JJ^'%E^,4BA@[Z)`9$+LOD8&\061TMM"V@<!T`L+#=;H*4-QG2'*&"O=!4D
M`4"DR4Q7U@`'5&@#`S#I``@TT\E*B<;+FX`!A"7JT+Z)E1XX5Z84\!V&9>H!
M"?!(J'2I:I@0^P&!\J&<*&#GDF7*<OD;P(JB_J4ABD$S3PZ`U;,[T#AJ,B`_
M!&@CDC*5@!49:E\SN7"%!"(J<M565(CJ%X']!9.A[7/6JJ)N>BQ@P0X<>ELO
M\=6-\!.494KT(KLRS[Q1"L)F>PMEX,XFL&)UHX:?#*55I"ZH,[UQ__BH)ZA3
M$TX88-$2(5E*7LIF38'DI#%ER"LC"GF-4(XB#<0\NE^;>3:=9!<?*45/XT1(
MS5O>ZIR4"4&/$GI?2)1-E^=D1%NB.=1ASG&J5]TG%9B6U8RB@6G)23?B;(HD
MK3YVLF?G`;)NR@1">W37%*"-3%&`+<L^=[K7W>YWQWO>];YWOO?=[W\'?.`%
M/WC"%][PAT=\XA6__GC&-][QCX=\Y"4_><I7WO*7QWSF-;]YSG?>\Y\'?>A%
M/WK2E][TIT=]ZE6_>M:WWO6OAWWL93][VM?>]K?'?>Y5$X$V7J`!('L`U(7R
M'0JXSBL/>(#-BQ*!X->([<6_]%(P\("W7^4"U,?*=XA'R-J$%4MK>D`$(*.!
MYNM^[\J3S_'@B>JB?+F4N_K^9C(E?*/D)_H>D$`>=Y(PM#+EG03&BN.QI*;`
MM;NRGB2QC0G0#YJP'F="D0%@*_.[.UJQH+@A%0S(%41ANX4XGE)R$>5;"H*2
M*JFPOQ+9)[;C/ZDH$J*;"@&<"NO1H@)"P-HHDJ6#(P>D"96)/@F<.];!_A</
M`!A0BXEG`QWN28!P:X"P,@`$N``/N(!-DB0)2$+0:0`,@(`#.`#VJ(`&D(\M
ME(\,6``#.$*&0*V%F3\%XAXDTI"M<9T%*``UZY&S0P#*&2U9@IH`F,(.B(`#
M,`"HJ(E=B8`L&HCK4@"!T#J%Z`"Q$D/V\#WV^#(#6``,:``RFI$'T``W-(LL
MV<.68)(*0``#>``'D)N:*`D#4`"OBX`&T(`L6IA'21BLH9O&X1Z7D*6S.P"+
MNPC?RP@#L(@,.)H$D)`9R9J/F,1"^D0XI,(+$"#ZT"1(;"D,^$6ORY,K7,)M
MRI\&2`^0.`GE04!<XT,'8"T,X\&[@QH)T:DZ_KP("-@G!<@/(-H5`L#"3-D`
M$,L4>H(_7UJ>)904@A#%4NK'ZA&``,@=W<J2D"&`[#G#A6"=`3@:7J$A`7@Q
M41&H"V/(0[FT;I&4Q@'"=J&QS[F(A/&FD!&`]U@F`<@>JSJHPT%(B_B_B1`5
MD,$4>H*0`(A(#;POO@F9`GB)91+(`HB4`2P(461(3!&632*`3UP9'JF4C'2J
MC&1'<?2`D(G'P2J(=SH4"S"M`'A*+@JD86F=,EH>&AN`H!!*28D6@=R5(\N?
M1GG*ZKM)!,J/D5#`_>``45E"3+&@"TN;=GD)CGF><:P[GPR*IDDNSPH``4B)
M4Q,JA,N23;((473'_BE2F0-(B%TAHW_T2H\)I-HA@,E9GI>0@(14B(,@"!FD
MH2FR'@"@+[5D'73LI+\,3;**&P/8BX2!,7QD@(U$KM3J$0$8R?QQ``EI276\
M3:B1R4BAG4A)D<^\R8X*I`X@,:`\0&IK%`W9)+98&VO;K!C<Q]59GA,ZG#4"
MF$,,3<)IPET9"1CT`-9Y(Q^"*)U22W7$%U$4@`MH*D0!30A(B9#QB/+1O^#Y
MG`QP`(N82W.Q2:&\P9>`FJ+T+<`DN[7A+<)DP>U*H`N+"_3TM"G"S%VQ")4I
M)94!'LS\1TRQ@#(1%:X3QR<;P2:!@`3`%.+2*:GJ(]6,&X'*SNAKFK^\_L<L
M"4BBPU!DTLE&P8`R4<Z+V*0`0**9:,D4],[CE"B,E#1>*9/0W#5,N1&5`4IU
M)+![=,SS@#(XXLX>:T!N0AX-V``0O8C0Q#=,F3)?@2CWU`#6<1#V+!/E>2-1
M!*&56AD$@("@P$CZ<-,GB<IZ;(!.*5`+]:?EP34`4``S?:=`V95#=%"JXQC>
MVK9$0D0$B(B6#,JOW%$,[<`,]0@T]<H0Y:3,_("',J!099\5+0@+)*65H2%+
MC10/4,`$*L&%R%&AR2I1B;Z$@:#E0:2'(CH->#5)`9Z6Y,]$/<X`"`J'X@!U
MU*<#F-'O4$>@A,R4;)5-DA.`D48PG9A]ZJWG_KDP?0+*1_VJAR((=7R`"R/0
MASHFS`2=31H5QU%5'#W642S0A!$6TU0_>!*HA/G62:6Z`>"MW0DT?'R>&I6(
M>_S1>\S6#[A'4LU64?P4J,&7_,``#N#8EJ'2CQ!-+[6(IH'11GF)&5W/=@$F
MU]S5W6F;/G)5/7HB`<'/@'22CMV+#L@0"KBP`#!0>8$:(`K-9EU#3$$Q1NU8
MK;G1\QG%A?A8+Y40;BT(;[T(]20M!"R@`X',I%63T`2A&TW:A%@I`@B`OS0<
M@4G:4F6(*048!:A4%<%9*,F0"KA#6UU`4F6=`[E5KBV(D-D*@JVZD(D*Q12`
M!"`QZ0*2_-BFT-&=_D^=HN-A@)?@4'P$HFP-30-`G?S`%Y7)S6B!L=HAFGX+
MV561KAE9F<NI3M-138R<+_6+/D1B&0]0'@+P$JB)P`G9IYH+&3*RS/40GD<)
M2(+(VY]%)F6I@/QHUF<UVAB5$3?T"*AQ6]-J6H6H%,+9+BV2VGGYT@/L`/K"
MVA,TG`+P#C[\VZE:0*:UG'USVPP]U6W;J2R*BX@-G0)H&<C='810WT<Q6`GI
MF><IT(6L.8!9G,.4D:.1#U$!0<#%+'5<$`T`F)D1/SF"E97IE(>=HM8$EXG]
M2K55S,-,&'SA`!)K%(+\`&GU)H/=DG?*E)=RUA@]V5H%SWHDL?NSEU91_K](
M$1B:2)AFP6&`LY=,&5A1BQB63%$3ULL`<U8>3:[RC)1`J\M,T<KIG:@)9K]Q
MNB.JE1)XH0#3)"T+ZJ9(H4H#9:LG;A2?BB])(9#0R93E(<L-]@"0C!0,89H?
M%K"%L)8U-BNOS9([U,JRK4HHYDL:&B`%IKJF`4"F:2HU`9L'6+)HLH`5R8!'
M%I`'D(`/D60-N(`4RN2/B`#]Y``+B(KU"#\2N;YMP@#OH8GKFX`4>60G;,(L
MN0"ORP`(,)M(#KD-@`#]A`GF0V4&;)[IBPA$G`!*GE`"8CX)^)$-`&7JG3+#
MN2O[1!EHA@D(>`!KE"4)")]/ML&)D`!&AA&F_F*M"X`ZKNM3W^F4];0:3'J`
M@47DBRR^""`15[X(#>CF58:)$ET(=?X:1'SG8J;G45X32^L1"Z`^>1XJYK-F
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M[,\&[=`6[=$F[=(V[=-&[=16[=5F[=8./2^#[=B6;9-S;;'6V=G&;?J;BF%5
MU8?2[=H&7`U8JJ7CV!H1/N%>*LA2".1V*N43Q=[6I]OE"MZ&[F(J9N`&7`,P
M6(MJ@$]YDG9=$XF`$`$8@`'`%`)IEO*.G)MX[NHVEK"@;O?^;>QVT#4ZMJ>H
M(N91"%0ZCS9:Y35:*?2VG#6JC/9V;^G&BOBN[NNF;X(M#_QVFS;B[VN*/QI"
M[U+*"0.O;@2_"@6'[OEN<,!\\(50.`'PN@DG@/C#/X/3HP;H@.[%"0V'^VX.
MWVWWAB<&#W$1MZ@2E_!`2?$QP9C^2YA,^4V;D/'>IG$5M/%B`O$<E\#RZ`!W
M.9_#Q!2!\DK?;!>[N)1OO1TO.P`BRHHE/]^O\/#>QG$G?_)=8RF8Z"OJ^8CD
M5KF"`.^;0``P7X@C5]4D=XHR5]4F1_/<*P^=VD$3KXD?Y\#;9;F^M?/]%G,]
M;PH^)]8_!]PK(@`!")E!9V=#5X@Y]Z*01(!@J@D\?RA'9PI(UR<_EW3:HP`)
M8'4)"&90B;G^:9+RC:Q6M^90;_2PP+\)</5>Y_5?[W663G6DQ@!@-W9?EP!)
:'?9E9_9F=_9GA_9HE_9II_9JMW;K"`@``#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>y00215y0021502.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y00215y0021502.gif
M1TE&.#EA[@*4`_<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````[@*4`P`(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1#Q8:0"@8H4&%@1H:2/C@X4&##`.36OBPH<$#
M#P,A7"6(P2O8@12<*KS00.E`MF8_6&U+UT&'#V+ITNV05V^#"7@;8/C0=*O`
M#'\'>J"@P("!!88/+EY0P`"#P0([./#;0(-!#@\0%$`0X6R%!A0&<FC@X*Q`
M":@)>MA<5P('@5TY3UW=>F!3S!\T.#A@((&$NP+%`O>M%\*%@9HY.Z`ZMZT#
M"1L42T!@X,"#VP@M_C!P#%DUYP;@CZI?S[[]40,``'@>B`#``/`6`"#XT&$`
M@`-G00#``Q]@`(``KA4`P%,#*1!?9!\P`$`#"D407P#911C?`&#Y%]^'`=Q&
MP(<D<J`@B?$I\`%\J<$W`'+YJ<B?@R@2:)`'"Z`8P%(?<(!B?,\1U,&)'R8`
M5@,`,`#5@>EQ((!]KG7P)(H">&;@C_MI`$``R'UP``!3?7#!E!\:D"&+!L&'
M(@-@2?FC`%21^:$`6'V0`(H%I$>0`S\J^4$&/\KGWJ"$%FKH2U<",-U`7R8I
MT`7Z\>=AF`(2:."+`RG((%<!Q)<`01)2F)"%\:7FP8A0?N`?!1IHL(&K_F"-
M*(&KM'KPZ@9W,N!J=FBJ*6H%`,C(IP`19)`!C742).".QDH(P%8<=(H!K1MT
M^1H`!5R@P02=;H6DG\$=V"6I`*26V9,5N(J!@DH:2.>KNX;+):-@]OCD`19H
M0,&("("%9D'P0="J!$]&P%^WM+H:9[FM8@#?`@4>2,$&%?C'(T$4Q'=5!@]T
M.I66=";LVJ$DEVSRR1-)>">F`M4'I)B1]K?A;95&C&"F"X:E7P`8#A1JA0#`
MI^0&0:?J7Y`%C;BI03G:*%"O'V(%K(I.EJN8`F/)5K!B.>X7+0#6&B2@D<DQ
MX*VC`H$,G@?PW;G?N0``]T"D[HZ<]I9=?CF5_H4$=(F!M"M:#3``@`G$]\&"
M%N3!DT@+:`!2`/0M$`4,A$F0T`3-38`'(-N-\N>@AXZRFQLH6/@']<%G@`>0
M[B<SNQ[4?&F7F@KD@8(7W.GTSZ,&2\#F$RAJ](02%"]!D"-*93R$.2[ZM-6J
M_^=!C)!SR!"@8!.4GP`=?#UMJWH*="4!#%20'I('&#\W]^)'OD&G\[F)60=?
MMKNE\<5[IF4`$1BOX%1W<M[S#*8@<UV.<$O"D)L>@+_!+`X`0>I`?2!6-0$L
M8`(9*D@'`+<D`+SJ0-_30-A$1\(2FE`HP=N/@`Y`KXH!(`*MDU0`+-"I"\CN
M0`G*&>0V!RS):4A4_@BQT`(4$``-Y`A8UO,0B2#V`521Z%,#:1I!"A@X%TI@
M:A^0`+8RHX`N*L!R`ME>0;0$``Y\C40"]$VGXB,`&R'I3>"1T'0<)"HW"6``
M`NC4`*P4J-20\4=3@0\8/^"@Z?SK@*?K0'PT4#443>>!=Q3`DP90)PLH,0`+
M"!O1>J:8^$SK1P8[H2A'24J;P`<P/@)`G>IS@8P%((4RY`"?"C`W2]F'=L\2
MB(,()#,&\2Z(2;*0!`9``$`E$0`0J$`%+%"!.HWH`<I4YG*:=\`6Q2UX`@B>
MBC*V.?Z0"%R/VE)!`!6BKUG'`1`B"`<DH(!)?0!)"%AF!;3(OJIY!HEW_G%3
M`5#5`.2XBP+1M$!V]@=09O[/2R\L2``#9\"!G%(UB]P@F)3)3,_H$U4,T%,'
M*(?1@A#-@T*2UOY8PQJDE?*D*$WI2+#'LS6*ZDO/65G,!A"B#HS(/P0"U,T$
M,B)H=:JE\7G;+P]B(08`2D$+T-(Q33H0I25$BCBSYF"^Y!\5&8B3'?"`A,#)
ME?@DZP/!X]#7PE>0"TQ@;5U[)]K")8#;:'%+/(L/8.0G%Q"V;Z<$V5_>ZI4C
M&=E.5@Q-$P(/@S>)SD=K$(S=EC"3`0K4R0,6LIYBT$402(%-IYY3J68WRUF*
M((D`!T``<<2%.@@&9XVNH^EM@!4?`OFHB'##_DID0WN`1GEFJ`8IJ@<FI8$`
MW.QH!W$J0JCI4.C%[;0IH@I2S^*!7!E$063KT8B4-%:%?,EI<]O/MY;$/0]\
M:32A'1$+Z>J!^DAN=@;1*[VFXLK&;8E7@D/D0.")N,-.]KC-O:5:H?@!)-K-
M0098VY=8V+G.&OC`"$Z(FY"VVWJQ,CE!C:5`[C0@JGS)`,MTD/4.2J_I2,@`
M#PCQ`TI#$`M1R&49>!^<&KP`$8<X.R-2@(L?D$'B/D^J`IE;L,(8'P-LQD-I
MA!FV?FR?[*1RA`1YJXQSE-#MWHU[5TT/&3-`5TY-*&(!F'%IU"L0O5&E/I@,
M36L%HB`9BQ@P\#'S_IT"\!PW><7%664<;IYDO_]8I5-,S*L>'>"`$05@,`5.
ML*`'S=G@=7,@<UO=@Y4[TQ#AIE,VTH`3#_0<2,UK(&'MP!M)Q#+#75E`'%)Q
MAP(UF$E_*#)0);-QYQ?C@;AP3E\YR*OC4X`Z55<ASOK0`HZT5K4AR:\M2U*5
ML[C81''Z3UMRC9?Y0^$+Q3IP*-J/FCY$`,-(]$<;>"#2@F=:":PQ/@<@:X$F
M/0##!)K0Z$ZW*#<P+0UB(`.<PT"7.-#N`L$;*AA(3P<L$($(5``Y]+8O53"`
M`5L1_-T$_VJ/,&#D=GO`6(<Y>`82?I>)(QSA76)W!H.3;XYGO-ZVXS<,_I$,
M'9%?P#4>>'=FQSB!_AU6XXI1N08Z3I`-&.OA!5?,Q*MU\(MC)>7W3AO-#]/R
MB>6UY^_67\\WCO.>3QPL$[<6P3/$`0KTCZF*NT"_+8!RE:O[ZV`/N]C'3O:R
MF_WL:$^[VM?.]K:[_>UPC[O<YT[WNMO][GC/N][WSO>^^_WO@`^\X`=/^,(;
M_O"(3[SB%\_XQCO^\9"/O.0G3_G*6_[RF,^\YC?/^<Y[_O.@#[WH1T_ZTIO^
M]*A/O>I7S_K6N_[UL(^][&=/^]K;_O:XS[WN=\_[WOO^]\`/OO"'3_SB&__X
MR$^^\I?/_.8[__G0C[[THQ\!!C!@`=;'_O65_F*!$3H@^^"_/@.X3W+53&`!
M!OA=`1(``85/+OS:CS_X&TJ5!HC?:0?!@/:Y&A[M+PH#X(=_`[$!X-<;"O%]
MXI>`V.<`Q>(Y%Y!]0*1!E)-^!#`:#Q!TV@-_&BA^A4,YUQ=DAL.!`ZB`&XA]
MH<0?\D>"#)AS"U$!X+<<'I6"^W<=`M<C)0A_%Y,!X(=D+HA]D7:#)!AK$J!]
M@P0=%(!^OV,9_Z80&Q`!";!/!&``7R1N$5$!VN<T6B5^Z909$)A9MA(!"@"%
M!^``+#A]"M%L@1(?U98T:8@B`R`!7@@!<H(B"2!P?-*&/Q*!_84B&U<0W"9.
M#"$@:F@[TQ9?MH.&_J>#$+>#AT42/F]U(#<2`7-((@B@<.3"B/'!1'<8.0CA
M,FME;(S(7Q^%B=FR$(689P8!BH$2``Q@+:.(B8_#8Q<B;IL8BY:%B;0&%LV&
MBK8S3&E8`%M('=]&)2=($;782=0V0JG$)`:A:</X1'UHA@J%BS.D&$2"B<68
M&9[8A@(`(9N(BWJ(AA6&$'\8``TAB)QX&-]V'P3QAY&R$*>"B]AB+8\()T)"
M(W@8``V%CKBHB=36B1\"+JK8AJ(HCW:%$-@#(E0XD($275TEC[$(.;-X$,<H
M9/)8`+JH:QJ$CVV8B%3!9'@H@!%1D53A2)\Q)^%3.HQ(2=*($.+8AIUF_FKY
MR'3;J(8$,(=L-A#?B(D1^#YNN'+E>([_B&A+-(!D4B4-(9-M*$#U*!L@26TW
M^2.;<HF8Z(^#>!">*)`&69`&N3H(L6D?DHT#P9"!<H*OR(@1F1\7$HT?4)&W
MB(L8:2<:R34Z\CL_8E*L-2=VB2)8]Q`DZ0$ZHG#+V%;J=(WV00!*I(94:(;-
MA@`;\)@V)X<D<CI.Q`"0"9D64(@7@Q<DDF4<X`&@>0';R([\<9D;\)8"=9G6
MPH\?LC3M"")">96V<XT,@H9B*1E$8IF7N2UD(EG$QD9)UID.D&T#MXT"D"$=
M8)K&-C&7"1Z;2```&1]:>6JF:9KI\8H89)J^_A@U!R$S>((0QI::KV(!VPB=
MN$$BS%F=CYD>:KDEM%@FME.=3C2<S3EA<RD0[C@`$W`7G,.17AEL:E@!H.D!
M')!K.V:,\&D[6#(R@ZDG3WD`)Q>:A0B"TMAL_)451<E3'P*"9W2@/?)M`@"#
M5&&@(GDWW*F(1$(F;V,001F(0SF6G,8![LA"#;&(\0&"[I@>39D9E[2%L_%-
M"+&,ID61+UH060FC)\H0KQB,>5DO!I$Q%T(B?6EL"E=>))(A2^H0[>EH!D&2
M!N%$FTD0NZ@83K1'3".EMD,FKNE='])I(YF@)?DC#=6@`Y&0^F$W-C4GY2=]
M%GH01+*B\XD0T[:B_OSHD=!!)+Z95R3B?F\!(H\(4BP*FRXJF_-%(@I`)K!5
MHT0"@@G)I;\)B?A)(F&J&(V"-P<AI'W9ED5*$$?:/DFZ$%EZDA\RJJ5UH]/&
MBZ[J54]*(I@1JPRQI6SII6P8'[0JEYGH:NAYJE.R(W`C5P9!3U&XIP<(IX#Y
M(YU&IP*Q:9Q4$'D9HBTYC9YR$(,ZFQO:G6229Z6:J`7QJ'WY1ZKT5!^B``\T
M9I%Z(;&9CD*BE,CT$#:J*$0%IY]JCX2DIPD!I?'AF@*!J@CQG-'YB8OJ$+Y*
M%LDZ1HM*+IZ*I+I:$`9[7`_Y(%JJD$3:8PD!IBYYG[F&5QJ;+B.3HA,`_IH=
M\9=I"$38VD3QJH@18`&+R9A%DE[?EF>!2A540:!/63CS"@"X6G,D<IONRJ@?
MVIIJM2&>TZ(+@8[F65:!\I^:^B$-X`'=PP&O$@'?UE`[2K/AFA`=6J(^^3(A
M&SE9U;9<RZ;2B;%@8@%T6[=U>W(#2"*1`18/=XTUJ&-!0Z#?)I94>J8?@J6B
M:K>*RW48.I%="K##NJ\',:;/4[8/`;AL]$4:L'(2`;,7TFQ_EK`HF;"#^ZT2
MT:=!VP$7<(V64Z:.80#[E)B1`QY">IOWI3$'L;0(\8C6LYSU"HA3NZH^$Y@0
MT:^,J(<[>FW^JA!*!&P0]2&INI.,.)V8Z)NO_AB%L+M/<^B\5.%$H82/<2FQ
M)PJ:JT$BAW:6W-@EP+JV$?FELUJRQTH52J2'#,$!^DH^>&L1GGL@&:!$`-(C
MHXML3FNZ$-%L`E`9OS.'I$FVF.BM)NJL"=%@\4NQKWI`N*MJ$>:'DAJ\E*I.
M<D*_\*BO**(`8;.C'6J[.&.Y2`N]"VN0#HN+UMN59+6^>\C"XJN&L(N8/W(Q
MZ)N&[".+[LF^(_N^DSN7;D*O$)$!(OP?(@H1^\LECXI*`?R6J4K`\,N(^D@0
M2WPA"F!?[DI_BN-$W!LN%9RK'$L8)")P4JL05(L0&\NV$;'%U&92)ERZ"O&G
MIXJF:XN+U+N2KM'#_M9J%P>!CRLJP49KM;CXO^>)BS\LD4'\N"*+$"1;Q/%;
MM"7*$!WP`+)+(@)0Q0SQQ%E5JFV%K51LQ0_QDM9*?TX4`'A$AV356Q]2A(@5
MM^GUL`:Q:>$+P.7ZFO8ZJ?BJ3IL,PA%,)`20``J0`,9\`)-&)P-1QQ]RR4VU
ML[*JMI"\)<:,S,=LS&32QPS8;][LS6#TBI%4(R37H0VEK7I"EI;JBM_TS>X,
MAXW[7D(LR41L$)1;M,+<$/O6``;PC'`\$:!<(-^640%L;`AKRE?,RL14@0<P
MA>ZK,:"9`=N8`&&CO/FLRTBLJ&5\Q-BR`![MT;TY,FN<$&ULN'?)KYMZ_B,4
M\&W\M:.&?+30\6T@G+9#6LU5:Z0!*;=,:Q"O**#[-FD0D%F7J``?O0#;6(S&
M-@!*G80(X`!8%[$*L:7BEFOM&[G%2KD,O**I6(-!>H3#:*@.$=!/>[`!_(HH
MC+,(;9^>,J`,\;,6]D1V0R0%H!#N>-"ZJ\'RV%`CC1`E31!-*B<%(*W6N,L&
MD6N7-K;IRKGMZ:0%H;!K>].LFM-FO-,>I;=0(2>W*<>Y*+<%Q[EY>VH.86Q<
MG6LT&ESU#*Z'K$MSLG+]7`!DF!GL1@%-_#>2W;G4"B(`IT1.1)CR6[-Y'``'
M``$Y&WVHFY2$'1R871!@&8Q=!K*U7,8UB8=:_KW7!]'7"9N8%L"1%'HC*7T0
MCSH?8XNY8#P0:,C5CFW3#=O'E+W"'HL6G0F#ZGS2DPVQEMT0[MK$Q?W0DFO/
M]UG7^4<B-I(`J-6P%^K$MWTA7?+&;)0>('FQ.F/#!)S?"^'6UP(B7V5L!"!N
M0XV0MMQ!\A@`R4+=8K.J3TDA&R`G3<S=QTT08`D>8PO+&\*6,QJD>HS>6%G;
MA=L04,V1N?P!3UF5C5K&"`'5"B;3S3B_0TRL5YQGC32[BE.J[ZJJ%R*B\3C!
M;QK)<6JJMA/=O.W(P6(W)TYMGDW<TFS<-ZHXV]@O8DHB!;`<F?S>"''7.CDG
MKN*U=GZ::(1I&\S&_D6ZV#[TJ#V.HBL^.=]V:&/KX^8+(;$SC*GZBM$KO`#Z
MPAFKI/6M&G)R,4V.'AMPYUZ+CUR:XY0.V@Y1B(F((Y.9Y/N-VJC(CVN8-A,M
MM\4D&P9Z@CTGV&*=-L_8Y;7J*8=E`9.&U`<GV,<GX0I!X8]VZD:)(@;`&@LP
MA]`LY[UMY8,#M:'Z(0AP[=B>[8O2U][9WE\&X`S1KP2`[<1A`++K-(=NO\K.
M``ZP`+++?\]+S07!L#=.RQ'S(:&5[?J.`.!!Y!N;J8_*M(L=2J`.JR1B`/NN
M[X=%E9;Q?8FIZU:]Y+)1DP,`NSIB7U`>``C`[`^?'F22XGMRX%I.E)RL_B=A
M;K[FKNPHIT1<S7S$CNH@^*@+7""3&"ALDA#0WJ3,_:F"XX[2G6,O:J"\"..+
M!8^&B8<^%+#CM,F!(J]F6^/S#NF[WL>8.!]$/K!%XB^0*QM.%)<%SX0N#!QP
MRXBR',U*3LFIK1I0OHJNJ0$U_R.)^/&?+/*7!AW+'#X8P/3FRW1DTO++]_+T
M?.8WLHU<I0%KKR,H3%BOVFSJ&E+67NV82*,EO=@S[VEEXMG&BX<%L'&'CAO1
MW9E!K1#G'?4=3!\X[L)67^G`C)YVFOB8^QQ?GQ"`G(;+P0&?#R+%:O:ION;2
M3A4.X,^TUI=*G(_P/!!ROQ"W'L_,Z%&H["E]_FC(?J]\E^I;8RRH>=1&<8Y'
MOL7,LI'=<A(`!2#<#.'VVY\L3G+]VRT0#+#]Q_D!*WW]U[_]ON5;4"2'>?0X
M'=#/DA0`!UU>\P\0`B)\(%C0X`<#`00(4*B0H8`!!1),Z'!P@L,!!PM>6,`0
MP,<`!1QLT*B1PT*%%TI^>/"PP,H$*!L4Q/#PH<.&*`60_+#!IH65%&P6:&"3
MPTJ"/ATR^%"SH0:D!S?@M)GS)@:-%`X(^`A2`(,,40D60#FPY`*'"U9N@(!@
M@$(""RAX0-I!PH$`70$$(.``ZL&W'\.*;:GP0$$/#P=4U*A`,6.-&!H86"C`
M0`.5&CT0>/A7[&?0_J%%CR9=VO1IU*E5KV:-U,.&#!DT'&U=V_;MVZ]C9Z"-
MV_=OX+X]:-C-,WCM#L1E]];8@4->X\>E3Z=>W?IU[-FU;^?>W?MW\.$_6P`P
M@*YX].G5KV??WOU[^/'EH_=P80``!_/U[^??W_]_``,4\#T./D+@O`$35'!!
M!AMT\$$(L6L@`@0CM/!"##/4<$,.._3P0Q!#%'%$$DLT\4044U1Q119;=/%%
M&&.4<48::[3Q1AQSU'%''GOT\4<@@Q1R2"*+-/)())-4<DDFFW3R22BCE')*
M*JNT\DHLL]1R2RZ[]/)+,,,4<TPRRS3S3#335'---MMT\TTXXY1S3CKK_K3S
M3CSSU'-//J/RH(,*.X",.D%K\^!/T02M\(,_%_T`T(,.';1/2BMM+X+R>LO+
MT>`*``"KU39(((``$(BN)%'S*H`"@CR8@```"&"5H`P.`$"`!L[;`(&\#`#*
M4F"#!0]3`'(E:%/K/`4U-0\\/<````J8U*!F`3`@@8]4NH#440,(:S,`W`+@
M`8*@-0"!6YD3=EUVIR,V`%"1)4@#"BI@S+G>.MB`,7HM..\U#NJCX"@.*+C@
M/&4SH&"P5A4^F"!]DZN`.?(..!3:64O"H#RZ&BCV@P4`@("ECRL`P.(,."Y0
M`+JPK:!=F&/^#=->Z4*V@Y`_$H!5#6YE+&0)_CSP^","PMH@6G1O?2`O`!(8
MJ^FN9F)4@:X,($D"`!3(2P*#L%;K`X^96JF#"S)[`+\/8,6*/`,^<`#MQ`#8
MP(.W]K6589GSUOLT3!>XCVMD/4X@`PONPPI=5D\2H(,)K-4`Z[9[QD\#=`.H
M`(.\PO*T``SL`P`H")K6X&RGL0XW@>C8I@M=IS_;X+X+.N`*JHTS"IG<M`%0
MR8+*1.9T;^"#+PE3!RA(]Z,_&>(I=*:,=[IQIM!]^0-/,SA:@*-";QU:E3R=
M]6RFU&;T+0ZP)L#1#CPUP-9P7?=4+=GE;NK6#Z@>.7>@(H"KZ6F%]]]_XGD`
M76@!P'#*4Y"*,4IY_K;"RGT0D``%W*<"/3//!S`E-F@!15D$<9X'/@+!F'P*
M:PI8B09L10!LM0XI&_"4`N@2/]H=\'8$@=4%CC:`@(7L?O_C(0#1I@&F%?!Z
MYS$9`@CBL;<5@"ZP6H`#G.@`ZW',@@`0FZTTJ#N"-(Z$>6G`$T?BM:@`ZFU2
M6PD'8&4L&G[J`R9KV]EF$K<-&(^$']!B#^T8/.(1Y&S(`Y=*/*##>77%+"&;
M`*,F8*\;TN6"Y<*BI_(#LG%]P(J/DH"_P&@2`R@Q?9_K"09.]0%T'0`#G2,)
M(,>X1FMY8&/GNT"L*L*`C]U1EC++XZ,\5<`/&$\`#J":M`IBJP#0!G,!_N!E
MM%XCQ45*DI.>^DK(L(?*`3B`=1ZX9*1."*L#D0QW&]'+1YBRL0``$RK5H@P`
M!E*M`4#+6[-D9[LH@(!"$L0"#SR/!?`R``90#`';_,`\%;(`@B%@CA5`@%D:
M@("P,"`!&."5*`M"@83@LR($-8M&4C6`!C#F5?RD(P(\^E&S5*``(?E53T8U
M@&UR@`$,.4!FVOE2F+Y'@/&,:4UMJJ&V].^F.^7I@'3:4Z`&5:A#)6I1C7I4
MI"95J4ME:E.=^E2H1E6J4Z5J5:UZ5:QF5:M;Y6I7O?I5L(95K&,E:UG->E:T
MIE6M:V5K6]WZ5KC&5:YSI6M=[7I7O.95KWOE_FM?_?I7P`96L(,E;&$->UC$
M)E:QBV5L8QW[6,A&5K*3I6QE+7M9S&96LYOE;&<]^UG0AE:THR5M:4U[6M2F
M5K6K96UK7?M:V,96MK.E;6UM>UO<YE:WN^5M;WW[6^`&5[C#)6YQC7M<Y"97
MN<ME;G.=^USH1E>ZTZ5N=:U[7>QF5[O;Y6YWO?M=\(97O.,E;WG->U[TIE>]
MZV5O>]W[7OC&5[[SI6]][7M?_.97O_OE;W_]^U\`!UC``R9P@0U\8`0G6,$+
M9G"#'?Q@"$=8PA.F<(4M?&$,9UC#&^9PASW\81"'6,0C)G&)37QB%*=8Q2MF
M<8M=_&(8QUC&,Z9Q_HUM?&,<YUC'.^9QCWW\8R`'6<A#)G*1C7QD)"=9R4MF
M<I.=_&0H1UG*4Q9/!:Q<+RM;0`.+LH"]!'2!N63G`A-3D`<H4%+KC/E>%7`I
MC[NI%UD9Q%.?Y,^<L\/`T73`+^PY&@&R@RY0'>TE/OZ(`A9PZ`4H`%8`F%ZU
MZ+R?!P#TSFH4#;;PAIX^9P<""^!)S]I&:/E1JY<%L3..\"R:N_$Y5MX1](\_
M\DD@AKK4!N&`!AY-D%IK0*?)V3)2:GWKDKQF-J$1]N\*L@%=BZ;8REQ607(]
MK51'ZM>DX77`ZF+KWR7G*)D.#;(1M.R25%LLGG9UJ*F5N:>E#B][*<#T_@Q2
M@82`9'"T=HS.\GD0>^8E``9PMVL@L.APMOD``S".!R)PGUA-X`$#`!4&HFF!
M6WY%7261P*(-@(%3,TH"(]69I#^0`8]`Q#/P!LD!T(R4#(1P+_PV2`0U4)2/
MM/L@'(!Y`!:0,C_[>@`+,.%'!L`J#-PRS@9A*%=6CF;'#*;5H/YDR@!0$0]`
MRS@7N94!%LVU@IB.`)DDVKV@91F.6ZP@5$\GPK&.E#T6H)SK3'=!AK;UO-20
M(!M+R+X7/4>DA"Y6(Q6`^(Y(-*L;B"X;T\M?B%7VO61L)2"O>KSA51!L02N=
M^EY6U&.NOE7[VEH$V/=]`C"!A:R=8=NJ.L<#_N`90"<E6N4^U09L9<2V]X0K
M06-4!1CREP[<9P+GT0"LIE=$?LF])UNCBP=L'X!;YUX`&7AAR,1&O5"#,\RN
MS];<#10P:NYEX@6)->TYD#10]4P`#U,E=!AE>0PP)@.DVKTA%;)]R%.1,1S`
M%AFQ]7FZ<`!:9,14T>AR`:[(N3+ZB`,@"0_`%@!8@(K0/Y'Y)?PXC^^+)()(
MO9Y8/5`[@(]"`&C9"X8IM=`A(X(('=S9``8`0;<!`*QKG`1`$`N8@.6)I8(0
MP;I0",_@@`A8EE*#I1WZ@)/`HOD!@-X`ETLS".:A-:YH.`;805"B-&9SNP8T
M"(\Y.\W@I4$A#[S#_I;GHZ.F*8@,,@CC$<"2*!``8!A=@@Q,D1JA<2$OI**"
MH,"EZ[$WDS>\*35T48`'N,,[#!G8HY8-J``(\!2LBS4!2``(\(P)S!H\S,/V
M00KV.8`&\)>#*#5/,<0/P!90::5!XT(FU`B7.0BJ:3:(T8`*6#@FC#:$2,!$
M?`"J^1JQ\``.N``)J,/X4SSR@+WG8!F#Z`"^B(H"60QN.HRL@T'$V(`+B`!T
M>3XWM$`X9+11ZIQDB\10V\`XS,0.>(!;THNS`SV]*("SD\8W^[02NL9;80#(
M*#6NF!18RHR-`48'!$6#@)9+\YAEV8`&6#2]<"E31+@XW,-@FX!UTXLK_N0D
M;H(](`)#1B$`@YRYS).G120(K"$C:HHWO4!&2GM#-S,WI"BU_8N`"(``CO3(
M>.J`#1R``UB`"*`:*60<E4-!1IJ0C_Q(FEJ)^F``SB-`4@NU^U"7=+0^=B2(
MC-.(GSS!0/,\DF2`NRC%,2R(^W``CNS(CU0\C8"EJK/#T`E(-&LEV.,VQ$!(
M7ES(#\#*KHFE/](9`U``"'@;B@PT9;Q(8(L]JHE)1C'#:,$;6*HH2&&4#`B9
M3\,6N#P48SN_8Y.`O/@+.F0T:N$>GCR(H#0(H#D(2R0(6#(5@[`5?$Q*GQ1(
MQ/C+E`D`2.2@+20(;+G*18P;YGB.A*0UKP3+_F"4FE8:/P2IIF3,1+;\C%*#
MG$$IBD>")7YZ'7,B"`<0`"E,F4&S32C<):1PN&RZR<&H36N!C,:AM%;JR28,
MBN;DOKP`%5M1/,S!3`HDF>2<&@%0PG>S%FI)H?@3S3W$%GX*G=-TMM1LR`]X
MR"R"SPZP%5:,3=:CS5#K`%CA-]CPF`#(#$SY.623`(3#'9,1"%N[`%MYI-P[
MF0KXS[UPQX)XT`7PI`QXF_.)O4TJ@`B8`*GTP7543";LEPIU%ANB@$4#E9`I
M``N`C9;X"'=#%PB8&Q[D"@1X40P(F=-#N8\HQ#[<0'8,38-0S1]L``T8G;CK
M2C`TTOB,)?((@`BP_C6(^J`VK,BUW+%7TT_CP`![!(F*,J-N(@"/8<6<T8L#
MZ`V'ZR8I%8L*""*=*:E9RX`O?181/1D2719,`<>/^]("^$1:,;JJ`23?[(I+
M%%20"#.DH!J]"("SV=!*Q,ROA$_!G,@!:$]<>T]^E,]#U(M=,J9#5$O9W+$2
MA#^#>(`&*,VV4#L&`$4.<(!,0@`(X`"5>H!_J0`%*`")D(!)X8"VV+I6!8T,
M:(`#((`#V+,8O+<*G8`&:("YB#8-8("*"D$&,(X+T,"9>X!,2E4*J%;N8X!,
MF@A5,DIG:P"U<ZD->(`#4#LH^@QJ0@!C15*64-8(8`!#C-9I;8H%*(`#_@@:
M!^"H@^@`!N`G?"U2!L@8#X"`=3W6N7&`C"*(>N4)E1)/*O,/"G@`O*$;Y",-
M"5"ABFTGK$$`QO"`MS&`O]2,@OI8F.*`^Q"`!_*\D_L,7/TIE>6AGJN:-B.V
MFK6I5[P`:]M9H`U:H1U:HET-FJ/8(FV`?DN-0:&`!J#0HK63GAE5C6@<$S2-
M:LQ"6(++J+V3J1VW"8#:T3`95OR`K>W:/?G:Z2!;@SA;M#T-9%.7X3!$59H`
M"7@86ALVQ$C2?^$-XYL`2CP(Z^%!"I``#%@4V/BXNZT0#;!;"U`7V&`.#Y"-
MBB".1>D`WOB,#J@`":``&Y4*SEU<:DG2IC#<_F^#17M16U_36Q[,@(K`@`F8
M@"&T*$Q)`%N#3`#8O0R(W=E]%,[UW+<-039<P^?#`&\D`#2KI5;9B_-(&09@
M5%P,MI``P*HQ1&AYTX^8%5'QU&GMO]YX&[%#G(.`I:6-%`@0U`!@``3!&3A%
M7H/@#*H3R*#KBG;+TJJ%P;=Y)X"D6?;Q)MR-@#--P$4YWZY(7YK=V:E8'(/`
MELQ@/`(HP5LJ*>5EE%MIWENQN1)T#;Z`"`9@@/L@@-ZPE71R@#3E069JHJ39
MH0,<WM8<#.?)18B@V3U"``<@H$=:X:]P``\NCY%EIF,]@(KPB5AI@)6Z#ZJU
M"/PMCZ:1IA^-"IJL_KK[@:7[4``F[LT8_*`:Y@J/C5ILR9@"4:)#5$-&T=#S
MF&`/"@`+SEUW[17:8,`=@A:Q.X^S*0#:,+.]\`S>M(`'/3O9"::'$D:3R(N,
M`:>*2!F".U$?K)85;-MP@<#-$0NK+8BW"="".!L^+0FV+0A8@I?S\)@]!")*
MQK7K?5N342%,N9^I\..M]$$SKF#K"X`#9I3K+%)EA!8I["-/?$*",!D"H!HQ
MQMVSZ\Z24,&#H``*6,!Z.8B0:318@<K[2!W[16(R>AN\^[A8^<M,QMTLW)A,
M#)U'*@B3J>:BU=BCL#R><-*_,XM61F-:`=56#(",@&$%/L4V>PY?-(C&_BE;
ML_4Y=1G1"KQDC?"8?$45"Y``8LT+=X,5O+FA@!6`(P[+:9;`I(!GL3">LJU+
M@^@9`:0:8T6``\!`:'EHH8U":][#<-:(L[F?5HY>;@8-#PB)2"$?1FHVK42@
MK#D(PKO::H$*3!EH908`J#R("_#&KF!F`+C7+*4;D9[/B)[6J:@@I,CF?8Y)
MC;[2.#R@MTT9B\E?F^;'=(988>P`YFWGI4:,791GQD!,9X/G1;%H:F&?QSL(
M3"&7D6I+6))"P8V[!7B`A5GF@H`50ZSI\<%4II9D*YYH2%T)J7;;0!)`;+G!
MV,"`#)#LWAU::.D]=@ZD>];$7\&:+-Q,"R[K_E;)"^9HZ9FFEONX--T\56MI
M'%\RB*DH@)39XN$9WDI6`*R`)7VV%:.F6ZZ(#M5=B4@N5*=FZZA8;#7FOH5\
MFV_&-9\-WB=UOH.`%@=X39_Q3$@=2Y:.9LW(B^?K`/741%",S'_9SF49IK"@
MFJO%%K\>-PX\MON`"FS90>,!ZE:9Q/'-FG\9M:@8[A,L[GB.ZIO6Y.1N;&X2
M@,I;1>CNP4WL)P.1@`E@U(J:BI.1@+N`Y\P63I=F&GB*`&@!8?$^"`TPX@]M
M@+Q@10[P%+/HP9,S&1X&#5C:I0F`@/OXFM`A)KNM')8\R*.6"J[HUPN'Z:C@
MU/^&;>-&"O(8`,/%_EVJ]DJJ"8`&L%M@JNRA;5%'$8I&S5?]*6!XVV[1EF44
MW$:\@19W]-)N(D<"_\XOE%RNN%J9#&#^@9C^]:8B3*/`]1R0`+VR]N^W*>[$
M#D.$:QW&_H"JKE`X'X"8[=I3+B-F;0`)V#X-@`!I)8DN.X\..+,-!X"F<%@O
M,P@+&)APJP"'+<1<K`!0?S<*H$1TH?)(P0!)?X"<-3X=CH"P*)B2,O7^89R!
M9;X*2'387IB"4!BZ3>9Q0U6LPP#@K5!,QVD(:-93AVZ$V-CN>&E-YXZI`&AH
MQQ%`&:'OH';MD!1"RO8>,3U6IPYOSXY4=F=QUY$6]77L$""OK@[^#)>V_EQW
M>[]W?,]W?8]:ASU9"P%1*@=XU;@`!BC??4\0NGFZ$(&EH&XYPTR-"3[X,GN+
M6(X0V`4VJC'XT8AXB1^0A*_X$,EXU>#XCE\-#RCHL-4(V?#=SF4.XI@4S(T.
MLOE0YD-M6)8*NWUVB,G<#(#PP(48S@5<T.``U_W*SCT5HG>.SAV4QI4`,G.V
MS*66V$B*HL]HNTWOAZ_0H/]YPKW;*6INI*`7"\=;6@OZ<F\56+S;_N&`K2^C
MMI=ZDBB8"-!C&ZL`?:1WQ+A4N^\*X"1P)3R;;=K[KI#,5KD/R,"91JUN<!Z7
M/?J(!:@0:D)4!12+T*$`1MT+6ZUD%$0XL=E>_K[?(9.13G]F>,0P<9!0Q:QW
M%415`'61`$$E1+2)BEWI)LXQB`A`U`(4BPP0QP'H-P^(T:Y@?6I9&H#LC0))
M@-OOB@'(V1?#WF.MQVBIX[>`YV:%E1Z='S"^[^MW\>>'E=?6V)$%IB8:%2HB
MHFBQEAH^<=O'XAW^SI(('6BAX136_`&(I@0`BDW*X:3!G=R[_K\#B`D?/C``
M0&'@AP8``BAP@`"````5$$H```"!@P8#`!SP@)""18P*`D1T@/`D0@\&`!!@
MX(!!Q`((+2Q<D'$C`I0H/1#@Z,#!R@`;$"H$D,#!@H@&/'[P4/1H4@!+!W*`
M"*!`@P81!S#5Z?4K_MBP8L>2+6OV+-JT:M>R;>OV+=RX<N?2K6O6P\8)3#TL
M`/!@(%Z.'09V*`!``F##&!!BN$BXIT#"??\VW3CX0\4!&A!>"`#@PL`*%ATP
M[0P@P\`-`0)80-CA@,&P$"Q&_C`!(H>!#Q8.1;B[``>F(`-L3@@`0DH!`G(3
MC/U!]6>F%25273V1\$/$`S<B'WBA9%C1!2Y_X!"QM\+:YH6";9P3H8+C`S,L
M;)VZ9X2!C5DCW("?JD4+,+5!1(O9=2"""2JX((,-.O@@A!'.=8%C)VW`$F`;
MV3>0`WXA%`$`#2!4T$$?T/1>?QA6%L!E#]6F&P`,A,925\915I&,)U&8_D"-
M*,V6P$D>/%3B;@H$:1AH)TTVWU5,B;;`B,[A&"1LU]T&Y4F-'<"D3"=U:!)8
M&E"0)$*PH69<`L5YH`%S7S4V@`5,<;`!4QTV4*-X'(:(DF@&I+90<0,-*2&A
MA1IZ***)*KHHH;,-<`"DD2Z46V"]#30;9<\%P%53REWF:*22!D"I90,)P)Z.
M',V8(T*B`=D<`:$>L-(`LAWFHX<?[)9I>221-Q!(1@ZTTIGQD4GB0`6]J"MU
MQL4:*JT>W<;J0#2!&=::%43`P$JGZ6<1``,H0$&;7WE@V$('0*!!5PDTZYIG
M'KF[(6'QEA=NC7V5R"B__?K[+\`!"\S6;N`:_FS14(']BNE)\WX@&JL%'VP1
M>WBQ.-!"/6H@E4>B\?J!>P/%-S'%MEY'T9[,\EH5`3WNB+))'`30<I0EQG?R
M0!5=UQ?)"PT&XK5,!JV3!Q3T!*YGWH:&+L4?Z[1!`DF'Q!QL!IX4D4=5ZV1O
M5;4JZ=S`88L]-MEEF_W6;`QDL#;;:WND\$D,MPH`E.Y:O9O:;;/]=JD?G%HN
MR*H^#,#0-+W:%P1ZK\TN6+,M*_>N)\D\P*\?!(N0S"U7U%VRSBF+ZW4%.:#X
MVCG'B%)C0_/IF0$,0$#!!L2B#@$"$8$-%@<3+'#TJP_1VY1%@@+P>P>K>=0U
M2OJ>O3SSS3O_O*(@_B%0HP<6J-GWI;EF*(!J70);84K69WCQ!U7BBJ5HTY\4
M.;/4EG>!I5[-)F+#SK$/6$]6#Z10T,;"%C^R/@`B]]TL>UARS06*TQCO#01H
M87D(KWCBK35=H"L=*(C[3M(!#`3*`Z(1@$?XAQ(*$6!_VO/.50#D-80H#WHN
M?"$,8RA#LI@'`"^:30'X!H"%G=`X\<D/YCSSHM_H\%-7:9,&-E(BT;Q+`Q$Y
M$WT"0":^&,56`CB3B4C"G/N9$`'DP8!G]&<X\'6N1!I8C=5,<YTS#B\E"GF/
M!+7SG)ZH[B2&V9<'9@,``ZVD`EW931T;"``%=.6,G*+0%5VS$C`A$HL=_EBD
M"I-WNQE2LI*6O*3`]*@`"4C`7<Z!&T+DAA#Z3`I7@^2D)Z]CL<MTH"<$>,`$
M'!`1]0UN-0R(940.^(&^!(`!G(1-`+`H/XL(P`$38(!G@/B!#G$N-1LI``0F
MT`#/""A(1]M7&8FRD`9(<U/O4D@`%L#)ATCQ(Q91P`0>,("-!+)S`H!E!(+2
M1LPLY)820&8`](>2&B(@`NFD(T+<)0!N0J`G`VB30`EJ4.8@[VO8Q"1$(RK1
MB2KH`5);B!Q!F3VG&>950;*HP0*04>S%[F`*:).K1A8@ZA7$8`/`V3`;T*V%
M/."//?Q`!IAF$094;ID0Z5$`F]+2D.SF9$XY_I@`'AH!J1'@-NU\CDX#\!/Y
M-*4HX!+`LG1B`=N!:P'DZ8!*+6*`0'T`K`<;*^;")<F'4K2M;GTK7,.R`0ED
M90+Q>Y@?3R(FLLZG`GSM#UVY";@*Y#5\#VA`XO@T2`\VX`'Z'&4$&N``<HT%
M4QV0YKI0D@&_>J4#%3AL!/Y*E3'I!`,5N"L&#DN!-<$.)1J(K#$!EQH(-"`"
M'.!`!83960ID1`)#V4`%R(33R`J6AK%$;`9Z!#+:/J""7L$`<YV;$L*B[K1Q
MO2YVLZM=@(E&6'01Y7;#*][QDK>\XNVN7<!KWO6RM[WN?2_9T%L7]<*WOO:]
M+W[S*Q<,(,!I<*$`_@*RJM\!$[C`!CXP@A.LX`4SN,$.?C"$(RSA"5.XPA:^
M,(8SK.$-<[C#'JY``3*U.]VB1`$%$*V'4ZSB%5,8)*S2&EC,Q.(9T[C&"_;`
M!L@#XZ_(V,8^_C&0\;MCK_0XR$8^,I+'H@$(+$`!XJQ<!R30Y`:L5BP=B$"<
M*-!DVQ*M`@U(P"U[5+T&.)G+0;(`F1=@YH&\EDQ5TP"9':#/(C<%S4[62Y+S
MK.<9@]2E@?+/666KUT$.-5SZ*ZG!"H!%*AI,`!OR0*$ALB$7E^DX7"7<28K<
M`4^"JP!WW3.H0SUAF@3@`16P0`1Z<L#X).#4$@!HF*RR@`I0@%:L7`D!_K`\
M`<,0@#D@(8`$+%`!=]',<BP)]K!I-)!I55HJ%/"R1?;58P\0&\L`ODI/1:WM
M;2,X/G+$:0I-13Z<BBLL&Z-J66$#Q-OT6I%450@>#>!I$^+Q`"?^WHLY]B%]
MET]I)"R7M[DM\($7>$U=\0!]2CB0CI)+N5[9&*?F]IZ`GX0F?OK`;'*=7)UD
M/`(;1PFE!P(;>G5@([WI,3,]H'*5&X[@+G]Y?3UP`0@P``$;49&Q.STZL6S,
MHW]2N.PT^-/RW#Q<L^X*!XHNKCB9DU4/`=Q#DM1C3D],X3"_.M;#NP'8((W7
M%8^:P2#@<#8/<I]J_8!A^.J!H3]'(P8[`'DV_N!V<,%]V:<3^0Y1XK!^GXF<
MROF[<AB8]<$3GJ(/@69N.\"R'N$6*!9!\0<VAB(F71PVPGT.S@$#74\VLRF;
M]TQW0M[ONP:]Q_%A:^%3KWJ(7FA4%5<V!R+P;0^,/-;+B=O=%4*_?;^'M[\"
M$99\?Q+@VSW?+SJC`"[3X]WH$F2F7CWTH^]"Z)S)`Q@PZ/%6LR$.](3$"#FW
M`B[SG3U^*P#[&G^)W$4:P(A.9"':BPB-G6_-4`4V^3X3&R4P(,/X5_K^_[_`
M!$4"+`!LG`KY=$@`',`")$!$\$BLK08!*``">`:U%(4!$*!G$-*WL(23&0;W
MZ(=G1.`">&!O,!O>_AE``"2``FP$`5A*D>E1`2Q@1!``>4#``&00`.:@#A8*
MHBU$`FS=9P"&`TA-+V7;]UU%!=C..U&/#5Y534W7T5C$`>A/!42A5%B-Z#U$
M!G#=19!5D7G`!!2=492+0GC7#IXA&CY(MEA`;RA>C73`!027H+E6"G&`!5B`
M$6Y0<&4;PA$6X^S$9G%6D'3`5U&*:?VA:\B6]9U:<.P$!QAA&D:B)`+,Q@C>
M)%XB)F)8)68B)W8BA6VB)X:B*"I8!T#`MXTB*J:B*JXB*[:B*[XB+,:B+,XB
M+=:B+=XB+N:B+NXB+_:B+_XB,`:C,`XC,1:C,1XC,B:C,BXC,S:C,SXC_C1&
MHS1.(S56HS5>(S9FHS9N(S=VHS=^(SB&HSB.(SF6HSF>(SJFHSJN(SNVHSN^
M(SS&HSS.(SW6HSW>(S[FHS[N(S_VHS_^(T`&I$`.)$$6I$$>)$(FI$(N)$,V
MI$,^)$1&I$1.)$56I$5>)$9FI$9N)$=VI$=^)$B&I$B.)$F6I$F>)$JFI$JN
M)$NVI$N^)$S&I$S.)$W6I$W>)$[FI$[N)$_VI$_^)%`&I5`.)5$6I5$>)5(F
MI5(N)5,VI5-VHM%`HD1F``$\UE,NR&U(940VQN5=Y8)4A%9")%=ZY8.`Y4:.
M)5DVB%EJ)%JFY5?F'5L&H5N^95@^9%O.)8*8_N78/:1'C.5>XF5;F-IM<``$
MP)1$3@`$4,@%2$#G`29<L!M+`(!L;9:P;8;,T04&]-1?>L=F?H!T(0@&="58
M_&5F?M\&<(#WM04&=*9FS4F@;!"V@$Q=KL5E.LAGHB98P.:@L>`\.:9<0(=8
M*9=,*<`*1D#LT,4!``[MC05PB,6YL"9;5,`!H-YS/=4!6,ID88"`M<5UHL4$
M:&>FO%9[B,@!0-Y;/!)TPL4#M,D%-%^6F.%`1.&X^69<,$T=-8!V4"4'7!P&
M4%9YG-I@R%P%,$<&M)8&Y59W%NA08`"</,>IO4T<#H:BY=8^`>BY#(:"UIF8
M,(=I;8#5R-QF708'_E#`8LC<!5P``R@`N\1A;G!`AW:`L.7&`R``:A0H<WC6
M%K8)E;DH'&X6@1JH:P@;AFJ`!3@7CB8G8P#7:A8I51`6AFY`.B&0S&UH2M#.
M%O9G]=UACVP`!:#&!IE6<#"=B^(8!6Q&8?2E=6U`!EP`T^$4D);5!82H9V9`
MG.`6:,`AFQ&IRE$FE,!HFU(F?#9'2-`G75C5[^R/0%2/`>SG,HD3`K#)`43`
M`VR)2\33926`!"#`%!D`;2U')V4J!F"``%0`!AS`/<F(`B!61T2@!"A:?QB`
M!#@$VD49IA[`@`Y405UJ/!V0>;B.`73`%DH9!)C'`VB9`F```S!`/!'I_@!$
M0*E"``2,QZ1F0`1L$@*L)J=J!78^6P,0"&+ET*=>JVM$Z@,L!5!$0`)`P&MT
MJHZ:J@$D0`38*@>0ZY8T0`5(0*9@P$G=8*I=A@=,ZP$@@`080)ST%P0XH'>8
M*CHYD0.4*[6A1@1@F<"V&GI"P"89P`5,``'0G(R$J]4D$0/,:`<@P";%SK;P
MU*_NT@5<)X!)@`*.+`0\`"%5@,`>0*""A$4T)J&V!4WXC%=H!0$$K07L9RMI
MP`9(JH>ZJ`!\``*LRR,:``8`EW=Y65,8P`8HF@94@)&4T-J,Z%AMR<,4QE#`
M4G]@``=<`%>,1W-J0'+23`)@P*+:!JMPGT=,_I8O;8`&``>G(";;2HL#6("1
MG"UJ>IH%,,"Y9`"7SIJ(J(2.<FO>#LO5(JZ68<X%N"@-.D!^9$"K+6[<[@]B
M0*MM/$#2,JA35$"4ZD?X<<K;<H:,3"%F0`#@XNT";$BKJ>F)=<FBQM('+.H!
ML&&I%@;P@DP"2%/5<@#6:NWW7=P"K.QB&)/(:<!DH>=U=J<%+``%,(#1ONVC
M>F:@RHQ%6.7.K@4_?05BS<GQC-4`-$"REJD"JI,'<,"DCE5+,`!B(01B#D2:
MW*#ZYD>ME*I-8*P9-J<I?E_[IJWQ4L6BYM`''"O-M"?FO$?$JB#],L#5Y@P$
MZ*MWS&Z?DJP#G%CA_I9<LM;6_7[`#R+$9'D9VXI<!NBOLCYP0_2:\VJ`P'9'
M">_/00QP.FT`R;JOO>(K8YR4`B^`U11N^6Q&.DU`ZZBOU5P@_39`"I?/TVKN
M!\QOR#[2<3Z'`4P`$%TK"RN3!@@++)4G0=C'L6HN;Y7/U7I$!JC9`4QP3GG$
M%WO%2BQM^,K%0^AL0KS(?IY+;A`6!.2':B3$8#``!1Q`C2H3!O!(*VW=9F``
M8K3,K'FFI^70PPIP;3Q`?CC1A1JRB23``2\P?Z$&DV$.Y2SP!6!R63F`\4K+
ML(Z'KL`NE%2`C)2<!J"H2@Q%QB:R![12XZ(PV$YO(\N1[IH'!\3PVRIR_KO9
M,,8A1CI%`'*H1NF>+LB$7Q"G$92(,6+RET=D5K(<1#$_<7<NH$`H0&ML0$V-
M!UI=[P0$[J^*L2-_7\L(R19NAJ26%7`("2=?IP*`QCT!;E.L9R3KCE=TB'O6
M,5O,1FK>DN3X22$G@"=GP+N.X(@>@$-O$$73J)<@0`(`Q\HFP/:JH`6\*P.`
M:\":1+L-L'Y$-'",1ZEZ-)MTR;&V-`+,[0!X=,PX]'1^,F/:1L!Z5?66Q[LJ
MP`$D4`%,0$<C`)W,Z$9OJR^+W`8<]9\%]5C%<$XXQ$8W[C*'+D0/H*?U<+X"
ML4<(\?<5@,L:\5],*IAUA0XG0.^"<VYLU6#(_C`":"IZ'G7N%`!;3X1,!PI5
MSC5RB#%8(<`!1`8$3,5ULJT*"D@#S+5);)T*&@DAI\IV&G1:D*ZY](B_JAQ@
MK%Q3:#9@\"%G[W)*O`UG-X6_;G:0<+:_DH=FAQ"[[#0"EW99[05IHW9G?_9M
MM_:O=(!GH[9'G+9I$\W*E393\'9OM_;;;'9KWW9*E)5M*[=M][8&[05A/#=Q
MD[:TU-3!\;9>30]MCS9X-X5R[\5NB[=T>P"J4+9;.$5<U9I&MPFCYIDTA\GD
M/<CNJ;=;S*$VIJ>$Z#=^_S>`![B`#SB!%[B!'SB")[B"+SB#-[B#/SB$1[B$
M3SB%5[B%7SB&9[B&_F\XAW>XAW\XB(>XB(\XB9>XB9]X65Q`1DB6`RC0BI?+
M!JQXPXI?5F2$*E/%8;'XC1Z6C?=&C$M68XFHC3?6CM?XC4?>D*MK:OQ$5CR`
MB.;X3S`']-:XDC_'D#LY55SYC3)Y8_7&E&=$E?]X1F!Y>4#YD4^Y9%5Y6&!`
MC==6*W(`D.M/!]CXY4D3D-O'OP*Y9%T&<66$_M#69%UCS#X`H1>ZH1?ZIX$%
MBDZP`0@+LB*3,"U`ZR3K`)1(X:HO`Q``F!14LH[TC=Q@LF)%LF`%I4=&!W?Z
MQC90^H8ZF$AZIU?Z_A1`"`^`=CP`%8>8R!@`IH_JJ+^ZJ<MZLN;:I<QO_@.\
MTD"X.J672`,`>Z;7.A6G^@(G,4P8IDX8P$PG:S"Q(IPSP`"\2`>H+[3_2:<G
M@,)5Q0)T>CX%#J8+]DDPQ+M>XZ7UC$6()EG03I!D.WQ<RV![Q0+0CP-XU`)0
MAKWO#_WT.T(([/ZL6G<\@$>YA,CH>V0D:T`!D0-X5\`+"N<4P'6DZL%K1P,H
MO&XT/)@D0*880(F<^\%3O,531M,BA,:/!0'L"[ZWXK[K!+P.FOAY356T8;IW
MQD=<W$`$$\/#N[P?#+U7UN2A-UDU1)D(F,$OT\I?"HIDQ;'OGJDF/'PLO,CC
M+\0GB].I/`NQ?,:?O-5[/,CKRM:3\+68?-5W_OS^1#W3CCW,RWQJCF+-ZYTR
M11Y<HBV`^-,$2$#/!\#/MWL&#+TUQKN\'SW14,#?3X!#W_O2=SU52,#?0Q.'
MP#T$@&U"%/SN(7Q"G+WA$P28,+W(13RKW#S4A[V@9,K++W#GFWW6A_R(C'S)
MG[S3:4?%JW[<NSRUHT3,(\3,LV(6>P7JDUW.$T8"&`"DK,1B^/RR`3V%,/R\
M52/B]XSBHT0$"$#`!BR]*#T'%`?IET]ME"JD!,!UY/ZQ"_S4<WZ9P+[(:/WL
M<WW3>WW*7[[ND[S+D[W;?W[LHWW\`\2'!`X^%#1`H2`#!@4_()!0L($"A@L>
M%$0`@6$!A`PY<B2P_O%#@`P=298T>1)E2I4K6;9T^1)F3)DO#TSP@*%C@@@W
M"VH`T*'@A0$E.P3`>2$`0PH&"FX(<.``@@),9U:U>A5K5JU;N785``!L6+%B
M+[1LL."DAP`:'DC\H(!@P9HE%S0HZ,#M!XH%(2!@V,"NWL`-'WXXRU`!Q@\/
M$C!D$!<NP[D?%#+4>3?OWH:*/Q2H4%#!X`.%#X-6S-AQW`05#6Y<L-`B:;2@
M65_,^#GE1X8BN_;V_1MX\*H&)E@@X(&C3@P"D/L$^D$H4:/0DQ9<6C`#`.0?
MC`OW_AU\>/%8OXXU#[8LR])$!63`"SKNA\D=7V.>R!K"@;^!ZTJ6C?BT_L82
M4BV^R2JS*`+["M+,MH(T6G`PAR":[:T`4RMH((8.@I`A!!+\X+T%:^/LP=Q`
MXFV\%%5<<;R:*C@NN0@N$``HYX(:BJ2BCJKN@PFHRFZ[[E@<DL@BC6RIO//&
M2F^E!A+8`,H-GO-@`PT"N(`!MQ1@($KB"J(RRM#N0B!,_`Z(\L`%%HAR-(B>
MA#*!T\B$LK^WN(322\H4B-+#N][<0`'6$F@@RA+59).T/:%L\($Y`87LS@WR
MS)+/#QWX<S6+'"@4I),(B"!*%(\<E=12O\0S`@E@_&#1!RA@[@.?,H"2`AP[
MXF`ZI**,X$<`-(!R`@),'9;88KU2TCPF56H`_H``F@4`-@J>!0NV")QU5@"<
M/H#@VF8WLB"`:P/8:,9G`YB@H`FZ%2`]"L)M-@`+"@)7W(VL%7>D'M\--[T*
M]@T`-VZ?;:\@"?[5UEUQY>7N7WO7S5==<?O]-^!U-5")@6X'X,#8CCT&+H-W
MP2J@*9$!@+&#`KK-BR,(?/V`@P&Z#2SE;F'[&.><=4X26?1:\J"#H(/>#FBA
M.]CN`Z.?^Z!HH3E2^FFCHQYZZJ"K7CIIH9'.VFF&H/9:ZZO%!KOK@HQ&NNFC
M&4H;Z[-72GMKG>6>FR6ED;9[;;=)`CKOLIF6FN[`!2^2YYZ5'1SQQ!5?G/'&
M'7_<U`00B(KRR2VG_CQ?R#7?G//./?\<]-!%'YWTTDT_'?7455^=]=9=?QWV
MV&6?G?;:;;\=]]QUWYWWWGW_'?C@A1^>^.*-/Q[YY)5?GOGFG7]^<0FDGY[Z
MZJV_'OOLM=^>^^Z]_Q[\\,4?G_SRS3\?_?357Y_]]MU_'_[XY9^?_OKMS[Z"
M_/7?G__^_?\?@`$4X``)6$`#'A"!"53@`AG80`<^$((1E.`$*5A!"UX0@QG4
MX`8YV$$`0@\\&\@`!D;(`2AAIP,B)"$&D#;"#&3.`QG0P-TPP#%6N9!C'"!A
M!N)VP^=H8(4VC-4(+P8S'KIPAD/<X9=DF#078J"(&N!A3UPXI2:NS853_MS`
M"J<8PR(R38K;`2)R1-@!*0)%AQSH`!<YP(%\06F-+UQ:&#O2@5EQ)`,V=&-3
M\E@0+M;PB4L#&M#<N$28U;`@A;QC#.VXG2WB4`,VQ$#0N&C%%6X@ADB3HB'7
MR#$[KC"2173C!LRF+0Y\,9%]9-4EF<C&(D(IAJQ,95-(>4@](M*.&]AC'S.I
MPRJJ<(1@G"((B;FX"!Q@``.H260^,(`*.$``4#F`#3L@@`(@$RT8($`!"&"`
M6C8@`+-A0#0-D"T(1'.;0O3``@10SH<8@`!001>&E#D`!7@@6!L`@`$.(``&
M>``!RCQ`8[19`'MFP``J.\`".'"`;0Y`7@$]_H!!J_30!6RG*-<<0`+6*5`$
M>$`#!>`F`CK``7ARLRP%``!.#```"R```)]1```FX"]I7H!;.%F``VQJT)$P
M8``&&$#F/F`M_2!&0`O@Z`*"*H"=(*"E!G#(4Z"B+<-LH`$:4!=4./J`:`K`
M`?A\BCOUB0$`U#(_`E!F!1ITI:U6U6S[A`H$?%)+^<1SH!^00%,CD`&'/H4!
M$B!9!-HY@']6(*:+$5!!O%K.L`(5*G'QP`&BZA!A488!&84*:XJZ4LK8I0%?
MK8C+[!(!:`7+`P3X**XVX%5I;F"<4"$I4[F)RF+>-G!U8J8S0\01#V2+.\PI
M@%T\D(#&>&``#P@`_G(JXP$#/``"QS5`?/9*2G!IP`"%20Y&-B"`"N0S`*1\
M50<:Q+3GPFQ-'W@1<PV`'`@,@+P8^>T$(E``*B&`FKS159TLLI`.+"`#"S@`
M<AYP'(,^H)KQ2H!AD2N`FMIJ6P#X*`,:\"*F*94#`I!7`[3[@>>N12D!.!K`
M)B``4B)E)!PX:X](1I("8,``&)A`BZF#$RM]M\4,^.@"_HNU!ME&+1>8<8X`
MD#F?"/$`'V+5E3QP@08@AP*7%6S(Y-7=FI[,`]%E"%)L#+`#W6K%0\:LCDAB
MV@E7&,0APVD[BSN`!:!V`#%E+6HF<C-<L9`!\\3MGN>FVP%,;ES0G!R%_JHI
MU>2J&&',,4XU/\.``CS``?'2,HC\`IJ\.!B>"""3911S@`?D$P`->$!4[CHY
M"""Z(^OMC&+TF0%-/R!C4E3K`A:6M``PH%'M9>KDG@RPM7VJ)[XJ@(`KD``-
M(V`!!+B`0Z]L.0Y`0*@4V&D%<#2!`7A``4^)P!P%P($"*+F:%*@`<Y3*D`$\
M1)\<4Y?EEA8!#;A[W:-Y`(T/X(`2/^`!`X#`&M?8D1_'$Z9"#@"[XRK5`UB@
MKI)1[0$@\*JX1;E@!=@K8A9`;0-`@,[;LJ]%&@!9!"@KW?J:G&&+8G#<%#7:
M%&[`45<]:@)DP)YY/@X!$D``*[56`).3B,?__IF`@>^$ST'7F6X7@('E/!,!
M1K?J;R6``6N9M5TT6@`"+'"`G1N`6>B:M`,J_1:W(%<"!VB`T9$6)[E\F@#Z
M=,!4@((`!A@]DIYE6D%430!6KU33"XA7(B>@]_04I0'PY-@"%&!T'OJ:::G]
M4'9"*@$!)`:BJR'`3@M0TVR1/;I1#HV%>S24-18X+P\P@`440)4%):`^Y6;:
MN6$69@(HO8<]>CT&-@`!>ML[N0%X\DD:)'8,($7(LV=A7"E@]%,"`,ECAZ+#
MOV0=*4O\VABJ^.O]N5C;;T?L#$B`T;&F8E(&R^@)R.RYC,^0OFB^`0XP?0$@
MT!<UB?W-QX&HV,,[_FJE4V;[)&3:!1Q@6*'_WV-T*RYXBV6^!+A4[`(*X)_(
M2P&J"0$D1\0J([2>S2\FB[H$X&+<10.2C"3,#E<L`+RJ1``JHKP\H``(`KM&
M0M4<[6@*++X$XCCPP@-2JS"*(H_\23`X`MD\P*0P8`$,`"@:P,`HX`!6"J(N
M8@%BBCBHK67\`@%TS\(\0/LRX.6VI;V8YIJ,ZV7FA5]Z!`/5ZV5"3LQ.8@R!
M[P,P@,1(1EH.1P<5HZV$C,:\IL@8(N'D0LF<P@(\@`(^Z@,@3J\*(&0^0P,<
MS,(R9K',,!"_C"/$,,<N:CHZ(@*<4/<LP+.`KR\D```<H.-0BP`L``W/_BKC
M].)F,&``2,D!6`X`4[%4!+`@>,N:$BI??JN;E"F&N"F>-B#*D&.^*J,#)N^<
MN`D(UP:H#.J=.HR>A.JB0K"HU@*9$JJ],(";[`DY5(T#%HR;(HJ[1I`*"2">
MGH/,W.4"V,D9JP2>_JRD`FJ;4HH"O*H7+2!.#,:DKLP9)T#+0H:G`D"D;*ZC
M#`HWT)!CG(NSD.NRI'``B#&1PBP`G+%3&&(,MZ6=1I#%F$8!-JXD?DR^W"HA
MIV(C.@``ID(!?<(C,:`9KZD#K*T`G,KY(DZOK&D`GLS"8F:Q'/(D"4(1&<+[
M(G+,`J";#(!"^B)6=`]$'A(CHBL[GBG^D&O#_D#Q%0T`2]II*C1``0H2HE21
M*DFEC9K"AC2@I#1`BI((C+C2*T$*DV#&KG3)A!(IE+BR)-SH.72))*KDCI)F
MAI((I$P(+.DRDKP&E:K$D6SHA,1R:_"RC62(*W7Q5Q;1*Z7$C&*%2H+F8A23
M*V5(C6I)E\RH,!FB2I9F,6EI$84(9K1R;9+(C`@3:VS2KM"2FHK(C&*/5?PR
M*X&&,/.2BK@2DR)3*ZND*\U&-N52-W4S-;&RCF3S+/=&-$6)E&S3KH;3+3_S
M.<YRAMIH,8N3!VUS*PF3C$"S*K-3.[>3.[O3.[\3/,-3/,=S/#A`>B9``IIC
M`B@@A\Z3`I"&`]!S_@)PHB0[X`(D`#UQPCSQ4P(NQ@,L0`)&`D#YDY0P0`(J
M`#G,$STK8(Y``I\XQD#SL`/X4P**CS\GP#ZEAP*PY@(N0*N0X_<PDS]'(@/0
M4P+RD&D`]`*:XSQ5DP(F(%\ZX+LR)P/ZDVDHX#3IL-;,IJ:"`C<J())&U+>.
M")\(-&E>U#_E<P(XQA,]D2%J%#_%"S\G0#4K($"#8DIMJ$0W-)%>U*[N\Q\E
MH#0_H$:MBCS/-.B0`C">K,24:@!^[]:$D$)"1B$$0`)43`,<K>,`!@U5;D4I
M:YRDIP&4J0'<P[`F2H>@10CS(EAL4B2LS=$8*B)N#0(<@`#6E`-^<.4(_D"(
M&.#-:`I$*`1<)O4^!0`P!``"`&JX:,X#]LI)UF(#5&N<4G5RQFEAC`TM4FLA
M88;4.*+$:(0R>&,T^C1C](P"Q,TF'@\P9.C/QFDGE!69I/`!1(TA"JP!$,#$
M"@`!G,3$O.T`@(HFA\NA.N"<=,SF>C$!HM(_"0`E]<FV9L16T51>]VQ&B`8E
M*>,`ZG5;+HM,NTVOTNZLFNNYT!!IK`TY+@`WLBM6/,NY'&`Y@&+BTH5?<27`
M\"L#6$-?0W&GL%#)/'4"``"^'$!4!<!!'D`"J$+'W"6'!(`"3I9I'(P!C@I<
M,L!.\>DS<$5=CD8W?&N;NLXBWJO1)$P^F@Y8_B.`7Z,KNGZ+211`0-REN\J"
M\0YT/<W/+SBR`BH/9JXD\$#45RK#)\`%-Y`M.U84`HY"WY@"3SM"QAJ"L^;5
M;9_G`N!E3>:P\RC1N.ZU7X$B;GTB3S<*F48(7M;B6DE"8=UE.Z[5K!X051ER
M8D4"YA*27.!K,>!%6#96(&[&8Z7*`426(<"E4EW*\23'NTY10TQ6WS(&H5B#
M(RV`6Q[O8L+NM]YS9]>F]GRVNV!KYZ*R`H856.-6C&B/A00@7(;"[@YR1@:*
MYEA%><W/[O1N`Z8B`4A2[':#`AC@XA8,L6SH^I*P)3F&PO@V;4EB1HCJ;<M7
M>6;D:'@0`-)CK\#6_@`XZDG]];H"%@%*["'0,'U!Y*C4QL,>PE^>0ZG0<'=)
MBG$=-0-*"@,>X&4REJ-F4"_B8EL=X\T,@&91KW,#`-_*0E6HS2[F[4L>;:^@
M"R>FM_4N0)?82C_FJ@#N:0!V=3%\EK`@(-LZ@,)F++L>ECL`H"1^*P^1X]&"
M;3D@`*ARE'FA:R1.$)IPPH*3)J:L%[JV:,5`I+UT:<8:H`/LZ9P>('PY0BA.
MSGR_&'GT52[P*Z0:H%ZMA+-HE@/6B4RZ=B&X981$;.Z0P@(Z@&D-XB&JZ<F0
MHOA$K+OB`[425"2L[B9X`X<90Q<%(X8T3()]!$0`8&0YPF4ID0*RPR;4_J5&
M3:^HLH6&7P]@/&#ET!C6`B!FWC-N?%)#$L.KI.W)8(IH@V;J=IA=S*\]_JL`
MJFE%^<DD&H4CL+;F2I)=0!F^OBRU>`SF&JZ6MW7<,"YZ56PD-&D$35B$P)B:
MB4<HX%,!!,!4FRSZ'*^(0B9<R(2U.HYI-`T-PR4`""+*!JZ()L.O=#)!<%A=
MBBAB`@`#V^.=]<V/HD^YT!E+AC=5'2//]*,7;\8"(,R1#8,`9%1E/$.O4'$Q
M9`8!+L9H$]+IC@JY@@6=VW;28L7$$D+\"()F`Q2=-VUO!H!)/"#?`B`!9@BE
M^U7/6F:QG`LA-D"?(8``GN*G!B-6?"ZYF&90_EEZ`^K$2N@E7'`#G,+ETR"Z
MFK<,TO#-`9[ZJ5FSJ:O:JJ_:*OHB`B(``K::J[=:CK%:K,>:K%D"XTX"6,M:
MK==:K<_:)-+Z=#C@6&'T#)FD`U[T6//E`K@49O(GA];32[FXDH\4*#K``@:;
M.Q#&,\GT6-GS27'4`[ZKL>\:L,U4`RC`/X'T1NWH6"O`,R][/5D(%_%Z`R3[
M1>\:C=ZS`AH;0A?&0[=L/1F4.P"[EOX3LYEFM0^6/3.@L3%IKL4M`Q8&%PO;
ML<G4A-\S5FIMKTD;X39[N:?6;'X;BG#C`O*%MX>ONI_FL&L;`XJ/[N:ZC@';
M*YD&L&%4KFO$`CJT_DM'>SU_Q8MO@@)6E%4:^V)`^U@7^TM6>P)65`^G1+_C
MNR<F@+N]6P_QVJIX^S&]FSN0N\#%#4)Q(K*%FTOUD)1*5+Y+&SLN@+(IH(ZW
M+#WD>@:[NRSP::X]^[>_Z`*FVX^LBKTAO+C5BY3ZF[?QVC-Y6[[E>CU1-+IS
M?`9?_$9K#;Y'XJZ1@[>IZ3W5&\8S8,0MP(MQD4;C>VLB&T=9I1^UY;([W+&[
MN\=Q,8=``L236[W`6\IKBDD!VXNWA34>`)/ZJB#@VG3,BO#B)2*>%)(]55Y^
M:UQ@1K40@%/!Y37>CB$LE:E`Y:R>ER<75ZB.!KA:QK`"JIW!"I23<$M\_F)+
M%J!3]$XBD*N]O*_`IJX4&8*P/-6I_,53W^XL6)H!^#:X>A'9D*D#F&4DRBL!
M>'(J.N-;L567#.#0*X(`5BJU5NJ]8G8`\M3GX`+:S(8`*F+>MJ-1*#%!(I$A
M)("I%@K&\M@H)E(A_ND@*YT"7$9>-O:]D@TM,J0IXBF;'Z+3!R!!KDDA'"!D
M",_!,!,`MH0!XAL`,"+L(B#ZU`_./76O2?9+@&H!M%4/;^T),R#47X.(7Q;9
M1M"9OZ19%^!#C`TVPEW?.++2]4R!.QA:DD9X/Z.:4"^AI/"B\DU;>E'9;WE0
M!YZDF!!$6AJ2DVVQ])W`VDO@:8X#M`^2QZ[._FD-,1K`M!IM,%Y%U).UUG0#
M3X-=X?_"S4@R;CW5_["CSI.+(XG*7X`5VU98W4-&A`8@K'HBO+*9E#2"EPE+
M6<:ITJPMV09CLJRN/1K5,-""L!1@HC:``U5&A-9BWL\05LY0CH_)!+\5UW[+
M[<:5W37#_%B#`A*`K;;#S4L'?^4#,/(B9+#F:IV$87C(W<>M)+`NLB%`GX8:
M?H7,N0#@`7[+3!6+XSP:IP7Y8K;8:^Q4Q'[]3NLOTR.X((YI013`Y6-?/T',
M`FB$`#ZCK!Q`PHJ+,S(E;KT-73YPV<_05P;`[AX7`WS2:LGT[TW/7V:$29H=
M`+H-VCF"`_O7UC*`_IDX8HM=1M<V93HT(%7)72_X\%5,RHI9MS.T2XV+:E6<
MPJXHT<0`0L*!#0$N>"@0`4.`#A\:4AC0\(.%`!H^=!@@H0+$#P0@1#@0,61(
M#P(N?'A0@`.`#`T]#+`0DD.`"`,8'F#@P0*$#BM%GAQ0P,,!`@P^4##`0(%%
M`1@^9`"P@<&""$Q#5BA84F'3#@0B:&SH($&&`!P^3!#@H2%!@P@G5NP@8(+3
MA1\4,A2IH$$$`$$9-(A(@4##!`_@PFQ(@,('E1H@@!3Y=&N!!Q?0?H`@N&$&
M`0P=*.#),J*"!P,45^#\X<($#0`P$`VI(<`&!0`6?"A`P0&"LX<;7I1`_O:#
M@@0=,#A(NQA`!0\0+`1NV&"!3,4>$/A5P$&`@0D3#*@,8`&#Y;JH/]Z6V[*D
M4P`:#$CPV1#"@X@+!E1LB!J^_OW\^_O_#V!_"D4`00`4)!714P,(,`!+HRG$
M00<)\/5`3@`,@.$&@`4@@`(8;`!5`1!\4($$$WB`%$7JA01!`F`A<%D",IDD
M4T4J,?A21-VY1(%+##0HVP-*?=``C`U1I8`"`E10P849+M448Q)Q1L`!"AAP
M@`<-)#!`!0B,.%@"$B!`P$$&*'"`=]9%9"!1!TBP0``88"8!`[+-Q1`$!H2D
M0`!%1?0``A8,D``#$1@9T0$1-&0`@P*LU">&_D,FAZ-.!Q0`IP-7(3>8`Q%-
MUI!*%U`@@``)-&5``!@ZL!E#%P!P%X@X7C!HH>8=T`"$&#C9X$,18191H:1*
MX$!!>V%8)GPDZ4642J&YA..B`L%5`8FE)G!!!QQBJ%A#@1*`P0!Y>9!`<YS!
MA8`"!2#@P8\`9(F7GQ_0)-H"7WT0%FL)*$#`7Q%9-]8&$`0U6%&QE:4@@Z$)
MIU>:$3#PIU%.!I"!81$EEIP&QPZ0K%D"T*?`JTD.`.9Z"P90@;,19:=!4AX\
M\)AF%P)@4D2QS;8`4XF1%D#'#550)@'O7;`@`M5&9&>S%$R\P*MW#6P!`1,<
M``'$#<C$@`&5(;<K_H8!9%F`HQ4*D.ZZ!^'H*8OS-53??1_D%V#<<L]-]WX*
M,:"IEI,&'*$'VC90H`0><)"!!"1;($"$9:W,005*LK:!`?-)T&<'VR4EIT@M
M0I?`00E$T&]R&CK;][\(1%!`YP14D$"<&PC)>42H3S#`<:=U$&&H`K!4XY0>
M$.#`CRPUP,`$52[:$`*X0J!A`0TX4%7K+0$0V%D'G#5G[0XTA>>\>R8(54B!
M1JV!``L@VI"BC.Y$$`9Y17A7<AGTW>*@"#@P$4,>I'5_1`:D#2(,<*!Q.3M(
M!'#G@<V4Y57((<C\.N`!HI5O`2"10+]<I)`-X,XH'VN(X9!CG:LX`'_>_L-=
M_$0"%P4X0`*XZ\D'>(3`#QS@=`50R@`KD#.5"!""@&H=`@K%`)DX``+4@PL$
M^*4A.YT%>>#3T%F0T[I[>88U4SO`"2VX)0^`#CFXZEX&8]B0O!R*:`GPEU$(
M@#L&9$D`O2F`7%2R@0@8P(0;0DZ2+F"@U'$J8!V`P`!4UI`EQHD##_@>!%FS
M@`40K"$W&XUC=@8`VJ4MC(HZ`$AP9X$&W$DM&YA`#0,3(:GL2D/X\DX`$/``
MU^"F1@4H8$.^Z)B#2`!^)'E`VVYS0`YP*CYKHT`"+,`N_)RP;L0LIC%]8I>(
M-&!O=`FD]F9H00T>`'\=#,E%1D0!BD`%,QIX_AEGMG.1UFA@<2=Q$0>Z,I81
M*F``@Z-(QD0BD^?9:0,#N$#YH`*[<S+1/$NSP+TB`A?N"4!P`_O=<M*D)9P@
M```E(TQ(W$BN`G0`>]Z\2`4.0#&F0`!]W=,3;`!`SI,(BIU$Y*CZ/N`>BU!,
MA3Z14GQ<1!L'P"4"'K"@A";I1PUT@`%H))E1%I)2S7"F7<'\`(A(F1IV[@4D
M,C%079IIE(U\(#:"FX@_I3JOF#DEI"]<D?Q:DB.U`&"$.23`?*X"HH4!2@$2
M8*A?0#?"`W1.3AU8UP<0!`$!N&VJ(#7J3"*(LJ=DH#H-.-@&!'"<E07`J50E
M44&\"%71Z`5&"P"`_ADI4`"P2)2-_\+)1#A@'G@&``(1%``%MA:;DK7*+&1Q
MX0<0<#\'#&`""K%`N\0"TL.N;:JR&<U!J!<H#TR`8KK#&P.@@A0/*.0^>,3`
M;8T'G05P!2<:\*D!6@,7V<#Q5>-)IGG<&!&2&,0`[`JJ3^3S0@5HZ`%'@]LQ
MWPO?N2F$4\==;`&>LM@`%"EM>,Q`G`(@HR;EMV1`4]4$COJR`?!E42F=0&L<
M&A\`<&@!'@A+J,#3N^\$``!#DD!FNVHXF!#Q=1(V'Z="NX#$2'BQ(PKHSP;0
M,]NNCK<2(!YO&[K;\QA5`!7R8P"TQA$+.*"G&`@49.BRE\6BA34A'5^9_@YB
M4N2E5%ON6_$F-<SAS1W64Q@H0,\4L]#%=JX!,#Y`10H\V]NL>`"[6NP!%@:B
M_(:,G2AZ3`)0T^;%.F!I^=U`!;R,$1)A-<F+Q6RWPNM5#0>`=BL6T6/@0@$T
ML]#*B!)29(A'M89,I'UUH9Y47F@VF_55(H!&W@,$\+4-'(RU:KWS7?YLX+2L
M&K^+-:,8892=RZYY.8]:;`0RX.6!SLO*1XM@J@9`TZU=9I.T%L`!5\Q0XMX5
M1L;[,0:8/*_,\78V\WD5!8PL%`.DQ7C(Z4B7547:B$#OQQEX#I%LDP&,(C8M
MT&,(`C(K$PVY\JD,^<AO%UL3]2C$DQM6U2[1_JL?]\9WX0SGSR[3`O$72OSA
MX:UXQ$=2<655W`+H:8G$/0YR3ET<Y!D/^<<Q[O&([Q+E)S_YRE?N\I)3O.49
M5SG)2T[SF&-\Y!>?.<UY+A**VUSCR!&YS">><OV\_.,PS[G-B\YRH2O]YE!/
M^M0=SG2<WSSG28>YT7=N<9TC?>DX-WK/?Y[UFJ.\ZE]O>=5]TO:V;UWL0;?Z
MS$=^)`+`=N]\CVS#_P[XP+_7(((OO.$/C_C$*W[QC&^\XQ\/^<A+?O*4K[SE
M+X_YS&M^\YSOO.<_;WD#B'[TI"^]Z4^/^M2K?O6L;[WK7P_[V,M^]K2OO>UO
MC_O<ZW[WO.^][W\/_OS@"W_XQ"^^\5.?`0UD(/G+5S[SG^_\Z#=_^M"GOO2K
MC_WK:]_ZW,]^][?O_?"#?_S?+[_XS4_^\ZL__>Q'O_O7__[VPW_^T1<(_>./
M__OK7_[\SW__]^]_`0B``_A_!2B`!DB`!ZB`T`=Z#>B`#PB!#7<!+A*!%6B!
M%XB!&:B!&\B!'0AX%\!1'BB"(TB")6B")XB"*0@@$ZB"+>B"+PB#,2B#,_B!
M(4B#-XB#.:B#.\B##<B"/0B$0=@0%Q`!$;`!'#`!+&$!)C),$4%XG506&E`1
M'S*%$Z4!&"`!$J!6H6(2&!`!$P!!$Y`M13A+RY$:4I@:0JB&:WAY(,B&_F](
M@PR``1^R`!C0`!F0*Q>08^&%`,[%`!?P%^C%7K;Q`!``B'%$`5QE%DI!&10`
M`<V12AF@`(.E-5HR`4H1,7"HB9M8>#_(B9]H@@P@A15`(P_0`(,S22$A,+^F
M&!O`')["7H7U``]``6>VA6#Q`(14`10P`0]P8`Q1%!@P`<?1`,.(`9D(BLFH
MC'3CALOHC!K(`(\H`5L1/`N0`(<6$A(@)!BPBPBP`0F0`*]3`456&+[4.+?8
M`=8Q`1"0A16"0R91%$/$+L5H',CXC/>(CTY(@?G(CZ#W)QIPBADA4Q4&']M3
M6)ZR`!2@D-]6`1KS/!Y``1E0`;=H`0D1C4<8_CP=D`%R411_6%C%HP%3TX\C
M^8S-2)(GB7GOH6D+\!XG\@$J.1**<6T34"XG`I$4\"$<(`&`."+7YA,4T&\'
M(HHM4Q@OV0&*H0%+>`&NF(HHZ91LZ(E/*9532955F8(F:959J97Z81SPT64%
M4`!Z]P'$T1]R40%,-#?GLS@#`Y8,H"%Z""`=<#1;J886L(]TB9=9"32VX1,7
MH``:L`&!>1N**!*"L4%T$SDAH1=2Z`!9,C@`XCYY*818*9F563=A20"9J9F;
MJ9FWJ!F<"9J:^6'PD0&A&9JCJ7@=4(Q\*1(7@(P2Q0'G(QT2D0!OTE;V,B)C
M@@"*434)T(<A`4Q?_N(!.6-&Q>@_&&`!#_"-GS.!7_)"&]6'7"(!LV$=`_1#
MCPA;U2(!:&F9)!B5W0F>``(5@4F>Y4F>!\`]R&0`YLF>@:E5(F&'[<F>`/!X
M%L":(8%'&#(`?R%1#-`C%<``=:5!,B(8O0B"'6`Y&A`\$,F:')`2'J``%+`!
M6F6<#5$\%5!8-6$YKL@`_J0`RB6'2B$H\W(UB7-.@]-B31B>'$B9'+!."'"+
MLJ6??R0WB9@!1?$1O1%T[\%>G=B4=9&><H.$_=&8"[.=#H$`*@H@5G1,&E";
M.GHD*NE+2NH?W[APP#0`OVDW32$C&G`32:IT[\DF_Z&ER"2F\&&#K[2'_OI!
MGXYGG_!Q`=(Q0`PA402P+PE0`!APEP4Z1"JY9\:9`?L8IS_3`!.JF!V7D!CJ
MI74A+F@R0AWG/G45*MXA&.U2`'*XHB?XG0V0BP+A$[C#.@,T-][H-RB%5"VU
M)PV`C7]7JB)!BW43F?MQ$"<4`?-A`05PJG,C4<?$`!60F)HS(A6PGL1DJ/!U
M`01@`8U#`(0)'=7"$,-H$;*:&3X1`$TG$NC)E6?J$VE:%VL*'VW:>&_:EZ^9
MH+B#`?&F:?1D%"L$)KWJ`'(1J!&AIX&DG!2*'A?1.(4%$EZ*H(#Y`(M24^YS
M$+)V``[Z0N,$2IE:@I2Y/XLA;G#J(EJB/',Y_AC#H0$*H#S<2#9Q*@$"<``+
M`!-6BC0\MB49*Q'*DU@`Q0`(8`!`^;&XX@&L,[$D,D.G>(A6\C^E>5\(4"3E
M\D,0M+(PR@%6<A/D$FCR"EO2]0`!\*&RTQS#FAHHZP'?^$.$`UN?P1PSVY]!
M&P&UR:'*\QX+L+)F)A*4XP!K^H@6X!V:ICP5$IPXD0%)BZ#G@P"`F24W@2N-
M:1L7F[$HHD9-ZQ,1&A')ZJ(_Y(IRE0`$4``:`*-A.34=\(T?JTMJQ%/Z4:W^
M4:;PJ:TBP:U%]A_@RGCB.@'D=`$&\(B/.*L1$#*<6AT94:>JH9P%4`'=T0'O
MZA3[*!02<*OS0Z$*_B`?_T,B^OI"IW,!Z*D!!:`3"Q!O`-D`$SBZF5573")N
M&%`S"MN!WZE,W.F$2E%C@Y,2(7$`U1(!,`&@KW6%2C%';UJ$,0$2#?`7.&0Y
M9;%G5O$>D7,136$O1^&]QUL6Q6,!;IDX*/(ZBM&RK_4>(?.(1E6P`G"X&8`!
M]WD0W10!Q[%(1X(``_`G\5MA%%"K$F&'[S&1?KD_!2M1"T!:>(,O.SDBYR0<
M-$4L(G$5=_DK=Y;!:]L`7N)<HUL\1J&@[\&X$_H[!H&LIFJ()!*@;#:6U?M0
M>W57,OD9!-!--XQ2.DE:WH$MZSH!?Q$NEOL?V.J5FQL2G>NM/@&ZBZ<!_D<S
M2S8SBVM<4PR1G&;8`1+`/*D!`1E@$@*3QA;`.]@8QQ#P%ATG$;-HB+*6K/<J
MQX,U51!@DQEA%)1A$2K9&$:8&DILO1I(F2_DOOMA`9AX&!X"OA6Q`6%A`+91
MMY&YMFCDC3&1JHH1J)L!6P9@1L]9FQ+U/;GAB(,!)YK6H6[Y/77[JF3KR3><
M`.2%``R<&1[RP*KX&$!<P?,"Q07LRBQ;J`8P&813`*;+`9@!6_54PC`QOQ$@
M.*I[P<)A$O\+G-[H1C+,3090+=%<`)JB=X+39533`98$6PP,-@RQMG7+`:),
M8;LJQ3[AQ8MQ$#-$)G7%$%+L';V((AR0I<J#_BLP@2*6:ZUA'*0A@0%@_"]V
M,\8B4<:5#-(.^)WIJ+WXZ2*V^UIJ1;:[V0&;_%H;8,KRNSGL2R2L'(Z/P0&G
M>K:02\MI4804X"_A:R3#^+^_ZLL$7!'!;)\U(T`?ALR38A$$HZ<#&Q(=7%WN
M&2JJEM.V5#$`R:Z:@=`@BR^*4800<#470<X2$<N^Z!2(!:Q.,0"J9B0Y[5QQ
M&Y$=0)1B\4(?DL]3;+XL;9\(3204^RL1$Z$#L=>S.MA3O(X-O;8:R=:_P\7^
M,=":2Z8<_;DAK=D/2)D-\#]G2R(7[9=.T;(;=:T542Y>XB)B,MIK.Q:KZJ!V
M:-/"H2F5#0'VDF+9_K%GWO$0O4AAA'$4&5#4O=P85P/,3=$`%E"\WR8=!.,A
M\:96?G%1MM7,!.)!5J1"%X4!OI1)#T`Y]GE@VS$MW3S6\[*="F"?[!0R$I&)
MP%8!#D#->Y7`\Y*DA"&L-XH_"$"$(!NA%_7>;MG7^^RD$'!1G0/0$PG;Y-68
MG4,!1O.0N_H`#C"TG50A<W1$FRP![0'4T^K177S1\JK1R8/9_O'1FVWBF?>=
M$U"$ZWL!6^AGC"0!/2(2B?C(HRL7&G/&1@%QNRH2SF%/BU$M$!D!3`R1TYF(
M!7`!TVD4Q2CC1:XA&V`!1^D0N)/A0$DB"Z0AA=,CPO4S94$!.AJSO_9"_C*>
M(-Q34]UTELPUOB]4D36CDV!H%CGQEA6Q?$6N`4#IJT9%R1JS'!AP0G/8$M-I
MYV,NYB02`363`5YA$3WBDC*>,G$\NHR>%DO9,G!WEK;U2N.[/RX)6AL`E%<8
MYZEQZ#"^W12-N1_^2B'^6B/>'R5^XJ].>9=LQK/(<);#*;D!Z_W!`:OJ>`'@
MX=EZV5S9T2'AZKEN[(V'O69,YO$%D;"!ZL=N>9?;'YF+T:HNQID-[=GN>+*N
M[5GIZY3][!D=[%XY[!%1[-V.[A(HP[HN%0N0W#X11R&!DZ7.'RK.<`GD'SG=
MEX!9,OJQZXI'[\0$)_'3`8GD[CH:\,2D4_LQ_BKQE4D=FGC2SA_4#N+CCDSE
MWA#GGNX;/WC<"A_TI)"&LX6QVJP;X)GA)7K,6C>9Y!\!#5`4MJ@.5UB)AZ'%
M=$ZGZM`AWR`18?+'E`!,'!+0^EZ%9"*X@7@!D(5)K_1*#RY<*31+#_4>9C=B
M$O5+_^T<C_4,E^S[L0'36CQ:Z!33>#^8>L/"6!<0P\3VZ=UJ$1TFT3*8^L`,
MP!*G950C4HP*<$!DDC*>05I+B/:EB=@182)3M2?'6(?X`@&39(?Z`9!LU>,U
M)HK$HR%O;Q(10`$F?(S'<?G$4Q',P5;*==M*W$>?WP!NO3(=PP`F$@$)*9/N
M7A%Q6J@:8Q$M5ABJ_GLUM5(<8EL1*F["[B[W%B$D0Z,8M>L44F$2'2`DK;BL
MC#0B-_J'@;0`$EZ[JW\TCB/]$<X\T4'8$;&+3.+]W__]S"J7X$_^3,+K`!5I
MY0_^YY_U[5\WW.[O;":1X`+QKBD><RA1-YP;&W!?I;M+`*'@@@8#'SP8L*"A
M@$(,&0AD,)`A0P$.#B9\R)#@`X$('`Y<H,#``P(+'!90D%!@`P4$'AA0\/!!
MY@<$&SYH..!AH88$'@A0L"GS8,R90@U@\(BAZ`25#Q9*8-#AZ(8#&Q0LX(!@
MP8:3%09DN&#`0P,('!Y$J*"RPTP/"SHV>(!S[4P.`QI:(("!P=8)#C8L_K1P
M`$/5P5(]5"#0X8(#"`\Z1!")``-.#1D.=&BP-:6&"@<^*)#`@4&$OA\Z%#B8
M08,"#PDHF*Q@06-1#@4F&]`P00$'EAP"`(THFT.%W0(N<$A@P2J'HLV=/X<>
M7?ITZM6M7\>>7?MV[MV]?P<?7OQX\N6S7YAM?8,``P=<?V!@X<.%!1@4R(S?
MH`(%!Q0:"*5-``@@$&`RSPRRX#Z#(H!`)HL>N"@CG9B#T(+_AH/```DD<.`#
M#@IJ0#ZV4,/(,P02"&TCYHHR8*ZB/%C)*1%E*LT"!CZPSP(#((@``0D6D*\!
M"CZ`0((*.OP@`8<&=`"!"A9H[K28/ORP.=\._C@`@2&%_&`"")'LX`$%>"P@
M@P8P:*"!"QC(P`,+(E#@/B4E0(!'`R[@LK33I/R`*OY,*T@!'S?H8(`!,Y.M
MN3\_8%!)@R(JB%'(W(*```T(B,F!`R#0P#Q//P4U5%%');544T]%M;L+$,#N
M+Z+PD\]&#*"$S\+]+/H/HU=[?$!,-@_4@`(%-3C+0?XB[(FB#RILP(--+3A+
M@@<\!+&"%TDDR"`,'!B@MA5G:M&Y#R6@;\8N.[01H^22N^`"JR[X0#\BC412
MR0(J:!>#)Z,DD<I(Z<*TJ#P?X%"F#!QPX`(++E!,3#,U:H"!"BK0*`$-(%/X
MN#P[E.K#F/SDN`!M_A_(BX"%+<A@@\1DRLH_F2*(P-$/(CH09K=.KHVH#"J%
M-U6??P8Z:*&')KIH3]%KE8#F''!L+PP&J*Q%_?C[:X.)7HV(Y6[O_!"#,O\*
M:P.%-H#,`P>27:M"!C@@@(,-=I26VGAA*JJFFR[#3:J_F,N`N:$P</&F%C,8
MP-J9:KPQ`P5.ZULR@>*UMDC$.`C+I0@>"Y'6HD`SVP&/7O4PX)D&)F@##!`Z
M@`.%.G`6@H,BH,F"#AA@-8&&#-C@[0TV!I0F"C"#P`($.I``TX@Z0"`#+<V&
MG78*.BMKH;<S^+&#SGP[[H!@=QLL9YHN:,MPH\<GO_SG/(@)?:&(0C]]_O>)
M6@M]U@UB77WUS<<_?^X2O4XT*QM0P`0BH`$'`#`#'Y``!BX@@?E<I5,LT]P'
M$J8!!B0'(PM0@%(N<!6E=.!L%)A65#Y`@9(L8`(42,!+)&"!BV`&1Q8K"FGZ
MU"'[**`"+ED+!."%IB0=,(8)<("1BL)"'#%0`PW*``:'!($#)G"$%L``!!:P
M%=,\(`&.P0#LHG0VU[FP*!V((`+A=8&+)&@!G2+.`GP8@0-&P":*6T`%_D,Q
M#I@17N3Z`!%=6)$$1`!]$$C`!/Z3Q/=PH`$)<)U!)!`GNLWJ<1Z00`(:P(':
M.$`!(II`"C4PNX]54(OZ`V4H4:4`C4#``683_H``1!(!`,@N``GH3`8`D($.
M"*`#!PA`*C>`@%P*8`,/2&4B13E,8JZ*F*7J@(*JTX!.=>28SS2/QZ`Y36J*
M2@$`N``$0D0`0FDH`@-P`%Y@*1@`)(`#MA3,3$@RDP%,8`,7F8!2JCE/H"&-
MGN9)2'4X<!'3W-.?U_'@/P4Z4.I<Y0`/8`RM'M``.!T@,^-TB);028`"F(BB
M.8F```C`P'P2U*/E,>9'13I2DI;4I)Y2@+`*8)&<?.8L##C`1B%JFP*@DP(:
ML,D!)H!3ZUDO`-\Z:5"K8T_K'`9TZ_/.6FZ8'0L<528:D*=,F@H=#BCE?L]1
M3-&6"AV&B4<UU+GJ_G:0XIS`7<=TV]DJ1C3@)J<*53Q-0D!<Y3I7NHK.I`%<
M3P.DXAYN0D93*(RETAH`@%LF8`$,V"4"]D*0$V'*B6Z%['-"6M25-8=-W:&`
M'R%05NH8`*B'RY5,-@N=#%SD3-')2-$<$YT,B@<"_)3.&;TS`1_2)3W8D>-V
M"N"B(GE@6I$M#V*O$X"V?M1=\SE@!RQ0@;54QG24JZ-R/30D"U#`NI2S[FNL
M5P'F8"`HP`4O_XI*D88\SP,$>0#Z6,B<#8`D6+F1YSY?TY8$K"0FN0'?83"P
MTZ=.@+DS^RR-0OL!Y@YD`@PCH8<&8@#'=,"Z<RFM>*'C8'<:9($/?,X[_J>Z
M5(DHMP)1+<H-$S*!J3HX04K1<$Q&+$\'_PXC&7A>_"9&,--8-R;EO:%"A%D4
MJ+K331-8T3OUY8'C>*"T=R0`O%*<1PS`A#=;!8D@L;JPU^"H4\K5"?4ZU=LA
M$;G"X/6.<*U#7#"7V<Q'8]5U?!*F`DQ@`7XQ@!_?/(&J((:V!#B);:@R`0A<
M9B]O4XQ.&3!)`00Q,:ORSXT\^QPI@\LD6BI```]@`1M1I2P'@%E/*J"E$TGG
M(!O:+01>DC7GG$Z0BF8.S#0@@`B`>"846<`!6#*!D0RH0#CIRW_B2H$#W+!.
M=.H`!-H\:/@TH'@3N&6FS68`W7`JSDZE``%V_CIH.N>.V0L0@$L6IJ4`4D#/
MS'[`C;3B3@U!X#YPFH`!!CR353L@`I>!T$UZ0H"41J1(4G(``YCRW3-?1\S5
M(7._!3YP[1"U.FMVM[IZ^!>)/``"3XJ)2I8%9-588`"0=%V+'KF0@"E)`Q]/
M-X`9/6#/GD2"#(09?3Y0'^)(Y)*.2FUT.N#="RS$`0M@6%N!]"@J22I;T"FY
MM2K``/O(Q':,P<#ILJ*4C*"G(7%L3)\N([*)NUDBD@GB"VF"X:*$I$]ERH##
M:>R!;,='1]R%D6=ZE0&E2X91#9"(]A:=6^?@)";QB3=/)C1"IDE`)QZX.$8"
M3'#H_)LZ`2=\XA7?_IS)'IPB--9`[21"`(2%<^@R:=O$"3*:BTN@0;M%P`,C
M0G4EZ8@!?1:Y<QHMDY++IS^24GE])'"`REN&.<B13E;&M!!()B#)SY%951:M
MZ@,]I_5YC,^-X*,7!50>>>R5M0$J'T784<4C,I&``!%0>0TTX"(\V?IS7.:0
MRLO1<)B*#X$9P)%=PJ?Y"$..4LY6>5?A:-U/51"$XIU:$M'GWA11FL6K#L.;
M#L0[*0^@@"G:BS@JK@T8D`'Q.[_K*--@((,Q%^D`"P\1P&-J/+!*#,B3O#U!
MH.6ZD;U[+1ZY">+BLX/`#`:J&JK+H)U+B]1KCM4#L)U[O92#$IS#@):0_J#N
MNP@4DHY]*92=::+?:@Z'^SIG.2"WP(GH.#X;\1B=R*)IX20M.1>[6Y:=J;Z<
MH(BV()>>B)<-L`B%"SWQ^X_38`[_<AD-("Z<VP^,J`G/*!@<LIT1*L&H2`!X
MT:;GN!3629X!Z9)D40J"^3^?L(F7V,#"X[<"?)5V`9^96XOV.@ZZL"H6JRT<
M09_D`IR;."#5T("JVD1*[)M\\0!1!`^J<":6Z;-&E(FP$#O8V:T)K`W0L@ZP
MD(I%'":#`ZO',R)6R9`-J``#T`KK4;[=TCQB7`#<\1H*:)$.2``$^(A:_(P,
MT!$$:`#4J`I&"P``Z,:W,0GY>(`AB8`5NI$(_L`-=#PH#TF``U@`C3`AK))&
M4D*9++$;LA*422.P`D@`!1B@XG..*+R1=)-&6H(I6:.)=MP-1FF/#D'!]@N+
M$Z&U!\"2!BG#U'J`15.47.D,=V0=F%*`BXL/Y)!&AI$^E\"2(4D>@V@`+/G%
M`U"`^[L)`I#&ZB/&0_J``HBU!?"`>Q.+TU&LXMI``I2.@",[#%((W]L9`U"`
MRB*0#J"*5U2FC=BLJB``W[.*@BB`O;```7`G!$!'!1C'2#L3FIS*[?")GFD.
M'7$JE2N*W:H`#/.>+M&K"D0V_WHMF_``-F*A`<@^A'J`"]3%HNG`1=07:#I#
MHJD`V*'&48F\P30/_J*,#J,<`-:)@`Z9@-'8K$4;B4F+R@9Z2]PY*-B)`#$1
MOKVX``+`';!T#`34*TB*BB'Q#HJ)CH]PCIJKO"'9+8FA"W!"&$GZS*I0K`M@
M$`+SO@=PB(]3H+R`3/+AQ45L$VB"(:(A20102U$!O^8<#\F$#J/4*"`:DHP@
MD`$XD-H0I,_<(!:YS`-(/PO`H`7X$:XL@,8`2XT:1XU:FP48@##2#F&)CG5B
MO#B#&?G8+7G1&IB)@`5H@.#<):6H$ISCC],0B@#2SO$IS`K%T`RE)NY\#LJD
MD7,D"S]:&0H0@`)8B`-)3T<S@!V9%H<;DSCC2L\J`+!LD!'*E2%3EN[H_@!+
M>0ZOX:PU:8[=G)&_`"T&7<DD\9ISD5`)0D(-#9H+395)S,3I6`FHP@Z%`:M3
M=#6JPI<ME8ZQ,I6^J:KKR"[9\2I7]+0/>Q4/\%+3B`VBT)<5<9.IPI$*0%,G
M=0X.=0ZC#$#D*0#<@9F<9`X3>AL+"(`_O0"-4I`6D0#/6M&@$X"A`Q+4@`"P
M),^4(L_0^]/;XH[322L$/(`IE<H-<!N;$%*Z(!&Z9!NH'(!=\B%GG!8OD1+=
M$$H\+97G3!6KF`_QF0Z?B``RNH[.X%7HV`I<=8XKH@#8JH[6,I7X**VB"H`I
M0@")`X]X*ZH34;?TR8SGJ(UV;(D)H#=N&@EI_H22E%@`'K75Z-#3YD"\[SK%
MF.B`29R2*8'*W(&1W&$9]/&;#9A7?J6D4S0(0LD=?L4IO;Q3[7@,!6"`?/-'
MSI()#""`B(U8Y`D3M<R*F:"`!JE4!M@--9*)TT"C!IDB+(FK&DU75('2Z."-
M*IL/H#`8_IJ/"JL,@[`6Y:``#(`DVZ@,R@$)OUDNB9@)Q'@-\*&T"[!3=]HG
M#`,C!3B@_>H4T[FIIRJ`7[4=ELV-3'2(`5(*_!**ZEH+ZW%99IT/O[$6WA`1
M-HVG/FDR=ZTN]L*`Y9(Q&RD)HEW;5[RIJ`*\F7@`6MFOH.`-\*FQ#:M2WC@@
M@J&`GMFNM9`((),)_@<TC=UJC7[L4=G$#=Q9%@E0'H.@B#NTUI/-TX/=TUH=
M*0^8'\\],V.%#JKPO)RXN93@@$A*-PS86SHCHVFIDKA*-PMHU/UZ@*=Q.!!A
M@.(Q6<2(#<02$+P(7@)(WKF8'06XF`#2$J_`7*G]50'X70)#`-V038S8J*$C
MB`1LD.9#QV1+B62*JKC)")R0@`;HD'"CL_W8*`Q[L]GC#8[`R2N"@`&@-.-U
MM]V"DY0(+;*;"5>1H@F0#()8I([`-#'9"/A4WI3XI8U:@/2JDQ[I20T!J@YP
MLX!U3^E0PP"TD47!.1V)M<'SW'4M"@,TW17>Q32SCJIJK\H,/._2GIOP_IH;
M"R3;+0BWDQ;P\Y+!P#SO4<*/+0CW9!N#:)N#Z)3$1"#704:<(([F"+T>Q+R1
MB,NP8)$Z(KI[X0"H%(OY:"_*B0BQ]9AQ9`R)\*SCR(#3\SIVBP@"BH`$-`UN
M\D$@D<*`29YP65^V$`"`V=')<+.L4XS,K`Q-76*ER*"Q,QF+22(+$,2UO+FY
MZ&#H`,,EI0\OP0\\$1(G8>&B0.&94.%.%F7S05T_=,?\/6*A0$:YD3I,KI)0
M':&X8)4?GHT3Q3Z3-0SZJ$6=6(M%DYDF7M(/N;RZ@:K9P)2M9-\F]:QT<<\"
M0$X71AZQ'&,0RR#4P*`"\IP'P,8%@`"7F0F(_L7FZOH/*LR__252FKAAXV2+
M`?CF%AD`]O4^WI0);2X@9E*6,TSD\TLW>*8^Z."2/.)/EO&1*C9.NK.=_@OH
M$_ZPI&/HAG;H4":IP]B+B:;3NF,0M!#=$7*1#;C`)N/68>6.8(,9";`)Y1"7
MBW:Q=$W9YRC.#0B`';6)38:7TI2XS/2Z)%U)+_'AWJUE-5PY7"YBQ!(97A:Y
MZ6SB#T@GXM@78L8`8PZ?&<IB&P'6O]C1M;@B*-E1Q0&Q33M'*YPD9&2`<1RP
M#UD+<G$9-6R1D=A?:@R]&BX@/F:9/E+B^9"`R[P))X$2L_&6\$OD#K$,Y8F)
MN$#!;QZ>6^J92;82_GV4"2?Q@)3:F]6YDYY$$E'N,RRQ[,O&;"S):(&R-`X@
MBE^ZQ^9(BU[)$M&5`!=Q2W7*4=I0UN[0`'`*MV[9N>8@/RM:;2<MY;I31MR)
M2)Y4GA.AG"PQ)X]0+,^`95F=3UJ6B5DDQCJ9B5S&BJ%&1E^N+<\KD;CBZ##*
M2-K<"!B)JW1R-!MI#6D<$F>D/>(6E!/[H@&`%S!*R7AQC\/RYL-11@<;9Z5Q
M1FDT9ZJ;8GL,X```<'"Z,7OLXE@3C+&H2$'E:]G%U@/*$&SLR4^:YU1"PDE>
MB)E@)0`/@`N`V`!@#2()`+_$D0)X)<_&C5%6/)VXSJ#]8M%6OM:`"2[L_N(*
M3#ID([!NCJ#(HS&4P;Z5D(F,58H*:(R'PY%NQKXW:0Z"((J4,J'7>I7,Q0^3
MQ6T75C.#8(L7P?(K;ZOT`9`)19]_SG+V:0ZAK%706=/SR7(TMW+0R<4T%W-*
MOO(QEW.A$*[!1JJCPG,WU_,]3_,X)^D7X?(NCW-!WVP4CRSN?@[;%&W-R<S!
M6*"<2)W&'@RR`1*M*`J"R99TB;RFEB`U20ZHJKG8L$Z$R<F$27+4@)&\B+4-
M^B0HSR-.S="5)IIW"TJ1NH!>^YG\7@"'S9\V-73/]4_HX&07/YRUT8`%4IHB
M^1SA8X[4]@D2LHN_*Q()(8#82%"9((O/"!Z+_E.1NM-P`@C?6%&^$B'L=)6P
M7T?W=#_9'>6ZF9@(SEIJ"=(A!@/7N[;NJB"1))H)O"`E]I0@7N.`C"@4!+66
M'XF)[4-0!3_UYMBY=#$8%X8,E:9R=:?XBJ_0TZGHPSB*YR`.2O**W;D(KUCL
M$Z\*?5N6<;<AK9DYIM2Z`\\LX9F+J-,`GE06H%*(YGB<=&$=VZ,<YC1AR#QW
MBQ?ZH5\\#C`W]N78T7H.BR.``7`[G`"BX1E$HR/5!<#&7+DE%WF)D0C/Q(E&
MK$"`YG8`S(@KI4``SZ;6/IEX-9F/#LD@PAD`\K26@_AY791UHL?[O`>O>.7U
M8[H<O7]%6`?\P2?\_L*OCG;'^[LW_,5G_,87^MQV_,B7_/+A#809QY^/SL:M
M>P^^T_-:*X-`?)7]%DIR#D(1%XE(F:=RJH#O,+N?^,F'_=@G&K-Q#8%EB?1Z
MC@ENW+0_C[/<_155B;FD#B]I[!':WIG`.>>0@`%H#P%?Y:+(WQ5MIT4,>MFW
M_NLW%;%T#M\*Z-I`Y(LP'?@!4R-[H$T:JPVR&M`IEK=30YS]V,E@-_?W$H?H
M&[W\JI5;<03*E;I@FZH*'("``.'#!PT#-A!,J'`APX8.'T*,*'$B18(7$##$
M``%#0P\2/$#D\.%"AH<<*$2<X(%DQ84>1%+HT))@APX>5,ZLF(%CSIX,_E]^
MJ(!0HE"*'5`F!.I3I,^F$#-<F`B4`E.*'RF>=*JU)8,#"+Z"#2LV`,BM9L]"
MQ%#`H8<")1E6.$!!P8<("!P8T*#!P(,#%3H@:+#`P8<%!_!:N#!@P8($"B<D
MN.`!)`<!"AH4\*#A<`+""A@X(-!AP@,*`B9$B`!8,.$%41=*:$"0PP`.!#H3
MJ"HP(0,):'\#=WK!L4(+!1X0J/"S0%6&%QA\>.#;85:(!CBP[%GZPP29,Q-H
MZ)`Y.$$,K\FG'+C`PD0*0R5NP)A00H2F!-#[E/!@(@24!S2T5(!W$E6'WUD,
MO"<1631EL-('&>AEG@4[O90!!P!B`!(&&WC0_L%;&EQPP8`CR91A!QADD!B*
M-G%THD@;7&`!!QY"I:)-YT%$P0(/)8`40PODU@$!(%6P0`7@74C:9`ALL,`$
M!1V`P0$$#:G07+>%-P!("6#0I0<8&#!:APA@0)IX=44P@0-+-HDC01(,X)4`
M#WA``$(-*$?0;GH.9*"??UI`7$(3!@6=2Z)I4,$$$+SG`0,&7/"`0*I]<!,$
M)6V`T@051%!601!4<!U)7SZ`4P<20`#@IIUF`,%'&QR@P`83B-2J!#)1@$&I
MGB:$`0$-<%"`!0^\QD%J"29*GT@55`!!!QM`$(%($2!409=1G9IJI10\P)Y"
MQC[`40;-EE0!L0N=_MKM!YD2I%H""&2@P**F1J#M:!%8X%ZD#Y3Z@;'4$F0!
MJ%/2])4&'I@K64*)$E3!P=Q&58$`]?W;7(J5UH>!!1%<=5.X_E*PZ%L)<<L>
MNQ]<%:ERL:':W(.N=L#!`0G`VBP%E*4FT@7F,M76L!EZ!))['I3L[Y,3Z(J4
ML1"(Y-''1*O[)V\)1K2@OVX)P($!L>%E``3_7>`D8<PU<``!2!/G@%<'E*4!
M`/YI`.O7!3B@``9"BI<``1A(4,`"`PP7P0$%--!`!#I.I(%H#0E)=4)AKTNP
M!@AX,'<%>"&0`'@+E-0!I,15^:9W%"00+$AV9_#5`@9X4+8"!91)YUJI_N&E
M.0(:N,:0!'9CT+2`'SB0YP=[?L#`DU(C']Q%#07*DT)U=F"!`"&O-1_-#Q1P
M@0/0+0"!!61B0)<!#IP7K,!9EYK!`9$2EH#WS(U/T@$6[-X!`P\`ID$&!FQ,
MN>87*&`ZWS+`7^9D`3MYP``4B,N`I!<RUBU``1?00`$4%:8C94!`2DH`O@ZP
M`0DP``,)\%:E"&B<60F+`Q!@0-A\Y($$2.`"ZPL?E3KP``9P8`$(`&"G##`!
MX\0M`!6(UX:ZA(`>+O``1XF,89+2``=T8'L`%*!X)A.FP@UG`AL80`8\E\0!
M54`V;:E+<B!`EP40"P%#%(`$*/"[=H5PA!D@_HX&(Y.`"4B@C'3I%?_L8C_\
MQ>HB?U$@`_LBHH00@(51JF)A,!"!.$[(,0=P#0)B0D@E-@`",M0`"$5(PC\A
MJ")6^X`""2@7V43K`W*)P`+F<@$"9/`EL$O;S0[P%KOLZ#^PXHYG)'#`"<BF
M2/KQ7`4P4@'H[(5,%(E`Z1:R`1@^Y#F56AP%0L@>*:FI71UPTH-VN,?0%8].
M04%`L`AB-P8H1RTB)(@!8G>FU&2S+MMT$\IDDY3?.<!'>\J`G9+G3[0,IR%A
MW(]+F&.!/0Y`(=)\0'TF9YL*#*L!-,S+8PAZG5(I+@('VX`!"'(PBCJ@`1:H
M`'/R^8';-0`I\(I,_E#LN9#;"0DD#+#`]YBE`!]98$<?2$`&C(0F@LST`PH8
M`$=0M3^(,@`"$S@`K3SE@0QDP(UE$F,!%B@!^1`$0A2H)`"IY!'U*,<"+-2I
M?CAJ3IX\<IPVG0M'XJ.0U+1%)K#RE&LPL`!&;N8#"24=LT:8D#!.LRY]*L`&
MJB?"O;"S*DMMZAP)DAEE/DL"A-&:0O!$$'AMQY8H`Y4:CS2L^MQ3)F'T'$@6
MP#>FUDJ2)4%5,4>:`'/U2"2+=9R!0DF143)@,`Q(*2KK,[-)3J``"@C`\O2Z
M3N"AQ&Z7?:4'/)C7;"H@<P203D&.*``"&*"QQS0GY2H"P`9(H`(@E"!$_B#'
MG0-T90.P8@`,.Y"`"#;``X;I"E2^Z2F9$:``L#.=4#%``0,TX'4<98`""*@D
MOJ3&O?"5[P3W^":75@J?UH(.!`:@7P*@I*?_W'!3`H6NLB3T4-'3Z7T&!1WJ
M3FX#!*!/#">:H-1<E@/]T@`$#,"`O'[`)@9`"`-Z0Q\;PBVH_>522QL"T_',
M=*L2H`^``D:8_JYG>-.QK`,$H*IP;8UC'+D`9H[GKP,T8`)DRF:=.-;&I""@
M-TZBX0>&M"BALD>L8B4(!1Q@UOZ.4V@(6+($Y@@@#F`536?R5T?_6KA!4J:C
M]Y$`#)ELZ,"FR;'J\RB\Y',=A7;YN`+Z3Z72_D5HA>1NIQGH%Z=)`QD^:X"A
M"QG/<QAIMY5TN;&E+LV>F8PP!A!`,MH[6_)L.Y%13B#7TZ-`;U4)HE;*I@"*
M\U`[]YC2.HFD`P$P0``P0*;4\5*HDL'PCD"(JCH%=+LH(VA+L&.!WDDD9@FY
M4%DT4Y6X$60]X:G44*CF@0T<C-ZSF0P'.,0AS=1D1M$.#U/@[2^;0%C="FGR
MC.[M+[WD.\>TY3#%RQOH#SPQ4QVMR3TYD%."A-@B.W*`;^+3EI*DR<4*L78'
M#"+C"6COWIE1M@?(M&/N,.`E";#ADVXW@9P7UKT<`2S'$W)DF5J`HQQPU,B,
M$S,!13E0,<N+E+[W_E6M<<@!&T-)-7N%$15?()ZO11BY3>>Y":COJ0+XJGSC
MC"#FO%`HA4;=I==U':9#@$YB?FM]$&`!CQB*(&UA7<W9D]8AJ:\F"VCR!P*U
MDH1&0`%?HIQ;/,`O'->]+IIJP%[4'L6!L&P_E$W(SS4C(%*K*E5AVB:-08O(
MOQL/VK;1R.9E?>6]U(0!&9!H=%+#]<"#<N(-&:5!.C``#1![>+X]=C8%!`$"
M$.#<`;A-:`I@J`HH0,;]@;ZF/'.W(2&@`'E!U0>$94Q[ZJ?B$`FU^FE"S_;#
MGSP!58C]L!0=+]>\`UPF",%FL^=(-\D'B%!@/!5TT`QL($!C=,#A8%SF_D3%
M<!S13B&$Y7U%5%A`E,@*!;)4"#7>?JA:0MC%Y("$`V3(5D7@H,S,#F'<:]A%
MC[Q0@SC`!%!`?5P$`M`)!T27K"0%`R0@GC0+031)`B:(VJ!1IZA-`R2`9OA%
M`SS@?A13!#X304C4HZC.!YA@?71``]R%3I7'_&Q`=.'00CS`DVD`&,H$$G+'
M5PA0I?"@`S@&,V4.@,P1`98A0333;$37`F1=8"2A_23@26"AH%3*`SC@2&`@
M@%#`1YC@1T2:0MS%78#$4BV`[N&@$&H`="@`(OK&(C[(NS!`S.2@\`6'KRD(
MKXC$TG5(CLD$*BZ=7%7*C-#;!LR(+)8%QZE;_L-UFK^`1+V!!,<)W"O2Q(C$
MW[X-8S$:H_Q=W#$B3U1U&/`IXS.2!XQ!XS3Z"2E6#:]0XV_`2&(L739ZXS=*
MS?R!(WIP2%/HRCBBXTQ,@)>E8SM6A#5"A-74"?1I0&@HP`(.``$L0%E,`.NX
ME0`"'_]P0!+BVB>RUTDU``OMS4#""0$H0`7DXP$`VHJ91:"`EWBQU_LE1%^4
MA1)MAC,VA`XFQ!9Y"P7T"4"Z8TJ2AX>I9$NZY$O"I#?"XT/(XP#8!.EDH4`X
MR\T)%2S=65<E1`%(Y`%(P%TMP.Y<AXVYQ@#0S!$Y"]$T@$U(5@YMA5VX3'RL
MX?,8@`)XBP:1&T3<_LY;'21WD-MDQ.19SD1QH>7SL"-^W$1$A$Q.I")5X,>+
M?-):XN4WSJ1#R*,`),`3/8D(1<!6LDV.%8!`[-)(.!@I&0]ZA16!/60"Y)9Q
MM-(1%0`'40`!(,!&,*7P^,2R,<Y!,,]Z[)&R%<#9&(!D;M-7E,37)`!A)<6.
MP::9C)!=:8T-7F`"1A%*R`PVYJ4[BF->:HUO!L?H.<0%:B1$]`<IB:)3R,RZ
M^,AO2B<T[N7PM1L7M4I]Y!0$X$F5O)(.X1A0LM->',:3$)L"U,T-N89;>`5W
M9D"F<(X&7(@%U(93((Y#]$A#K`>TE5^VU,G!2,>]V1+EV`;CK5/><0<2_J93
M]M5&6R"$I-`0:4QG2ZHE16C`L>08?8S,NE@`:G1`LT3;HD0%5-!955!`J_S=
M36Q*XWD/0:!=B_J+L@B@P.R/!X#6!GCF!J3)*LJH>4A`=RP92!"-MJP;`6E4
M5O7'9!@&>T0*>]P$!:"$1GBFS,C*_("*X)DDX^48!0@,C!!IL_#$D*K*`+C'
MRJ"H1T6`H@CCA+)I\(E2NY68XF"/P-3'XCC`4>[-=&G2<4S'%;43`3Q?^%!`
M`%33>F2&#C%3FFP5QUB`UXR'.;).1[@%0U2&G`R$!D$`])R45R#`:1"42!8/
M`1R``0S)H,)F^)C./\Y1<P&:EK;I.`8G?/!/_G#)%[[PY$A,3VB@1A+N6:-"
MR)0PDAWZW1UQ0``@3>0!T$!DSO?<C`]1@!+5F`4@%I&9%!!6T`/<50'(('-`
M@+`D``$EE5!YCV;-1@`\`$EQ0-4]0'R9D8Y*4/<87P1@0#%QV4EN$R!QI5^(
MZP6.3+%RS`"41F;<T$$I!VA\3Y?`$N3XS04()`$]0`"XS*M*["@VIT+(HP!=
M*$=T"7?@"DQD0+U0BT`<CTIPP)-\;+E\T`:,U*P41*Z(;*NXRDH<J58H0*:Z
MQ`WYY@28EG_-G'_^CG*-Q)R=5),)R05TR?P0VUP(8/:M13D5RO`0(G%.[#16
M:+KMQ`1H"6/\G4(Y_D9>G0D&)(J^_L?E*`21.=1]Q-75&%LG?@]-/>1N#&<8
M)="`I)\`)E]TH,I`9)-8V09-C>&Z54^IW`]-B0;9,L?5X,U)^5(%E!A!;$=V
M;5;?#LN3^0O:5@ES5!#][-P`T!1W4I;"(H2KD!]_3FWI_D9U,L0HL:GEW=0&
MM!SIV"Q#1$E"0`JF:NH%UEG.;0T$",!0Z`@_R@N=O!:JCL<"I-3Z%,3$F"XX
MQFI$[$\,B@;1*``L/0Y=3(YAUAP#,)-R+`I/E2U":$TYM44O/I9(3(Z8I48$
M9.>GB8?0Z@EHC09!N<IN2*A8951JD-!SU@6C&0Y<`5:5M`5_(1C'*(1)_G$:
MJMPOO@!N8"60;43+X=!&^LI(1RGLM-1+GT;L\FKP3/0&LU3``GDP"#/+`JEN
MFY[$&)YK!E<*3I3'!=R,!I1@VX17+_Z0!7A'=F0H#$.GQQ&-D(H7X]'*!F=C
MU49$!.P'!I"%'K:.CW35]8H'1W6(`A%:_]EA?4QE]8P=]JG2DQ@Q[CD*C0W$
MZ#4`I!1'$JK8_MA$E*12_<:7LFG>NO5NS3G2FC0)PJS)307%SHV'X3P(\.53
M<P'(M[DQ`\[&6M1)"0&&9/P@S?WHF50PFHB09L3QF@IQ)3]$42I`!&ER)G/R
M)N^C)8-R*/=$\T)$?/#A!EA;F@T(!B#3C@!&_NL@P&4<3\TNQ'OIIOY^82PC
M1`*J<AINYO[FF'PPU_-`0`7ZLF\0\`R.!&&D<LZM6RQ'("RKX+#X2R@V5R]V
MA?<.2CL=H#(W\WU-27-=5LOEH$@,X"=ZP&=@@&Q(),H\R=<`"78LIBC3<SW;
M\SUO!1$G3\VYC#9'A`>U!+?@\T-8@&Q`\4`C]#UCA]&J<$+7,RE+#:!E9?&X
MJD/H845`P,XYM$MH(4MM]$=O\'#T1B)FI'(6IE84P`!86%M&$P(,@-\-3W0N
M!"&#-%JP9$WC=$[K-#A:I3,A``N[Q,PD9T4<Q(7DAD3XC,>)!G4Y1+_LM%;H
M\U-+]513]9^H&"7;_@9M`5!.@<1A3%(Q)V$.L>9J*E-"V*1A*AX"R,5.-0:<
M-MG=$.*W1D4Q'\;]4>#\=$!A-F)5,\1-\_5?`W9@^\1]-D1^_LC?'74%D=*3
M<`D?[X^'C8M""$``4#9TB!>4J%(%\$JC6A]'X.Q!;4#.-7"I%$F.A4GN`+1@
M6T0RJG9KN[9J@PE;3.I"5,97*._AAJ5KM'/Y/=.O:*E-OH3?=8`9#<[:7G"_
M@8RRH1A&Z$BG0HM^%,!7<)']LO9?0_1K8W=V/[7[_`0$<.%CN(8+SYQ(Y+:U
ME42=J!<'2$"A@9QW.``$.,`#<$`Y<9IY[,1)HU,,5E>@<,B.E4K,/HB._NFW
M:T>U=AOX@3NT!]2-4-P;Z8B3[)Y'[8J$][I&,1T3YQGI8@Y`?#/`\0WL]*ZM
M0A18W9R>;TR.#%E`E=&8!!16(A9F`YRU:_LU@M-XC0_T2814::APT#Q.F8B6
M2"2=`"KP@QS.B-`'QP`(T;"X2M#E\UQ`D8]$YZ#$QF@,*F-*(P.A3`MV@=MX
MEWOYEX,Y<%QWF).Y3OL7E*)YFJLYE)9YF_?$C+MYG(,T@3%&G=OYG2]`";?I
M9-B$G*<DE_MYH-,SZBZ$U;S296[38:J2?IU'X01%GW#@;.17]BC1[>R/+74K
MX01;`4C6:5(Q<*C09VQ/S5)RX^56;DWT1&Q3_F[)=T4`WHC8D$)4P%`?^)@+
M^JU;,J%;;%GDU(PX@)VM3VUH<81EQMT"[;HPATA$$%W(!?:1W(QTL6CH2*GG
M,P$YU7]MZ,)`:;"=9$ML$90Z0'4W1&%1C7%*&9D#.JZK^_+J>D)8S0'=%*>E
MQ@#PX'2($)?4F1TZSP8(P"1J!@!D2(DI^%;.X`(,IJFCAY!4](,LCD-D-$CD
M%+"LRYT:'H!$T0)C+VHLP$D,ADB4!AK)%\!:X6#4Q%IL0$*"%[H+XKJSO!"W
M.T&\>V3$1TE(QP`<D_Q^16G8$WE)NM'>A/)J2?3$]P7HZ&$`R,>1A](Z!$P+
MU.]8&XQ0CA=RB83F_CL0!H`"O$Y]"$:FT$Q<-!>P.$GB81^.9E]'S0\%L;2-
MPWG+L_W4OOP'O+NA+-7S;1'"B-%AJ,VS'LYE:(N*_6AA*<8V1="O]\;&G*3[
M`L>1/,3\-`0_-5G=U$L%$4"]D#SK^#-MT-1Z<T"8X9FQP0M9NM4DU@L![,7H
M$7"8IWO;JWY>OKW5,$S#:,M`L*R-3H:\\@N4\DN+\`NQJ`3:V>A'#$NIF,?"
M>.9OM,7[-:IOMF]"Q#=-&2W_)`:`<"5[(WM"C%!*=;X'S=KU=D]B3+#IIWV-
MI_[JDW],MK[4YF5\/.5L%#-MO5>(&*T,74A22D8K-1Z@*@38A=U!8/\$_MPC
M0%@PX.&`A@\3(&A`<'!!!PP'.!3X<,`"AP,2/F34N)%C1X\?0884.9)D29,G
M0UY(@))E2Y<O8<:4.9-F39LW<>;4*9/!!I,!/&CDX&$#AJ`?#78\"C)IR*89
MB7KTP.&EAPH,%F!E4&'I1@\+$"1`@(#!!PH*%F3XH(%!`HP?/"3P*50L@@47
M/D3`^T%"@@8^'?BT0&&#@XQ]&6CHT&`J`P41+.R4/)GRQPL+*V?6O)ES9\^?
M08?N^7-I!+83&H"\T#4C!)`2..P-:=CK@X\10N?6O9MW1Y6]@0<7/IQX\<RC
M2P+-N&&"!0D>,G1XT*!#!0<5#F]XT%-"`PP&_BPXF##!@X0+#<Y.B,#!`80.
M#AI<0(TAXP+Q[!U(U]"@^?X.$BI0R[@!"2S0-\P,3%#!!1ELL";D2%+N@PJ,
MBD"!ZYJ3(+&R/GA`@P@RF""Q#!SXJ@,(/(!OPO4:6$\"#*C;3@,!RW(`L@DJ
M>.`!Z3"@``'G,J#`P2&)S,R"E8I,4LDEF>0-PI$DI""#"PQZ`(('S$-`O8P\
MG$"#"2Z`H#L/'N#`/0<,^Y"#!G:DP`(4'P@3MPX[M/%%-#^`@`,&)E``@R]=
M\@"#[1A@X`'ZI*J`JHRH_,@"#ZQ"=*,.-II1HPL6'<F#R+P*<K4F';P,U%%)
M+=74EYX42<(,*MA@_H'I]G/@`BMIZ_++!B"@(,X'XGK`1BL!=``#^,PDL[T)
M,E+`5Q@;R."!'`U38(,#/+A`MI,X4*!92CO(P+%,-WI@@8PR*(!2CPPP\RZ.
MO-U(`MH^2$!2D3HH8*D.$"B`@0,../?4`7_[5^"!"08UU9`D]`"WJ8+J@-*I
M-.H`4@\DIHIB2CG8`&-('?Z@8VXASJ@##8+B@-L/AO)890G\-8D@(3N:``'6
MX`+/@Q\_L&""N3B8X+L,R-I@4Y_)/$!`ON!-`*\ON9JPQP]"I*^#@31R@,,4
MR;-`ZYQW)A?,C#!XL>#,1!W;[+/1+NY@D"3\8%[CWB[)`@0Y\L"`N-TN_@""
MU!K@\P!,#7@W``T2"(P!!RBX&X*"-)(``0D@+P"#N2E@(#5]*:`@@3XIF'JI
M`IKB>(`'+.A[@K\?.@O`!'S$+NV<`GY=]MEII\S0"'#/7??=V_[W+)`2<+TC
M!\RM-Z@+%*#`,+O9$[(B#!0`D\/##&@`/@*HU$`#"0[XP`"##@C0@GZISF@`
M2I%7P#T"IK+W`^0%4M0#F2WHN'::RKY?__WY/RD#K2N@-0L$$(`"#*#P!,:!
M`8!+(QL@``,O599I940AN,L(`A:#G;8X0`'FF1[2-"*O"AS`4`LIP%`(@*;V
M>$XC=T-9!2QDO`FN92$66``!(N`!"MP09OUS_LF1?!A$(0XQB`(Y&J,H`A(+
ME,4#!?!)=S"P$@6R1U$$@(M;+C"NQB4->7A)W`=.^`$%1,99+,P(!20WE0<H
MP'A-]$D$KB,DH#7G?0H@(DKR=T<][I&/I]I``[2UM\+-Q3(<NH`!$*``JCS@
M``DP5P,T:(`$O"HB<P)A1D18`+_8RP`^V0`"#H"`Z)3OC`8`P``88#+W'3*1
M#A,+13@PE@/@K8\<B5TM<9E+72XH8RW;Y?WR^$MA#I.8Q33F2VYY3&4NDYG-
MQ&4PG1E-:3H3`Q`H%`,@<$2.<(`"%>@F!%E2G6Y^JB,=D(T%""D2#M#R)!OP
M9@4^]:B.8."=Z91=_C*GF4]]_I(#6<$`MS"`%7!:@`!H2<``[,F2#`Q@`0M`
MI"_=AAD()`"B'X&>3"9`@(8:0`%-A*`"[**``?3PGG3;YTE1JD>"(*LCCJ.9
M!>R8$09@A)OR?!\%-$"?FAXO2$?)0/?@L@#7<`0#"XD`!L&&4TAIC9X;D)+;
M%'"!"ISK`H1!&3TS8!4+8`""(H(*0@L0I"..D5SGHQT^4YI6M=YO;B!Q(4>.
MI#T,%,`"&@A<`\9E(0D4H`$<")S5Q+@YGP(U9TC:2%$E8(!S16!S"*``!P1`
M.HWN=4J1?<#,Q"6S#&1``'I)@(X$P*F->'4M`NA`02<05HV0-2.S/*M)_M<:
M6]F>[7<?"5Y'+!"``@R@LQ_@3VLSH%B^X,H!VNLD:\E%V(?,4P`(((!:F+<6
MB+`/C#YY@,\P(Z_G;L\[W8LB)D6KD0D$8`#EQ0@!K,M2,8HV`>%-&UIG&U_Y
MDFJ*'G$@!&V(L@,(B0&<&J/[EN@`OS2@KU'=R$\ULL-YFJL"BJU71OP:$;B$
M44P!E>D$!D!@_@`M9QSJ;\P68+)SA?&ZJQ4MZ%X[7Q6O>%0CU.9#;+H1F)9U
M`W#TV`E%^0'XH`8NU#&P1A"\%KK.$S-XG0A]*J!(B7S@@7D"TT#LM@$GYHP"
MW]4`M>SF7K-\D,F+5"]9%4:MLQJ6Q64V<X/V_G,A"`CX+XZ*:8<2X`&0[M=M
MH40`8_9U$3%>*P,`"$``<#AA0A959`:8P$_'L@$)>]3)ATQ`X'(6R@2L$S,1
M""5X-+#DC)!6(Q3V6?<4\.?F^B33)3WSJ5&=H*DHFF9U\PI4H#(:",QI*32;
MV*MQ#6NX:.0HM=8UKX']1T@=P+JNQG6OH0*I7*,-OJEV]K.7E+A6$L@##>#7
MPK2Y2VA"F]O=]O;^FOUM<8\[)H*"'-%`<C&'5=0KK*%8KUO=$G;'%HCDMO>]
M`^4X"%Q@2A!XG&4"(``!#,!]2OQ@1@=``&0YX"WM'.I&TK7B;>.;XA7G2-]8
MTX'#>>0"'Z28R!HF_K0.\YH`!LDT>R9@LHBEC&(IXT#*CM2!E[,Z75.QG\36
M&FZ+[YS<Y6KU:9_"*&EM0-$2_L!=)JH`B"R1UW3=F`,,X%`A4>``"V#C!0J@
M@*LH`*1R)D#E&AJ`X')``@LH:E`2$/23UIOG;:>X@FU+4D8)@`!U-XR\IB8=
M2"U`:Q_,P`(*0&=?N2W.YN*+7KIG)K@4!`-:]*UK#`"!CMY,`Y^,=SXG[G;-
M<SL#U"UGR7W#9>7IBB]B*4``I[<!O$!GEEBBX0::"\HXV=$#_CZH!K)XF`4$
MQ0`<S4CN&I[6S&^>^*FVFB\[\"J.<[F)"LC`!H2K=:93T/!BS!%&%&*\_K5@
M`'GOHZCW,M#X"<TL(\<5DD40D-"3ZKSX[2_S!!(`@:U:X`&LL\P`$J"`!'Q_
M7RC3&P,*H#D^R`'P3Y-2!/L6HOX@P`"FQ(XR#0)NB$H"<`!L!$321<JH8O]D
M:_C<KP-7##K&X]`NKP,$2&N"PH)0!ITV0`,X0)LVP`($I/+@`E&F!&,$Y`4Y
M@`7=9G($J"B"XOET#('2BNT\L`C;;G'FK3-J#ZEBBP.-\`F_+0/`*33^:;;8
M#PJQ\*2(HO(N+PM;P@F],`R;R5LN!(X4(#$^PBI`*3_$:`I9PJ%Z3Y*Z$"0J
M(/@Z@@,8"0&$$"[8B)BN4`P!L9BH3IN":P_S_N8"8&1<PF@F9@0^,D#M2D+F
MTLT`A,4""N!:)LP-^P@,`[$3=ZF^.N*^<&OWX$)("L`![()2&.O?%@"0EM!/
MXL(!#J!$."(";.,][((%8ZHG-`"D2B2*$,`U*.`Y5E&]S,*P)B<OP@(O4H@L
M($5FY*5.]@\2P8W,//$:!?'-.N*VZ@8`.XA2`M`#&$!*=B\BIH8"YF?WQDX`
M5L.U-L(6.X17+H#8@`H!-&`!A"0A$,`HRF0"'N#OIL+S.N3A,B+).@`#OT[.
M+$`E9$ZQ"J4\4F.(.!$;*?*.YM&MXF8HS*D!"H\J+"@\%,"T.NGH]D)IW.?#
MWM$VB"TC0,<`+LB=_K(.'3-J`;##'R>$@P2@9WSF2GCM/6"&[T@,(0P`*P@@
MH+`C]R32&BMR*6OI9HQ1(QB+9FP$*M@GC'"G`N2%`PA@:GP")8W&\%`2*FW#
M'N&BY%S2>XB.!!,@`C1FA"K`'[&2JQXH<S!@KH[B*L0C6;#.RVPQ8_YI*Z"*
MB":2*0ES?S3.[+@EBQB@HC2``%HD_\#((R/@+*HI`/S*)^8Q;#`(+-T+'N%O
M4'9O`.1C`#3``?X1'Q\C`]K+'_LD`R#`,C?"H>"H*(.KJA0K*.U*:QP2.\1O
MB(BP,(%3CSZD4%J$&I<#CL@C3]#'*";``72FQAYF6%BF]H*B`H+N`C@E_CR2
M<U@H8`(<YEVXH@/@*#(F9WZ<,^6\PCH@8"X&14_R)"A@<"UTQ">>RJD$$[:"
M,S_U\Y?^<#_]\S_Y9S`!=$`)]&SZLT`1-$%/14`5M$$=M$@.]$$E=$(3A$$I
M]$(Q%#@B-$,YM$,_PT(]-$1%="<V=$1-]$1G`D11=$59M"1*M$5A-$8/1$9I
MM$9/XD5M-$=-5$5UM$<[%$=]-$@OE$>%M$@=%$B--$D1E$B5M$G_$TF=-$KS
MDTFEM$J9$DJM-$NQD4JUM$L!$4N]-$RSD$O%M$R+$$S--$W;CTS5M$W=#DW=
M-$XMCDWEM$[M#4[M-$^_C4[UM$^?#4_]-%!/_HU/!;50)4XI#351\8U0%;51
MU0I0'35248I1);52I0E2+353FXE2-;53BPE3/354A8E31;54:PE43355]XA4
M5;55@PA57356`Q0_9;56CPE6;357WXM6=;57<PE7?358_X55A;582058C359
MEX18E75`^HEPJ&(A-*=$?&0L5A$!<(,!Z$-6^$)9OF(L$`!Y/.`>R8H"4J.:
MWB-YNJ(N$,`-Q3-CXM,LU"X"SJ5S0&)D-$#N-F(]&0@Z2B*K.D(O7L(V8H95
M(L:2[+!QDI`C\I4D>L@J4*)5-J)SL!-<6;`MA.2HR")3!N\#T'!""!)HQD)7
MR,/Y2B^''"?10"IX_C36L;0U(B\%49MU;#9@`/K,-@!``T8J_D(D`%XD`":`
M`@0@N"+#L2A@`!(+`BJ@`0Q`2A;(,2%``#3@`0"`5=2'=4BS*RX`(X+"U^!B
M*G2F.8(BFY#-MRQF/6"MU@H#`W((V*""[&RJ9*[&;;M6IBPF7':M;'<M;]UV
M49`M/W`.+OQV>=+6;)/-;?GVW?;6:[=G;W?$U9"MUTQCUQ9C,$XG:"VB@P9@
M:6G2+[[*M+QG+R;`\7+FZZ2$H"9@(#)JK[HC>1X+:2-``,(&:)VE-.%*9F>6
M8&JV\\PE`#"``-#)(#P@)S\@)^WF.XI6<W!#`R)#<U!&`!I,IB!@`6FR_A73
M(CHDP)+8MELYQ#S$1&<*!5OU#R'T3TKV;T_80^FH(EN29P-<XS%.K^KR0_^J
M*GGTC^OF)S(RRELVQVZG5@+.,"+D+_\HY7>7J(-ZT3;$T7(X(/_B`S=BBHWL
M8C'1(JH8ZR#,E7`*Q32F-HL2(`/Z:BWRKT3T+X!`JBU>9&_`HF?0HEK.-R%@
MJJ,&:"/PZLZ(S9HZ:@'BCRV@RX+[!%)@[P1;T34B@$/F*HG>JNPVXI"T)R@.
M(`"P0TO6HG2*RR<$0&@"0.8"(".>QY9X-7<%9G<-X`$B``!2A+=PHP,6Z`,`
MC0`&`CP^P+'"9V*E"&EC:F^LQ``L9`,20+?J_E(VME;C\H0^/@1-LJF_0O`K
MY"_Y%G-JFR4U4FDMM$>1;$-:A"5:S.,K$$*,FL-P,"8^,((4O<F#%":@DH\#
MO"DCO`,WS"ZF-H4@LL5CT3<BV6@ET`-9_`2.]N2//&1/.#A..F`"NH,JV,)C
M<>3H8&@#&$#.7).BO*DA/"@V-*3:ZO(@"1:3\)">Q%9:%"L"\#%F_*PHEVQ\
M&B#A9+<UK,<P)$?W9`P`!(X^HI8J+E$C&B#@V&<`],\E.6"+50-WP?A?Q%C*
M`(`#'J4"!@!2B#<`$-$R#0`[]DM]W`99G!>R+#$H%L`6(2"C_$0Q"H6H6,0L
M(J/:IB,_$)F.U">K_AJ*8OIF4/*$*KP%D/!0C-86@CWDZ(*6DQ>2M-:$CI;9
M8_IF32:D<CI@%ITS(^+(MRZ`-C2.>(":I.E(C`29X2)#5O1"1)9Z*&QD1G+%
M,889:FP#F]0"'PDC6EQS]VP338H*32I@]PK#'H%:(W8OFW0&/CK)J)0E9B8M
M8T#7F@A,-><D#B7"`/9"B2^%L#R@[ESCWZH*5S1B=&`#9?C9,K[XGTU%C'UK
MH".K_X:7*F"3-*'.`:[8H!_@ZXX191:H`%KQBJ?WM*)';P(G<R[E.19`F>>"
M`6R1I"T@`DR:;%]%/E!C`Q2I7?,$.Q6)`7[JCRX`@G,;A&\Z>KA"SU#&_KC_
M@A0]MD1FNR>P.T0XY0%HV^QHHYHR[8]\:W[$#*IK!$8^*;E?9J>E!T!LD9(C
M((2G%JD]9"O&6HS*NEIVJ,9@A)XJ)T5J#`919"[B^G^\V2(^*2]ZD8'Z)(00
MX`'8D;%U!+(A)P"@#U?J4(_=HW1GS3DHXGR.=K27=BW7\XJ%(K(YSI\INU36
M1#L^P%7<YG!\HMHH93%U3#&LB5.N@J6V=S&(PA$G!#N&,1V?(Y4IB(P@22,"
M9'*"F3WB$T">2#I0Q#N/9,-1CEZGXSDJD2_*PP%B@S[8,EKF@DR<J@&:@D+6
M(LFW=DW:=D(FI%GL$RZFEP*JRBR(XLUR2*+%_A.!(T-/YJ?:[J.#*.0Z)I-2
MW.D@AFN=_BEC7_`Y<FH_:*H]=(A*6D2'N&JHBGP#I@0NWR1GUDD(MS9BMD-_
M(^,MO3HH#D5<A"J+&LJE&VH!_!$OXF/+IN[503A3!%DU)GO%1^5-K.1*IO?7
M@3W8IY?8C5W8?UW8ASW9B_W8,;$X]N0S=$A?B:/VPH5BM(Q@D)77\8W.I9U7
M$B1TU&]LF)7;S3TGJF4[GF4.N5C%SSVM&O;%UU*9W>2,XH:_1J+&.F(]4>(1
M(>S91^)K4`)M=0)F/98CJ)TC)*!AIX=T-6)ZX,4D')XDJ,,E@@L`,![C@7<D
MROW=^8?H/"8'R04#_EAJ&(4F>5Q'Q'308])/6BP&8#6"!8G"84Q&+0*C6^YE
MY:7P(-="3*J3,42>UZ+#8P`6.LH#!GL-YU'&)QPFJ]2"9`[RY1\&YB51:+K%
M8R2&9V1N*$0>Y(<.*M)O7/W%Y%Y<T5K>ZQ4-+@#6CA3-X%&&9,J^4JA"`70^
MZZ-",3+FX5>07*CB(*>"&C5``#)^\!5:)+;=X_7'.L;(`;*"`M8L>EKC57JQ
MFPX#ZRXK**#OD%!Q3R0OP=J"_AQG6N'H'J>CTR[_\1L81BSG,-+.+]2+33KJ
M,>),61BN<(9J?'RE%\<1@+FN10(#`38?]A59BVPWQ#Y+_J:*0W3&%@?#_D^P
MXB$$C.GI:LV^[^A.:TWBY!)G,>THL5V%:ES\Y$)(%[AUI./2XHP$3"OK[SW6
MZ(^*ZCW\0B[J`RMRFX,:."VTQ4NNN3X&O__/$B`^"!PX\`("@@@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#/M3`(0($!QDX/%C@X<($@1<J/-"@@$(%
M@1(,?GC`0:""#PD^2*"@X`(##0(7?-APP<'0"1<\8'A0@<$%!1T$'GRP(<$%
M"!4H%-A@4V`&"!$P?%#Z@4/1HQDR&+@@X0,&"3=_?K`0X0.#F1X61+"``4)@
M!UT]2+#P]NJ%!1L^!-[@@(*%P!8J=&`@4.6#_@80W%9H@(%#`@\3+/C\\#.L
MP`<7O#J`D.'G:9M!(TQXL),FX`8$.3!-0,$!AJP?(-#N$!0EYYP,(BRX0.&V
M:K\<,$3PJAM!AP@Y62+T0`"`^?/G`_1D&%ND^_?PX\N?3[^^_?OXWT=P,)NK
M2J49O/3!!18@5M--0EVUTWH__23!!,1-P.`''5SPP&!I?:!!90M0(`%R/T&P
M`0(43)"!!01P4-8'9T&@06"=19A!`A(88`$%+.;$FD`6O,2``ST)AH%VAVWP
MTP051!A;B>M=V.,%:V76`5L?-/"``\!A950$#D*YHU(]\LA`51/0UN`'-OVD
M&P3)U<:5!\`5M(`$_@ET8,$"`G*0)&,?H`2<9?Q)P(!;'U1P'0,=G$4B!1AL
M%0$%.(Y7'GKHJ=>03OEEJNFFG';JZ:>@<FI5`_QMH)(#$S`@X`46TK1B3C_Q
M)%`"1B:H`&/K09"J3(-EH.I)M=WIP6H\C<D`!K<^0`&;+(ZZFT`>W/H6BC2-
MIJ->88XJ001IT57DD<CBF@!CR%E00`<;+%"5K](-Y`!XG"DP@6Y<)IB4KQ5`
MUAD!'1"@@9DTH5F!FE<Q%NT%#4RP0'8X32`!`N!)4%>?,N7;9[H#J[A`!@7L
M:*A`B)[5P&B-#MA`<1QX.1`#E*)WT*4OARKSS#37;//-.'/$@00;5'!<_@?'
M@8744MG9J<'0*:EVG$!#JI;2!A(,+1D%%P"=060N2=6!!CP/I'0''4Q0&I05
MJ#@L:BU1,&QG41=:P=4!)AK9=1L@I1IU'J3$008>$&8GBQSLG,%2;7?&F5T3
M9#64RAEHL(%:ET':-XN1L5BUB03=5(%4>V.@VM%."]>U:@Y7W9=D8E^@HMH"
MA7W3W6"WG?+DGU<>57:H01FI2QTP3-`&DU(JP."7!I7S\<@GK_SRS#?O?$<>
M/(I\HC9W%0``UP=P`/$P/^_]]^"'+_[XY&ODP>;E;ZK!O!)P[Y`%QJ<O__ST
MUV___?CGOQ"F^O?O__\`#*``!YB1]A#P@`A,_J`"%\C`X_&O@1",8`,[H(`$
M**""&,2@!35X00MNT(,=S"`(.4C"$9I0A"C\8`I#J,(6LO"%)5QA#%TX0QB>
MD(8WM*$,<UC#'O+PASL,(@Z%J,,A&K&(+SQ`_"3(Q"8*L&^9L8`4#35%*4;Q
MBEBDXA6UR$4K4K&+50PC&+,81C**T8MH/&,9P3A&-J;1C&U,8QS5:,8MOM&-
M:Y3C'?681SK.<8YV[&,@Z_C%/8H1`DMTHB(7R<A&.I)^#WRD)"=)R4I:4E,&
MO*0F-\G)3GK2(9'\I"A'2<I20C"3IDRE*E?)ROF%LI6PC*4L9QDJ5-+REKC,
MI2Y!\LI=^O*7P`SF_H`2*<QB&O.8JNPE,I?)S&8^TI;.C*8TI\E`95+SFMC,
M)B2)J<UN>O.;SK,F.,=)SG)V"IKF3*<ZURD?<;+SG?",IT30*<]ZVO.>!8D9
M/O?)3WC2LY\`#:@VW2G0@AKTF/\\J$(7^DN",O2A$&5E0B-*T8J2TJ$6S:A&
M)SG1C7KTHXO$*$A'2E($=K2D*$TI`$6JTI:Z-'TG?:E,9PH^EM+TICC%64QS
MRM.>RLRF/@VJ4.VSTZ$:]:CP`2I2E\I4C!2UJ5"-ZCSU*=6J6K4B3[VJ5JNJ
MU*UZ%:E9_:I8C=K5L9HUIV$]JUIO6M:UNE6E:7VK7%':UKG:=:-QO:M>_C-:
MU[WZE:%Y_:M@%=K7P1JVGX$]K&+W6=C%.M:?W'RL9`_:V,E:=IR)O:QFP5G9
MS7J6FIG]K&BGV=G1FA:AD3VM:CE+U=6Z]INA?:UL=5G:V=H6EK&]K6Y;6=O=
M^G:4N?VM<$79V^$:UY+!/:YR*UG<Y3HWI*E]KG1+V=SI6K>:T;VN=C59W>UZ
M-X#)_:YX!=C=\9K7?N$]KWKO5][UNE=\Z7VO?,?7WOG:=WGQO:]^F5??_?JW
M9OG]KX!MUM\!&YA3`3ZP@L_9V@4[.'P)?K"$ZU/@"5LX)!&^L(8QW.`->QC`
MV?VPB!D\XA+3+,,F3C%$*JSB%B,$Q2Z.,4%8_BSC%L.XQC&F,8Y-?.,=JUC'
M/A9QCX-<8B`3><-#/O*'C:QD"R>YR1IF,I0?_.0I3UC*5E9PE;/L8"QS><!;
M_O*!O=QD#V@@+F=N')K7K.8VI_G-;(:SF^-,YSG;6<YXKG.>[ZSG/O/YSWL.
MM)\%#>A!&[K0B":TH@^]Z$0SFLT0$G.F.F"`2EOZTIC.M*8WS>E.>_K3H`ZU
MJ$=-ZE*;^M2H3K6J5\WJ31,@Q)*>,IFA7`$$&*``$'/(`=:F$38IH'(3.<I`
M%+">\C&+(0C@=48T0*6&$-,PI&F(ARYBF(3$:2`5.#99)E*G3(59S-D6B`8P
MH.P*]<0`N),,!O@F_AP,5.YQ@6M+U0:B@;$D0`/S9A'?@J,Z<?L**4<C]K@Y
M()6AI2PK!5=V7"1S-7(/A'A\`UIDA-.6O6V`>U+9=X60@P&D>&!V+!H6WQKN
M@0T8P'V`<[AW]`VM(76FWRPGB+F-=.;6N;MU5?-`4#@P-)/["@/Y'C>O*9"6
M]1Q<*NHF"+Y[=_*'.VYPG,N`3!KW`845NT(`/[A9NH(<_,`OUIL*-YT<<`#D
M;.``#S``\!;```7H_`$_$LL#"C`DM!>`:@EX``+6@Z+8Y'W7<'?`X?:"``BH
MO3H.&,`&N-0`Q1/`.`H0?`0T<``(',`M#L#30-C.`$01@`$+N#:Q/7!Y_@/H
MO0+A=M@"-"\9!*QD)J9'-]L5@!>TRQXI"M#`YT./`0(@:"`6=$"RD]V`XC?@
M[0QHP-DMOP'C7]OD:;?``!J0@`ATP/6W@K[::?5KIOF>`:X_EP06X`"W"T3N
M)[^`[37```N<;"`06,`##M#[2'W``%8Q`%`:H``$5*``#C`7\U<YE`<!"&`!
MX/<`!.`!$*``#<`OWM9A8#<?X;9K.X$@$E-Q!3`L^@=TB"0352<H@P,!1/$C
M"2`@'W``0($4M/)X#I`B`O$XM18;/7$4%OAK'6@`_&$`&&``D_<!"-``E]$9
M+X,`)M<6\5,B%I*!'.!_;.(P"H!Q'J@`5+$4_AIP$&:6`#TA,?I"*_IG&BF8
M$+3B%QE@A`#X@D!S`1%@AK3!`2X(@4)1%]D1%+XR`0B`)=7W$H%S``4@-4#H
M`5:Q%AJ@@P&H%FC")AC0`!NS%SQA`,V6`1@@%DW(:QN8@K[2%O[G`&B2%IIH
M<U41`8'X:Q;8;?GQ;5]6@<,"%@*A*TMA<L-R>95'`?[7%ZJ'%(]R*Y`(;"HX
MAK1"?QD0%:N()T6AA55"><,"&2KX&'%Q'!D0`3RH,8=3*RMX$&#8.@IP%`^"
MB:DW?E+#`94W`51X$\,A&318==+!@B."A&&($,1(&D:X/;_HC228;%QS``\3
M%\#X`;JQ%'S";!+P_@!Q<18XL@$F)R@$L6O'0H8\"(GK,6V^L@!V`R2.2!"1
M1P&7EVP#80"O>(G7%VY$AP&=N!<T\@`0(&RBZ!-==Q]?-X'Y$6YP-P'H)FX'
M((L]^(IG1P$+<`"IAR0GZ'O5(8O<4P`S$AE:^"-VN#96(@$$8`'CIY0:\!D1
M0`!G1R'V^!E+D@"-(@$0<&V%MX8>0(U+U``'07D*TSX&((L2D'OT-I/]UR@3
M<`!7N!\7@B=P69)1.95@R(-',Q`(H"K#1T$/\#`FAY-P22*WD@`00"</-Y.&
MJ2$,8'(3T``1D`$SN3U!L0#7D8)&H19'\9)[=WX&8(<Q01STUWZ5,1`'_E`F
M`N"-*J.1*?B5@J*3O/&18UAU=%F2@_-K_!&5*3D1D!(6-O&;PAF<C)(0LS9E
M%\<C$J)TF(,@-X$!)E(!R7DT4C<!#G`9T.F'A&$!67$9YT,!5V<3'=<2%3!O
MF5$U"*(BZ`.=@Z.>O-8!-M$!D_,W`Y&!2R$VP\*>2T<0['D3`8(4\'D34C$!
MD>$!5,.=JC$YGM.,P$<=/>&=89$5_<DB8D,A$<J<&5`A%`(E&P`5P[(^@Z,:
M'?![GM-O.=<CQ?8X%$`\V3FB%CH0.V,!JN,YV"80FO&;M#(X%V>@E?.=OSAO
M.6<H^4@1'A``JW>D2)JD"W"-";&2+.D]%G``_@MP&L[S,+V)'PLW*\4V0%\Y
MI;]W'T4J$1S0;#`A@4\J$I.C$-EQ-0VQI0/1.\IV'WNY=10!-AJZ$#WQI1*1
MG#!QI6HJ'[YC/B6"%QYPI]##`0CGIYV1IG]J$6$:$1LP>/ETIO6!=`IA(2G!
M$&-*,T,Q$+!A$4"S$!F@B?I7$=/F$VZJ*8G8$6=)`2O!;.Y1(GBZ,!U&01?Q
MJ!"QJ2\&:Y3*$1T0&I_QF%5'A<J2H2M!.@[(`1`P`-*IB-RS/FTQ>:"G%IKH
M`0]@K8'8%L$:&3CY`+]:J(;!*E[#=GPC'2=CK6S7(R?1`0^@`#<!CM?*?@M@
MB-'Z+YU7;`Q``!A0_@#QIQ88$'I;"HX-0'#C]RX<4'Q[IQP1<+#S6BB15R%L
M!VP,>Q,.`'=\DY8.D!5<\A(8T'G`AB;7F!W7F+%"H0"&P1L[8:`F&Z<#07IG
MTX=*D2\9JQ@/FP%L]R(#XZT%$7\.X`$,*"_7IW:/T0!=MZQO*7A(010#NZQZ
M&A&X^A"1VJ2\VJL:81K`LSZD06Q6\@`%PC,02;2[D1@)<#6DJ'.*\98=5W8J
M2'K]\B+BYB^1:;-Z0I(8\'^!L1YW^QC6Z19E$AH'T!3>.C)CVH-Z8K,6`*WB
M-J\%H*S'UK$>,``7T"A66QL#T7QAP[6#,B?JHGNF00$4Y&Y:N+@^`Y<T_KJ*
M"]L7D-LHA<&N$T`!@](`97AQ>K$41%L<^PHURC(H<\ESQS(HR[(0'F``:!%Y
MS$83'%`@A:&L=KAN*[H`(QJ2U<$!8T*2TNLA/*.%1E&Y+2AUD`&V/$&E%?&T
M#J&K,V:F5-L15OL3["<]&?``L/&9DH%(!P`D6#$`"'"_P/8`R*(!QL,`E"D9
MNZ:"E0L@#"`!N!:$3UFQ=T(0:8D`"0"[:$(4/1$!3:$:!W"_!_B`D&$!!C"3
M]'8LP&$!*,LBP*%_7XD!]HL`YA>_"3"_G\J4%C@HM-(O&/R4!)![2ND5BUD`
M??$RM.(`">"##N`E&9#"9;L=!W`LO&$:T68D_E\!`6IXP"&9$#9RN!J")P>,
M*`\0Q(^":TQYP-=&=$(1O0."*DARP%3B%DVX%&XGOP,[NT0:`'LJJ65ZOO%A
MM01<`9KHJERK`-2Z'P;ZQFQ;=;S&;"QA`%EQ`*[(`8@LP#&8QYJH)U4"NQXL
M;J>!`8CY$LHBA'Y1P:P1HG6K&)6!+JYYQ:LJP@]7P@"<&*@Q$,6!&D[1%]LR
MAI='RSU!`61AH*HB%3%C`::BR.?2`94G`0QH$G6!%\G6RCQR?%6!+';!`(E9
M*,"1`+?!&QN0F>-A@8F;O7K"+<4\`69F`'K\<;\W;8_2?OJH&V*C%/`)H\1&
MC>YZ?"@SM>,AQQ%!_KX%0<]V7!',D2Z.N18JK!R'BP!H-X@.C"AG60$=?&P"
M<0"J89$'T!>&!W[7]SL`<GP,<,&#,P'@7,H4<K\)X!TA31Q->+\6XC07S!(+
M<+]2=\''QGX@.2#:9B,F?!"6IY/T9@`''2TJ+`$8<,&7UWU1BG95<L':<<'V
M1YE]Z0$%T,(^H]-YQQPJK!@=;']GY\!^7,,4A+_)P1N!P=(<,,70@I'BQAD9
MC0!#`M6H<L'$?-;T.FU#,2(J7"$&L"$'\+=OZH-!D2XFI\*'C((3(;X-$;4(
MX:3[K#R3J$J.K$J"K:ED.B#F>]@S$Q@J8TIB;4J-O1"$7;Z2+1_+^1%N_IL0
M@:,!31O8I_.F'_L0B<,1Z(-M+,L0+V(!*/<>&Z"H&L$]TFD1'W(I5],3LPTM
M$X,0X+D1F:VFCVV*D@:1(*'-"`$;"*,1J=VI$D%L&\&@!'$C$I%L53@?P@82
M7^DN],IMJ2IS'0"[_JP0S*$0&_#:<3S'4MO9(O$PM,)V=SA,$&,D"D!_'B!\
M%6NM?:DG#NPE%2``7-%_U]H6!.#0*FR$Z5)X]3FM(8TCM=9V@0$G"+`P!3`6
M8GE\H`@9*VT8,Y+?ZT'??5$=)$)!X`<A;@<_!^@7ZRV6B*)S`X')""`!IM%_
M7F(!`E"Q*\T`+1'2F1D;$*,8*EPW$6[A"^,:_DB2?`4]`.9'`=0'S:FICR8=
M)G21%.#')A9POQ40`0(@()EWAR77?Z>]AO>&&-B1`.!7%Z&7FOW'`0Y#`$'(
MK'[WKD'X,MA-%XA!XPP=V/:<J\<=V?!-$2-"GAU">B6QA_56(5;!&1$P,@W`
M-7IW`4S!EY0-B-?AW,E6)AW";(:H'%]Y`5=X=ENS@`A`>?`V%";Q+_\8`8!(
M`>QG$!I`:>M!?Y3&@.BR:RE"%("H?G%1=@<1NZ7!&K7^(EYQ+H]AZ21)V;ZH
MS0OKC65(GF/+NGN<,,=<'9=1=OI2=3Y^@-[X'2WAO&[7W0@0%>B&;K0>,^_2
MR;="$U!W<F?FOZS1_A67X85Q@<CT`N57PQ)H39G>R,N=\1-'`9$+*\RVW1#%
MG1";/:F#[A'/?2_S3B<*T(?J&QTXD@&@H>8-X--<;.DK)\8[P2HA/'_)EY#)
MX;D%T`#)E^Q_N&L1<-<:$`%5X8#3>Q-]N?("O#!:D<C6:D$:>1"H7!D$H/(#
MBX7.>.I^X7$"_`#@>,7*3K$5,/0JCQP27P!Z/!`=\QJJT;EU\2C$6)1#P]%K
ML=[>07T7E/0Q0XRGKA<0J>YJX2$%4/+$4VOB;))&DA7OVSL_071#8=X+,_0K
MSQG1,A"P>YD=:D%PV-[W?-SZW/"#778%HMPXN#5"6?&/P8`.4!5IPQ.,_FSI
MZH(9KR'RC#@FT3,T)&B)^^V->V/J,1\]X$%TAF$957BN[8.5C+P>*Z?(R78!
MB'P0%M(G43KK/3N6$ET7U&V)UZ<@L+KS7-LGO"_\9X/(]4:9([K%58,`D8D:
MD!X8$@R$FQ'V;+[>],<2U0'9P=UM>X=N''`NCOPNE%T4#%B@WHHL(],O3:@9
M1IALM>(ACT(:1@(0'@YHZ."@@X$.%Q!\8*A0PH<%&A!J*,"!X46,&3-Z"!`A
M@@2/(#^&#/F`@48+"32N9-G2Y4N8,67.I%G3YDV<.77NY-G3YT^@/BDD6,#A
MP88/1R4@8+`@PX,/&Z!"0+#`@0>J##A<2)#@_L+%!PXX,$`0P4-#!!<B?,`@
M82P""!<G?,V@(`&%#RD7'/#``"O3#A@0:'"`P.#<#V_C;E"PH$$'AH\_^'V`
MH,&"#@W8/I20`4-7"Q\::$@*V(."BQKL4N#@("I4AA`:2/C:^7."T`R7+B@Z
MM.B&!0DJ_&W`H0.#!`\LB!7=@8*"LQ4J).70MZ_A!F<'6(P,V2]7KQX6//P0
MH?):X`C(>QBJ((,&HL4=5)[^N'5>"A0LI.2@@`(&NZ9+R0'7&#H-LJ,FJ*HH
MG"JP0+H''81PP@<ST$BAH#+4<$,.._3P0Q!#%''$G"Y0X((&\"+1`P,LF&`!
M$EW2("Z,*)@NQ@R=_CL)1QY!Y*I'((,4<D@BBS1RP[-DLD"Y)#5J4L,,()#@
MR2`]L.#)W(Z\B0,((-/RRYE2`G-,,LLT\TPT,8*@+PMCXZZF"#J08(*7%'@S
M33SSU+,G#/?T\T]``P5T@P(R8.`""RS*P(.$VF0(@PTN\""#-C>PH`,.#K#@
MHPM(B^I2ABBU4U!22]VS3U-357555H/"@``+R(*@@`XB4L`D.ADJX#($'C`@
M@Y0@2`"#`B20P(!9-:``K@,VD$`!![9K=5IJ<?RQ6FRSU795!/KZ*J(%-F!J
MN(L*\$"U\IYCH`$$)DB@@X\^@*""!)":(`($(!MU6W[[+7$A?P,6>&`B_@^8
M#`.(-`AW@PH8V/$#@Q7^0(*A+J!T@W>-33<!BRB@"C(&"19Y9%1'-OEDE'G2
ME`$+P87//,T8XDN#DR+(+P$%59M`XP@JF$`!"0:*@($(MGLO9:2KO39IIIMV
M^H,,+L#`(@P2\H`#!YL,+;`/-$`*`PI(8U@#TKQFBP*D/D`4@TD]??KM/TN&
M>VZZZ[;[[FF7QGMOOOOV^V\@Y09\<,(+-_QPEO1&?''&@_(``\@CEWQRRBNW
M_'+,,]=\<\X[]_QST$,7?7322S?]=,N7:GQUUGGJX(`#$(!=]MAGM[UVW&G7
M_?;=<^?]=]^#[WUXX(D7OGCDCU?>>.:3;WYY_N>CAW[ZYZN7WGKJK[>]P-:[
M]QYI#\(_2_SP/R!_?/+-3_]\]<5OOWSVXU]_?O?EKY]^^/%'_W[^\^]_?_\%
M$(`#--_W#'A`!`9%:I%;(`,GUT#(01`#$J3@`RTHN0IB\((.U&`'.?C!"&XP
MA!X<(0@G*,(3DO"$6;))U"[P0AC&4(8SI&$-;7A#'+X08=F:8`Y]^$,@!E&(
M0R1B$8U8PQWB!&M'9"(3<W6XKR2P0U&\"17U9$5J85&*"M3)!M)VQ<5I<8L_
M$:-,RGBF,ZHJC6/4R1I?XD4_N7%O<F2C3>BXDCMJ*8^`VF,=8])'C,#Q5&'T
M(Q=Q`D@B(1*,A21C_A>_F"=%/BV2C,R((B<9.&U=DI(-<60<";E)GE@R;ID$
M92@[.4C$:7*3HO1DME1)R4@*<I%0+.5.6(E*;+V2D;%\))YT.9,-V*P#"8G)
MG62B@2D]"@*AF=H?O801#NR0:WBL91L9XK$(N,U`QKS(+T?T%0X8JSHL;`DW
M80(O[F2@9Q[8@*-DI$V&$),AY,2(-^OX%7A!8`+/C"<_,R)+2,:H`\*90';@
MR1+4U*0!Y*K+!1PP`0BXLR4/.&B4&"*5Q%6S1`Q1P(,&@Q$,K(6:GO1/!5!S
M4"?!J"826%/7<`.!"+@H)C;2B`9@`Y&6V).-7V',!124$0?T,I!"19-._EW2
M@8Y"IC47B!T#%(2L@3+%`@.H`(PBBH`$9$!VY!$-5C,P@)BIAFWR2H`!)B"N
M`U#T``R@0.QLJ@`#5$`#LHM`E"IP@%MI(';ZZ97:-'I(ABS@+!>`@$(,0`$'
M%``^!S#+`P8[R@6PY@.9T2L"$)`!`U0%(I:]@``H`*,(8"`X"H'+1?`UD`(`
MK*=GL8#LKJ(`!$`'KTP]P`66=8`N)>``HWE`!O"J@*A"@`,&4*E1M\C3`C4@
M2@@P`$4.!3L,:.")`/4ECC@P`08(UP&8V8!3*2">#EB``@7X`'1@U%N5P+2U
M#-&`9B9``09XZ5S/JD!A.5`<\0Y$,PAPT7P@_D4@"V45`M#!0%@FD))-<?*O
M=@SL63+@``T0E@$AG8!RWM7-47:@`@WP"P-ZZX&LN@8Z#VJ6><OSF0Y4N+5G
M02I;'A!:`SDKLA58"W#%:X#^0,1&_J&3?_#2@"4U8`.U4C$"@(/A!=<$N0QY
M`.1,NAS&2$>E%Z%NFHS+D@QD!\12P0S-#BR>)4FDO*>93`9`&UKR='=B#?,2
MQ:*2W0QD9F=ZM2F(7PCEUCB`;<."`&8*[(#_2$"F?DTR3:(H6'DAU@(76`"%
M(="6)EUYBD@-GYVR6S4!E[>[=5'8:3R@9\%"%-+F(_"+=TB!AW17IHV&\`$X
M`",&5``#[YU.9!]R_B@"::`_%&BR!#80,T(7VHQ1<8T'$-"?!U<@J`M8M(JH
M3%0TXJ@R"*@`ES!P@`2P]4H,T*MN0;SAV-(L,;`5:6DP(YG),@#;ZHRS`Y@*
MVQE]H`)>A0!!CI*`=JE3(0N`@+@00`';*EC8?V0(OBWC@0D<8`$,V$!S81N7
M`DF:0U]I:UD\(&2L7G8M6LFXF7D=6PSX!:FE98B"ZM49`Y$%`1@0KV@V@&TC
M:T:K_)6.:$[3*ZF(RV$CURZ2!PX3<*;VWYN]"W8%DQ;I/KN509+2BTLE\0/>
M<I88J<`#)`!L04'=@+Q<.I"<<Z6G_YS@@.WZ13Q0`0KXDX]B!_HIIUZX_@MX
M<0->DSO=O6CWN<L][W77.][]WG?`\UWP=P\\X0>_=\,G'O&+__OA&Z_XQS.^
M\(NWU$;+/BT+1%[SD]^\XSG_><^''O*@'[WH)6_ZSB>>GC2I<E$7Q\X-<,"+
MLI=][&UO^]K3?O:WUSWN=Y][W@<?^,/_??%]?_S>)U_XQE<^\9&__.<[O_F[
MC[W:9[*5)F:?B.9D%0>D#_WI1Y_YX"?_]\T__O.+7_WA9W_YT3][[LMDB=JG
M_P^?R';\YU__H%P4U+;DF0ZXFIR`MIL@0+BICHNBD@Z@E/AS">.(BK/P(BIQ
M0.O;":)*&P%,C";)0+,SP);H):$:)H9`0)?@_L"5^"*AVH`);`D15,&H>$"9
M,,%``A,7Q`@1I#*86,$2Y!`=_`D5;$"-\$`'[,&N>:8?;!4`F``/&(",.#"8
M,(G"L*F<N)&=<*R'L9L7BJAY\B>3BD([ZC&\8`#FD`G$"`J_V(B8L2BV>!,K
M49/CL(DW-+LK;`@5J;<WXIZ50+?XR@A0D8FV**\PE(`D@HD-&$2SHT(/Z1*:
M0#2,.)J+<+:D6`G'BHD-F`!EF4*)RHA)Y!"M6#V6N+B<@)26T*HO$K*;4A4`
M(``.8$)Z$2X"<+6FX``+X"JPL(C">H!7BR\3R0YW&8[+2!O&R`ZS<)@YN0SN
MR$5T8HT'P`T/>(`3_B$`"7`J#M"`W.`*S7#&4XL]&TF`*7F("/@U&NDSS:"7
M!^@`9_PL.HF`83$0!W`/AU*1=C0+"<"9MS*I"S@./TL`&BD/G#$*W,``82&(
M7U0-S!@:I/@T]]@P!4@;L@B+A9R`^UK(:PH-\8H`]U"`Q^B2":B`.+N_R7J,
ML-@`"""0HE"-JWB`!=C$>701!E``KUF`A8S&]@H7DTR2H5B3!Q@-:$F2E!0L
MKIB2XL!(D:H`2^'&%*.`!EA(`C`)"^A(C%#'JFG)J&2X!``:`R&*M5C&"=*/
MJJ1&HR20>6H7#JC*[TI*:M2U"3"(9TF`\7'&#-BG`0NJ!L`-EL@,<Q0+_BDQ
M2\:XBJ$Y0WFCQT7+-JFX%0^@F*1LIP1H@!T"$+]8%A7!BJS2(9;#F0\8"I_I
M``VH``)X-'W$"D;\2ZB(`)@<3).2-0QHQS41Q.3XJK1TMP0(J@&@`'=)NP:X
M*<CTF`)(K(C<`/A"RO!HQV!ZG"0BBJL#.`_(IM?4`*IRE]"`2@,1%JE)D6M*
MS'`JCT_#C0>;@)^IE[!I#"Y9ER<9&L=Z#&.LBTYLEV9T#W;DMZ;DC+$(F04H
M`+3A35-L%0$0P^T@@&5Q%_.(+:TXJ`>(G7`)BZCIF;'P+8Z4`+DJD`A0S.-0
MT)!3COR(C`C+)O601=6@,4OI,-O*IFNJ%0QH_A%/R0!C,9'C:*\R>YAZ$3+6
M<`^..38%*+!:N::SLK6+.`"DTC!QP0#ELK0F`TBB&:NS$Y>Q1*JJZZZ8(HQ$
M>8"J\I0*<`L%L)D$DS<+@`#]D(`'4(BX8X@*R*Q\R1>&HS'!.*MYH2<@0Y'_
M`++\8+C\.#;,,)\#X,A[*3!(,9:'E*L&&,FQJDP..#:V9+B-#"QULH!SHYG>
M@BC=J(O,N(`'L-)9%`N&<]2+>(I:H10+:(">B9I\40DX1:I-Z0_Q`B[WP`P]
M2Z@/N(NIX1@%>"_@F("IR4F:>9VSR!0+V`!W$XO!*(HITP@@N]0*N`!C*3`6
M?0Z;VB%4;0M=G:L<_B6:*RT*=^/2I?JW-OE4OU``OS@W1:VP:"HHI.(2A>"G
M%D61/E48<3'2>:N5L7"`1^L+QJA,I*(9F@$Q=+F(\!(7#4"S)%V7"2J.R$(;
MISK--Q%$Y;*MS'B`)F/7^&JT<D0T&;T+D:J5#C@VS=`*BSD17(RORUHF+AD*
M6]6F8\O2V6A*!UA2>OF/61P++I4`U>B,^,)4BX$-G\JF>V6X4TP5`=B``1``
MB6C&H5'(!X!$C,#%BS*)1ET2T80<65'77.D`"*BM[(J]VMR*7.&W93J(3FD`
M=W%"0YF,B\L.AG``BP06:[V(!A`RUQ#$DYBP?3R)>IN-K++"R:@J"*"1_KK2
ML2Q)V[%0$)\228BHS7FQ51Q+C-DP,JA(D>GP,'6E`(\`M#V<&(19`)FE$0>)
M*'4ZBIODTBR!$1B1BH-`F+*=P)&$%[\0"Y_2QT<[B3$4+9R)NP>`J+FU*J7E
MDE\QG\%%6=/=H<9LJ[EMK\>(-\?5#`5M5`T@48,XB<^]"`M0@+EUJ&@,J@5,
MV_%)6R=D`/&R*M^:V]-,C088"-?@-])8@+F0"N6*B\8UJ=J4S839N)9H4-&5
MD_]2WL+BQ1VBF=J*1GD1M^+`5+(1S0\H0YBB7D/IELK,KK6HS=?!7IDCW8)"
MV>K-"+=]TH19DY-8`.E`W;$P"@/HKM;@69><_K"U<(`'"R2LO:S.P%(5%,-M
MG8P&U:?6P+K.4.#CD%U#R0#335Z88BV\H.`;N0\ATXR(P-J.0ANHX#8I&4GL
M*@]M\@NTJ\W$C8"1I(`L.X!HA"G=>%Q7!0EE2UPZK"MUJD]6$0!Y$0`0*P`"
ML-4"F"K]G%*,&$.I,"D*QL@"X(IV_`P&((_GB-$)J\JH]:EK@LDE$2VN6``C
MJXIH;)BD*+?7C&/+`#;S*"]V&:@&^)6UO5_+((#LG>"(+5OV8@I)98BTU;DX
M]K6X8+;&\!BRL(@^90!5+(!UL8"U"JULN[KMQ2XOF2L/B]QYXC=*,0_!R"[,
MO0@8D0!!/LV00[C'_D!$M5&)S_@`!1X:/&9F[GC-565=DX`+&*%AHA'FK(+3
M!BCCFD&.-FG,AIG+L3`IY=4-A6$76^TW$K6ZD^!6%8%DIX+)0ZE*0S[#OI@,
M6VX`V^*PYEJ7!"",BUB7F(,(K;HTIG"`XDA,`V`QRR`0G6NNC9-%/%()&G9<
M6Q5F/$8XW)U+G^(P`L#?^\HF=8(`!FB1P(KDJIK+"$Q,/8.`W@+H_KB,GUG5
MAW*`4X:1[V*(2J;A2)Z1B^L+&['@["(+C%$V$&N``@@Y>B'GJU`16VZNE4L+
MXE3@,LLV\OT/3T'*XGBYR]!FU4@)8TS,'>E3#D,[`X%CLZXMHD@+)<1(_DDN
M6_6H&65)$LN06#J.QEDFZ+FJS8NJ"J#)@`T@@(1HC%RQ+7KA-R]>%0N9%/.)
ML\D2&]+H`*$B00&$(\PTCDF)0&TRFT+,#UP,GS>!(Z0P#ETK;=*HO4]SF\P>
MIOXSG]YZ;!:3P-'6P-:V"*1`B@5LDFE,#".,BJCPHF&Z[.`V'UU[-B^B*"L)
MFQ$DC4G!E$?J[>K@P`R8;N^[&M;^[:[![:B`EROI)78R']QF%,@X[M).DLW6
M[.J(,T'J[>V^B&FLCK0Y[HOR[7.!C-SV/B;3@,V^&NNF;!6,`$GAJMW>[MS.
M;>"N;]VVD.'6M?"),PY\;N)V;X*0/>/^(@ZP_A#9HPW,&&]S"N_P5N_W/F\#
M@?!P8C0+EV_K/C#EBJ<X6V_>YF\59*?GENWM-@ZD@&RD2*;$<'#,/,+<'J;S
M1HKCIKW(-@[OV^VK*4SD[IISP6[;QN\>3[=HVJ%S<4';>^_K[K\"=_')DB]!
MPPP`-W`1O/(E?_'SWB=/'K++=NX7K_%I3)(,T(_BB,"+JD$1U#79DT'$N:_B
MX`DU=@F`),(Q<8Y0,40@>0I"SY/[6G1%GRP_:4:G"!&3VNG$@5P1J4`/T?29
MF%!.[PEA]D2:>"9:K(F"8#A6.0Z'6756;_5/-S1X"2^6\PGAT@A9XPK(F)JK
M>`F+H8ERVY#PHL;K_BMU7W<)K7J3+!7UFD#FG%#$3\1#7W,F/,P(LUA?;IH/
MQT#TEU#SDM-T\7"VL"F01GDA<_2)<F<)U\#4)GQUL_MUFV!VEJCUB?ET*,8)
MAG$)=W^C3%R)9C20?,^):<]!HOSW1TDC1"&1AFEUA7<8C]00#@``B(]XB9]X
M(*0)X9@@W$@[YA[!_^@:R3*?7V4+MF`G9=R/)SFP\0@L['JAR=IXC]<]X[0M
MTIAS3)&:1[&2+.&`CH\GYKZ`X=``#/`,R<*`"J!LBYGSK:@7@NAYCL2(QV$-
MD3P[A'$.ND@[M2&7EE\4MEDT2O'Y)*E-MM&U6+L1J8>:M-L*)RN;LY<:_MY\
MCV-3%B])"-;P`((=WFK[KK*/C!=ZG)$O^(@PCBB)+I$W']MZG*LY:F9#&)T?
M,I:#%.VLFGK7>2$;P;/2JZ6`%.<@#:(_ETXQNT4+^KECBSCS><U?M$>Y+,UG
M62Y=2/B(E<?!^K,9)BA.$F6)[]U>M.-`FY6(B(%XE+1;%-Z\@&U5E.^*&D]A
MFYV/BGI_%+DR>R\B^L&PK:\9CD@1^HOS^34$&WZ*IK03Q,R/BK.Z^O"1-?@.
M&\S4L+@C^B1*?ZN/BCD?_RMA.8.U?BOY"I;#FJB4*^&<H"2!'+P'"`L4.FS(
M,)#"A@\;)G#XX'`!A@L>+GSHD,&A!X$>-'"8_F@A`08'%#1\X$#A(H8*&390
MF,#0),D.%"14<*C!8(</.#M@H&`20T4*0"]<L.#P*-*D1QT`:.KTZ=,%2J=2
MK:J4`]2L3Q-:[9I4004&%Q((9"!!`5<'$Q!L0`"!@L,)"R!P8/"!00<$$AHX
M<,#`Z-$)%A9,<,A@0@(("#@L.-O0`X(($RA<T$N`0P$)"30T;F!!P<6[%11`
MX/I@[6,&$1:$A:"6`08#FB\LB-"`@MC#"BXHL"!7\P;9!SP<[2`[P08(#R#`
M/JT`@]L*%AI`B.#P@0,('0[[=>VWY@<'#QAXF("!007PR]$KD+#@<X;C&1*<
MQ0"RP80#&A#,EV!7_J%LSRWW@'\,,*#6`ZN%ML`#"UQ@UW\9S$4?!APHET$#
M'C3@T`7+*<>!0&`=(,%B]"60P0$/LI0`!0V<M4%[!B3D@8DH(B:!!:J]QP`$
M$$S``$D.M<B7`QHXT(%X&V2&@`:D(<!A`A5(<)<$&?Q7`6L4]`9;;0\XE($#
MMF'W`'$?'""9><E-T(!GF24PU0+[D<3!F18\L`%]!*#HGH01).C`C#Q21YR&
M:Y5YW`:Z86D!?V[VZ0"6E4%@05]_.5#9:DAEH)=9Y[UX&%L'0(#!>D!]0%H$
M&4@0)@(5C'A`3G=-H,!R0LYU6@1_M:<<<_A)\(!GNS+P``>R(:!A`^,!_N8`
M7V_U*)*3FG&0@*$.)<8`!0]H,`%%'TR@W&E&O0=2`1,8D!=BFTHP07H1#*`!
M?6BUQZ)#9^6:07L+!(?EKQW0]YY;NWF%%%-:9275P`E3A97!636D<%<.U,7!
MI6LQ9VH%BFGP@&PV(8"<70T8Z9#$OB$E6`1!0L"9!ZF*ND!H#YQ)0;8?-,#!
MAMC.]5YAAK6UF4,9\_>!!PI<EQ!A%U`<W@,7+4"!!1U$H!@'#V!@VP=E:5AF
M10Z$EP$$B=UF0=@7.'#`!-A!L.$'%QRPP'8-=*"!:QQ@T#.W&9J''GA&>TO1
M7X79-;51GEGWK0$X#P;!`L31?5?5S$F`@04J_D60`'9PV;P1X=;][4&GR:TL
M$F#)]76D0$<:;;77$M1,W@40?.`6>EX#JI"7J>+E0.5^V\8<MTC)3;'$8]\9
MLF`?((PD!E.:):%-$%Q`P9%F)?N?A0VZ#?=U9TZ>'%X5V85P4E+]!_H!%3P0
M^UT96&<6CZJ9JN'V#TL``:R&?9!JCZW6A%?.?L2<]*"O`H"ZP`0N]3ZNJ8I*
MDH+-U&"E``2,96V:RT\#5&67]-A%8H:!&I*$!#@,`$\JZ5F9JN82)JE`!RWC
M`YW<-N"E\&Q@`PX`FP.>YI,-]28Q<7I(23+(G#*1T"^"\8"^`.4U!F3`2[Y1
M@`?2PP$*;D!4Z#&A_N8F=RK_0$`!&MB0N?0EE29"L0*:2UC!&N84\D&LC0Q3
MHU.XTD:J6(T!C)F>@R+`%9`<H(F5<4CJ*)"`"R1ND`N0V`4DP(%8<:LT#I%>
MXU+UG`@\9GT($`Q($I<S##3@:B8S#`*K8RWHA&8WJGE`CKC5@12!A7?8LH#9
M7%47!)K22C8CB$-6B0$OKLTWNX2.G3Y"`>GA;3`/DLRS[(:W\WSF/.EQ2`,,
MN)?/F,P`NWS06*[6@><4@`.@@8WL%"([U4P@5Y.KG/L\,X'08`N5&C!`D#A9
M`195IT<:L,!P'CG,9+7(@!B0BK9`\IPEXBL#G$EDD]PV(Y`DH"Y(DLYN_AI#
M3`E<H`/VDT`$^F(2!'3@3AOJY%^>U#4-L*=*_]F`9ZAG)3LE,BX2<(]@('*=
MR@QS:A#`Z)J4IY#R@<XA%L*2MIYC`/?=Q6S-@T!H"A46BMRQ`+&R)E@>X*IG
MHB5G9DND%">E@)(ET#ZT\0!7\$6;R>41FP780`1PH\[02(^"_LE16,+SL,,H
M;8;]S*&GI&*!"*1,`WZB@'2D`MAH0J@#;/H6>`!E0P<Q#K`X4UZ3FA@KL-Q4
M>3,\5>QJ)TC&@`ER"/CG/S]0@0F4*P/3(B&>'I1%SSBHDQ[]P*A":C8*-,Z,
MBT0C'-<XQSF^,;</VZU25`6746%`AF>TTTC,_A::#E1G(F_Q`*DR$+6;7(`K
M&-"`TFSBNK9Q8&/@:9L#,&#0;"6@`S6I0!2U=9.C4*!EV@'D`T;B$!E:H#QT
M*2YCM.4MNAC4`S>=@'\Q4%RI?@`NZ/6:^)K6`:55%KGWO.$'[O>PJA5F),J)
M0-0*XI#B>I<EZZU(?`M\)PT`A4%`49\&-@"4;$V@`Q)X<)`X0!&?Q%<H&]``
M1Q@L@3*-MC`T0LI,!@(!Z50T44>AF&.EFH$,3"9K%EE?!XPBG;X@)+X;.4VL
MP+3BC."8OMXB%H=[)CK>>:`#A8G:>3EP/X1EQ`.NJT!Q-1?@#/2DO=F:L(]H
MW+.)A)>Y%:AH!"1@_MX">^",0BHP>[5E`9,\`#D8B&*A[Y1=HE6`PF7Z5HL?
M8K662<:@WDJ):"-=$))D2P,5(`CE.'DGYGXI62JN88CO!^"T<<!".[8)I.Q&
M*L_4)&I"ZB]@AJD=,/T9+A9:M-VD%H%"E^2F@VYO!5P$8$!VP+Q&&NV2GPW>
M;A5X`K<.[U&:2#/_FC'`4H8N@=N+W=/=),3&#0U&Z1+%&PYZ8U/:F)UU0N?0
M>"6-<&0C<+W26SC*,>`&/[C!$X``!".\*B$\^'(9?G!7,:GA^K-X&Q5@:*KD
MQ508QWBM`7F`H56EB@C8^,=3GA0:(>"R!_\/QHE*M"`UL.&**>_`*)-R_KFE
M/%,JMXH6?YX4?ZL1X#\?N!I_*_2E'YQK3'=ZPZ%N<*DWG>D()Y35+4[UJ6P]
MZUK'>-=3'O8VCATI9??ZP,Z.]I03O6%&5SG2&U;PM=.][G:_.][SKO>]\[WO
M?O\[X.G>=H.]/>5Q-YC2`Z_XQ3.^\8Y_/.0C+_G)KWWP6BG\QP^OE;E3OO.>
M_SSH0R_ZT9.>\I8_6-8Y,``!K+[UK']]ZQ-?^MG3OO:VOSWN<T_Y![B^][`7
M`,QU+_SA$[_XQC\^\I.O_.4SO_G.?S[THR_]Z5._^M:_/O:SK_WM<[_[WO\^
G^,,O_O&3O_SF/S_ZTZ_^];.__>Y_/_SC+__Y"=.__O:_O^T#`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>y00215y0021503.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y00215y0021503.gif
M1TE&.#EA[@+*`_<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)24E)R<G*6EI:VMK;6UM;V]O<;&QL[.
MSM;6UM[>WN?GY^_O[_?W]_______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````[@+*`P`(_@`_"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7
MKV##BAU+MJS9LVC3JEW+MJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX`#"QY,N+#A
MPS@O/)!0<,*#"P,W/*#PP0,$"!H&8GC\@<.#"!X&2GB0>6"&SZ$'6GA@0>%F
M"!)2GT;](<*#!Q!NYPX]&K?N!QU&Y_8]^8,$"!D^.,8P4$/Q@1<8($#0@'G"
MZ`@2."C]H4/NX;DW_ACT$$$!@@434J]N+=`SA-0"*;`F:)DX!`H=VO_V/:$S
M;OB.)=<>!.8M0`%\HPE(D&.^2:!@?>#A5IEMOMV7GT`>4+!`=A%<>!`&#DSG
M@'7^10@<8BBFN-$!```@WD`(`##`A1<`@$!W`]B8&@0`//`!!@`(`%\!`%1`
MT`(M0C80`P`TH%`$+0;`@4!,RAA:CBUF*>4'!&3IY08&>)FE`A^$25F8!%Q8
M`0!D5E:EEQ$<Y$$#8@;`6&<!B`F`D@-Y0*27"X1&)P/-!3FE0!T(8.5`B>HY
M@'A`ZGFC!@`$X"&+=V*`998''&JF06&*Z4!HC8HI0&6*BCE`:4AZ:8"'_@3Q
M*.8#H5&J)W<JYJJK0QEDZ0!!,38I4(TW=H`E91_PZ".0,PY$I)'MY<DF04PZ
MF1"4+4+[YP!7`B`!!N""*U"7$80+K@<9@)L```N`F]FGH?[ZP9IM/E#I8Q:L
M&P"N`F'KP`46*%`I9!RT:(&YL"H'``$48`!!GI`-6J@`'DJ0);3=*3H!N!9T
MZ220`EQ@;F:46CH0IC@"4$##$BB:@$!$(DM0F`]@<,'#`/3709X-FXNJMQP3
MN<`'O0KP[02*QEF0!2TN<$%T+?97LLCAPK?KU5@71&>,W)X<)7/$IBQC?LK^
M&.2010X$Y0$!!/#B!]4^"4"8A&X0`)%=Y\@G_D%=8FP0DCX.!&^4R=';F<9]
M(J``B1CF"`%!Z[[,09Z'(L1CFQ\XH("1$@M$J0"5AQGCC8@J2J*]-X)LM>>5
M7NIM;3)6?D&>R7U:4)C]"<1C`=WER>_/?/)HP`=,%W#A!`DH31"+0P_DP,(?
M?+YZUM1GW:@&7<H<(Y$'>!"VL0L+6S:S'CZ+89@6Q/@XE<)>R^8`O$_0Y*(Y
M/E`!!?=;UZ4#]^=_)`#R$LC@B(0`#S"-3$P3$D-Z!8#*$>]L!0.`!CA`P81]
MH$9S>PQ\MM8_*%%,(,S20)Y>U"CK>"!&0P,9!?"'/_&4;(7W(Q)CUA5`F`$@
M3K:;6<X*):6=W;!__A1(C@<4I20/"(Q,DUM8`RI@P=X!@'&VVL#G-D!!#DRO
M>EA$#`4`<(!DV<AK%,B1!+XW@`!4($\.ZY'9%&A#:-6(`!E:6&KBYKX%"&P#
M2%I3WO34O"Z)Z64#`1Q!8E:F(FGL@`KCG9L8T``&R$P@"2P(`RDH+5\=Y`&5
M'$!L/D`G/8%.('3Z%0U+M[`"%$!1`DA.I,1$&5OIB3%ANM-`!/8K0MYNAXAJ
MD09\**J?$:``!,B1`*Q#@4H*H`&KVT"EWE:9%F'`E5E27A:G>1B4*3,``HK1
M!>0G@"T6JXP<8-(![+6LL3D+`.Q!TJ_`QQXZ(@1*#("2!(+9JSTZ8`+X_IR`
MDCR6SPFP1R#JU.&9GFBQ`<B/3/(C0"ZS1"B","T`DFQ1!R*X@(HZ$B$:@``"
MI$49.AT@GSSZ8*,*MZA&#0!+#'@1D.S43_'TBJ7X[!(L;UB04>90<+CLC"Y]
M"(%^,F>(,L+2`IC)`0DD(%4U_(`R7400'SZS4A5=``/^2<VJ"B8#>1I`,/,D
M+Q9!AD5=^J:4.)"C+OFH:/#I4FM\*("M`@"0[CP(/($4)@50:H][&TC?$B+(
M<PX4`QY`T[16.B4/;&`#3&IHH21(D"UR*XD.-$@&F-@>@;VL<]$SE,(6=M(6
M4::$<Y*1@)@UO9*YCC$":QZ&9%K(1PHPIR_E_L#UQD-$#SQO`-;9@`5*XYU%
M,4I1?HL4!Z1GU>(6YK:F!*8YM4DT:8EU2O)KD8^N^2*@)L=B`D@ND=P&M_:]
M$P`,`.H-E8G7@^P5(0'%Z5]_)"TR><!CJ3$B>`U")`6DI@-"PU,#%1*F]7GQ
M1IC]7`=.6$I3YJA8IJL,BPH0&M49Q+1>8XS\`D`BB^VKM:#*J;VZZ,/?`14R
M!$Y3=S''M*Y!CHL7\L"ZNHA6X[H8,.QD5([ZP]S,M>BY`@F6CP)K(Y$Q28&Q
M[!/-NGL`"43`R.DA")2<%"P,V$V!.6J`D:<\I2XQ8,I'?EM?;;A>3K:H35NT
MD6W^9"V"K(F+MNF2_@`R$\$FJJU2\6Q`GAX7X"!UX*5OL]4N$QR]/)4S`$<.
M=']>"A^4\?B8Y<F3M<*T`"P;B=%&KM):%?49+`^8B)Y3U*@BE;P'Y`ASFLE3
M`2X3*L@0]\6HWHMCK?:\+GH546'%T9;ZK,8?;:I21B(L00KJ@3=ER<3]$M_9
MGER96V>).7X4TS_3^]HN@Z]-'D":EP+0@"9.H)(+4Q)D%>*!5F4I`?FI,^B>
M!TBO59O/7L3F*KW$+0@+!&6=89&7POM:,=TH5+]&%@=2):8-?%@T+<J`9<14
M`&:JYM;=9!T;4\UPNVC``@IJCP4LX`$,6,!##_\IP.!C<>YTP#'W?)%N_O/:
M@8FC:^(HM\`%K*;;S.@6L`94$L!2/O$IS9SFE<O`;@EB<4A=O#D':RH%'#"9
MR!:$`T.WGX<,2'&&.,P!$.#3PQ54\I5WO"`9]][/,33Q7=)\XI`I.55[WJ>G
M2P!7%J<Y<](^<<#VZ>LFU_K2N^XY"4"]`E=$5`4>X``*5*[J>6^XX`=/^,(;
M_O"(3[SB%\_XQCO^\9"/O.0G3_G*6_[RF,^\YC?/^<Y[_O.@#[WH1T_ZTIO^
M]*A/O>I7S_K6N_[UL(^][&=/^]K;_O:XS[WN=\_[WOO^]\`/OO"'3_SB&__X
MR$^^\I?/_.8[__G0C[[TIT_]ZEO_^MC/OO:W_L_][GO_^^`/O_AEPB"B$YWO
MN)F`P`UBF_.;_S905W_@N>Z`!!S@``A@P`2,3CSTH]_]_D=T5%49$&!^LG00
M&?!^#:$81*<TIV&`!^$9Z/<>"]%^`8A^$4`!!@="$X@0WO,`]H=_C;:!%P1_
M%PB`1(<LJ]&`"#$!YR<SDO%_)HB"N=,=)VB"&>AO3O=^OQ,9-W@;$5`!1M<!
M*#B#)BA+SG%^3;2"GR$0DE&$,HB!`E%^KM4G%U!_]Y<`-3-_'4`!TI&%2S1_
M#L&$LN0!_L<XC.)_>=>%7W@`"A`!/?A\ZZ(G8F(`:)AL=)@E!.`W]#$!QJ8E
M#!!9SY.'=%AFD#1M_B0XA5K2$+("/97Q)P9C$`(330OQ7H0(B)%E,2UR*@9!
M`7@X;4-5$-ARB8`B$(/HB`81+/,%0J3H)>6V5*V(`!%W$/+6(HIE$.N6AP)`
M*P0!BZTX/(<8)?QWBL"(0:W8(@SV`7/(+N-1`9`H)@<PBQC2,GDX`%48$<38
M)UZ2C$>7)9]4$);!;Z#(?\VWC)<8,GQSC%$S'I-XB;A%$*=XC(;X`>W8(OYE
M$-%5*8RHA]#A)2(V$&'6(MW#$)](B`,)<)L(CKZFBU0UBL?8/*>H4`>ABHJ5
MBY?XBNH8)'&865[R01^BCH$2&1D)C`\DC`>1C1>4D2H3&LNH6AC2281H_D8&
M`9.$*$T2@9+-Y"7WV![>&%D<4(MY2`")N'SF>(EPA"'/2(K?B"'>YHT"@&U!
M0B+QV(J&F$3^F'?Y"%$,T8@2"4I>4F9DI272.!Y)>8GWJ(E!4A`+&21/62=\
MXI"M")'\.)$,I1D9B9$964`(,96O\Y'J6(.^2(HDR3110H(H:8S'F(PM21\T
M62EM.6T11YA:(@#B6"EH"!$XZ0&FPB\1I%F,@F]1\IA98CS2MXP'8"X6(&=>
M(C/)UB[F@@$3@(?2A)9PE@$#AG3/^(\;\)H!"0`]$R[,!)>1>!!9N8\MTI7=
M@8=*TI0[Z8&M^9HW4TE'*1!HR8GQ(2;M<IL5_@":`W`H'/":D@DTYO(B$8D0
M%&F76;(QKSDR(AE-Z_D`XCB6'O"')%D0Z_:;VP2:BJ14<+*>YJ(@DCEK!8&2
M';">F\(`KRD@BSD09[:)$.!O'7`!JLA%)[:)$B!;=U:/+HF-64*2FBDFH*93
MF^A`-+DR5H1T>!@XT+>,Y0:0\Z97EF00=I,EJK5O6L*'W6&.S<DZ63*6YZ,E
M8]*"B[B5<ZD:V]@!#3HW8HB4,2J*6E(YU<DH>'@@X-B42=6>2;*715H0Y\F*
M/>H0OCB`UYF>!]&@V':99O.E306:AQ*F8_BD)]FA"9%L.ZJ,--HGD#A,X%B/
M)K0IKN4GO[:D6MHB_AY*AW[3F4LI0AT:61N0;,#F?"Q*EEE".ES2I/2!;Y1*
MFS8I8WIX1=#DHVE:*8W(7?@XI`O!E7\S;YM"80X!J"URI40#I]3IC2YJJ?21
MITW4F7LRJ*C(I77II0$'IEXBIB)JCP>QC`P`B;>(GL':&%Z26\/ZIH49IX0Z
MIUE2IPM:DBUR@)%12>M3*K[)?HY)`.3($)E)AZ3)DR/J/%K2@P$9`'G%?)&:
M83?&I*\J)YNB6JK8+);SK`?QJ0GQ)N#&;SM:G$1ZG`81EG0(JQX(B;":C]QH
M'+0*4%KB9ILUG-V8)?%JBEL*++\:J@``J@7AIKCH)378K<?6B![)<UXB_HU)
M:AW01*P'$:##**<(0:<(D:TP&0!Y=V078$7VNC!-UR<8*JB\6JATJ**(6CF0
MV*)-=4\88+')-Z^]6$F8DVQ7V@$T>2?BQ8P)`4W<*A`,U*P&`:Z4\2;3N2"F
MJA"H:A!).II2"XX.BR&W*6W;NFL36ZGUFA"ZJJ($H:L;:V,(2Y>VR*R^F0&(
MF[B)BRLDVXL3^CN-R&`S>K?VV;(&X6LBYR4.HKB<ZU"R.J`V:U[7FK-W^FZ3
MRJ'^V``64*XW&;H?6BFJ>&'%^HU625/>1[5B"Y3*DVP$D`"^>W\&(([=J:[&
MFA`>4$GSR*-DZZR;F!^(*:8&>ZH=.TMZ$K@-_JLE`?"4;8-M]H6W"9DQMFH0
M^1J!7A*X\?B4E)F]V?NBP$J*P.:+!^"["'!_!8!ME(JGH_L!JEB?PV*Y?8(S
M+6)B@4F(*QN@AAFZ!H&SQUJZ\_FQ#F&C>A(`!D`:&'&N7\-O"1`:2RNV7H*C
MV;>,`Y`=!V``G_B-KMJ*,JF\.24GK?FO_FL0M:A8R>:T%ZN5TCNX,BJ.R\H0
M)WR)W>N]::E?Q9L037L0D[NKU*J.%:F.[YN10FD0QBB[O8F&ZQ:_"&``IS0K
M6*J4'D*S2<R_Z3C$-56ZX.JW#G$!?^@E=F41%FPHC9@V&YR2&OM]14F(!UB0
M='B:!`%-U]@GFQ*B_BH\EM`4/%IB<-'+MM,;C!UJM*NEC@:`*U$JQ+9+Q*>;
ML.7+J\>XQ,?8Q`_)?][61:14N"R;F!XRP+K8Q9\+CPA<$`IL$`O:M68,IFO)
M;B*[$&UL*2<\(W&,F-9K?74<P0?8PW28`+\#MMQVH"ZLIJ![G/#ABV9\R`G1
MM@71`049RPOAJ`:0S=E,`-CV*`@9Q+5;IS#:(C1<K$AL$*<HP=J\SORFR4WC
M`/#<`/`\SWYKRK-"CKS4E^RSKH9KD`[DBPHPS_(LT+RHR*2ZS'-CK6)<H5[;
MM<G[$!^G`&F<KJU;K1A2L7+\JG&\;AZ,?>:XO6U#`./T.\E6;24'FO36_E25
MQ+#$6VM8]\)^W*'PC'[\EK8U;)R].A"-23@/<<)7.G!!.JO?V[4;.LV5M,/F
M;+Z)K+\?NVZUO,5,Q`%V6RDG"\3@Q7=$5X\'N&YM4RG96P`&DDS1VA!>?+FK
M',8`@*VEJ[=O];5QBR$:$`%`&:X3<<L7XFT!()G?:,P(L7[3QZ(=,&`$V:0<
M\(PI/<X)G1!)>HT`6Q!O>XE4!<W]BL/]"*2+W*IS>Q#>YI&1_`&U:-,%@9AA
MJU25I-24[;&B#+)/[81CW5PF>Q"@>8GUB9A1^]:-NQ"(28)O`LJBN]`#D:T@
MG'=L@P!PB"&&]4PS>]048=?MP6]Y>BA$C1`=_B`C"N!WT8>[UVRI6/7:U.*O
M<K*,![W',"T0OYR'+2K9!R'-L+::$RK.<AN^0MTB+]+9\=C1']"48PFXO(J<
MJ+V*JBVL64)5M)E*$961).+4`(ZQ"S&V3W00[5C.XY*_KKS6M$FLT"0O"R`M
M$*Z*$&ZNKHO1\=V1E=..*VO5,CNUW_806%L0;RP`S(28KW(0O7F_XJW,K)V1
M!XW>!J'>7D:C'J"H4;*1]+'B2<Q4$ON]L:J'_!>>8.R$I;W?YMG4XYT0MTU@
MG&(U.WV)[ARR"8Y.#I'/L=S`J9W`$C[&33,0M4O1&&*.UK&S'@:)@.P0S(TA
M<^V9\\*^?[LICUJ._BGN$$0N9&IL-4!Y`+CB`1*`;8';V`,QJE3#FUZBHCK.
MXELZ.[]V*&]\D-E]KU#,;R;6V?3H*A&7(=C6T?J=Q/P-(U)NXPIQVZ2MN;]%
MH_Z)`:KXC0C>$*RN$)"8PA@2CZ,=X;Y-WFLMN`*I(!S0E+P-X\P$U$/,`8>E
M@[;\X5$"*Q@`E4O)8PR5<Z!YC\WN[,>'W0KQYZ8QZGN,;0&@`!`0`0Z0E$@=
MR$,>U`<!B=.9C^`E5?3.`/2^/M*,7ZL)Z)18B9!8`/;.``J@``D0VP'DZ1L@
MC@&0`.?N`+$=YTX^QZ8>Y:F];@D0\/5>[VW:VM\<)"\RQ0B1I)DRY0CA_HOY
ME_$8SP#<\<8!@`#G_@!`*:!D_NMV>N:?.6T&D``(H/`D8NV;R``-#YH'S6]H
MBM!(VSI:8RH.E`'B*`!N:`#81M%BSEC(Y^T*#4#C\<;_"$E0:=Z!I^C:FC;?
M%>"*>(RD8R\X'(]..^WMZN\9.;SQ;9W#4IEY>``66^KHO-1="K*M6!JW;N4V
M7XO[.1Z;4HPD;\0J22+ZWHKNW<IF[K61499Z4M5LWXK25$E%K\H6G9-(WU0(
M%UD6T/6F$NJ;(N2_9_4W"]\^C_4\A\=:X@!2"_;MR*\16$F`).^7",IMNVXN
M;A!H?V/S)\R$.``1Y^EB&]MZP@!2B_<(?>HY_I;JZNCW'(^R`0Y-[AV/:W?X
M,IKXO8C\8H),WU[F#%W4Q3[\UV@!:>PE247T'K[YKVLR!=&;2VD:WD^H_-*U
MIN][J-_;K"]9E000`3)\($C0@X0#`!0N',!@8$&($#4L!/#P`X<`"QE$Y*A@
M88`-'R90)$D2`<$'"PE\Z&"`H@2.'SP4>!FSX,R2%`,(,`"!0T0)"P7$]$#A
M0$:*`A9@L`F1`\4+-AVHM(E`8T$,.;4"T$!P`T4+-H,N+-"`8LBF$Z]F76BQ
MJ=>M.9E"[!"!)LD`"**^_4!@(02;"18N()J!00&D`@Y$^&F3@P._))7.A8@4
M`.6F4Q4:N/FQ`T</_E85"F@<T4,%!0,8)J#@`;1JA5WYSJ9=V_9MW+EU[^;=
MVS=?#QV$NZX=?'A3X<F)<^2`P<)S#<MG)_]\D[ITHM=E4N?.G;CQ#J[!A\=N
M73G?[M[+&Z3^MH-SZ.MM:L^>W"9XZ>GU5R=(/Z9WY>0K2+OQ;!MO/_N(:JZ"
MYS#@#[WSZ@OO+0^,$]"T#2ZPH((+-'C0*0TRDHW""/L;;KT"*;30O01_<_%%
M&&.4<48::[3Q1AQSU'%''GOT\4<@.;H```$N#/)())-4<DDFFW3R22BCE'+*
M&#6@:2,JL]1R2RZ[]/)+,,,4L\FO`##@PS'35'---MMT\TTXX^RH`33E_K3S
M3CSSU'-//OOT\T]``Q5T4$(+-?101!-5=%%&&W7T44@CE7122BNU]%),,]5T
M4TX[]?134$,5=5122S7U5%1357555EMU]5588Y5U5EIKM?567'/5=5=>>_7U
M5V"#%7988HLU]EADDU5V66:;=?99:*.5=EIJJ[7V6FRSU79;;KOU]EMPPQ67
M2@8$4*`@#13KT0,!"*@S-PL.X(F"V31(;0`%1I2@`'-'Q``!GBHHJ`)Y"7C`
MR'$35AA(CP`0^(,,S.RQ`P`">/>V"S)R"0!ZF^)`-0+\(N`G"BJFJ8#/.!``
M`,0N^P`#C5=^8&&::SZR87<A-G.YYD;DJSFT_B+*X*'F&O.@X@XVP$`Z#S)8
MFJ,-W/I`L`F*`F"EID8ZH$*7Z'6I`@\2HA<"``B+`(!S4VK@Y:MM=OOM'!L&
MP`&=.6-)[@-"6@``P"X*8(#P&!C,M9(72`@`!"+(*`"8C@Y@;R+#^L#*T28@
M2'`',MJ+()H&P@B`H#G*8(*]!*,`(XL_4'MJ`"R/>``/SJ8[X@/@MOUV&#T2
M7*")#'!-,`4NF`KE(0MP+:B-4D+``H_H+AF`!RQ860`*R!Z*8@`.L"`ETG""
MH((!`F`*<@-\AR@A@4,$8/.W0@1IHB(_""J!#V@*ZRF+.[#*``$$P`QW``:P
M-AZAP-X0$#'.O$X\_E3#"5-<LC35=`4C0RE9`0@B&+IU("/A4<A#K#(!"V2/
M($%9FP%C<K8!-.`N#WO+!E0SLZS`3GZ(Z\OZ+E(Q#G3`(QDA@.0$^$,@QH2`
M*IN;Q$I&/X*0;6UG:P`"/8"_!CB@`1G90,E.\H&]-6Z#1Q-`=<SR@+,50(H>
M.<G>^F::*9II9>R+B0;\P@#7O.XS\ZL?`.Z'PY3`,6-=#&(?^TC`&6K,:DA4
MW=S\)H"I1."&`4B``ARI``X<D2`>T2(`.!B`QI@%`F<CP",50+>]*=(Q&6`7
M5]KWPH(\A8]Y_(!5Z#41V+ED+S3YGQ]M:3M`AFTSDR/29W3YL!V21B9^_NE*
M!SKT`4EB$0"5Y*`="8*^$-8.8ACX219C,@$$6&Y(!'`-!T+7'Y<P@`/>K)!?
MF$*U#YAE;59LY3)9LC*?W5*>;@/DRP2IS`-,8&];(\B0RE80LAE@`AZA7S(I
M*9,M5HP`$1`<-ST03@GXA5[6Y$@%B+2`E<'D`P'`)%!*8CFR=;*7$.,H1ATF
MDHHM@";\G&=+;=:`'A8$,DCT@`-4HQ3^A(T`F_/``U86`$A^P`($P!)DZ#43
M=WF``-E4C0$>L@$$9&0`HC0J42"PLJD6!#&EN5S(O$J`HS9@9078'`7\(H"^
MQ<XOC/RF2]V*.P]LX&(1Z4`.=U-7[(QSKG3E_H!TTH4PNO35-':%R!.Y^E;$
M)O9)2CVC8AW[6#RU%;*3I6QE+7M9S&96LYOE;&<]^UG0AE:THR5M:4U[6M2F
M5K6K96UK7?M:V,96MK.E;6UM>UO<YE:WN^5M;WW[6^`&5[C#)6YQC7M<Y"97
MN<ME;G.=^USH1E>ZTZ5N=:U[7>QF5[O;Y6YWO?M=\(97O.,E;WD=Y8'G;"B]
MZDTO@]J[7O<^)[[LE2]\[?M>_-8WO_3E[WS]>U_]!KB_`![P?O]K8`(?6,`*
M+O""$_Q@!$?8P1)N<(499-Y</24N&^9PASW\81"'6,0C)G&)37QB%*?8PQC&
MU5<:0`$8QUC&,Z9Q_HUM?&,<YUC'.^9QCWW\8R`'6<A#)G*1>[PW%M_J*1#`
MP-"<YN0F#RW*3Y8RE*U<92Q36<M3YO*5M^SE+F<YS%\6,YC-7&8TDUG-8V;S
MF=?LYC:G.<YOEC.<[8QELR395E^!`)6C_&<T`]K/5Q:TH`=]Z#`7.M!8-K2B
M#XUH1A,ZTF1V=*(G;6E(7WK2F6ZTIBGM:4XO.M-/SK.>:;7D.'<ZU)Y6=:4E
M/6I7?QK6K'ZUHU>-:5O'&M>;UG6M>4UK8._ZT1@HM:EEQ>=9_SK9L;ZUKX<-
M[&8'V]FM!G6OI7WM:&?;VMJ&MN",/2M4GYG:HN;VJLO-[&VG&]KJ-C>[_M&]
M;GBW.]ZQ+O:W7X7L7+]ZV>(6=;[E_>]W`[S:\QZXP/=]<'\'7.&:KK>]6Q7N
M?NN[RQ:80,4K?@$I5\#B%:^`H"\0@2A*X,\:I\"3,<#QBF/@SQ0`X9\O7F6*
ME]QI%X!`%"?@Y`ML?.,:FD`%,I!S"HR<=%6FP`,:\`"9>WP")3_Y!/Y,\0M$
MN>A'MX#3,,!RG;=<YT&/,L5]WN2F_QD#$I"BTX>F\:R7G.48MSK9&Q`!MJL\
MY5*&>I0K8/3H"7O<A6ZXPU>%;V4_^]`I(4D"FBP8DA#@YDZ+P,I4$O0,D"T`
M-\>`X`10`;\HP,EC23H&_.*`/R=D`4[+'$4,_F"!L6ME`H)#P-45$H$HNT0"
M0[N`:!;2^D&'-`,AG%N4!?,`IT%N(0[8O64HXH"1X,4A&)C*`;J>D:IG@`*P
M44@!JHYXD@P@`ZJ)P-#,FI0^%Q\`372:1X"/`>$K!/01E[6@^^[W5$&\_1*W
M<DI2R`#$-U$P96$``T369`G@(098@)OZ.JL@`-?CFPPXFP#@.K\8O2H3'`.(
MLHQIG0P@/`-@``58F9VR``9H`,A9@`9@``]$G-%1B`'`.`Q(B-E;P8I)``80
MC='C,MWCO0"(OM_+@*!@)`8XG*#[0`;("!AL@(JKF/[#/X68O>9[/CO:/0[4
M0(W!`(9J@(0@*@8@_C[N<\*+.HPD=`Z%N,'R@QX=?,$>5`BFPS97>S_X.Q7`
M$SS!$[24<*K@RQX,`!XG>YZJ6RFPNP"_2("AL8",\#_$`;O]83X`&`"5(SJ%
M0+W(NQH,N("568JS6QGR<P[HDS*S:+WD*YNAD;T%K!C(RP"S*`!&J\';"T/@
M,PL_;#(#"(#U<YHL=)J1$("XNY(,6,(_O$2/*`"PFX"_B3YBRQXHRT*/Z"$I
MLPI>!$2%."`,,#]1!`##Z\0`J$0TO#0U7,-2D3]A<\,FBT,ID\`,L$-97$3>
MD[FAL1ZP([S(<3)E=("5Z3X_\[RY<1JK<(@=C#O#,!,F!,9,/+F*`<4,_O!$
MJ]"\I_.RE$C&?URF9A1#R5L`D3.T6/1'6I0RFF@BLSB`)U/&JE,-)F-'L!N:
MBZ2R+)091728$$**[G/&AGS(:]L[D`0`;&25-E2U-\2RE%@HALJ(!JA#EE&`
M!=C`01P)\:&RD@%#I]F8\Y,R=3P@+1L:"50Y,[Q%E@$TZZ&[2W2:3#S!`A",
M"63!#*`)XLN`"MBD"(``?&Q$`M@](FFH"W!&#-B8BD&`4&RR6#Q!H%J`!7")
M`/`Y7!0_U%.(Q1NSD'PR[O.G,W2:C`HA`6!+MSR<N`S%^:M)4H/)F%05;70V
M;KS`DG"^<)2,I4B]H7PRBVI"I[D+:CS*B@%&_BRC`.@C&U(TQ-=TLK/QGUPD
MS6#41):1'NCQ1+]X@"8SBX4PQR8S1?]1#0T40Z=Y@%;\0K.#10"`1W\DB0.`
MO+Y4QJ@SPTXS1(PDS.<TS"K#@'<$1/%Y([?$`.5$"L9IR7Z[QLH,E9FLL\B\
MR0=X``B`/)YD#<LS.SRLLGO$RH](NI?<SD0#2ZL@/W2LLJE(RR;32$P,2I:1
M2@&@B=D3/:<I.LT`4,U$2`'XQ`!PB?.+NI^SBT%TLH@42@J(`-601*GD3+5<
MGPQ8F?!K,@?H."<;3+I\3IAY3IC+"!#:"=#TT)EKLH];*?9+N)=LS_CCFU0C
MMR[SQH\<&CODR<M#_DP`<(@GVY\*S0@'H(D)I#(;%;/AN40O5$"KRSRKM,VL
M'(G7A$LE/$00=9JHK#+B=!KL`[Y6[,@,K;*ZG$6,&XOU.TC1K!B,X\HH"T"'
MF4P!W3X=30@6#4;_44PZ70C@.PK@2\X'S<Q]8T\D]93WI#-A\T9&$\<+4`W.
M!$X&8#G$ZSX,X-*KT\DJ^U)&XSTSJ3+!<$66T\ND8U#_Q,W7?)YE^CG5*(`(
M&,N[P-`Y%4O'`S[+^QX)4`T_Y$Y5/<&)S("]V4OI4P@F6T@%K0"-<8!R$<8H
M^](L'(L$6+H@K%*UW%!D50AE)1)F[4/VDS4_T]1-Y93+++@V<U(L$T<I_LR(
M/N-)DMC)9[368"389TS4+]N8L)PYN/S"?ZU-?G104AP:R)F]T:&^A5``.)Q*
M2"4]=MV]R!`*GX-6*>/3,M7'#&B8_GF])VL\BK"^5Q5&D@U&DUA0(I$RS0"^
MH9*,KR.X3?.V>BV53EU23].GL*3*!8`]G!5!L(N`!"B``E``RJN\!<!3]*M:
M*9.`!4C*2=/:!5#-Y$0`J%T`&GVR"\#+N--:G15!*3M;LC5;*BR`#*110"N@
M)CI;*U6Y`5R\"^A!`IA;*QM`<ZR`!6"`E?/)KWL`!""`K:2\MGV`PH4]0%/;
M/P-!<QPHJ$T<L$,_P_W&!>#;!C``N?U::\.T_D.CUZ#-E'L]N"_;MLATMWA]
M4CI+-I.+M"5UR<!CMM?-7<SL,D7SMW.3--1-W4L96G[#5_6,-MQ%N-YMWMUE
M4NA]WM*-7><E6LD<MWFE3.(-E=4UTNB=7N6EWNNM7OI[7LD\7]P%WVW$7O;]
MWN@=WNVE%.-U7WG5N^1=7N]=7_HU./2E7_457]-MW_I5MBZ#W_B5E.XEX..E
MW?]E7N2-S/XU7P$.X")-7M:=X/+5WRTSX`.&E/D=X`AFX/LE7PCVW@@V80Q6
MX/`=7Q4^X0PF-Z#MX$Y)X!#&7^==80?.X13FWQU.7PM&X?U-84SC8!ENE`^F
MX!KF74S-7Q+68"2V_M\6[N$19F$7CF(`?L8BGF$E/5XDIF(-%N$25F$G?F&?
MK6(6;N`+#F+_)30BSF)%.6(R[F+@G6,KKF,;!F$H-F,AGN(TQF,R3K8V=F-$
M>8JM3``$,&1$/F1%3N0$8.1%?F1$=F1)AF1(GF1+MF1*ON1,SF1,EN1.KN1-
M]N10#N5/;F1./N52/N14%N557F1,]@M!UA0.D%NH%5U;IN5;OF5<WN5<IF5>
M_N5>[F5@'N9A#F9B-F9C+N9?5F9A1N9E=F9G9N9:?F9JAF9?MN9DQN9J!N98
M[F9O_F9P#F=Q'F=R+F=S/F=T3F=U7F=V;F=W?F=XCN=*\0`-V`#`DF?X_FN`
M`<`7F=IG0KJ(?>X8@IB^D["``9"FW:@IV!@`""".`A!H&4F<]F&C&CD`C7*1
M!:";H=HK0]F^P_J`_C,0R_D`!S@7?`83P:D8\8B,*THBA4!HE.(,B[(@WO"I
MT^&``!0E"Y`L%RF`QN((G]:1H'Z1)OL`;N7H0HF8ME(YVX``FH[!DT9I(K&A
MKU@9F(X,@2B(D9!IEND-,8((%8J)J$&3L:X-#>B*H;Z(H5F.M)X<!W&/)L..
M]SBLLYZ)GX:(J!&/#+!GB=AK[#AJ`\&`>/(8J;D)ORZL#*B.#LB`P=X-#4AL
MNECKB*AG@Z`FI9Z-YG@7I[X<!*!G4J(+#.#I_JA&$L'Y/92RBI8N'L%9&X+8
M:J/N:MXX``3(*>(8@)%.Z13BC`G(0!2DZ(C@@,-1``(`#`\X5S?]`+VL'0X0
M#0&XZ,(R;D3\@`U`J\7I&P[8&.&^ZZ$J/5[<&-8.R-O[#`78","&"$@<$0-0
M)`EP/`/H"@_82X)0F:API)6!:)`V'(5(@,_`/,$X"9?-GI"8@`V5B4/^&(%N
M`).6B,.A'IDHO4,,"PVRO`X`GXHQB[;2P)>A[HH9:8@XFXK1``8P`,0K`-GX
M;P3XZ-$^$L%Y@`#8&C.BH4E2TI&*Z=>FZ=T`1*68`*YJ;OG9RZ((@)5`'F\R
M`)@6(E+L`$WJ\0N(_BL#.`G/&[W00(#H\$6*#L`EWX`FOR$2[X`@_(FG]1#!
MT6ZTX8!TH1X/()N0D&U[YE;+@4&C3IW"&FZ"R`"0`$0(2)H#,)ZC>9BGB(H$
M$!^YBHB]>0!C2J'7IA,-X-8(Z``-*!^92`#?N2J]N:(.&`#[1NX#\!"QBB0?
MARK?H9@#X(`,P`A$IXFV^DFVR1L=BA^\]K\E7_'%;H@W;XU&3_`43Q+!B8"C
M^!BP$B&_`9TZ&FG7GNG9J)`*:2.86D;9&`"8,`"Z(0B8$HF.^@`4=8^3D@F&
MAA@6VNSZ`8R)B(X*20#"$)IMMZ"OZ)B(26QGPG8Q?PA#A@NFJ(`1"6HW_B]O
MB'!JUW"`,NIL@IB();_V/I\:?N>($"^(QD.F`)"-1BZ(B&&*CUF`R>LG`/@)
M\/F0=#<("6!T@6Y6EFB=$9(AH0)V03^7K)@+0/SH!WAJ;N+LJ8&C"@%$T;YU
M'LGUE$@)LH5Q3GH.C[";88?MM*"*IM@`%#6>#Q``RVG`@M@7^0'Y:F^*R[Z@
MOEG`&`1RS@&,T:2((I]S")AZ"WJ*N9@(IP&)@D``[89S<8]OET&O!U``F@",
M>H=SO*X(I;(<`YB9@FCN/4=[/Q]WCA#!@A@2#BAO.2\(CAEH:+R)A?J`\>8(
MUBP/#0"YJ!J`CI><!FCIISAUDA?YC&DK;H=J_FBOG9!=B%J2>1\1'`E0S-:Q
M*&FZ"Y)@BIZW<9LH\P@5&@/@JB%A"J/?*`ZWBZ4GCJ:WB8@9D00`#-8L``;8
M>JP):FZ-.K`;;%_,0`A0*>EV&5Z"TZ`9?HX`Q.IP\^D_I[P@0CE_^SI!``?(
MF,]P=HC`>X"WH;./B0_\^XDO[[1^[Z-*T-*`@#,)`(JVJ.5P#6X%B`(+(#08
MX*$#``L?/C0XL/`#!P`;'CY<H.`#!@`<%EX(,)'B!P@%%C)`\+#A!P(-,&3`
MP+(#R)@R9]*L:?,FSIPZ=_+LZ?,GT*!"AQ(M:O2H3P8`)"`$`""#!0`F+P`0
M$$'"U0,`&'R8`,#`_H<*`$;^[!`@`D6J&CX(F/`!P<4/'A*,E&!P880!-<U2
M6-B!`(0/`A\R(`OX@X:$#R<H!%F`*\F1$3$L3)R![T(/`P*#M!``YH<$D"=G
M4/RAP^;07"M\EDEA`(,%"Q<X7)@1`\*^&`%<""U;)NV'$/2R!IW`I.VG'SQ7
M,/#[PP8`$`AXB%F:,L0!%A`D>.A`+\+&$P2`COJ1HL7=&S]0/2^<+(/:#!T>
M?Y@A`FBD^O?S[^__/X`!"CC@@$JY50``!D7ET`);4226`!Q0\%58``10`(88
M9K#3`P$\H(&$!21075OL;45!@W7=]4%>'/464T$6;*!48`<8D,$&$`2@_M<'
M!C"P$0($R!C!4C'9J($&.A(`'0#86?8!`P-<H`&-,7EFW&^3)?;`!ADD`,`#
MOH756DP>""!`8Q@$T,`&&!A@0'4$'*`!!EKUEL!S("G%)056?4`!F9YQ>4$!
M#G%``%=JZO:6AS,A8``&&B@P0`=TX1B!``&<9MJA"=")H'NS79311QV%RJ(`
M&WA0TDD.1<4E!@7`22"MM=IZ*ZZYZKJK3PX0T-<#`\B&`0$*=%```2]F9L"O
M%!#0G04#$"`MM1OJY,%T3@G``&@&Z%;!`00LT`!8%,S:%5@?+(`<2!TL$```
M"B@@`48$6)B`LQMUN"0'"L`[0)@Q76!O``E,_D``!X=:NP$!&[H;0`#RT@L2
MH:`MX,!""G_P@``)/M"`;`Q@/'!U,D59\I\$)_"1!?8*(`&DZC8P$P,&(`"Q
M`]594$!^!UNHP$8.'``:!`:L-^%:,FV0`+P%4)8!@@$@X.P&?S6&D0%53;<>
M10UPE0'"MH4-4@8=8_!`7!O'-<$`%B*0-*]QRSTWW77;S>L&&VB0]]Y\ZYWW
MWWWO+;C?A>?=DP<<5"T38P\IT!U-E=*4,,IR;<#U0Y<_I'A^96J>$^5!=;`X
M3P=@3)$'GS^4>N<U,3!BPC6ECCE-#\@WD^(HSVX3ZT:-7KGG'`!_-_'%&W\\
M\L<?@"$!S&?8/++/_DOO//70/XL4!`(\(`$#`5PMDP03)T_@!`VDJM\"D!-E
M@8X5C/\^_/'+/S_]]1_E@00V*O"]TL/;;U1\^%>4CQD%9FCY'P(3J,`%,K"!
M#GP@!",HP0E2L((6O"`&,ZC!#7*P@QX4R@44X+^Y2>!T#X(,3AK@E@_V!`*!
MH0`*,X>`4[&PAC:\(0[WTZ<1RLT"*Z1(!):4$]/E$"<5Z,MT8I(8N!6QB4Y\
M(@0](,4R\1!U4UP(V_)S19!L<755E,OPMMC%FTPQB%:DX@>(*!,I`F^,7`PC
M'-=813:^D7=QK*,7_2<2.BZD-'!S(Q0#*<A!WDT"]B*`!'0VK[8=8$,$_JS,
M`29BR`1-C&W5T<#-I/:1!4@``0!`Y$,LD#4!Y"PFY>M0`+CUI]@``&-U@AC0
MU'7`Y2#``Q&`C+.DT@`A<N!=4K&6!QJ`,P,$C"(=B%)5&'#)`T!L3DKTI-2L
MU2]X-3(SP_GDQ"S`249:"W7?J8JQY&*^3_[P(1B86L=6EK'N?>5%F(07`C;D
M`0=T#)0;"]-T="2`!<!DB:<9IP&41<B!$K2@!)+`R^X3`+<`Z@`7:%DM6;.>
M!X!E/!'(@`06^B<!)$Y.%[C``2C5HP`X``,.\!Y&/(0!9S4`>#IR:)^X0B0&
M8.`"&Q!``AXJ*VQ11U0,,4E&&I`!)<D%`0>P_@`&)A4T`5```U\J)F$&4`&%
MTNL`":CIFXQTU0MDU0,&*(`%+I"`\W5(`AB```#<,H$`'!6B,>$8!3*PUC#9
MI0(F#4`W%Q*5`E1@9[,*DEW?M2$$(*"F-O+`>.SZ`.6DYZ47>`U7_*D`OF+`
M?$PT*&8SJ]F@$&"6#Q@)TO`B@-,,@%X>*$`$3LN9C17``SM$Z'HX\+(>J2\!
MW4G/0B0*$AVM9SP<R.A$>XJ8`%0@.KTQB_L:8))U561):OJ(!P!CIHFA!JIX
M<=]"3*>9!_13H'(A0"DUT)NH)"VZW$W-0AK0VM"BRI2+4H!LR+41#U2@=5%Y
M408"<(';+$N9X.WN_@<<4(#YUO<#\@H)F0#5`3]&IYL&,.%F(RSA"<>$`SO*
MT``^TR?0C*<ZK'JNA0D`O0QW8(>L>@@"N&(`\07QM`)X7I-VRZ[H8,`N)<,3
M10Z3XJ[<1;D]*J:S/B"!L60H``MXTD(4`.',50`"[\*8`Q*T``H,+\H#4`"5
M0R+$V7A*.;D-@(3(@T6.5K@"M]QG2MD:@5-=@,QR*6V'O0.6Q5Z9`C#)KYJ3
MUM@9-VF)8G&>`-A%X4$3&K,6=L`$$CT!*F]XS-5Y[NL@0E)%)QJQE(HTBE6\
MJ!87B](3H!T$U#>9O-PXA@4(DR41,+.?"F:U%5@2ICP])0#`[6(QT=$`_@ZP
MR]-9@`'V.A=%>OWK#HB$(B7QIU[!O,.%(#0F&<UU87ZS`=M!S+O1HL@`(F#)
MAWQ6K[O\"DQR9(!J&_@B$&`7:6@-*`E06H"%?C>\FVBF6;9DHQPFLVH'T!?-
MK+;>.YP.:/C=(Q.RZ@#/V<`%7+IESW"`U.E-%T1*U(&7X36])DE`VI+(FO/(
M"#,+(29(-A``")2L`#F[P'SOBSJ4R^6^"L[,`;@5@$4-Q[5B[HJ;_3*`4KYE
M`1Z@TT(V\!B*@3GHWC//0S#N`99[("H6`#I$!M/8A7MDB1GIYI3BK?6MYS!*
MO=$``4RR;)R7+'LB98@`OEZ`6NY0`R3MP#P#_K"6`@P``TW7J%>HS($$G%TX
M`$CM!@S0'1LG)[7NBM!L!'`N'[.F+QB0%FD3(+RUNF4!!=``_L`4\K\?9+$-
M0`VW7$MK8\(&[DB;.#^QI5\#-PPC`IC9V)MMS-=+D4@7\?5:P+Y:O0*`G^ZB
MSE\DCU@`4%E8<!<+E0BP%H:%J;'229W@/^#'TT9R3('Q0`:^R/7M<[^!E4K0
M5R;2:+('W4%^44!5+C21+&XT4TS]>$@SU=+T!B!34KKU``R0J>H['"_U#X"0
M/`15S)*/Q=V9+(`0#<S_S1\',-.+'8!U04E5X)0"B%W]9<KN+42?_!]G7$"&
MG<D!<8`GM4TXC5^<_E'$8IU)S(V$T/T?`M@7`(P5`+X(L7"@!KK?R$%'UF38
MT)1;2!C``62*`4R$/T'-__F<B7A7]RTA$S(05-A=9FA1Y\`=2&B`797,03Q$
M!X15?CP8!SQ=R'&A3$S'TD&A7+3.%UY`ZU!A%#Z$!LA(%F;&0[F'!V"`!<!=
M&%DAYL7A%UJ`\,@$!\RA,3T4YF!?!?R1%,J$%<I3P&'`5`T/57!`377.TODA
M102BC*R.(V9?&Q[$TB6<%F*A(R)B$Y:B*6+6@_E$$BTAPYVB*[XB+/)$*K;0
MEG%?*\8B+N:B+NXB+_:B+_XB,`:C,`XC,1:C,1XC,B:C?F#+`1P`R7G`_J,`
MX2PI(S56HS4BT"Y]%'AIA@3(U>A=(SB&HS@2CYFLT'B@Q@1L`*#0T#BVHSN^
MHWXH3FSQ1K)QP`!DV`#\T,^I"CSVHS_^HTY\5EP(G):A1ECYB=@,&$`N)$,V
M)$@@U`-P3")IQ\8(P&4Y)$9FI#]>P`.4E%Q`@#P]`'9I)$F6)/UTP$O4RL]A
M`.W<2INTS@5)(B<BQ4JRHTG>)/P`"L3L),1H`"KQ9`#02T8)&A8!)<X$&$\*
MP%$MQ$FAD,C=W`;XBU,8V7JHB0!@1VBL7@0890[N1%Y,92S11`2TE@>@%$C4
M5$TL@&P4#>/`2P8*Q5_P".,4```^0,EDP,W8_M,_G<F/R(2_[&2@6<M?[J1*
MY`=>.D55?)Y<,!/D>,"['`#^2,UP&65MY))3.`U.9J;\@-2C.,4!&!4'T-EG
MCJ;[#!E1"EE5C*91T4L#)(A1=4S%11D*)49K'(IG9LTG;41&``!D+H0G]09:
M!9IJEM--G%0$"$_+`%M,F)$'F`:VB8]?KB59@(0!B-!1=(`GC99,1`5O=DQ@
M_,57P(MN*(6TQ(M,>%+8!6%5;,27R(E1P<MO:`!LVHA3U)+TP0M#60AE#)E#
ME`9O&I51S4Q^?1("=`SB:2:"O@]MHLQBY<E#F*:S\:9,M.:J'8OF1=EST"9,
M*$7K(4;;S,QNII5O_M(C6JE/3V1$.76$;F#?!<QDBS4G_VA&:F7&)#J.;'0;
M%Q%3=3Q:>=4H18@7/\;$JVG+3+1F8%"%0WB%28@%6%@8F-FC1,3$ETS,38GH
M4SW$A`2`%'F2T7`$O!Q0"F9`VYP.?TI?5<`D6L4%:HAH@K;I\2PHM_4>^$A%
MA-[.20#`JJF+@\BF&UI(!TP<\5'$A'!4B"+>;X9$#`(%/0$/)QHAO'0I<SKG
M0K0-G=8@Q!P0?(7$=.K<5)K%7THB`4`,4U5'!Z`?Q"B3D7A(5<P$6I%<5'1'
ME2#$9T1%NGC2HJ!8D7S<WX6&YB4'`'1`1,18G*;+:5G(6(!&F9;&S0'1_B?=
M(6*PI)M&*_'`Z4*DX)N\20]"Z$-:R+6^R42T)K=T0`5T#+U$F>*]2=1T0&)H
M!$5$AT1D!!`ZR*$&9[=V:4X0%DU\YD:T&5J\J*1*'REAW@`('Y'T1J;B*$6`
MC5"9A0&H:W2%WE:NA7JMQ>.]I03HS:K*1`=HQ;BUGB=-#+QH@)+.AG1(J70`
MZUHIQI<H0`4<D5:X2L:&4E64#%4XA;(DJU/4J_M`:54@`%-(*]#6#;5NC(4,
M@``8K4AI*T4,6?TA[0!(+&(B9L,&6-$>+6PNF)\:DU.TQ%?XIUB1J(58[3W2
M3N(D#.U8%4UDG5R`7*0*4&E5"-<8G(%)ITR`_EQ9'I!G7$["G%I9?EK"")C_
M1(=VGH;9)DYV[DAO>-(*P0M&):J>A@FP4LZ71&V\5,?D(B9;B5^"D(U3E`R4
M'BAJ]J>VW./1ZH8&^-)EVF30KBZ!#&V#SNEIEBF,?)):,L`$@`:?5H:?NJM[
MK&N;4$B4Q2MP.F[D=$S6)IV=H@X%-$`"V$N8^*O;]FLMHD2F%MOR,@`#*(0!
M7)]&L0CE]IZ[1NVRMFO,XB9O[,G=$0!VYFK(:FN#!`:ETMJ7.(<"-$"6\6H"
M1`#'KD=4Y-QRS"S).L5SX.SXMHL%G!2>LJX"XXKKRFF$QJZ$SFZ>4@2&]NEG
MK.DT$HE!P.MIV(O-_B*JB6HLLHA8YV0/)?KL6PB``CP`!9P:BRP)C,;$V\I>
M>CG$P8)6[;I/`7"O;N0%D@R.XA#?X.S-3"3&X#:OB!&+<D07K34(6LCJ%U((
MK[I%N(C8TN0J2%RIA=IGL(ZD!-8&=T89`&`7`<-D0V`ED23O`J_Q?S2P@S(;
MG6ZK&E.H3.0N8F2MN5(9?<%+F'!PA7QPB0*%R$'5A#R=:537"TO1OWY`MID(
M,!7`S%3OICZ$W<X<[P'3`]@=P&`I=)+OX%*GB(J<1]C>THT%=-0?!ZSI17ZL
M3%QI2I6L@25(PMD2?I+65JQ*;H:NF6II3*!?]>V=>;*Q,`-(`^_(/=XC_L8P
M[3'?XP8H\S)?!!W'1`7K;FMLK%,8K6?"A!_S*M@:\S''T$WH"$T-E0HGSE9D
MP`7<S,RT;4P@BJHLCP5D@&#-K:;*Q`[+A26O+5AE0/<`YUF(+$D5<<QN:\38
M2W?(5@RVS<2@WYO$<19C,46X,M'*'71X,#;WGH<ER$;8IC+A;((L<VL-Z([`
MR^H-LTGSA]`!FP1@R%>U=)BT<$O+RH!5`$O+M(_\X%NRB`L''1""1@<\@`<3
M@%WVT6#P-&9.@$W+])+Q3@O#BU"7C%U\$@0\`%=,0'><EA)V2),R33LQ93*G
M#47,R]I>350VS8H&2V*.4."I,5ZX##_9QB@-_C5$_*4ZP4@!W.I)%(#XS`4D
M9TQ!6`AJ54<&O,E(TO2-T'1D?552VV<ZD_12GC1D%T4&M,1D4S9+3/9E9W9E
ML\1E4[9G:_9GAS9FC[9E8_9'<79EE[9JKS:T\L2?MA$;ZL2?:B%,`L5K<U%L
M_\1!M,YNQ\1L\\=N:Y]/_&EM1[9Q]T0"-",0VHAR-R-S/_=R0W=S2S=U/W=U
M1_=R`R%V6_=V<W=S$^=QWXU9<"5YE[=YGS=ZI[=ZKS=[M[=[OS=\Q[=\SS=]
MU[=Z1V!X+W!3?"]_][=__S>`![B`#SB!%[B!'SB")[B"+SB#-[B#\_=2Y[<"
M-P4%?)2%7SB&9[B&_F\XAW>XAW\XB(>XB(\XB9>XAK?F`IBXBJ\XB[>XBV.X
M)T6XA!\/'S5A4URD.`Z9C!=:@^QXW5#`-&+`&[MAS2@`5OXT82720U1`<CM`
M2VZ,`T1YE-ME!4BYE%M+"!D<CB]'D[?D!8C/3W_F!%R2E4=Y7[!;%>'+B<($
MDPOW3$`C<:)POO;&TNF$!8P(37@`4%N(0V5,7I6)$MH*=H+UYI2Y`ZR6GCM3
M9=`&`HSY@-QX/^HX]_5X\C`,UX@IQ(&$;"%`!+P+=BP`P)P49[`&`TR'<LH%
M`SS.XP@`=4B`O&`<@E"&9RQ`!#!+2TX(K2.`0F:.4F8&WT$`/6%,!KQZ_@5J
MWJ&H;C?R1)O!A%T4-TYL%T@(0$X_1`2LQ0.<)DUL&\WDHTN\2V]`8$U<^ZXX
MYB<IXO<*UX1X694:[[3O!Z3#HZ1O'Z4CC\AD!D+EWTPT>W9%EK"2FE>MFL@%
M^I)7W"6BU]!!Q*_(,&1X53%!8Z_?YXL@5.LH0&]NS)!'SA_21'$(F4$`*_!X
MO.QL,D5HCS%E?-<(&K#R]N2MB&_/%B7+QCUG1NA87,FOH<G71.RTB[/7B5/4
MHA:&3_@@2%]P0&MN+5Y4+E7XO'^\^SO&.]?-N_%86-*`'04X0*8O[=GMF+9/
MAH4IBQH!(GJA1V\B&>XXI]4+1\S)!]?TGP92_K31V>0!G#D#"%,`#.%,#$RS
MV@7'C(4T<77,O+G(/X2TTQ*FC`5V@!6F7,A&?"7)RT4NF1S+M\O.76)9JW!8
MT"4YA800+G[;-/[#?-(T6@<SU;VU)$"P!`!6H@Y=HI_2=\8M$RT"M(VU2+K(
MM3Y_,+T[.OW607WQ&)(7!=C5;TYUEL\`.!+$3=Q41:E/%:EP"6!)L\:P%\N?
MGT8^JTM//9X&H$1:?$<Y1=>2H19-O*V.*``Z"PON"-/%FF9+%,IB%E8&F`\[
M0OO(AXE8%%:L].88G]-==\!XI&.?`$2$#QD".-`P0<``#Q\8-FSX`,`!"!@6
M?J@P($&%#0(::,B@_D!`!PP("DSP($'`A`T4!`B$0.""!H@:'#KL,``!A@P)
M!'#X8$"`!0L=:C9L<"$#``)%'7HHT)/A!`D>"`#(P+!#@0`+M$Y@^A5LV)H=
M``"@*19M6K5KV;9U^Q9N7`D`',2U>Q=OWK<+Z.KU^W6!@J(.#'SUP$```0$)
M?#HXT-##@`D8`/ADR"#!5PX!O-9$D#EJ``(/)O#<4!2!`0X>+@@0X"&K5P:/
M'39`(`""0Y26&RH0_'6`A`\0`E1L4/AKA0!$)00X_2&"@`\7`EAVFIMIY`<U
M<7^@8)4ARH4`*GRP_>%ZPY<>CC=TH!"L!PH(`@`8X(!H@=P;(!`="."T_O/2
M8VB]!@HXC;6*BD+(LIMR,^`WL9):"JP)^JJIJJO0<Z`LI33\"RRRS`*1Q!)-
M/-&NN>I"D<46_^)K11?M0H"!P9#[0((<IVJ`@-,X^,P#QQJZB0+*>`OLI!Q-
M(A`^AS0(P(*&+.R,J@<ZT)$"#S;0:@`"&"#@L-\:H*TF"\AKR(`::Q+R*P&$
M>^FA`L"R8#D<!_!O@@!PM&^`/@.(L";MN-NN@I"B>NV#,\_CP+4^!Q``@`X0
M:*`A"YH,BP,+&`!@@0\*V.Z##BR(P$``S4,@U``2ZA-2D00(P(`'SF)J3(<2
MZ-2`&,.BC$(.')43O0,"F+6A#,,#`(&5[.L@_@-'R2111&)EG);::M=2T=IL
MM:T)QFW9HM%&ACPXP(`"5-.OTD@CH#!5"S8`CZ$$&.B@7`,.J"C-HB*XM`)3
MXUU@RW)!\T"H#AQ+"@'?%%/@.8<*H/0##0"X(%S@W@3V@P<P+DHYYIK,$SH!
M*AB9@@HP`(L`73T(0""6_*.@N$3+6S2`!TH>N0(/)FWH@DO+9$!!Z)9#=TL!
M#%B`PP!1W>P!DD=>B`,(;@N`8EI1;>C6GW0%:T*&WBU+NH@!N!$R8S]`X,R?
M)DZJK(U!C-;;N.5N$=NY[4:QV[O!"JSBHD9+EX,+(F6(N@TBHY(`@8K:+$K/
M.FWHW<:U7O##7#=P_@!SPN[;X(("K!L`5(2"9HAOBX?#6.,YZY3@8SV5F[4"
M:1U"X&J&DHK2989@'F]F5`6U/<K9&MIW=)X!.%G*H7-[8`#+S%0:/=`;RB!*
M#*KFX.&O]O4OLMP*V/JKKK'J@/RH+L00W@0`$(ZJXV$CW[\2X=:;_OK;JMO^
M_./*6W^&(BA@=(3Y"O,HI@$#9"8R"^C`!@YP-1YEP`,/J`Y3!,<;<06G)@DH
M@`8\D"?D.60!JND`<:0EO`]L(``-()\#AG699S4$7::#$T-2]Q4ZG89U%0%9
M!PB0K),`@`)@^4Y_!G(``A"E4"^+V9D<`"P)EB<#/?P`92+@@6;YK"D(_B!`
MSE@S`%Q1Z@$"N`H&"C"B)M(P`%"4X@((<)4,M.0K&V$`!SK0@!;F*BWBHQ4`
M.H,^#<U%``]0'Q9/-+_^';)_^$/D(L/"O_Z]JV$,$6!V^%*69#'$`I`2S7,X
M8("R!""(3!%=31A'2K0%(`#"*<J6`*"J\M2D5@PI5"M%UA!PU02%LFL(!B&`
M.K<Y9"-\S&%H;%>55CZ@>`XA3H<,<)8D'HIW%FDE!S=5%@,\ISFH9``A&\(!
M!71H*PMI@%(V8,R4@%*:PSH,,T^S`4^610')Q.0`RC*`5WXOCTH!RS>KUA2S
M!:D^'IJ6(1E9T+DITJ`)_8`C^Y<`[*PE<-+R_H!.1J<!#,0/+Q;%:%$R0)&T
M3!2":(E`[?P2.`LRI:,G-4P&+A#)M%BT(A$=RP54^A617!0R&;B*%3WJI)[*
MU$DT10M/Y3E0BE*+H`I5*K40NM1%,E1_S=JH4PM9@`]2%:M9E5%2U6*!!300
M`A;LH`(.D(`'\"8##G@`J"*&.61V8*UNC<"'T`,!!UP5`PY0'`VM5`$'/'2*
M:L5H7O>:,2MYQP']U(!>%V)7!WP(`@]([$#<BKD(?-"ODE4KYJYB@<KJ]:IJ
M::I6[0=5_3V@L*0%D03`IUK7OC8N7!7+.CNDE+-PX`"U!8``JO:=LIP%(JTD
M7T!KVT?*```TQTK;_@=:]20^BLN3$&O(7);;J@]\DZUFHA"D`*"FS91%(!;2
M+0`45TW=!I%#XP5L6B)P/MC2S[3OE>]\Z5O?ML@V+.UE608H4!70?---&:A`
M;@5P&M^NCR&Y%>YW+=#105:DDO[:DU+\8UT(+&M/!#@I=8_($.MB-UU@^@`]
M`0!`[W0HO"76:08N;*A-+6#%.B4*AQ*P8@Y-\%KNM:^WXKMC'_\8R*K%+\H0
MS!`,'`"9$IO8D,JXG>]H)3,=@%4KZ5B?YWS-1Z_*+5NI>R'K.H4NO@)B4;J\
MH@\#(+OZ9.[83#7.,J;X1IMQ,0"DZQ`./2Y490FM6$8;9!GUF'YI94"6_H8D
M`08X0'+BPAQ8\LJ`"*"5`A.(="CEPP!9.00##6B`!8J*E2^IZ409T&(HWW(!
M!W1Z;G3D:`-0S:+#T+4H["$`H!R2`58'J9]^><X$4FNM(3/E:S6UD(D?@JP3
MD^LU9AIG3Z3L+S--<"X),%.3YE+&`%S%NM-II?J2JYL2MQ+;@P,Q)I6R$'J.
MTR0%&,`W4TR`27^3U1_8%`(F+6E)<DI<_7(.6_KLYQ8!^FXPZU`"H/;.LNCJ
MPNRJB<#+HF'2U191$18`\I33H?7J*Y6Y+A%))J!+M9CZD+Z"]4!4Z*V5)7I!
M`8``RANB'`]0I==WH0"P&$#2;/VZ*,<=H+$=_F*AI7QG4L?CD+X[\%T%8*8^
M",QMEJH2RKDP@"\(\$"VY0TV73X]ZE,7-YI#[&'R`(!A?^)+BG4[`.29MT.(
MNC$!"$#BUH:EW_[&FX[M%QGR1/&Y%SZ`!BKNHVHJ'#*>C(`&U*>X,C(`\:>F
MS``R`!$$5F4"U,'Q5V+)HAC2]UTCGYL'`,!R9?[2(2Z'.8AZ>1F;^_JW;&%;
M,B]L\VJ?F-X`@(`!G+/;*M?6BSZAC*$@<K6Y-""8"!D<0Q@E^Z_\/OAG3K.)
MZ7E%"T5@4^VFP/0W=>VJTWOZ)5L(AQ)3'P)XGL]TE_N_Q4\_B5%H+J@::2C+
M>++<>G(`7R'`OMN;_ALIQU^9=/X`!X0K,?B@C=2*HI<$0`$T``(F0(LNX"34
M#0&JI@(.L``((*RVR0#V##(60``*8`%>KHG6[2PB0`(2X/ODPP`&X``:1U-L
M)P%,\`(4P"<80%,&H"308@)*\`"JYB.Z!`(6H@,40$,X8`%H`@(HP`'8;@<Y
M0'T0H`(R@`%89P$P8`/10P+4+0&09R>ZI.3"P@(0H$L8!CT4H`4'P``:IP.^
MI`"4`_QPY"D4X&0&3`Q#J6,^('%TQP;+0P,6P#(H0'$.PP(M8@TY8#8D@.VR
M$!"Q<*K^`N=(J3X^:`,0P"2^`U$:8E,RXSL8X]L.0,JJH]DR@`-6PRAH_NE1
M4N_W]F0`Z@.CJN*5R$S_YJ(4!X<OV*I?@`52-N";RH@)R>L#+(1LT&8[-J7.
MW`/?,`!2?C$MXF[\2@3@YN;\%F(N``^%)B@!)$"/:J*]$``"'H4F%J_MYFBA
MC&_-^&YL+L,;1:D$#8(^'D`"9$+E*$`!`N!D($``#H`(Q\8!**!<Y"F"XA&9
M5E`"*.``!N`TVM$!TA$AFL:.*$80/<!7Z`T>3:5/&J`"ODGSIJL@(G)8-$``
MZ"TZ:H3_JN9=3H8G%&`>*:`,.<4"J,,`(NV9PB@"*``#.:@`,H)UB!'3`H`!
M*H!U$,@^FN8`H&(%I:(JTM`?!>"QO@,BT<TB_HIC])H#(AD`E(@DP>"#(&IJ
M.GK2`0`Q`!BR9M"C`.1Q`@K@]!`Q]=@B"8G"`_@"@+YK!VT'4H2C$N7PX#*Q
MZ&9Q+"#%`.X2*/IB%,>E0TYQN6IB+Q5L<.YL>'B.GC:@O79KG>!L=OK"%YF"
M,$]LS/BM_([11))1;NQNY<HH$D,ENL3E/P"OFP1S1:BK!"/"`]1'E2`%`RR$
M-L;I[1CB/,X&.39#E<XF,R[,)Q)(ENH$+-"%,JJ&A^I"`8AM#DD'57)H>_S'
M(7]C9?J(*5)&7!;@`AC``"JB7S:`_QKG(S]`@Z"+4C)/VQJG4*HL%0^@`?CO
ME80B+"H`U-8EST!%_F)T@FH(I_/"HO2<`M1XQ#L,)3BH(D880$X6H%,XH.U.
M1I#PD^8,Y;I090+NA"&>1./$<D38`B/M0P3+XI6"RZ$:P"Z)XCL$HY*&`I6*
MSLIJ8M@4!!)_"&(P(*#\,A4!4_^FZ$4_P$QD#P,H@)ZP8Q;9!E7&*<4&(`(@
M(`(JB6(VY0"&5$DI)C*[L7DH,S8MDT0P4VXJ;K=VJYL\"0$P2GR0\#,R0WT@
M,K<$0@,N:__HZ0(*S^MR-")DLS)/A2$0X'%<M&&(9X9&ST9]\RO0A74<HN:\
M\S?>Y8`^H^U.`DP4`,\DYC2$M"'<!"PZLB9B!3*`"%)/Z'B\$\_`13P%_N<Y
MDDAP:.<SQ/`#<DLB)K(F^"X"_A$]TH9Q6*(B(B-&!5!.2LD^.2!W@J,[>Y,#
M+F*L%B`WW$U!7<@H'@,Q$N`SZ"/F]"(1.<K@)`,R@JM##N`Y0C07J:P#7F4N
M)2S!QA$]($4J9I0]R@)&CP]<QVGXTJM#MI0AZ(F.("4W@+1:=4OE%@+M.J0N
MFE3,0(V]WE1*7X1?[\8`)2`6B<^3%&"CQ`>%/HG_X(,RY"1HODD"^"(W5@9`
M^@4Y)#8L9O.6Z(0W'M0#[O0X!><082@WX'-8KRM0NRNR(JN*<BAKO,8A]\I1
MX^A2'4("'8(SR(([+U5>;*E&-K4R9"DDS.2O_M8*`H2C`U*U+.+M*S2`,P]`
M53FO<1C'8\7E^X*5_SZ(,C9`]!)'8CZ$.MJU!2=@`@[@C4:60&BN=FKE2QX@
MLMQV0OUB68$-*8IG`R8`M:Y*I@+'HRZ`(EA#`9OB`B[@8&,"J$)E<(/&>JCR
M<#L@<:='`N#6(1YW<4^HI?9O<#,7IR(T<SOW-#0@)H(J<$7K7_LU+Z@T;O2P
ML?"-+X&&H]1LHOP6`R0&400'@-Y#<7+K`;O+4E^#=A="=S/V:FXI*3ZHB3S`
M9.50<40V+-#E.^(G`03#-[!B,D_()W*(,+#3(6]S9K,#G39D/O#L76CJ/O\#
M)$%-4\&#4X66`XJW_B$TH`,\@(-"A86HTCNOR7_B3V>)#TK,I$&@)%BOM8^>
M-PX31\I(#26(`FEZ!(4<`,^^HO3D;6T?HPASJM5B:RQ-][6,48/Q`G6]);<:
M0/@H)C'MQ5X^9!K+AE,&C'<M1#(@XDX(`I2^Z7$\2:]4!6WA]&S4Q`,,0%W?
M:#LB&$^9]S?MCR->3CF"*'JQYD#V#RQQ!$P(PDHPH"H6569ODRD2P`"(@CIP
MLCX[8`'N9&5.[2QY%GU_]E(K2&CC%RQ]0@,&@`&2PBM.`BJ^HJP6(HJD0VKY
ME]/@^.4@(@U/AW1ZY(1B,BE?;@ZUN)T(X'$N`EAH+Y"'@T),R#P>@XJ8_G')
M3&1N.[B@.)B3]Z=TY:8U/@D[#*Y#/B@I\*\H>H:9=C/"!J!J+JSAG@,#2.Q[
MP4)C0:U9C"8`$H`H0'9YAV]/L:-09#"%%F)ZO48K@((`:&*8A&\K]@V#/`R+
M5^DI:&\#SS(`U`V6[TW=,/!D;FF'0Z5/(D"-DY(HJ)B75<,\2DPKDC4T"$#=
M-H5\RK>4,HGM2C!6:R*".PE6C.8T"E@@BH;V#J!!B%*2.C,Y2DP#_E0V:8,X
MY#F4X6*3/QF1/-FBW>*#O>5N.^Y]8TRG%,2*/"Y4<)+3,*T?+2@#^A&C;#4=
MT8(#GD,#+*@#<+*?.&!69AHKYA<L=)KX*$`:_B$GD@@F`BK`/SJ`)C9@`YBE
MI@W%IR/&?K'"IE&:)"$#`R1``>'7>H4Z0B7@HD(J5'BZ`X#ZI(U,`CQ:0E+:
MBO"8>[3ZA"1-?G,8IR'#`B2@K)$:/=S:`TPZ:+03*US*AB0@IALFIM]7*DQ5
M63,XHZD*HQ=[+3;:L5\+9BJ``S#@@"(;LYFBHC-;;QJ;L_=FHC^;M-A#DQA#
MM#E[LT\[;CQ;M4$HM%L;JQ8HJF';=%.;MJV%M6D;LF^;MWN[?FS;MUTDMV%[
MMZV%/=OB@L7"/X[;12H`Y9P[N#5#`G+X+9(V?E]:NJ=J`A#[6KA;6X`[NE%D
MN%N[N*M%K=K"@*A;_BS8D8:B%$02QC-H+;RG*&C_PIT,YY9?UZ7PU"XBHYKM
M!KSGNT3&6[7+^Y">*2YFLUK@>W8>6,"-Q$169I\;8FL#A0#^VRTB`YZ])<`%
M?+5>6[=!/%M*9CHHX`(6(`&JR,@6@$:NX@X+PJ+(-@$B[S8M@$I",!I9XQ_[
M8V2P(@*B5Y5&Z'(FA9,>(&&61"T8O"$.X'&BQE@?X#0NX#:1]RHXP,BI<W$@
MH&$L((A.(@%R/#SZR:M+/`0#$#I8C,AER0(@(`$H!@-JKB.DD-(BP`(JH(\^
M%K#?/,W;ZC/6<H0P0`%4:(00P`&4`["=G-!]HJXA8ZY([C.F(E3.2L*-_JSF
M%`#2B[?F5!Q/-<`V&$!V*@"!SX(_;B("?OP)(<<!Y!1Y<A304SRY*5JQ/=Q;
M"/RT#7Q:$'4XNL0!-B4W",)7A<6BRB@GHB-76`MC8HDG',".&D`0%P.,!6-<
MB-*..N5=&)EY3.P`/L4I+PXL$N;EOAV^L^)3WD-.Z.0LMM978F4!\AL]_@8]
M#&`'>:(!6`B!/J58ED<,ZY$["`#)U.T%,W+3S,0:A>5D8(:$!>`@&!3!T\6L
M2A"GL_(!G)(CE:(!@.8?'9A=QZ(`QET&M>W<G<-%'>H5Q0:"TDC;%``"VK'7
M[>/0_J3=!4(8K9$^0FN4-F-%I"8R,O(!:.]S_DWP`=HQ2JXQ93:%K>0GUF5=
M6VA=M&U=1G!=@LZ"K*!#Q/C0(@REO8#KV!]#<)"G;-GC:O@F3\Y"<%J*ZVP4
M0"HU1]8";<:K4ZC8>:H#3_]T3"KB)39JA@B":]W1R#K/*=CJ9B&BIC*2!Z4'
M,?Q#`\4E`6B#*UR4?=#)`XZN*`X_5,Y0`J2.AF:U[%_GWD[*[<EM-6X63ME<
M$A_C:R?=@1L"Q?]#Q;=^Q(1#G%E<$2FFOZ[S)Z8")XCON5)?D@#HPLXBA%"D
MPY$^+Y3^LYG>19R>779>VY`,K)^)>';_9&>H-KY>1).K[W,U*2!H&XWZ6W)"
M)S#`LO%,(4W-5`0(_BJ[,G/X`M90B$E199(8(E?Z_MXS1C37E=3^U(38OR%@
MAB@,M)<!XH-`!@@^<!!P0:#"#@`L*'SH88,%!0,,-A3HX(#"#``X/%3H@0,&
M!P`V?'A@P(.'`1,62D1@X(,&`!D\!*C@LL*!@AP]?O!`(`+0"!T"*'"`%$$`
M#Q\3./B@0$*`#1L"<%@90>$`"4`1('6@H",$`@H?%/B(-JU:M0P!:%@+-Z[<
MN73KVKV+-Z]>A1(`/-T+.+#@P7@7^"6,6*V"!2=C8G1,02F``F\K!.CP(<(`
MIB?/"FR@,2/:!@4_+%#P(0%CA08<;*`I<&8&F0P$`!`@H>Z!U0H1H/;@_F#`
M[0(E9;JM(``S@0(*FB=0\+9I`Z`M&21XB(#!AP(/%!*`T%DM0H4.8A*,[5;A
M!:L#`;04B&'J!`*<%;[&\)'#@@`!!!`@RP$`"7U@G4(!^@12<+<1,)5Q&5B0
MW`<;),"??S')9A-.&E#8WP`\+<7:`T!)P$$`!S2'(F8/35"`!P)P<,`$$5R'
ME59""6``BL]Q,%99GB7V4%LU=:`2D41ZT$&22B[)9)-./MD!!QQ$.:645%YI
M9995;HDE!U1I\.4&8(I))IEC@GEFF6A^F4$&&+3YYIMNSCFGG''"2>>=;E[`
MYP46].DGH'_V.2B?#0"P0*&!\EE!HXX^"FFD_I).2L$$EEZ*::::;KJI!!%\
M"FJHHHY**JD0/(!JJJJN:M9A0+X*%6-FD1<3D@950`!JR&&F&6<._,B`1F-Q
MM@$$'9`FT&D$(L`94!"\-IN#'V#6`08*L#>7;Q\AP%@$`4R@@0?KF?3!`6!I
MM]U?/ZGX$7(0>E1>?04\Q9U`-3Y`5EH#4*#0`M>=)V$`#@DT083K*?"BO09$
M@$!W'S$TL`<28+```19LX(%F%@TXJT`]?205N!Y@4%RY#BRP&DP7`W<A31EZ
M<(`!%YATWL<_;?7!5D6]]U-]!GX;$P0*',#O2KD)-(!0WX'$%`0_=@SKM`#<
M-H``50]PM0#\;<UU_M=>?PUV`%./37;99I^-=MIJK\UVVVZ_#7?<<L]-=]UV
MSZUNU(0M]H'3M#:F8@+7(>>1!)L)%$'"'!"@$<D#/R"`!Z`EJRL`^'TP@>70
MHM?F>!]4T!%=VCZT&X$M_F08N1(0X+D#`I"++X(@#6#`:A=<]+F`'^3(E`4`
M9`7U1P(P*Y,`+2U0VNX),-7!3M,6P`#,RR->@`#1?G3`]!H87\!J'!A048`#
MKC?PH;*;SI0'J0NTN@`##_#7!@2T7---+H(GH8<?D`P!4Q,$$*Z@I,8`F/'`
MT-*2@'GMSVH>J1'2LL(``C20`2WRFT""]ZJV6,UJ6</:!CUXM0YB;0`$_B"A
M"4N(PA.J,(4L7&$!7@C#&,IPAC2DH0$.@,,<ZG"'/.QA#Q$@N"`*<8A$+*(1
M58.R)*+,`)-1HA.?",4D-F"*5*RB%:^(Q2RFR@&JXN(6NPC&+XHQ`A`@XZ?*
M6$8SIA&-9P15&LW8Q@A(@(EYTYM@^`:U\GP@`P+HGE(20K($8*!7L0E`]PB`
M`(U(SB@4RHVW%J"?WUQ+`102T>:DA0`!-$<`#1!(`CH)E]'U1E<FBF`"+">0
M$M%'(!VH'O(`@#^TD&1@!`K`<P*`K@@`P#?+`0\&%6*UV@V/*0!;(/1*&*X(
M>D0#`3A:B0[@,X5@`$<+&``T'V!+!2!R*>)3_@@#C((`XIS/=[LI``)0:9``
MK+*6S6'<9J"5(=,8A2('(`M'#""X`'1G1'LDX0(,<).T9"XA*T'-S8Z6LZS(
M;P`+.$`S^_:T'\%*2"JIJ$4K>J2+8C2:=NRH1S\*,E>!=*0DK8MAZEC2NEP`
M/P_:R,`T``$&/"`ZF&,`!C2`$WMIP`$-N(`&:%F!!CA@0!V`0`,XL%)[!76H
MS*.`BCK@U)],8(H5X,R?XI+4AUC@<A>@J@<J0-.M!FD"#'``!CC*/@*PRP,6
MF"(M/]>`!VS`IWM\ZT-P0]8)<`8#`Q)(L1@0@092X'H7R.E0UO)7"120`D+%
M`%231`$$?94!$.``_@4XVM4&X(0"8;V<5&6:`<LBR:D>H(!))"93#8@6JCQJ
M`%"CPX$(I)8MEQ4(707"686`E941:&QL<EI7.[:%IBDMKG&/VQ>4'G>Y'STI
M<Y\+W>,BR0`.2PQN",,4"B0LNMSM;EZ&Z]WPBK<NR1VO>??BW/.J=[UQ^68!
MV(68ZPYF`[9!*'OO^USPXG>_T"TO?_^;+)$">,#<E0A\$7,Q[%[@>@1NL-[T
MZ^`(1\V_$E9O>BN,X0QK>,/,A3"'/TQ>`8,8NA<>L5Y$HI(+H-7$+&ZQ>CWL
MXAA3.,;&+3&-YZ)=#W"$N#?NL8^-"^,??WC&0FZNB(N,EASO&,E,;G(&_J?&
M8R=7F,A2?I6-Q2N1^KSI)Q5P``2B]56?A#DM&8"``RQ`K`AX.5I*3D^5WPQG
MN@0YS@.F,IT%<^7P,G-`+KHLA1)P`/?\!``Y+9%=/R`5?`:@DQ8(0(X8E)`V
M1_G.E'[SG"N-7SMC.B]Y#F]V!+(K"5CO@E;Q`*%3*;"'!:!_']#N!IICKP)T
M4M*;KK64+VWK\VHZUW3IM'>UBQF4I88W);KLJ=-I5]^)F5K4TL`!M$-K7DN[
MQ[B>MG=W;>VU^+J['=A741)"W8<DS=2%3O6*!("6#5!0:[AL=>26G.UXC[C:
M<,G`!(#[$)@NH`%1?<A(%G#FCWRU`0!'LT(L_@`NA6C@WKB=`+ED,@'\<,JS
ML6&X0BK%E`M$W#X3X%>K+473"EAJ-@O'5`40I'%-F43DF+K`@>>";7E_9-O=
M;4`"*'"X3]O+>.1.)>XN#B(NPZ@`$K@`!Q(`[7>[F==0G4"T+"`!"6Q<Y@ZF
M]UJ8N%V%0$!L8S.`F`U#M@40*]!D0X!/SHG0S-5*.-=!W&%L8S90\@4``>BK
M;3`3ENKZ;I7"`0`H2S2UK&2N;`'P.`/.QB\FEFT`#(;YD:F>%IIS-SX-N^``
M?$*!]/P.MS_WZ[%O9QF/<X"A[M;QTFTMO^P(`#P*,`#!ZPYY`EN=S&/+BFZG
MQ@`*0,`V!GW`;1[`_EBQ9<4#YUR][FU#/+0K1.TWFUI.=?F41E&`.`RHP&!#
M"H"4".3N4`&`W@&0+[@[QG>!QQSXK4^!PQ_N\#>WOO5-PL3J4V#ZN[P+]&,?
M%\ESEXG16EP!C+IH`I%)#^``K'-H#2``7#0`"@`4_X<O`W`=M(8!"7`^=]90
M`M%HK_87`H1__S5[HY%]DU$?3*1W#!42M@%<9M$=OA,`GA4?%Z%\!)-]S0=^
MO")@@69?#]$7Y?<!W)=W!P=^3"$<Q&$2)$$`F\=\J'89!.)W:<%$"`4ZD6,7
M,1=[^A==#>`8J901"<`S')`1"P!34>8!$X``"&`L,M%0"L!7X)$!(N*%_AZ1
M`0Y0@706;E)S`=H$:`0P:1WX8E"&%RY"$[8Q((!'7%8%`(=C+PIQ*&W7&X<1
M@^:W=H=X&/>G$#BH%GTA'*_3@P"`=]X'A.$'`(?'+P4`@4@X&1B`BB3!@$RH
MAJCX)DSQA%H'?G=!A9!GA<_%3WR(&!Q0AM%R`'\G(,TA%1[W$V785[HH7A^X
M(@"@$8>R&AP!`&C5%]J'%F%11X>"&H_(?"OQ+727`90H$):8%GU!$`"`&C[H
MB1@8A#D#`)G'`%6A&J:X>-%Q>&4CA4QD3HDT-3DH%[5(=;>X7!5S.L@X&.+B
M<H@C`(X500;D`!Z`30_')W-(D-"EC)4(`+G!_A'L`8TO9WX2]1#6^!'8^`':
MR(PW,Q6'=P#@6"X7>8E^QTP-@8[?=SK"D0$DE'DQ98H#<"H/<$X#0#/,^`"G
M`@&LIGAC<P"'UH^/IXL`>5P5$%@3&34/,``!@`!O`7`_D2-0N5X5:1S9AT-3
M`QZ`YUD=P``)X3L1`A\/,!N+Z#/G]!3G9'OFITA3*26V04>DPY+CV(2^QR"<
M:!KIF#N>81L3PHR6<WB"-X,6V1V')W</\80.>1O'2!?^*'-,J967B9ESP94D
M42'\(8(C:8Z<X7N;T6VP9"^G5!`LZ()3XQ`7!@'F:)(F,7@WF)=HT1>=U$IC
M@QF'@BZ(5I+L6"Q3_I,<APF)#W%*G<283IB787%YM*B4?&B9F2F=T[D0?E@7
M@$A+!W$1+^AZY[1YOKE+6$AW!!5HJU<!D,.,3-$7`E`!'7`!1P@>W'A:9)<W
MXFB;3?@!Y.>7H%-X')`!Q/$7PK$!)%.2AX*8!.`HV'1J[`<I;Q&+!B$<O$$7
M*CF1T4F=%WJ9%9EYB!A@!F4!1S@U`="0"I$X8V,\!D)V1BEFWMEU!427'B,V
M]5F;(05*ZC,U!1069%,`/F$;4V(;W6&@YF<VT<.$9O,4#]IJK#F%S]F!%HJA
M3XJ,%:EQ=E5RG.&>$F!::,$!(M>>`A=4^U95$,%8"\``>F4OE<(N4$=Q_B+7
M>`HW,08B=<WRI0R@6!?'%1_W%AC@=!`G=5*WI_#1IQ/0I_C!I@]1*4BY%A1*
MD$X*I8T:>USIJ$NJ7$O)I)%JJ5%JG9>:&)0I;XRJJ9]::Y`*JFO!J?'FJ:.*
MJG$FJJD:4I,*G97*JK&Z::LJJ[[IJDT*J]#E``GP%H+C$Q,"'L@C.$#D%4<'
M1`EPK$2"K,M:?:"&`''),"8!`<0ZK!0@`<NZK&8'&!!`@=WE`!HP?^O5IB`6
M'Q>0-+!B+1Q)&+0JJZ6:;:?Z4>>$'V(#2C/!&'U'-@?P&F:3)(B7&71'+H8Q
M&SE*-D9U-@^'%QT@``(0E\_U:B.IKM&E/AQJ_F(=H(9E!"N-%K&"P:ZQZJ[6
M!J\>):\?(#8`9!R\86H5X7D>*34JZP&O61"OB2@!-K"=]Y'H!!@%@R\<I1)H
MP;,_Z[,KMA$'H`$RTUT]:Q^'Z#-(&[1IL;1"^X=,"Q$KQK3U07P<\`#XIA92
MRS0^^SEH.5&96JO.>:OX%[(=-;)<AQKV"A*'F+0LRQ`JNT>3\:]3,QL"VWV(
M&A:2F1?/]AIO=0'E2:0O.X1A*CEV.2`;H!0F$BT8$&BVA+`?,2$9H`#S=P!'
M`VCXL0&[00&7*Q!#H[F[D1'X`2,'@!D6<`"QY`&`%AV.BRZ.RQ\(,!O?0W<'
MD!`;PA\*H#I$<RWG_OH3)[)U&M$!4@E^K,:+1_D!@8L`BDNTN&4NDHLPDQ&F
MR>M05!DM.B$!^[%Z%D`<!:"YE]6P/LLBM1L="S`!%)*`ZL%$!K![$CD8'<NJ
M'SMM9VM':?L?EL.V]N*VGI>`2-$`+1&W2<(!SM@WNU1_>!L61_$5"!(6%)<7
M'($?V:-PFH0!VO44V#0Q#1``LQ%!%8`!&CP;QABX9P$4"X`!'VI0<L$1&C$3
MIGF;*]R5W7&;Y95YNF,8Q,B$#G-XN1$?(NH`_)$!'7!.MH0!B^-WAW<Z)*%)
MZ%DT=,<?VA$6J1M_`O&:!+`!Q)$588$_I\0S/W&$,J4U^+$>":C!`O`6_GT1
M```G-@EX2EDH%XT&`1B`*VT'4`^``;[G$/2EAJ(&MD]V>F,;8F5;A;GZ7&E;
M`)DGNS.KOW*[KV2#&FU!-@/P%KI$?Q9@&+UJ-@^WMX'Q*_[3(!_0R;C%%3II
M+PZ0`57A6;\(%-,A(0YA:G?J)G0!%%8Q>`5Q2BHF3K6<&@)2%6<!=B)2-;)#
M,F2AL`ES2D>C2ZCQ&H?3%P9U2CA!$L23>;4"EB$QS,Q#D\4HB<3C.S%1(EF7
MI&W'6`EQ3N_QFHPQC;#HB:\AA7-A`;$4`?F"3_9"RL-"Q7T,)/";JO(K;?2K
M-X;L`4QTSFW+R."G`1F@`6`B-49QA`?@$Y3<_LUA4;-.E]#AHA`-#!>_4@!N
M'"0#(&L,8!@.HQJ2B[/J&$,"("R'6+DJ8A@$4'U0&Y*$9A@'\")6PQ0D00&&
MH10'L1DP4Q++@=*!A!9,=`&9QQB`2"[L+"%*RX0+,'\@21(.4Q4!,&@E\YJ]
M:1A'0U^W02XKX1:9E\(8`9BLU*/H41'-+(#M*#7X#!=7V@"D*!"MH1#_!Q4I
M/$T;&QCZC*K\S&O^'#6&G+RWH<B#5M!PZ[8=`)],0<F@:1LUJ[>ZHVTABE:6
ML1@@#3Y,H7-)VWB@XZ>"FE,6$$&344`54$T`,#US<3O5E))^$8JVA2BTDURM
M7<`D\7J'TL7LXW?G_I00"ALZ2TW5R\P4AN$?*`2DIFD12V%JV/*:<D><$$IW
M-$420G-LBCC6TR(V*C(39ZW(YX03`<+6:H$!59,C"9`O]2(0]<(WA837@*'7
MH\K7N>;7L`+8NSS8*?NV:!&WKKW!_\HO+P@;8?'8#IP?5!&Y"H&L_J;6!,$9
M$Z``14&,"N!T.'M3(T,NC595%E!`?;&'/CN5?C$38A,Q'?ZM='=L&4EHF<,?
M%5@46C.03#0PH*,1P'T2Z3@E8FU0MT/"=*<BB,P9Q$%0S)E]G#$3K#,`!Z9+
MMO,`#N'CG%<0?9$RI^;=ZRV`VGH2\EQ==!TOH`;.^2RV@#R9A%R98+Y<_O.=
M`6*#LON[U`)P&DFD`?D=8#&KUG_YW[N$,HL1EYNL%U71Q1Y@3OE9>!'1/5!1
M`!B3>2IV0Q@#QXB]`$1B&:>L3RJ1..Z+%O6H8D<(MO7H$)G(+L1Q&?M:&A!`
MRNUAW+Y9`'QRA-T=F?[9'W]2-?A!$A?IN*:9W$]UA&I)$M#DFU9<ZQ8IVU*9
M&_3U+1G`1"VA2Z7^H1?AY&F-ZM^=%CM!)!=@-7%=74O#$4*Q`0;`[._;Y5Z>
ME()LBV)^7//=U`2=M&;C6&B^U4X9YU61'J=4-BF,T7JQ=>>C2[.Q=5KC=0;A
M4%KC,/\9`,*QBMJUL/J$./VA-;<=%_P9;+`)_H1+>'AA?>M,<82VYWO513+8
M\A,*2G='X]-(R'4$#\JFW7?3,^L;493+6SP7P8(#,G@#$MV@AJ^#J_$\YYM/
MONQ2_CD&3P"^YQ%UN!T.(Q4+NP#9SK';SNUP\=ZV%M\91"33LE9)$B3P524"
MW/10OQ!'TO2L5/54/R7LDB0PW=8OAR3$XL%6>\*%*,?$A505@+`280&2[K16
M'Q)+*_=7`1%6__7V8O<&\G(<8`%O#Q%_KR)^GV!B75EB92]6#Q(94`'7@R19
MG_=)NDYSOQ"%%;F$__1/E?4U7A=;JF)C/RWUD?6W$BXXKQ?M#:I)7VM+GQ@,
MPFZOWYG]$?M:0_NS_F_[LH_[L*_[N<_[L02J+P\D&G`!Q.'[E-86'NR*R:_\
MR\_\R>\G?P_]T2_]TT_]U(]^\X?]V:_]V\_]VR^H@MJGX0_^XQ]UY"_^Y5_^
M:J3^;,3^Z^_^[)\JYW0`!$C_].]%7'3_]8__J++_5<0``-%`8`,&`PD:+#@P
MH<"%!QDL@!A1XD2*%2LJ2)!1XT:.'3UJ'`#`P0>2)4V>1)E2Y4J6)R]8>&D!
MILR9-67&I%D3)TZ;/&/^I`DTJ,P-+8T>19I4Z5*F39DZ``#!*4NH``YTF)I5
MZU:G'0!\!1M6[%BR9<V>19M6[5JV;=V^A1M7[ERZ=>&.Y)I7[UZ^??W^_@7L
MU(-?#A<R!$:<.*57JP@.('`,^3$"C)436,9\67-F!9@K*W@8>H%HTJ--ET8]
MNJ"#!JQ=MX;]FC5LVK-M"W3P0/=NWKU]__X-(<)PXL6-'Q^N```"Y,0G/(<>
M7?ITZM4K7,>>7?MV[MTO?`<?7OQX\N4Q9$"?X7SZ]>@Q)!"I6/Y\^O7MW\>?
M7S]2QAC*_P<P0`$')+!``P7T[X($%_R.004;A/!!"0\D[X'X]L-0O@4NS+`E
M"`Y80*4+(OC``P>*VJH#K#AP@(,.YWO@L*5<S,J#%5N4[P((!BM)1QY?!%(O
MQL)+D$CQBHP0O"*73%+)"!UT,$DHC:3222J9_K1R0@JWG%+"+B'@,$@QM]H0
MKS%-LD`D"E2"H(`2`;A@*P\*B%,#`&0\TZ\%XE1J`:FFZJ``##[@0`$:$WM@
M@),2S;-1IOH;#\DFM:0T0$D-O-2\*B?-]$A-LT022RFOW#(\"\UT-%6CRE15
M@@%^1"D"-SV`,\5:[=1`5?WF_-,I#@`8M#X(!%B4`%AU1;8D2+.<E%))1>U4
MU`FCK;)33CUM-EMJR=LVTFJ_/359<4]BU=$*#A"`@4'?*R"!"DB"P``/:(W3
M@PD.*&"!7">0@"034;2@5Y(V=-?."A0H0`$4/8C```-P1*F#!QQV`"L/&L"`
M@7:#/6D#C0]X@$<-_CY>TP,&*C!``1OC->`!K$ILV(`&7H[`@HD/F"`EC#^H
MX+D##-BQQ'@+8*"H80T@T8%S$>"`@5P)98!&"Q!(.`,/-E2@@J9=].##`AJ@
MT0$,&B@``3X[<,!AL)."X%63'C#V`XGQ1>!=#=8F*8(UT78X9)24+BD#!^:5
M`%]]2:*`1)+X_>!N"@Q@P"4(S@5Z,`R$*T`J%OO&*@.G2;*@@;N?_B!QP(:L
M]%EO-_VTTFRG9?U;;)F5_?5N9U\]]FS#';?W<AL]-X`%_`M`@0D8"&#->.6N
M]8$`'+AW@`TF<#L#`/K](($'3+IZN0KL'.`!"0@P@"0&!H!`@K*/]2"!_@&&
M(^"`>0,8H`$)#!C@99,..$""8;??P`#Z!Q4*T(H`$=B1`@X8`0(DP'SHNY_\
MLB>`!$Q`.1PKB0#6Y(`!&$`"#0!`SMH6`?65[P$"J-P`T->B6C4.`+FJ0``8
M(`$$"&`#RBD8`#9P-0&DKP`%Z(`'"#"`!=PK`"YB``$DP$`'(F58&X`B%#DX
MF`0<4`()"(`&.B``[&VQ`A[`UQ()H+*3-*!\YE.9`YY7N`'DJ@$'*,D"''B!
M`!1@B2>1@``.Z+R14"``_9M`!PRPP`$@8%Z.\4``1U(`O,P)>WY9%NLNI;K:
M_>=V`[(6[IR%*69)RY.T2UWKP(2JWB'K=XT:_M]@$-#$BQ6`8;."4P<"T$5&
M<B``@VJ3`SD@`#R1Q"MUNA[B`-`!#01`1KM\ETDN<">2%/.+`6@`2:R'0;D%
M()D44!X!7N:`"'CE3Q@(`(HV`*QB'E,`[TJ`*TN$/I1H\`,.$`"-$!"B>38S
M:`20B@?JY\L6XNH#D/,7`C#PJT'9:0/6X],&!#`!?8;H`^.TP`<*L+T/8$`"
MQUH)F,:BJ`XDX&S6_``#$+"X_%%``"_+P"U/8KU<=6``%=A``')6(J)]X(TE
M$>D'EAE1E$@`6"21P!$IP,P/3""<T@2I0B.0`'E]@(&6.^I?(CE)37*K=9]L
M$K0VI54$U4Y:I>IJ_NY@9ZHPE5)7I\Q3*C^PT!X=,5[S@A,=#^4`^2%@1S@[
MZ>..]4L7R@@#`."`41>@@,$*@*(E:=/^!I<\DA#4`QK(@`9RA8``)"`"*$I`
MY+@'`)Y&0'B$5<`L!0M:PWX``9K]YV$SN,$S?F"P3@5`RX+%JW5VL9\OW")/
M2S+.@KZ0>C]*0(C>YR^0-N"/$.BE41*U`0YP@+E3]*4&*N"\-=&Q*`B(9@,&
M`-K0*LXD+>-9_F*HOP>XB0%P--](EXDB/+JIL7#RX\MR6A)&+BX`QFQL`"+:
M@"9*]2L%RE0F,PE6L7)2=P#N9(*S2KL!>XIW9C5E6<^D5@`D\P/6VX"L_M[T
MD@"0MWR%VZ40+Z``@?$3F'X%;`0$8)`&6)@D$S-)9CW`6$+!:9Q?<1,')@:`
M`&P/`:3T"D\3Q6(+Y)'%Z$3M1-NY0?2ZUH$>H`!EES.OS-76Q,U\H2WY5!*"
MNC##<1N8`CXP`.S-^%T,.T```+``C++);26!VV"&!0`"4+9DF8OIH))(Y)X:
M"S2E.REB"6#3)N=TF8<R"0U+0BL+3"#0'^C,_J+9N`!HLR2@Z0`!UG2ZKV")
MDJ`,U>RX.BI06;+4S:+JJ5U75=N9&G>A_LZ#(:PJM$XX;L,ER7C?2B^6XG2D
MMHR`F`O2QHC=ZH4D^>L&XKO;8[GJ1Q,U\WLQ_F`C%6%EAP\U;@<BG>L(,!JH
M;WZH!\;+[.RA%KPG<2==XRCF#KBH`Q.H\`?PN<Z9!AG9+_2`.X5F@2[C*H8\
M`F,TR4S<=W%@11$@JG(5]39C_54"')C?IN,EJ\$X8-"[30DR!1"G]>(4CC<E
M249T"MB4J+6O)MUF:X68S\?4%'3G?+1_@>5J26JRP0>^W<T/O',%%QB4I&8P
MZT8YZPB3TM:#2:*[#>#`Y?U2B&R^\"Q)4L.<F;2U)N&KG5#<W!X/AHXN?B@`
M%&?4:=/X5ULF24PW[>@.^+&E1+,WI;O-LP!<P)9X^;IIS:U:DJ2[M:\U@$-C
M&M$JZ_.1/3;?L15P_I4+5[C?.K0E1=-D`2&6N<+ZI.A?DYM18KWM514X]@<L
MM.EBSKNB(10FVN-8@+BYE`&#R4`/13\`%VE``.HE>4\!4+(%N!+E)%GFIGUZ
MF!-N`)S)%&*^$(,Z6%O*YJ+^^:H##'V@/RGHVL+Y56G^.@C)FNB-JO68U,H!
M`]Q^``3(U:YK=0$]ICD!//)I48"=$GTJ4>OW=I%1"W```)#Q))[=/P#8GFBK
M,6JZ&*M(LWP*+00XOQWBK)(`0/[3K*':O\JBHB3CN[5BLG4KG4JK(4.:H`;0
MIYEZ)ZMHH"QZJ"&B+)6I/PD8IWVI(_Z+ILHC.-@J&^$AB<#S$'#[@+;Q_@`.
M((#;BQ_3\P#*8B^H<!@`0*V32)/#LH!*<S_8$P`!&@"1.[22HY\#",(X8;N2
M0$(#B(J*8BP3H;T7:R%.F[GK:[YKX;E6LZHW1+!2:3"L6K4Z_#3Q\+[O.Y/P
M$Q,.X!@H@X!`2KO#\(`+>!D.\!^TZX!I0S;]62D(L(`.N``>D4210:!)5`D-
M0"`\L3M_,<24T)$(^,.`$<1"=,0,N$23R#!(#!S2R0#V*HF!:AP\D:QFDH`'
MH+S&B@"&DL62")@OPH"7>;?)"1Q(+$1+A`".P0#VZL0+2T5D(QV5,+Z."19$
M9,7(VBUJP@`$HB:3\*?=\A_=>J@ETH"#DAM,_NPIVB,A&O%#6-G&"'@:#6#$
M$FG&IUJ^3FN=FC,PUZ'#-:2^L=)'+6D^G<O'K0*04,E#/103/E3(AG3(AS0*
M%<&(OG"VO.B`#2@`[T)#58N^YPLK`A/(`[E#5LN=3[LD4%.PA(1(#&'(E73)
ME]3#H2(VOJA(KF``JV@SOH@D./1(-JR^?M0=D^Q(H33(@]R^2N(^LC(ZF,R/
MEF3*IX1*5?&`#'!$O>"`:-0*#M@\F?-'4NG(!=O'5RM(.$RUCP1(DORJGD1(
M"8O*^G#*MH3+N)3+5$&=D$S*?\S'M+Q+._S*ZZL^FAO([1M)*U')N0R,M]3#
MMJM*.:$`%U&0E6@[_D3+-:QL"G&C3,-<"1[Q#_F0+LQLB9UTOK_DR:[\R:#,
M/M$D3:`C2(X<L$PI3,_L"\3\OF^T2@(XC.!:B7':O"K;"M.#S96P`#%S,OFH
MR=\\"=`<-:.TOJ]<3=(<3`);38!,39X4M=<TSKR03:*CS;X@K-Q,./HJL<KT
MS>M<E#.2(^+D0?*L2YU+3@(!RKZL0Z^RDL!4M>GT2[L4S0NP3O+4BNS<#PUX
M``5X`!3A``B`B(LJ$0GPG,'Q``E8@`?HN..4``8@,1?!`!(LJL/8``@@+(9*
M4!?!S<8)4`;PT''2SP5`4(GZDPUX@`5P`,K$@$WCF:=!Q$R#``I8@)WQ_B4.
M;0`9R8#O:8`BVBL7#)Q-HX"'\%">V3(*Z$:=:@`%:(`MVP`'$-"%J0`DY9$I
MK5)??`@(H)$.B(#1^**3P``$4*(.D*,+8("3X3(>W;P,D%$+D)$.>+C&H=('
MH!%7\1P&$$=?Q(`*R%$\$1S0L+`.X%`(V``)>)FQ48!N0A;0/$OW[,DXS$_\
ME$.P(LK0W$LK&3K^_`O_S`\,0"&RH3T.&("O60`<-"`&2``TE:$J"KU%8\`U
M%0!7^JMX-";;>QCE&(DNRZP+$X`#<``L`B`Z.RT*(HDJTP`!>B,!H*8*"+0M
MFC3U$:(.(AL4Y(`?XB^0<A4"&"P!1(GZFKIH_D*>T:"@P3B`2?LGHPLJ*#4`
ME1)5F2F`,E0CT)"AB@K6M"$V/\I1`E`G,WW2`-#(#W"5`#``#EB`\Q.IW2,4
M;<6B/NVX.1'."G@54<4N_,F5/!H`5A58E$`8`C@OE:*C'T,`U/,`_&D`,R4Y
MHX)2\EG,,YDJP.PYGRS*^"S)FAVUG.-(3&K#^AR/_?14IP!5_(`,7]*T"0`B
M>#$66IE!<.(3J(#%"QL`&>DX)>M!5VH8'C&C`LR>$'F`0H.C<1J<D9NV*L,(
M'EF`)O.E<_H`"SC5J9,*ER44+GJGIO*`\FK0%M*86(D;6\*`OTHF<%J3="V)
M<]L?BEJY[`'!0)F`_F*:*0K0I@/0K/81,\(:#`TPE+/+F_!4-]<2@*?1P3?:
M)G4RB0'(F0Q0H<'(T7\2P1*I)Y\2LOPY"06P(=<=*0HMB7IRM*(P&1TRO,&P
M45VI2[PLR)$L2['<5)"4/K-,3G^,S@3IU*#EBZ&UCRV248"3&\\1`+B2.-+=
M3G\I$4T\-@@8M#E1'.#%``7BVNXL$;EYC_)Y0?K:GLS1)Q*#``,%`%CQ`"BU
M*0@()UO*%0(XK'DKF_N%@)O4@#SBD0A8.).PI8C2,/(UB=-BW<)=RL'@`+=U
M&;8"7T?[$1L1'@-VGZY9LPF@$2$B``=`Q_(<F)%*+XFRJ_N]25B\&#&#_H`&
M((!)'`"[4T(1?A63XZW9?3W$"8#!P.`+.``'VK;3*PP!-&`#<&&ZQ,>[U,M-
MBIWG[!;ZE,[HLQ:]C$ZUW%F@E=ZEH-[Z>.#CY*"O2%U:2:;.K::H;5`"4.-C
MXRUP*HH..!\>.S^NQ<VF$0`>0Z&PTQ_"S1Q9*IO'>`S)A%PAT@`$D(`)."/?
M5++S@XS(2&`P8Z"4Z$Z@>2>U/4_"S<$,+%,U$X`>.V.3R&15C*W(2.(@@INO
M(*,,P"(`,-V_,<_^RBE*9F6L9+\..(`+>%`+,)9Q@F)$5IG"6;1X,PD2\\4C
MNJ$_#@!DI6`LVX`T063'6,)&@51+)5[CU522_H1/LZQ9M.RY*D8P,1[CI"AC
M^K#>DJ@`#("G";`:#V9CI=TM'3H)/TK&#N@UTQ*()DI8"K`:"?;5R*DB"M"`
MNRT?@RH)`H8`EWJD]CU.#3*6I6I4DI#D[1%@[B'8-V/@E+``7L)G"<[=R)&9
MAN:[+4H`"RB*EFGG$GEG#_8E"7`FCF[?#/!?[^H`"\`BR82QX7SAC68)?:*`
MDI*97GW`12-8T@WB9597/SI9`_B>X9ROD6MB]LK),6&^F8W4L.1B[2-+G[W9
M^]S9<,Y9VD'G=#Z*=::/5<)@]#D`X2S"[:UG,>0I,,%*B^,1J)`1ZM$TC)XT
M01HT7Q4NO`@4^(V*_L%(DT&I,J:2+PF:W9J*O=J5MUY1,NVB$?*E4TR^N),0
MHL>XM\!E++>..E)"*&1#/-)VJ0<HIK4+)R@VXHG\U1+!)]0-EAB2S+09&%R^
M70*@D?):3++1)0'@I61]OQ*Y#(+]*3(\%@7B&LJ0)>S9@`:BNTGL@)+=`&GU
MI8<1WBD6YW&.S^-%RG#^9IZ%SRPF;ZM*:[5N";:>#U$55G\MT/XCFW>%.&4.
M*1E2('Q&D^5(63`\&^)^&>/JU_+[P9_J3N194_)YE7%*&`5/5JE`70)(6:E#
MB:%*ID+REXPFE"%Z4G"MR8]."0LAP7)E@'-5[LSR5[ZKUB!56'Q-5];#_@HU
M&HWG$4.9H:QW@;<$H"L;`J-T.1^'0F5H0EC>)I3SV]8,'+E^.5G2I2.92;.(
MRB.050X9O30],J//-2T@[Z`SNLGR*X`C*BK_+@`MUP`#:-(7B5FP_.K[%.^;
MFS[59,VR!FMN_LBS_H[H9>_^9,LQT0`J]=(2F0`QI5.(H^E%&_075524L("'
MN"AY=F<+8YC1L#M%+70EE9M@4Y=$51$7=``A19Q@85%*5PDZ?1D+X)@)X!@F
M;2P.Y5-I*B!IPE"3&#=_.5)01YS1R`!41PDM'=`8;:8[/91;CW4[A5*.:?0M
MS72(2%*LH])JUBT+2*8"!8T^7;0ZU2FT^W,%_A`;6-]3U2.)S@#4$_&E`.W1
M!)X7#]C&"X!6&F'4`6TL(LV3X:5.^P3OXZ5#FU5>Y$W>.>_WG^WS/2?C@!?X
ME2S";"[XI5CBEE`?=U.`J^N=G31GL9IX*_YNL=[BTJ1XO&Q-F97S]4YX<B'X
MD%?(1)$>DF^*A6<)0:HT/4KS1_5NY?PY`0M(C$_O2[WYC7=#?:^0D4=YE7#O
MGW<498M:H3>*[TB*0J2`2"2ZK:;9YXQ4;Y94C,=S??\J>P=G^4P2/3?Z5?'Y
MK@?[L)_WF&]#+?8Y,.[9?6]/-Q]O_(Q.D/_YH!?[E62@[2J*A)W"5IW[4EKS
ML)[Z4#K*F:=ZF[]X_KZD3NX[:[A'>;G?^X9T-+OKO?V=F0"*Z,;O[K@B7IT/
M;_#>_'T?Z^5%M;$$?9Z/M:\/>\:W_.^;9H(B+`QX0BM/?2E.P\X'_-$,?+,?
M?#G_>YKW]ZS'>*Z/?=<R_>!O2'7_1(FBJ"!3@/.[GA]1$,DD_@[9YHDO2^<E
MZ_)6WK77?$K%V0%1?))'_>A7%0Z`C&!9`!!\0LP=G+*1502P=O'?#Z<W?-*G
MD.H7?-VO5+^W<^WG1X]_$(!X`,#!AX(&#R),J'`APX8.'T*,*#'B@H$3+V+,
MJ'$CQXX>/VK4,"!!@P$$%1#$$$`"R)8N7\*,J;$#```8+N#,F?,F3IXZ_G?V
MU.GSPE"?0W\21:HTZ=*F1X$&C=IT*M.I1H4N?=I4($&97K]^K=@5+-FR9L^>
MY3`A`H:"%2ZXG8!V+MVZ'VG:A%H5Z56^6/7^+.I7ZM.^50M3_7M8\=[%B0$K
M-HR!J]W*E<5:SJQY,^?.GC][Q9O8L%*M3DL'?MQ8M6#"JO>:'@P;]6N<E$'C
M]H@Y]\$(#39\:-"@0T$.#>0>K""\`0,(&0I*6,Y`N(4/$Y8W<$#!@T$*"`H@
MD,"]^(,#!114+WBA`06#UX$_G."`N$$/#UCRCNB!0_X,P^<^`%=^8.'5FE2R
MF6:@@:E%!IEC#]8F&6N,T7:@7A+B!(%%`W)(_M&&`R)@TP<!``!!01H`L`!"
M`M544P!M)=!BBR96)&.*T-G80'$$V`@!=Q$`(`!_'S``P',/91#`6-:)V&%#
M"SR0GP4`#'E6`^DY"1->#W#9I9=?@AFFF&.26::99Z*9IIIKLAFF`@`D0(&<
M<])9IYUWXIFGGGORV:>??_IIP(?YA=@6B4)^@***!SE0X@89O*G`!S%2L($&
M&VQ`7$426&H!B1MX0$``$VPP00`!\/>F`1=H``&);0$)@(Y$&AF1JVU]L($`
M46;)D`%+@N9IE;T2BQ!>-B*;K+++,MNLL\]"&ZVTTU);K;778INMMMO6!&QN
MA8Y8$P.)WGB00,BA_EC`I``(>%!%%1AT`+L>#"``?!`P@"D``<#W@4`JQAJ`
M!A]4=.1#'AA@@`<>)*#P!QPX4``!#`Q)`:_6F8B0!PM@H,``"FQ`@0$$^%@0
M!@D00,`"`T]P<0<,&%Q0`_":S`!W&2Q`0`$E0R!``5U=@``!!]"\(G*)+D"<
M!CD7\,!X$!S]0'L;,$`!`0J,9U`%!PR-W)05")W`P`]'/'1['USP``0$1.E!
M!`8,L')Q#*1,L4)7YLH`!F'';%`$%#A@MD$=E-W`D-H=8$`&]DFL`*X>2'#`
M2+AJH'?88\O4@<2;Z]PYYY]['CKHHXM>.NFGFYXZZJNKWCKKK[L>.^RS_LM>
M.^VWVY[[[!F#*&(``PP00`:*(M0H<A0`<,"Z#4C0O`2:`D"S!@(``%R,`BQ`
M`7T5P'E0!@`0\`&0@DI:9-\-)0D!!<)_X`'7S1=0`'$.&&!0`\IK#/X#$PQ0
MP`$4-(!=B0I`]B0PM`],J6(#H(_]ZE<0!4AJ>@B80,_&%0$!&,!$%A!`U1P0
M@+/U9@#C*<_#!G"`M7R,.P<85T%^]8'O%6`M"$F2=@((ERD1(`(3((##OB,!
M"B1`8-8)P`3;4Y*_(6``'/"``@PP@1TB0"$Y_``&P*=#G67-(`D0``(H4"1X
M><"'$T@8=PH@``A`@`,0&,`/)<>=!P1`:D%L_DL5<[A#AQ4KCWK<(Q_[:!!P
M!:``0%(`\<P%``,H``$D8DF,9,0O@@5)``(@$0LW4(`6"4`N$P``"XOS.[<!
M8(<V*=A$7#6`"+B%?0];R0?H9S_\'<0#&X(C?`:@0:P5A'_$(5E!2)*0*@ZL
M`P&H#@,*,![N`<<`O#K`K/RE+H1L8)@%(0!+'K!`]=2*F09QX?=`>)`)"(`^
M$GC.UW(II`XXKB`>^""3CL2!``C(`TVC5\8P<+2#\+*;J>R7%HW9OD2B#56>
MK(`\$Z!%23TL`AUX)W[":-`JTLQ4P_(C12MJT8O.!9#&Y)$$RF601K6(;=R)
M$00L4`&3<J<B*=O7_G;J4P$&#*`F&=CDH@JR`0"($$AR2AXI#Z*`!"0`E0F1
M)QX?X,""($!%KI09+.L3O8)$@`#CV9E!-G`!"2`@G/ZJWSMQ%4NJ\H\[+E0G
M.UW8`0P"M6$`8*!!%*"B*A('`9VD%RI7N$V"?.]\B9*D`B8PI`2J1Z`?Z``&
M``>`]H!S>W!*ZP"B6"1E>A4A4_S>V*K(SUZ.!9P><%5:MTB0GQFDHP6X$G<L
MZS<1FC:@$\4H:UOKVM=*1*,?0%Y,:UH0@8BG`UF+4;L,\BX/%.D`W.'`2=59
MD0A<``#/+,B4ZJ=3]^&T5@<AD4<1@@"$!J>I;@W.4>\W5`"D)ZH&H2H'_N05
M``-DE3@WG:E4%0(!8R*@*U0UR*@^H,R'"4`!#W#`?A_`5K>$LP$(U:9!IDA@
M^^)5N@FI'(\$`"_`HHU*]B$1`8*(6*W.5DG\W:]<(*=(.&5QFJC\'GQ2>Y"@
M:BV<#AA`?_<+KZ8E1P$D*@`'A.4>$29W2#F&+8][[./7RA:ZU6UE*!/"VX2\
M:[`\,E$5_1F<$GF`>F?K0(BBI-,(RQ0A.='K!ZY[VJR!-F*^;:HZP0O5\(F8
M2`1XC@<2BU0'(.!BT`Q`!5Z$U)IRP,PNI*=!.+#:]A$`G#3[:9_9:=?V@3:O
M"O$`<#R@@0,HS\8!W4`5)\`=65Z8/LG%7*9R_D6<#G2TMVDFL<FJ9^1FKDU\
M`LB:!LIX,3^WSU,14'1!Q+SC2?\XU[K>-;%DBV7;^JO("(D1E+H$KR1_@'O\
MDN<A'U"CMF@H10^XI!+%=]A_9GDB7CY1`$S49@%&X)$9X&)":!)>-'^`J@D0
M;JX,@&&K"7$A0ENN!.R\,:T>H"LP#:;0%A(X$19D?=7Q0`,0I0!_<B_!>NU9
MHP$*X0OPBWNM]H#QK(-A>N%RW//956D57&`3D9J*IAZV``:V`0(01`-QY`[W
MV@/C%B9@N`(03P$20!R-B_RO@N4USWON\\SX^@-O`G;%AXTL%2%[76^-:8LN
M!M*:$`!75QZ@QR&R_FVH!K(`<;1IO>`&T/R=^^/)#@`/.3CR*),9(<@3:OLJ
M`C<!I&<!`<`:!PP0`,D)0-0&05$S@7M(4=$,X@,867Q?6/7B:)UK`FB+I"&>
M*5%Q[3M1TJQ!-CCXNQ,'2`6PN\T2,MF1F[B?&,0\=,@N*!7)\V*>,B$&2PL\
MN]L\Y]C\\\]K;_O;@T0#&;BYP0A[60Y@8+6ZQP`&,D!\X%":@1PP?D$Z0`$=
M8NY$:[&`\C'`0..'^"&70H@&FA=]M7"*`]$WB/6+8S`-#"D#S0/5[M7)QH9X
MH/P'N8`.J]2!)U[:`G^C?:[L?!`,U-]!=-\$=`"FM`\&9)\Z54``#M;B_C2?
M`]X?<B4*<"P?0JA%!%A`UJ@?6R1@!O!'_(U'!SC@L*V,!!"4`*Z%5WG@090*
M!F:-\R%7"(Z@""8@[MG@#>(@0R"``6Q>PO3@YOT@#PKA$`:A#QJA$?8@$1XA
M$"[A$`IA$A8`EG3(?D3`-<W%0C$`N^%>`@!;#GKA%X+A66C`&`X/&8ZA[IUA
M&:+A&I:A&K9A&IHA&\;A&M+A&\9A^V7).[$37237`'!9SW%A&`KB(!)B(>;'
M!O`?6##:?]D>K!GB(T)B)$KB)%)B)5KB)7Z&!>A=1V3-PG2$!K24)G[$>%!`
M9&&$!5B:68!B]EV5J&&`!&PB1(R'*&)B+=KB_BWBQG:U!`3P2@9HX490P*H%
MAYQIA`*`T<ME1`<$3RS"A`0`'$*\B9.UD*QD!`/@1W/@8C9JXS:BA2Z"1+[E
MTC,"HS""Q+6E&S%.!`6,!':!A3-F7Q.ITEX50"=-Q"EQXSWB8SZZA%M1@`+`
M3,!A"0<H5$*L!Q>>C3J&AP8HP!DUV@1`4"HBT`58``2!$`<\0`)`S345E]ML
M``20!.9H0`,$E?HE!)`L0`8VC4,N0+M`#D768%+56;]D``7@C`)$P'A,@/JY
M%>7<Y(GT)`(Q`!>FAP&]HP(<P,5$P`(8``NY#3\*H$C^!G0(0)S,UL!%0$>2
M1+]8P`(8HP5(H3Z"_F58VJ+'H-P!V-G:C(<!)42=H42,R$4#_,Y*0EY;+*1P
M<%!!,(T#4,I@20R<`0]WR%7[*%<"_!MW3(\RP0VZ_9%R14D!#)X#F.61),``
MV&4#9-]-49\MG18!-$!%\(K.Y)O=`4>=58Q6U1N4A$AUN&-"0-#;C,?_V%48
M<28#"$!7J$2<'8``/(>,<>:DC`M-U-R*$0!Q(`]*``\]BF5R*F<D>LP'(H!!
M19.`'&5",$`G)55!@*-U`)RGE)B=T>:0&`#`5!L3"6,"C(LLL5`5M<4"L)O[
M#(!"F&/\<,=9H1)WEMKY/$![-4![61NN%-,TL=L[R05I!IQ6$>9X$011_K(F
MR`B1KG2``>A(,.H<<!S:I"#4^W79;W)2J;4%RG&'KG3A<HKHB'JA/[I'>8Z+
MRHU??6R`!2`2=G:%+K42BW&)!Z'2`D31`TF*-U;`-9FG8-),GL'%%)V90NPA
M:!4$C.UG?WD0?AS$QV@BD-!,%3X-FK&-0=ACG=''^C`0HU5`;ZXF-$I*!HG/
MF(Y+SG1)HU#`.RW`AB41=]BC;P[64ST,NZ"(P7@CB>KIGMZ>?FE-`!!G.$'`
M+^Z=(@4`7\%H.'('3'46509E6TD*`C03!@!<8,I2>KQ3==17P+UG0L3GQ;@0
M;3:J-R%0D)P*]1B4^/!GJGT`D7Y`E@I6,!('_@:8)4X)@(XHJ)A^P*"Z3WO8
ME<<T:@7<U`%T%BYA:&":6W&P2\@128CRZ;-":X^9*'0`'+U00`$X:7WXSP6`
M"E<FJG;.SW(-%EZFJM#M*';U*''\Z*5Z4G4@8W["Y]D@HPLUP%&-*S0V5;T-
M3%15:9H5!*P.26(I8P)<P!*!8YCZ5`3!DU8M)<'D:/L,%YW5QWC$J:3.J8!$
MIY"JTW5&:\=Z[&LUYV"%YROMW."PTEX-6(Q>4SFA#=P12;E"D,6QF<>HZWF:
MV2I51\\,3`800*<B!#NEWEV5:GI<0-X=!$,=K9*H:K^V*MO98W*U!<.$TTW1
MC$K@*G\F;)(:0*I"_NAL"5"RZ>8'0-JE`=6_"A6RWJS&(L`!Z%:=.>O'PFW<
M$LO!38QCRB0`X%)"9-4"+,#@X8_'1,F4+,!S,,#<+0`7+2K,2DH8Q8UY5*K-
M8JHTA9%R^8QB%I@!L,2\=H6,N54`Q%QOE"S!+!"_%@2KNJH]=D#/,@!Z`2K"
MQ(W'O"C"0NIMF6/#2BT$$5!I^<SJ2I/84I7%T@3&PE.B$(``].S$X"5RRNWR
M,B]N$(4%,,`##(LP%8VQ).4#C&%+;8!P_`C'M,]+,0!$XH1!C.]@20`#7&4H
M1JU?-5^E#)8'7,`$:(!1*00&8&,%&`S^JA,`A6^(74#U2I_X@5`&T`Q-_G;'
MV&S``X0O![24&BT`!#P*08&B0I2O6M"'!3R.%[%'UG0DE!B,?P3N^@[)_?$'
M!W1`!:QI=GIE\[)P"P_(CV`MAP0E?VC`:.'C/'F`IP"P"_-P#V\&I>ZAD_"L
M``0/`B0B)@8C$0>`9?IP$SMQ97A`!;0:L<`O_M8@+M:8L#[Q%G-Q%WOQ%X-Q
M&(OQ&)-Q&9OQ&:-Q&B_$PK!Q&[OQ&\-Q',OQ'--Q'=OQ'>-Q'NOQ'O-Q'_OQ
M'P-R(`OR(!-R(1OR(2-R(BOR(C-R(_MQEF#`5";`<P(5)4]R6EER)F/R)E<R
M)U]R)X/R)XNR)H<R*8^R)YMR*J/R*I<R*Y]R_BO#\BO+LBK',BW/LBO;<B[C
M\B[7,B_?<B\#\R\+LRX',S$/LR\;<S(C\S(7,S,?<S-#\S-+LS)',S5?,I)R
M"*VJ\39S<UA&@+?DQMYT\SB3<S9^LY-H,P4;CO=$)14?,6XL5/LXP(I*Q`3L
ML$-<%D;<BRG*Q!(QQ`4PHD',)`(.SO_RTPE;`.U)!_-4#',X-$1^[\$=)7W8
MQSU9@`,LS#R_D$,[-.]4@$1#`",:QQ7'TCYCQ`(>;3LKA)P4!TGWV7]8H%$5
MP$J.1S['TCN_!/`MFIT,2_`)X%O48`>8U+#4F/LBA$\O!"@2M,G0"7S`KU$W
MWU`GX`4X0,EHQCEW_H@X*T3JUM2#=AZQ),`]3>$!#%P#T'-$_-!$7("X8D12
MUAH_P\0&5!L%QR-"P*6H?"X'F%'PG$T&U`L1\S/:\6W.$`!_P-1@!]'G!D<`
M6./:$`!\K`_EO)\P58?@#C:4!-P24Y#_)`35!'1"2`!"Q1!&0"8+'EYWL(0&
M%#9$W-1E(8P!Z%#APLM:-T18HP65*6^N'&_Q-DE`'8G;_`X&,>(0UPO-;)`2
M9ZM*P+6__`X1C<<6I<P`#%QN!H]069(2[S`'",!T;@969W/:D:_$^LMP%@>H
M7,0BVM2P,)IY2P0'L'=]:``#82X+OK=-N715U?<:Y[=^^W/[2/>B=1J+_GYV
M9ZLW(AZ3SPY6?R\$IHR'`[#CX`0XBZHW^C%$`?:+RJW69E&/7J$(7.@*O-S/
M$N7G2&%-!^#H4`E`10H`*CUJY=5*G;5+!T":<=&8^R#4654VH"H$=_??<D-X
M`CIXDEI:A+>/@2M$:5>5@C'::HV;_1%YKKCW(_W?SC5`%%D-B[[W:.-W%KGW
M@'?`%!_M?\4?YSF$^W1%!UQ0DPA3>W"`J_Y1`O"'A+:J96KXIZ4Y7$<3O,AU
MAPV`J!D0J(`3?X2X?<3P"^U</)=WB!7@I3UY1WCW@&CU0I0$80TO!P01^*2'
M`:2'BR:$`T`F3FWEJ60,_]1$`0R,`O".;1\$_CI1F'2N$:@3R:$2Q`9\F.(H
M60#9%E;YC<T\&HG8NEZ/36@GRDP#@)P)AT%@(P9H'0`@@/4$R4T:`(SD9Y"<
MS5H'21:&6`.82`0P0(@P-G/%E.>*X"0I43]JW4?C!\\:9JT>0*E,DO(@`!@]
M`/6<T1O=S[YTA3KN2]X>1,_LBP$L44P-@"EB517I56L#VG9HN3`MCO\ER41%
MF3>!5HMSJ(4>M72E+@,$#GT(TPWIN-XN0-:8,/?)3^JF^9JIW:DHS\3PR`#T
MM=TQ>SXCN4W5B@0LP*6'O+_,A\`OSKSC%'YP0(C<*I4<M?\E^+B!#P>L-8G\
M=Y'L2JYXNP$,#,$=_DJV-A]<_GQ!5*<DJ3<U+4!N][N330`"&'SSV=L!\(XZ
MN6Q!.-AF#4F>#0P%'(!R*T0T3?UH1Q.F5,F!)GRKGLT[Q8Q?XQ0%]:WPL#KX
MG`U&\D@!T&J0W+-&/'I^I/-"9'QV-A$&;(`'`0<!G$V/AECADLH62:\#A%.>
M1<#RV=4.?6CH=GL&;,`%\4?*<&L"J`L&3$Q;)-6E-(`Q"5,"6`H+AFVZ;0=Z
MC:$"#"?#EZ[RH$B^\-,&R9P'JHSN[2`"[4I\][E]2?<&].W"J(Q5#4"A^ZE`
MG'Y'+<[.`!_G$T[;;Y($H!\""-7W+,P!(,`8'@`AK9N[MH<$I+A:I'BL_I,*
M0$`(L,'#``D<+A"P\($A0PP!*'#`0"#"AP@!#C9DZ($C@`P:-3X@H,"``@\=
M!EQH2(#"!@`<&'((\%&C!P$4-E8(4.$#@P(2@$(@8(#C@(HU;S:\$"``AH8=
M`JC4&0$H4)H7!!!8,&$#2(89!'"`>B"#!@,)0&Y(<&!A@90;%!#XX*&`@PT:
M%"#PZN"`1I<?(P"`L($"`)4-&'@0.('#!`(7.%`0H'*!@;()`'2MR0#`@0<7
M/'SHT&!`A0X$&FS8L*!O0@89/!Q@H&$#`Z(8!&#@$(%`!Y`/!EC8'?5#@@$8
M:&KTS8"!5[\"%F[LZ)2AA)$&$/BN24!"3(P@_B,4".W;`W'G0DDF\&TA@`$`
M`1)_*#"A(0(('7(W+*U\\08'`2QPB@$",-C@@0`T^,"`E#0HX":X#'!.P@D;
MBL`!"C',4,,-'=*+P@L`(.H#F51BB#L/".#I@PH&\(H!#R<8(#0-7O+`J0XP
M4$`!T5+Z``*TE!/`@0B(O`G%HU@,S0#Z7(*`2($P@"HZD!*X$+<.:-0,/^%F
M8@@"O3(`($&0"N)I`J)8U(Y&#0I:J""5#+CP`ZPZH),AQT+32($'/GB@@(T`
M5/``"=ADB`*Y/I!`1H;L^PH`#UP:4[4/'-A1/IP\:Z@!M%YD""H,4$1@`C;S
M;,C&$3$XX$(-`H#)_CD//'*N@P,.V+0`#?"C[@,"1FW5T_R0"D"`80&(CP$!
M#"A`6`=@LHF^F@QJ:(-AQQ0-N@\L"-&`;0W`*:8($A``OE*_"@LJ%2'H"Z1*
M&2J`3VP%J#,`(B-XX*5UU67H+XL(R',`G!#[`"S?$$B`7@,:L"DZ&EVMZ8(&
ME'WL@T._Z@#+!A"=[X,FGVSJH08JX(#<=H_Z0('F%%B`0N8H;,##FF(538$"
M&HA+UX8@$!*"!4O^8(+):FI*U@003J"`CRQ00#<+!H!@5V\_0."!3U>"^JL`
M?&M`79M45-#I.!ERV=!^.<30PK+13AO#5#.D2-_,&DJ`3Y882A(DEGW^_O,#
M&GV#8`"F!+`4,;JL'C&``@XP('&<Z%YQ`-\,Z`Z#$!-//,HNO;*@WX#9TX@E
M#@2@*=V]??7J`;0&351OA@``-;BY@#;@J(<:6SVAD??L$\@/!.`I@P,`"/$C
M%N]<O5&!'WU(NX8<4/E2NIZU*,(&G(=*I0N`[ZS:C4@#?-72O8*5I@7$C7?G
MC1@P"6B&2N/@7L,UN$A<IX2TH`(+-.L)2-R<-K'_IP"@(@\@``&TRI.4L(4U
M#'E`,MW1"%C$`JP(1&A=EM+8!ZY$@?8D3G'Y8PA?_"(FB^2+5Q\(6`842``"
M5,X`4Q.AM3SHE=7(B&(3(P!3!I`Q^H!(<=LZ_H!3>/.>^)CJ6A]$BP+D)"&\
M/41<1T%)X>;2NK%IYP$'&*"PY.(!"13,`I';R`/69RKS-$!880E/GC;E%;%Y
MD5$0L(FN]O-`!;)K1"_\P`(:H*"C4&]L(U,;0\[V1T'^$0,OFY#;#*>K`E2D
M<3%RD?,FH#>&Z80";'(`D,!R@<>!9$O2"DWC[.;%+&VD*S))SG8TIY(PN6I+
M5.M37UC5,(VP"C<P2=/;V/2Z-RG(@<JS@`#R="C<\>D!+^O=QCS`@0J<945D
MBV1]^@<B#[!*,QJP@`?H6`!,O8M2G*H>T`@2F0(T1R-"J0!!JD0Z6<*,)AFP
M@`5`P\?J1(B-IK1)_HF4MX%W6J`#-H&B_AI2F.C8AEP3*!UP.*`!`?2OD^Q9
MGK00I)$%D+,A$(0*3<*S%PL^ZTJ_U`ZDO,*;4BVE*Q$@(7U.J,!,Z8LC1=S`
M0$`B3X90DV*L@@"N'-,N^E"3E',A2`8NTC43.?".S4GGA/#6@7UJQJ/AB]GH
MZB8C#+Q3E:Z2R8V,MCU`4<>=[\2FI?(VL2FE$8D;29$'EA03.UX-)G0LSY0R
MQ49Y"G.0&@ED7?&J(;9A:)%Q.P";!)*@LW1@`PL:&=Z>N;>72$``!*F``':G
M.(KJR3(>F(`40;E)`_2O``G80`<.Q`%32N@!!B`;71(@E@;$RR8.L-$*_M7Y
MJL19"G0-Z``'C#:7$KY1CPYI%4H<@*4"D$U/Q-Q=[_#S@)/H:$7`5%U#%'``
MT6*&(P58P'01@$V]H)4^$9B,!W[9'7E:3R81.`D")FM"`XC%H'F,E(0Z$#.0
M2`8T#<JCGW`U((;D90.X3<#(_.D<!NRN.+W9FP`8H)U?RHD]T9&`T*R70/+,
M92.#G2EW0&)1"5(P).HJ(0;CA1(&B(4!F]3(0R@0&@_,#)`G-6%S4-B5G($&
M*Q6I3'\7\+Z&Z$2`?F.@C):B$@P,-S1]1:U80BL9IX!E2A\D$`-W8K(D"CB]
M(3&DJ:2(08A`"@%@;<@"4LL!GX1F+:XB5WEN_M:0!D/*`"J+P''F)`#Z_`Q4
M.6OKK3J@WPPKL&;0-0";+N(4N3J/KGF]:UX1+:%"MJUD&\A>4IH+``$`QT7D
M3"S#.%"`X&EE=9=-<TRR%X#^938TG-E1@X*7E(M*R"7<S``!-EVBBP!@`"",
MI80NVS6F!>]6#,%,PGK$1MK!ZST)0%1Q^V1,,PF`UPEBE9@2"^+WV"LTKV[V
MQ"1]J;EPYCT),^$W53+K$,4P`P/@M0+0@I(`RDJ^ZPH>`-0CFNSU:&^:!@`!
MM`J[?P[X.7F<$P$$<(`;QF<#M=93;]Z*K7>_VU>O#D#B`F"2#)L+<QF=K["@
MYY!X_3MX]'8WX@0`_N<1K@2ES>&`N:_)[0`L(#0<R!X#8.KN%0)\(<_6``)2
M3<;E`$!E&;!W4E;\[B$^10'!$W5HRHK4*D/7WV2*F0?$+5T9VKO7DUNX'<M3
M(M,%('C9F4N.WR.GH$OZ62[ON-8K.D>P<@#GDG;@H/N(Z$,GFNX-V2N%,K!.
M#8!*.5'JP"GU-28.T,1&*LX`;/X>S&,[9^_+R[NGJ..!LE24[W.IO`PC^D#8
M:$0BR4Q0X24$>E,=OB:ZD;QO'B\:4'6`,;HQZ<AHL[%J10GRFX\)J`9?>I'I
M2O*VW]M'4H^JAMUE([17?:'"AX$$Y5[U#SVQ\SE?()#L_<R']Z-#UAGX_NG;
MW@,5H$K^.M]WF-`>1Q@P__GSU'TB?=KREL\3\[<O,%;RWOH3RL`$($"!Y<'_
M\9-J_NUC2`/8Q/=F"?\BHB'"[_#ZB>\D3S-Z[Z$V0#<F)`*7)_8F,-\:P@*]
MPO@@#P,W@O0@[_S,[Z$XT"LD(H8B<)TH,,,(\"GXCOAFZ?)2#P;A#Z_FKN[H
M;M%P,*\TX%"(:@<II`,J(`$(#`@'2<2\KVF,<`F9L`F=\`FA,`JE<`JIL`JM
MT*ZF[`HSY.ZTT"LT:>BDL`,0)X:Z<`,18``*P(W*<`W9L`W=\`WA,`[E<`EO
M,`YU<`[Q,`_U<`_YL`_]\`\!40[K$`ZY,!`-_O$0$3$1%7$1&;$1@7`0W_`.
M'7$2*;$2+?$2,3$3G1`2W;`0.0E7U&::\+"_-+$4Z8X418L*-Z`L!'#X0''T
MU@E+!)`5/9`)[V(6!1!7:E%M.(`,RR85TP92H`^^-"#[!&F:KF\*:8,CBI$-
MD0^O((";\%`2)PX`I)%#<",9I=`#4L,K<N<2-2`+33%M1L,W$L!IFD="+(#`
M/&`!_@F,!B#DZ,,#1((`$LPKLL?H)`YX_L<B>`XD0.3J%B]#PC&O\G'A:JBN
M(D`EOF20^DQM&@=#-@#6E@YM,(!/W&<7C_$!-/++WF,B`<#+J+`@=\G0Q-$.
M\\4K(*``1"84AY$*_F4BW_H)$TUJ'`<)@D0C--+1*QZ+PSR`,Z)'(]#K?LZ)
M4@1``BB`@+PB3BR&`W[):1!@*#1"X)Q'*1#$8F[K)26D)O$**[5&+/I)*SFD
M37SDRM!&ILH&1?[)*V*$(/#J=.!G!U<M0\IC`H2PL<32"26`@F;2)/>0&I4"
M`=+08GYD`:+C`BS@`1:@*RI`1R2@Y<QK;S9%`BK`*2@`J!*@&S,'S"*S`\#%
M,!GB`KHF`KJ"4$XGN'P$`!Q``S+`^Q2@-:G#`C@S3V13;J"/`PJS1"[@`IJG
M8>PG)IX%ZB2`JU1D-T@S-*E#`Z*'`K3NG4;D=%YC;XSM,2U+1[PE`R@@_FFB
MTV<P8`%<JP-R<RXB@#HP@#0C<T3.4S0^LT0X`#IIHC(EP#:U4ZN@SE4P`">P
M\P)2!O"P)3H\LY\B0`,VQ8VX,0`>0)F<`BT9HL2B2U\(8#H;8C@9(HSF8@">
MQ94:0E7T!"T08+4DQ1ZK,C3!A_-.1P$>4SP38"NDDR(X8@*L\RM<$SLQ4S/W
M(E^4$X/NYV3N8@$40.LH0$>"\DX$8`$PX$N29@%\%,PFP(_:,P$DX"$O8,`8
MP"DP('INU%1XY9+.$S<3(#HS0`&:QI9F<T0H4P%X0D"K9)TR0#`/PC`VY3S1
MU"Z<PP(&+#()15\JXB(:`/"J4P&65#$`H`%<_E0`CE,C&E,!(I,#RE2H\C-E
M[B)]IN103U0TH-,IU()%(P`F)B`#?J0!K.J2(,`Y*803V]`3JP/@I$O@FB<`
MZ`.,4A0W!:`!'&``FB,;"TY5E(5/HA(!'(``5J<A#,H[!X#E#J#6%N`[X)(A
MH@)%1L(!AC1J0N0"?J96,.`<$P7!>G5''H(!1.+*.L"TF@<```:R1FS'G.E>
M,*#6@`1C0F.+Y(8A#@!(&"")H*I,.,!7BRDJ)B(`_FM`&F"UG$91",`!$""B
M%H0!$@9<<PPG_.:VC**3$L6*-N(,*Z4I[M5=,$,EXH)7!0`!6D@J@X0Z:C)&
M!A8!0@<D\$BM<.5P_A`V`%S+/?ZJ4792(_2/*_5)/J+'3S<&`.(32:VE1)P%
M)%9J+F3C`P[@1_HG`A`C1.=D1,VJA6"N.WK5`<AH.`&N7VL-8'TFX!J@D`B`
M5WU50D!H;/BE+@I@6PC65X#C7PU.(V!N/G+&70X`IOR&;9NNPDKV675B`?)5
M(DHG93TG<)RU.<30,Q2@*2K@AOY*(.85LJ;I<!Q@5""KB@A`EI@F<-S''F'.
M:31@`.3F#->I,+SS61N':8+.`(2J)V)UM1(,Y]I,6<BBG.##6='B(1#&:B@`
M#1T@68H&;KSK7^U1-+9%,?45X+(CV!YT5O7B--S%`%;.;$Z2$,VR(>#R_K&:
MY<WHD6QR948$8.^`B2_&8P!TU4-`Q/G2,#0P`&0:"Y!D)%D_8%F#-U'Z)29]
MIG3DABR3*3<D@"4A)75CQ%6$`IL&TEH^PFAP@FH'AB[P+6HFX$PV9KCZ:0"2
MXZ421'/`LP"T@P'ZHB85JBL\`"NT:'T'*(_:S%#"PDO(!@%X-+N^C6B)BJ08
MX@$J8"4SN"]((C3`:#T>)61;K'X]&+U0UM]B$BHB$X1PTEH#QCDF""0NR%!#
M4C'7C8"0C&>%UC,>H(J$QCXF0%T.($J9-B`7SFE60\7X2%76`S!@J;%"@TX,
M2CN4<DX`8!C'=F+^Q+NZ`D14(KYT(W2J;43)_M+.YF(G<F4N>$K-3GB`=H0"
MCB+K>(F`M\/?2$H"K$@GT6(OK>597LH":*1$O%/%CO8W=D0F'$AL6(8CWE4C
MSA>#$J9T@6DNI<4P1'1E/R*GE`,B9BHJPN33#"I!)L=->@?-N%<YB0*']<*2
M=ZDDZ@9K'(,\2GA4HS<24_(WT**8,O`EJ!EYKBY`@.EX[DA7WX5A.`]88OAE
M7,)`P`I^O25)W*<K:-ED'N"EKJXES(UFM.J2*BJ.[=DK^/8T)&!'"@!4"J`R
M.Q0"0,=BNE<"^`*>.&PNWM4[3:;I?FGD*N#JH.UE1D=V/@BLPL0WIF5]!29>
M%*IAN)+IU"P`'AJ0_B@H3,AED$=NBRLDF@$W(UUIB8\8'9GVI9DX2'VJ(32X
MWH)G`9J8(4PK`0AH3]L(=&BC7QC@BW<"`R[`J35C`R!`@Y_7H!XN`GRC)B?Z
MZI3SV*1FIG1,(^:88I88>;0C*L#XW6[FCTF(`JQNX9JL(;W$4BR@4C1-)229
M@<0#)!1B(R:#V]Y-+BP9G(4Z0&/.WMZ-:>$R([VD+]QCX;R,I:N&(4QWD"7@
M`1P``NRF0DVC2Q+249;G)U`H^VC9)5RE-,(DFQO@ZEK$F(-M=K`&;_KDIL'C
MF3MQ>F-XFE^&89(U3)[Z_'!DF[F);Z.F?PC;4X1F(^1:L9JT(0!$+:,J_IG@
M)MK.D54J\_Q@H@,H8`$`SH/HR*R_VU!1=S%S8Z^G^@$BH`(00`*<QTD3X`(@
MX%_[D8Y!YR,4H.D>2Z)S0P2UR*+U@HWR66!\1:$R3T'PC\#*FL+NVY"EK(<Q
M:(>?0H+ZPJ4=_,N$6$SF,J-JNH65.)J#6CHB%%$:4&&$]AK;J#BH(H^6&B"=
M]J-KI9^=)WX*=D>T>K_1+]J.9Y6<8ZSK.*45Z'UW4U^!&UH68KE9XB$"9,AQ
MQJ)5QEGW1(-4`JD-ADPDYF<'3`0_PI)'NR%DY];DPP%$,(86._,NNFO/;WLP
M])/26496[9)2=+,59M7:&;0;0K1;_-+>![4!_B#)1]!EL#Q1(N2889L#9$HQ
MH?<OHSDDT.*QQD0DZ!%(\,.!,B"U0+BT6DY\H^:;PQJME`M;6(+,>V-GT-<P
M4$1%<C>9(HJZE4L)-R8!>M"U$HEF/=H!Q".\364`%``GSN*;AP)7!@`!3#TJ
M;62X8@@EM"8T>,-5%D`O.#A0L,4D&,N#-92-)$,S:)TC9./8J\-CA6HIQ@2)
MDITA6*/!I<=15AKH2&)KI3T+^0W;9!FE!=P<;7HK4Q*M?C"&]WK%=H0!GD4R
MG$]#O:)1MA@!5&+%-6(ILF\E/069&4!%<JK9#Q/:C<>XPYIY\H5B+!EY\B0J
M9,);<D26V+IJH.)9_B9=EF`8D7=E=O9<W%>+#%&C;L)"40"83RP9)8X"A2[`
MRY==Q1B@<!;[A6I2@WG>:CA]C1\G#>=B5D]"G/4ERE9D(%;MLZU%TIL"A:"O
MM-_GEX]RICRK+;V$Y@,]V'JI51RC6:SKT/40,*D7+0:(5A/`EMWW(KK4<VT$
MF$[.``9DTHI#TT,WXL@G8<YPP%BU:='+04"#U*`B`:IT=:S5H.;>BI:B0Y/E
MS(KU1:+,UGD:IOZC6DPK-,[P@`*G0CU$`J('YIQHN#0X/]JK0!>`?)J#L<;)
MM&`"H^<B\-\>)T3"8@B`H4)NC>7$.%XD-S+-'@O6*9*.*R=G9,+E1;9E_FOM
MT;1BJ#!2U'EQ9<-V5@$T`(EI>^10.7H>8"$*#F&*-4&"]5COW6A-W&B=!G3(
MQN"5HE@0]E]M2R>ZU"WTXC\FRN!6GXQ:'S[""B`^?$``06`&`!P$*A3HX(!"
M"@4^1#!@,$`'@0$N?(`00,$"`0H6?O!0X$`%"`@4$J"PL>."`0D\B$P@@,$!
M`B$5#&"@,P#+#Q@`)!`YDD"!!`L"//C0P<#.!#X_2*`HU27(#QD"),0ZH$`#
M`P(TB(P@P`$'`&(E.M30]:N`#"(K!$C`H.:'!@$8)'#JP8,`!!H7.@BP(*D#
MI@'@3B!`-$+'NB$Q"-BZD`+C#QL0"AQ00>+<_KHQ.QQX&G5"@`8<!F@T$$$@
M!HM-"3``NX#HV,.V<^O>S;OW0@P.<Y\4Z$'"@@88!%)HK=!"@P429&I@T%>#
M`P85"&[L_('#@HLB,31@,$%F\>/)!5I@T&"#`[C(73>026'!A0NX)7*_\%P"
M>/$+0$"90AT8]YY`$TB0&P:X99#?!Q0H^$$%$@H$@04"18"A1!5FP`!E'$2P
MP`-I=7!=!QY4P``#%,@D00$7,/#`5@]LR)2!R7'`0'H8?"@0`@VH%^1(!L+%
ME(@.I"7!!.HMA=D",BW4`00+3(#!4A,4T.,#&]A&@8P;H-8!`UU^8,%2YV40
M06<1YG:F2`\$=A=W_AP\,&*9$[)W090+/?"32!!P!X&$"8JD06&(%G91!<=5
M(-Y($ZS8(E,/,("BBBS*A)]"@0KD'7@B45"0:X>]^624#!B):7E$7;``!<,Q
M%)AS58*JT'D24,@4E22N*5`'`_RY$')4<G<D>@)MFNR*K'ZJT`9V<DD4!R<N
ML)6I&U"9I&WBD6>><1%H,"2CQCZT(G=C=ODH4;1.NH&EK>+F[%WIT1K=K\8U
M$)@'E7+0@%@U"K3!=QYD6^6*O$7PH&\,-^PP!BDY++%$"%PDF8T39ZSQQAQW
MO'&6'H^DP5LA3PQRR2BGK/+*++>\<8H#V.KRS#37O'(%!22D`0$5YJ:P_LTA
M`T<S!P4$0```4`*M]-(K3Q4R`GDQK=#)4E=M]=58_TI``#UG[?77(8MF=``5
M)[PPV-Q&/','%U"0%MIP6[T!QAMG8`&?3,\=]]Y\]VV;!>GY+;C@'F!`0>"[
M_3RX:\$M[OCCD$<N^>245VZYS8HO#O'EG'?N^>>@AR[ZZ!-G/KC0I*>N^NJL
MM^[ZZQV;+OCFO640DVZ(PZ[[[KSW[OOO'LON-^J\72``WI5%!/SRS#?O_/.C
M"]\W[;EU8($&%P00Y=P7@/=B7R/=)S/TY)=O_OGHLRP]W\03)5D`(&GO`0/P
M!S"`!D$!H!4&6PLP0.[I"Z``!TA`]*UO;]03_@E)+,4!!!Q/,ACP``<.\(`I
M$2`#'B``!#Q@0>05\(,@#*$(27?`N+5O(9DITVMDP@$.9&`"!@@2R+*RHN<`
MP$@CS*$.=\A#OY40;@E<R$&B-#()0D4`!2"`#"-B`<(DZFT]C*(4ITA%]9UM
M>HT3"0<"4*_C0>"",DG`$C^@`;3\:D]53*,:U\A&W?P0;4&\E0(,<!\#:.\!
M!+A`!AX```9`Z"T>.,`!]*B3BVA@?&U,I"(72<`W@NV$"^'`$1TCP0/H3P$-
M<,@&!@"`#6P`*@`P0'H$T#5&FO*4J%R>([\61Y&@B(,$N@@L1P(>#MH*1:G,
MI2YWV;I5>@V2O`RF_C"'"3U?9JV5Q$RF,I?).F-B#9C,C*8TITDY9UX-F=3,
MIC:W"39K6@T#`W"`.,=)SG*:\YSH3*<ZU\G.=KKSG?",ISSG2<]ZVO.>^,RG
M/O?)SW[Z\Y\`#:A`!TI0>2+@BGP+4006RM"&.O2A$(VH1">Z4`?TD:(8S:A&
M-\K1CGKTHR`-J4A'2M*2FO2D*$VI2E?*TI:ZE*)">:E,(P!`$9:Q7-S,J4XI
M!X!1[31E%=C`33>`TY\:]:BLQ%!/.5!*I$Z,`@)H@%`$0#>G6O6J-MM`7@`P
M&B=A=6):!8!8+6*;FPQ`-AU83LI,M1`-5#54/M5-H6;V@`/4U$N(;))"_B0Y
MD+QJC*\.ZP`"/#!8A2P`BJ'B@&`]B+(("(MFRA*(`O!$E`7@*0,AJ<!9S]I4
MJU%@0+LAZ@<2`%J&+0EW`(S/;C00DID5YP,38,YN`CD^V4ZL`TRR30'$*E8Y
M?55B!N"MVD1R00YL0`%^0JC&*C"DA4C`MK:1@'(5(H&XKHPD?B6*`4JK$.;N
ME2+<Y1@'J.(P#F"70(P5R`%:6(#TANP!N;79+']$69$@X&T92$FD6K@!]TKM
M`/75304.$][>X#(W?JJL;VVC@2RR+(,2L:YM,B@S"&M,`\,=%F^/]]N,652L
M$A8(`<H4J0DL10((.`!+,)"``Y"V`PM`0`+@_H(2!)0+PPC`Y(000!"BY3$[
M!X`2OU*,@0G(V`#"ND"+25O=C1P``4RZ#I$G]&0%_*D^*<:0!7B\E`HD0,9S
MT1&/DX.`!2A@3"FF`%03,*4G8PC'.O8411"@(P:D6"S9T0Z!8GP`"TQP`0?P
M(XP1,)N%',`!94:)`@KW93HWD"1\4H`&[-3BP%$@S#L)-&84D.,!42#%K9F`
M`O92`5&IMP,0.Z@'!L6O)W>&/3SN4HW+=1P9;T`T"7@`Q`[0@`X\H#,-M(`#
M/!"!`RB@`+>V\XRE8NP"X%>_S5U(`L0BGN/:6C0RT1>![*QBT6!RT`G`DVAL
M`B4.<'K:%?@+>"8P_JH#="`"*9Y`;++C+VYC\`$R=O>O#N"BYY:G`2FNT,X*
MD($\%\0^'@`X`N`"I!QW8&<*H"!6>/R=#1C[T&3\\G<6`N\#*`@"$4\+1Q@`
M[Q9W)K]``A6%*2W*D5,,`2PILY5'C60S<?D#"A``=-7#VZ%T>&(6X"T.B?N`
M"$!@`!8P<7Y1A(!W`2Q7(<D`!2ZP:-%0)@$:<0!JMNL!^SS7`V?&^06\C!4&
MH-@#&B#O!ZSE`0<DZ$*A,8"X@E2?IBBVYLHQ0,%RQG4&6.#3?6GO`S:H@?8:
MX&X5:$W:/[!="T"I*1U00-:;.]X/Y$P!!9'N>,UKGX<P"6(<$$!_Y0Z!_H)0
M0.T%J(`'#,`D!/1(+!"(P'C/^Z.YIZ@V"EEOZ#40R$-UQO'/,@"*%("!",0D
M`^O5N^U6WU_XPK<^$LS9`@Y3`058H.K"5PAR8?NAR62P^1#`0$@HX(#U-%B"
M`\A603"<=@D2`+\.,8T`_,?Q@OC]51[8,J0_P``Y)9Z,>G<_=_%Y/L<4`X!!
MKF=E-C<0>%)YXG<!@R4:!7<8VS4B'C`!#7!]:`<`H-)Y`#8H%[!!'7`9`N$G
MXX4B]F$?$;`4%K=Z3`(!)#(`YL5WR1$![>%].>-Z'D!^"@$Q*'(`>S0?MQ(1
MQE<X*2%WQ"9;%'8=$[)HC,%B')1\=V-D:%<`_G8W/]>38002`&+563^W&QT@
M```P`.FE1`Z@:SOH`!)```F0``10`0Z"``4``8)5`$D"`4>!`'E$'.WU`?QQ
M`3"1`'/89/R!`$CW`!4R`8?1%$($<`4@`=4%7PQ!`0W`$K8C?I/X$$Z2`!,P
M`$?F)WX$:?<E$-N%;",1`9P6$=OE`$>1`/_3A_SQ78QG;AJQ'A80B`4@6U,2
M<>NE/,2G`'`A&@N1,P,A%@N``>(BB`*B=WU8>VZ'%07X`;K7A_9!`#(FA]W%
MAH+X7`51><3G)UK5A@;``(/2`-QA'\#(%`;P`*WX/PHQ;=U1B@43,5"X73.V
M'NPF$.&68E\F`"8F_EG/!EN]-E_QN'H99!Y\=Q%^=RNH*(<=T(<&P&,T02!6
MR'\60``(&4B4-6,.D'C,\7P4Z!T8XBJ2:'F@8GXIP6K&X4!]0@&W^&6YB(Y/
M1A.01T;W%1Q`2!7CM0%4L7">^&6-LU`6(@&(N!`09G3Q&(9M:&RW0@`FPB08
M1A(2H8T$8`&FJ(A,H24"T(9SB&&Z@0!BA5A?Z!M@V5JV,6(+86+D5QT;`"-3
M$@$;8%S%5EU]D0&UE'W,!84%LP'/U988M``G,2H1(%U9V9015'35A91KYQR6
M*&D1PR(/@1M]-EA[J2(CT5[$=YE-T24/8!9M.8NLY@%VN5T30GD48862_F<F
M.[)H>ZD0Y,@!#48TDM4C&#)!PY@0HV@?;FETLU>1M=<`3&([AL9>,F$?!M!?
M'8!#KE(=(=*-%#%@5CA[$C1I)B8A"8`!G6=Q1E>7H)*9%O>0T:<>M5%Z#K$>
MWL6`DM<7&+`>M:<0^260N9$`$!`DQ/B0X"EV"B%.QF6%?;APZDF1,N%WI#F"
MA$59Y-=>1"D0E3A@L[@`([D`0OD!,7,K!O",@Q(!'P(L+:F7GF0?V*&>JY<0
M5-=@ZE5X,I%?/%E[5LA!.(25=T$!1=F4$=8=[M9>T]F43VF3$&9BW'F<L+6(
M!!<3>^F5N0$!`("18RDQ1AI?1(&64S,CK'=Z_D2C9@3P`!EP>*@XI3`$*B*2
M'?-!$!4@=Q.P`!GPAA(0+&U9`7:"E8Q('"NQ&(,"`3P9(<)7B=`X$!'0B7^B
MIR#G`?)9`79EF9!F`7WF`+5!C)7B>!@)<X5'`3!$;`[*:[*X7:FY'H&T)G*G
M$`U0?GM!-#)!?,"A(JB'F\9X`06@9G;8FWQR7\\HG`H!99ZZ=L5G?>1(H;ER
MG"L8CT6!>PI0?H`!7X67>/P&:-<W`7/ZJ-J'`!:0`)_5A\@%J!HQ,@6Q'DT1
M6Z)'J&<"):Q'%O`'GUXB`,DA`0G@>$MQ`'E:E0J1J`O@E$CZ:<+67/?I=^)*
MK@/!*L2Q$]UQJE/1_@%>QI/>T1FNPI,#1E::.J$7ZJ!UP2?S.4&8>BCW81(@
MQWC6!Q@D*HWUMF44D*(,:"?75R'C-0$P5"<]0Q(6@)25QQ[+^B=+")6#!2-$
M,P&GMYD_JHZ$=2$&D`%^67#NTT=)*C$'$6#492L9H!%,)0$ZXUAN!12.=1$A
M8K0B4;+KR12Q)1;OE@$9$"A#BQF.)9H:<8%MA;06D`')P9?^829BP0&JEW21
M8B.4*`&3<H'A0D8;(B%7JWJP)4M36QY76S"#"1Y0:R->6QY!A1D8@EMQ2R"Q
MM0'REEL5D!!7:SAI>1$4L"BPB;2JQR3WHAP<H$?=(2QJP@&,*Z(7XDI]_HD5
M7<NX1K*#-`44<*$!>?JIHA(89&LKS!H!72LAJIL6%Z@SM9DKDXL56]L=;EL!
MM:2XA:-Z'(0W&NN'$!`8(3)U>`*WBHM;48(!@<(G%R@3%M`E(8A&&D"'E9$6
M(3(!"5$<168]73(W<V.[2/HLN84!&+0<&B!O>Q4NABL6VTM&K\MX%@`!P9A;
MDYLBJXM;RH$B_;M@17L1G+L0%R`!&)`<:342)Y$[T<&Y$=S`PNNT])NU7GN_
MR@&'5>47C]6SO$%8_L4Z#[DDI*D<TR5-G<<;F6DSDM2&--R&N(<5P,DY&(!D
M=E(S*^P\"E!@),PMRP.ZY-M6=T5-^<L;?@9'_B-,.1B0*R<<,K_[/$D\Q%B<
MQ5J\Q5S<Q5[\Q6`<QF(\QF1<QF9\QFB<QFJ\QFS<QF[\QG`<QW(\QW1<QW9\
MQWB<QWJ\QWS<QW[\QX`<R((\R(1<R(9\R(B<R(J\R(S<R([\R)`<R9(\R91<
MR99\R9B<R9J\R9S<R9[\R:`<RJ(\RJ1<RK^CN(ZJ9N"Q`:D\(&F5RG9+1JD,
MLU&2(C`[`;&<(JE<Q:\,L[FL9KY<RZ4&LY/"%,`,*P1RS+E<`;<<RQQPS'?S
M*\I<R\=<S+I,S%&25K<<S<8,R\+<S-D\RV]%%*Q\RPM6Q[U,63L(LU!4.+/\
M-L.<RE'2-K<\($EW_CBD;`$5L,_\W,_]+,2A8@`"[11^-"$";48%.]`"P!TP
MI-""*0`*S1P3`-$"'4X,,0`*_1,00-%@(2$2P-$","H-@-$"'0#<\0`D#1:Y
M1181+1`,D-(!L"$.D-("H-$@[=$@/2HO/=`Q78(@O=(@S1POP=/G3!0WP=-B
M.<<-9D=,.D%@85M;--`%H#QG40`##0#)448#;8T+$0`%`!.D+(:\-=9D#0!%
M[1LH890!`$6]FGM,:EA#X@!F.2(6HC8-,"3'\:H2\AS:-RH/4(`,@!MMK5ZY
MA3#ZR!QR;5A.HF>6QQUQ-A![?<.85X*`C1NYIA!XE]<_LM=SO=@^E7J]_K$2
M"I$8?'P`;WW8;<6!R3(`GM))OP*N?A@`#Z%VB?'785W6N&W6&I/6MT+:VI<?
MIFT;FIW8`D'7&V'7>-U<'J>@DNW7E:V/P%W8!8VG#-'9/^)5IUK<RAW9?4W9
MKFG9^9'9TXT`$D+<:^?9"I'=O"':&#%T>!S<1)$`ME5&X`&(K1VV8LM%L3W;
M7;U'T0C*8IW;8WW6N:$!5BL>P^470S?8TAA?HBFV$O<!YFW<O'T7R:W7S-W=
M'V#;+BW8T>W2TRW?U:W8^HC=CMU<Y)WADN7<WUWBF/T3A@W9"FK=`_'91=6D
M?^+;>LQZMB'B"D'?J_TK`S!_\X?5^XT@Y+5%_E^B;Z(<X`+>6PUS:?[C/R.[
MUK/$X/!M)E,.`#)-XQ#0.'>MW;G'W2ONW1T.W6X-XJ^*V#3.V.JMV3)^%\UM
MYOP'WB]>W.--YCB'W@*AWKO!WA^@XWD<W*`EXEL!Y'[(VL31`8R^1<F1/?S=
M'4/N/W,QRD[^Y`1.%`U0=00Y$FM-)9+UX;'4`0F`&Q/N)!4>YFN'XGH^V1O^
MW#@GZC'NXZ?^(S8N6=NMXCC'XF<^6EZ5V2C.YB1>X^E]X\25X^Y]QZQGJG@C
MW_PC':J=Z+;1`?H-Z7EG$!QX*20(X$\^X`W#U[GA`6M-W%A^VJL^XL6-ZL@M
MYNK5ZKQ>YVA.V&K^_B/"GN[7G=X_`><I+N<:SN'P/EKAG>\A7N_G;>OX'MK(
M7MJXW+Z';3S07M^*[DK5+MM(CNU1<I&6WNV\E>DB`>[3_A;D+NHBL0`%7>M.
MIJD7OMFZ[NK^'MBAGN;\-_#H7O"^7NRXCN'\7N:OWN(U3XHPGN<S/NQN;NP+
M`>B"CL>L5P$,/UJVRV&(;M]$0>V/3O$00A5#I![;_LF7+N`</RSV,P!@/R04
M`/9CV!$,\?4#T-,2`?9@'P`2C?9<HQQP[]=PSQV.P?8!`,!CV/:(#?<;PA%X
M_Q,2`/=[#?>!\0!UGR%PGUNF@?=]C_=_#_>"3_@N[3]MW_4T@?=`*\=L_I'V
M\X>D&T``:0\_'!9Z;`_1MA$!-T1&:+^5GF+Y0ZZ%G;SUN=WU/WX?%V`!%U`F
M;(/[NT\<ZWD?@;.Y]P$XMX(!N!]!/9C\M1S\%Q`XA</\RR_\M>S[T(_\NH\X
MSJ_\X8/[.%0XNO_\QY_[XC_]@%/]WG_\X:_]ZW\KOI_LT^[[23W''N#[UZ,0
MOK_`F.'[W,4!W`\0&BY<L'"APP>$&P8./(C0X4.($25.I%C1XD6,&35NY-C1
MXT>0(1T*`%#2Y,F3%T2N9-G2Y4N8,67.I%G3YDV<.77NY-G3)T^2*(665/G3
MZ%&D294N9=K4Z5.H4:6VS("AJE4,6+5F:#C5_NM7L&'%CB5;UNQ9M&G5KF7;
MUNU;N''ESJ5;U^Y=O'GU[N7;U^]?P($%#R9<V/!AQ(D5+V;<V/%CR)$E3Z9<
MV?)EN%4S:+;*>3/6SYH]CP9-6G1IU*=5=T[->G5HU[%ASS8MNS;MUKA?W^:=
MN_=NW\&!#[<MO#AQW<>5)V?^>[GSYL:C(X=>7;IUZM>U9^?^?+OW[M/!CQ=?
M'GOQ`P<,I%?/?GWZ]^_;PW=/W_[\^?+UU\>_W[[__NX#,#[^`C30P`'Y2_"_
M`OU;,+\&%8R000$EK)#"`PF\$,(--<RP0PL_%)%#$1_T<$$30<00Q0E)9%'%
M%$<\<<(8:VQQQ@MM_H3Q1A5=I)%'&7O$$<$;,3/R2"235'+)NQPP*0`(%'``
MH0$J<!*```+8`*$.!BA)``@^X""!``1@H"$(`&@`(09*"L"`#=($0(`%/'@H
M@@'>5.D`-Q]P*(&2!@AS`@(V<%.`"#Q`P,T!Q"134`Q..L"#!@0((`$-/E@T
M```0Z*`#,A%UJ`-.LYQR@4,_7:#,*3NH]-(M"P`@TT4M`-2"#]J<H`(W`:@`
M`@&V9*`!7K%,@(,/)+`4`60=H@``!>Q$"`$&[&S@@&3S-,"@H.:,H%=<$8(@
M@P@PF,!-`CRH@```"J#@@W.Q),""#0+`0$LV3YH`@3`_"."">#D-EU0W_AG0
M`(!F">9T@0\P,*#=@K`LZ8`%UK3@80(D^(`">S^`((&'@`W@``QR=5,!+KM%
MM``VSPPJ`(81B@#?83=FMX`*/`;`SW,9(-0#`ACF0,L')`Y`@S:Q#*`#D1/H
MBDFH"ZL8(2FIM!)EB#P0H&0*!-#4TPT,8.`##PI88``[&1B[@P(>^/B##0B(
MP*$*_O4@`@$X,$!CB!((\P)[":UW2V4[X/<A!*+%@(!,UT7H`<8[8*``1</D
M0(`)(BB@@PN"Y3*`##ZH>X.I'5K`4PT*P,"!0CM8P(`/"@!3ZP`L0$"`-0D(
M8-=&'4J3X04<<)P#!!8@U8(.#NB7[.(#:#99_@$\`%H""VJ_VW,.$(:7Y8@.
MT,#[";C_((/=10?`7)8].-V#8Q5X_@._$5(>H7_#CZ@#`$)'Z.`M/R"U9(1<
M3@)W0X"=*$``JC5@`XCR`.`LP"ML/0!D")G`UCSP@`%(;FP1R1ZR[)>K,W4,
M(M\"7@/N]:X)@`X"(_N``@+@LW3E"0/9BQ,"'J(VAPS-(`:86]1\.)C2*<``
M#G!``*Q$`"(N3VO!HU;VBC(!M&$@;__*%0(LT#4*O.T##;`A0A8P0:U1P``(
M(&)7XO<!`T!`<`"8@`460#D$'("(%-`A1-9EI[;M+W_%LT`*!P*`!$3@>:2*
M@`4:D,'7$7&``G@7_D*`UL-(;:``"4B`!0X@`%LEP``9*``!=A4`(CZ`:038
M6L4<EZQT&0")10G@T3R9P]H!C@,,Z*('!C`!N`%@2Q4,I;0^L``,,,!<`B"B
M!2!`.808X`%0?*#8.#"!#N`2<?V*(Q$!`#!B.N`!TL(?`XB8@8,E#&9$Q$`%
MH@>1`R:P@M)*``,H,(`!9'&"\(N9!P!@@<D1,5,.,=0NLVD`XXW3`0#\0`1(
M>8%A.0!V""D`!""@RK@E8`$_(T`!#C`XR"7QET-TP``K^@!6_E"D?@DB`B*`
M-RL5X*32)!ON(K```F3@?`CI6@<<H`##C8T!!'A8HK3H`&Q1K9X#D(`!_A1P
M4C/V2XYKO!V<-!7(0F9/?W1K%-#Z92@,(*``!0A`(R_0`-GICU2W8]PO#W#2
M"AS/(;;DV\%2A[<&8-!V&'0`6'>%J`A(@&D)>`#%A(=`>*&-`Q%`0`#\)#,#
M2*Z+"&DG`U"F`*Q]@*APPQ<43SI`B53PI!AX@/@0T(`*+JI.%#G<4T]:OP%<
MEIL`<,!)-<"_S[4V`AI8)SH!JX`&&%1:"EC`N@[H@'E^UI%=9<!9(]"_A%0V
MM1$X0`AE.U7"0H!B#;B60Y0)`00D0*%JH^@!9[:!SEXV5SR,P+LX@%THC52]
M?`GBE"1[M8AHK63XL\``#EM<6PI@``*(GMK8_D<Y+;;3=P0XR+T<UL.'Q,^6
M$Q"<EJKWKODY<K*2V](=6UA`>.6-7VRS800@(+V,?<XJ`9A;Z1CJ)P\P(`.)
MLU/A"C`!`]1N`+;Z6%=?7('>B<MILB,68(&J@6-Y3'P&T*^ED-NU*GF,`,@B
MGTIHN#V+?%!T^+H<@UGV``'L4R*EC7#]Q#>J_#DDG")V"/E"AX$&&/"V#0!<
MZ+H$`<?=;IY@M=,%9H5##NH2RB#\7T0(R[8!@#9OE/T5OU[8`!C:\H$DX8`$
M;[C!\3GM`WU=;Z7QTEZKL4YM!G.D`!1`RPQV30$)&`!!,N@_(^)P@6XC@&.S
MG$,#%(`!@?;`62.B_LGB&L`##=[2(8DGMF%YH&NOVYSH>J<!`E!,`!H[W+T^
M^<4!](]4H5NA!MZX:0YT3@$'*%0&!E`\S,6.`@U8VHS]]JVP?7+3Q@19]8CU
MP@5@T@,&$)N@]H>O1XZ*OW9*GJP'L$%#>=!,:@NI0Z3L`06TF@`%M-^\,;QE
M:O:K?@-G0%'P]VD&S!8`"U#;O3">J`8$+6@T77.*_VW1#CA.`Y?*80'$)@`_
MX1DB`=^SVDB%\>41]@-V3C,"%!ZMCT5JW(F>%_QTB<%-6UO6:DO=RQ%L::C'
MY0(`G#I--V`N!D^@6<)F,`7ZMP$*T'%\X1)=5HJ"`0IDH.OO(UL?`5@!_BT[
M!&"[.H@&T@I-_TU``WW,NITV0/>$5(";%=`[0BR@/PO@2@-A?]ZN#[+K#,R=
MP0?A``4JT"P.5(`"^ZS`!NPNN@U80`-@]X#H_YYU#60@7!7`P.DWSR7"$W3Q
M<@]IXM?J]K7BG;:HE\CGUVJN"]C)][1]VD,.;WC]:7WW#-[GKK..O*Q/X/0,
M#I>Y,"`ML".DZ@UKH]]S]H&"/*0#?=0?!@KNR`D(__OFA]?SR[SZDC5P`M<?
MGT'H&'F["QM9?_>`VK.>[>C[%,*;JJ@K0`,\0`1,0`5<0`9L0`=\0`B,0`F<
M0`JL0*CH'/X2@`[@``6`)P=HH`PD@._[@)7C_B\$V(#+V8!*,<&KR\#RH0#9
M28`-4`#^*I/#(RN-D2+^(H!&VACQX8`!R(`-N)T"$+T,%("V.4*DX2][<PA$
M@Z),>0!(LX`,9)8*XB_5$1TB,P!<J:`RJ1,/@`!2PA2;\;1FP;(P*9L1#)G(
M0@@I"BHZTY0)(!_^DD$Q@X`XZ0#=X2_!@QQ/VP"@*9,!F!(%@(`%6!Y@X:]J
M(3)%M!.#$H`$")T5M"\/V(`$$``"^+!)@Z<T8RQ,$I-7>X@Q$0!FL4!3/$6(
MZ)Q/D1X$8);4<0#`^12P*K-@X<`3O+,ZX8!,[!P.\(`.Z#\CZH!/DQX>\@`@
M;`#.8:1[X0";`BQX_G'&H<D`!G`:,90>*NQ%"?K%@ZB8!JH=AV"`B8(6#W"`
MF`$_#=R`U)(`R@$5!2`?:)(`T"DJ8*P`99FAR;D<.E(FLB&`!$@?'LR:HEDL
MA&@`,@F=-@F3`Y``*>*`,9DG")``I)*W@\"3&7J=#I`W7@$[.$/$28F4"RB`
M`;J7"^B:"^``!\@@<!2V63$;#L"`U#(S#1"`G%D@B<JEN$N6`]";Y4%%GJ1`
MP'&;R[LFA)"`>?F7"TB`Q<H`#00_+=&E:20(S(D4MX&`1@NJA]@;\`.`AE@`
M!;B7@A`B@X-&%0J`!J"`AKB`4X,<ARHQ]R*C;YRH_;(`<G0(*A23="2`_H$0
MF\YRB(8J*A(TH@-8$S&YIJV"`/I#RWJYOG]\B''D(L;$RP.(.=G1&X5<RKHQ
M.`>@``>X2`:`@$09(CV2H@BX@!7J``EX)N3"KO$A3%B$QPRH2?^Y)QSBE6?I
M'Z`:&I/2`$>TH@`PQEF)K[+AFYX<S@C\20C8O#`++`L`@`,(@%)$"/(IL%FY
MLP&0E0^[EP=PFUF:)^O2&(YQ0@2(E.:\J+"$I="9`!HL-K0\"+5\`+9D+$@#
M1QB+``-H@')<3F,Q30%XF#.I+OGI*#>I$WV,30NHRIT!H5K;IL6$"$>CRPPR
MJ%QI@$]+2"DZ"#OSI;4R$_?\@$P,H&O:3_TB_BB(D!,S*9L"B,L/"$R'(*XO
M@0`[:Y9C(D&PZBHTTBM&RIZ;)!NDQ%#B[-$%[!QN$I5<.0`@A4>"4LJ#D(!H
M<\IJ00!=NQ=?(LJ#H`!IPDJ9BK_ZO)=HHB(*$LL,>`#SFBD@G33N#!ZR4:FW
MA+%Y&X#[]!J'\,M*^;M!JS*_-)V@JIX+P*F"VAQ+R9(8ZL&0$<A5R9+\J1AT
M7+8*126)N$A6HB2:TA(!N("5V\E`?8@7NYPU:0!=:YC\D;EZR1E%40"$\J(%
M()\L"0`%,)2;9)_1\E%7_=%SHJ`7HL&!B!Y%V=3Q(<M#D@!5Q:%)C90&(**T
M6H]*Z1>LW"+<X;86_CR(?I26%"(B!ZB7+\4=K2JPI<PH?4JD!%BR-(6=2&G3
MA_!+ML$IGV.=`JK3_?FV2A$EESM)!Z!"O_N7`="N=WV(!U@L1DTF!ZB9;U%(
M70VW^XG4,E/7V1'8F<E1CUFLLL$ECKF`N`G,0`,A>\4=4GLM2*P4"KA7A*B;
M@_$F!]`?"0``>HN`"BC'5\T(7_P4E5W9XCM9Q=@`X=P?"=`ZN.&;#1"D`,JK
M<O$?O2((PY,^B(3(^*,`A726J<*`\K(3#L"LP>H?#;BLTSS-G9O9AN"_AKFL
MX[J`DQ([N1.]1J(`LH/9A\B`1LH`O2J]0K(3LH6(:"I:_Z&`T=RY<-DU_G/1
M61$MIQS"K)VC@($@&PG(@*7-*Q%E3*G-(;@-'0^0VL0=7#=<P\*#%USI`+BE
M.K*#3JI-B`GX6W4!H+MY6IW=)PNPV]ESV8Q8H2,\7:TD7=5=7=;U"@@X+(E8
MRM:=7=JMW9YX78J07=O=7=[M79;`7;A1VH;07<#PM@'@QT:#-`V`)P*8+$TA
M@/@3PX9J(.9-,C=$@'D=O4(I*`/(7DUAF+(AP(*"I[:1EI,TRQ-M7L8Y7GC:
M23%,0]#4Q<$BWVWZ1O8UGOIJWBKI7OV%,7&IDP-@WFUZ@$U5`.$\&P)X)>P]
MWDZ$L0%0@$R!J!8*0CQ)8&)AWW^3@`G*`+S<_KD"V*>7L@#H399RG#7VK8`$
MP"4]E$;V12:[9%_W+`!D:8`PT8`.)-)?4B+-"9HM6;%OHQ7V18#E/=Y4S:'J
M==$.1L^;HJEMP>`V^K*L&H`#P)5U.5[C(4KF%5]'2E\#F*&R(IONM>+'<5X?
M%F(]9%[W\IC)>J<I490!R!1`2^`PJ:OQ:2CH[.#%23WL/8"<N9C_7=[F=1>'
M`"XF[H`HGF)=9%[5P6#A9(`'4,<MT2:J:EXA+AM6XF.[U``EU=^I>DTI?A>7
M/%XN%#/F[>(N(<#E?3AU)`!D1+9>+*YFB9NP\9.X.2^&D:0TSI;#LD0I%M'P
M:35U":H'6!/2&8!B_L3D-]I`Z`TQ3I(6#CZ("0"9!5ZXLE'?#\->2A[1PUJ`
MTS2`?2+>O[@7SR.`88XL\M$`AA0^`9"CA@$=P"FGO$EGAPA,#I1!75)2A_TB
M-+HF^6+08Y$B%?XV&^*`@YFA[#'HIRD`K;*3/`%<HOEG@&VA!B!HS#$GANQ%
MBBY0'$,(!R@@3^*`Y=2`!@"`,#&I/W&`\UH:E<JV?S$G.IHU/>RJRSD?Z<JV
M:SHO`V!&^OQ&71O02;.B3B&@4=')7L3*:<.MB\ZA\V%(IE&37_I`5CXORM&N
M-XW4&=2U)CJ=V!$DAE3*T7/4Y$)H.YL4"9AB?&DG<4[GKN$GF'LF>\&Q_I;$
M'/J\:![MM,[;-JF2,#IBQGW4I&EA``XX'?PI2;Y^'.=L(;)L&&/VDXN\O-H$
MQ[BI%IZN-90>1+>^@(W^`.!:.<#%(&D!G"UIIU5SZQD"''0^9WFFFM8"`)T2
M3)MAR,_2&K+[1QR=Z]3NDHGFF(*H1098J(;)LNW,:X>X5]#9F%+3@+V1*0XX
M)"U;N>4]FGHQ268I@&AYB`,@M;0Y%@?X02-"-@E(IUP1T%3M'`D(GBZ)U/JJ
M%PV$4C=<2N8J&Z[^E'BJ/%U::8;4Y@":).$$9[_04K:I*W,FZ9-"E@=0@)]9
M.0/7S>JYK*Y(.)#J@)6;94>R$U72-1'RG0ER_BS141TJ.YK!=,_C<@@I,I0,
M`!I^Q"BLT7"A4CTCJAL&]Y^M,3:.3H!'P@!X5$%2&D($0P">T<JV(5M[@:S/
M61<^:DX,4,V#40GF$A??OLAM[8I[I4*95$WK[B&C.JG\40"3(EFE!O$XV2\;
MAL6E(1L[H6KY$4P2AZD'CYVC&DVE1);JP;Z=.2F%"(!X>F^BTJ%[\4Q!>J<W
M19O_]',@A,CEBEGQB]04R\GDM*6,VUFTY.Q?(N>2)!79TK*^RJ!O&YM]U1P8
MG\/2I"6+PM`N\;EHDEUJR>S-OB9I=&&VTB$EE19VCLYVYO/GP2T\$0!IA+1W
M.JEYD6V'H.U9$4/Q_J(IV6VGZJF*;2LS**%/O4K.,ZT`MTP`P92>@QEI$75N
M(L8H]7#A_<DR*L*R=QTD*?Y;R<4KBHDDCD[(+FZU['2?`&!E*9*6/8^`;2N;
M!3BIX%LV<G$>L\%W_!870$<(_NZ+2+&4BY+0,E,3(MH2'JRC"X"I?ZD>:.T*
MIFG.5-4EN8$?.^^`O0%)@;77">IHA%-0C1F:3,D>C]4R^TS1#XRG6R(:K'%,
MJH$G$E,74"HC&"\95*?Q!-:OG$&T!3@=!".3,@F33N*O=Z&6%=UU=M^:-+&4
MT:K3G7:6>[)7*_*D3!3(%+5R,AKI#!`B15+JE/\8@@R>NL%0,X^=?G&B_HI'
MU=BAUPI`TIU+W5Q*>;0D%.G:(@3XF7L)5I1>:W%QQG9ZEF7I`#SI)8F@G7<O
MT$5_8")2"1Q*(_^1+E1%^6\:[@10'H!*,Q&4UHODJ@YNDQB[R6?!%3PQ'078
M^8-Y&&]^B&OYF1C]Z[]D,H6/5H>P=3*B%M?N&B+*Q(N<[3!]VD&4Y*%TTUQ)
M`#M[F!-4]F`%*/PY6@TD2LH>VSD91%_"]G<Z%Y,4V9G"?/@9F\0MK$D1,[!B
M(]Y7J`6P,S0I`*5$-`JX;D&Z)\SI33<DRX[&%H465JV1G1F+'3(""`<5/A`D
M".$!00X%%D`H**!#P8@2)U*L:/$BQHP:*V((_L#!`T$&"@IF"`"1(`8``0(`
M:&`!H8<$#2H(F.BA088/%@!D`+!!P4@/%DP:F&!!0``,$B$D(*B``0<!*@$<
M^,#!IU4`&B1Z(#"5@(<!%B8,\/D@Z-.""AQT*-"TP@")'00HO2``9(,%82MH
M$("P`8,-`P8T))C`@0>0'PI,$-S@0P,#('MB($"!0`"[&"`<2%Q0@@&"$4*3
M]!CQ`0(+`SP@&(!`XH$(!`U(^-`A0(:U$Z]N-9B``X$!#GINW?`@IH.""9KJ
M#*`!YX<+`-K6)IA!`(</9!5O"+"AX(75K:MV+("PH^(/%.(2K.#]0U<(<!.#
MC%#UH@<!%CQ?S0E?_FQ!^:T$0`$>.*!42AK@-M$#"3P@``,12C<@8DFE5!L#
M!W2`0&<1:0!`=D-MY8%Y1^&U@((<3)!91.4A1,%[8<E6$D0=G121`@U$@$`'
MP3U&$`4%B$;`7!841-L'&_ADWT07+$BB`W9Y`,&"UCVD$X@\%=2`2BQAL`!S
M$ESPX07N*460@AH,<($$97'P`)$+%$@0B5/=]8"1"OJ700.).7#`903EI:21
M'R2@0%@"4+`!4AAPX)T#`]R%DDD?V$?B!`$*<$%'LC%6T4%.3="!`?Y=N1&J
MJ:JZ*JKH;6D>!!'T],`#\C6`J`=M.LF``P%4,-1!$%Q0$`+F'7"`DAOT_K46
M`6`5]<$"`&#P0*8$/6`>`P)D,`%8'Z2TP:-;7=7`0100Y"1$2H9GY`%F%0!!
MMOY]H%M*$[@7[+!S*=7!`(<),$%7`T6`FP,+?"`!`(49BE!!GU(`P`6"(?#`
M``:+M0!V=$'P6D2@B39`K1!X\&%V!:%F`5@?<EQ0;+/5=AL&"AP0[$GCELN4
M>@`DQP`!UR(0T\P/4'#=6@(DET#/QRZ6P$$1=/1`I+(1I"2Y0H<W<@!5=;5@
M1PX<9`&,P7*`0-(%<`!71!$05FL&#!2JZ;`)M50K!A4?)`%<$)44<\\(&-#!
MW!!4^\%9.U'``&!Z>1`!D9L2[AT#!I<D-9H@_L*']`,'$,`!OT4/;5H"!=Q8
MYXAD/V"`Z!^D^,&LM0[DE(ZO5=!2010(<-!"^3'TP+0@^[WXVA#XYX$"?6]N
MX@?'*E:2UP?\#0`#!]5=06('--#7`@WX6M)WH9^4YIH>M,N!`TUUQS`&`GSW
MJ`4-@(QTS?U2+#@!@AKL@-$*:#NO=R3>==4&>C0I;U6*26YI&K^,1*4-'/`!
M$4C/!T+E@;@IBR"G8A4&,ZC!C'!`9`6Q``1"*($.AA`"8SE3!R#``0U$``)*
MT4`)A14@"@C.`RF$B(KD`Y()Y&0#$-B`!!1V@1!&8"N_HI.L;FB;&)HK.DT\
M&)N^`\,.##%6O6E/_J$H,`$8EE`I4RH9!X(8MR+")P(6.&,9SZ2>N!%$`O[!
MFVTF8,(V:@`#`(L`!R[P1)14:S,EM`H$;N1$#4@`)!38HW;.-`$OJK`",3Q)
M"DM(`0PT,0)Q`R$%($+#$)HKC"ZD$PU'I9T21L"'(63C$DM8@0U(K0+5LD!U
M3!E""W`QA!WP@",!ICK*>2N&A+PB$K]#IQAFH(4BM,#K+(4!#X3REDP$3P52
MF$=8^J>#UH2/L)`)I$(6I(,G$4H-$]+"87D3D,"$98`<20'%=!`D))QE07Y%
MR3:^K9:%7%P7P2F!&ODR(KE,UP-5]\.$D/(C,03A22Z0*4_FI)P^],\-_DLI
M4"HVL0(!M6-!)G`!7$)@A!'QI)$R4!UM1J>C)<-`*S,U)7YVTX,8#2(1%_>=
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MHG5``9A+W>EJM[O1W2YXO6M=\5:WO-S]+GG/.U[TLG>][C5O>-L+W_3&][WG
M/2M^\ZO?_6;U`BOC+X`#+.`!$[C`!CXP@O%[`>8DN,$.?C"$(RSA"5-XJOZM
M,(8SK.$-<[C#'B;K@C\LXA&3N,0F/K&'+XSB%;,X(W7,@`U'E($,E(PK8!3F
M1SS`@1QWH`,:&%D&?LR5]<T831_)``8RT(&9[CA=+7XRE/<;XBA3F<4(B$`1
M&0*5!$A@`<+TT,\TP`"A>6`!%^A`!-R6@<.)D,L0U$E30N@`TSZ``1B0P`%&
M6"H/,.!P'V!`E0,M_FBNJGC0ANXPH`F7':,DAP*H),@$&G#-C=8*S5`KILB4
MPC")/*`!*=R`#QV@`0Y\!]`:J-5-)N#E1!^ZU:XVZI1?+>L('T`!$/@1FPZP
M@+]-Q`$3H,!QO(92!J`9`A3`&P444)M-!V@!$7!DY$98OJT`^MDCZ?-+6#WK
M;7,;587N-K@'G&BG1?`"R>$A5YSMM8]X+0(*8&$@%6!&PM%;(AB('KDVP&?9
M$/+/?V8*!QC`PQV%N^`&!P^##ZYPL_ZH`Y$+9$,J\.@,#.0!&TC`[J)3`0G(
MQHR`,9?""H)'R$!@`0M`Y@("`YD.G(<"#J#`J/^[\)FW^MLTO[F!/8/S_IWS
M'(.Q[CG0@[X1#ZCQHX<\)/7V@Y%T$555:U8,)0_9FPT4?>E"'[3-KZYUK?/9
M8$TB0.1X12)!4B0T\V15CT0)F0.(A``S&AQ&VK;U*O]\[G;OZ03RKO>]\[W&
M$E$1WP.?=T1^5/"")SQ368-QBEQ`VXO1VR+IE%8.I`_F#55KC32@5@CBD@+9
MD0`!DMF`:@F&U!CH`#*7.18P&F5*!D"0!+:"^@HXREZ3J?K=)YSUW/,^50&(
M$/"#'_P!X!XE`Q`^\B-4/XX8(/G(!X!4/;`!"WA=(A?(\V>')3H*("#9YG+0
M:-('-@=PP``MY!%V)V#K`#D(-!N80`'8.'JU_E2@`M<3@"47X.L#D)HQ^K=/
M!D"``E#``51`5)@08YR%3KQ-[TE8W7F+!#`@>*36FV7$+7&`D801,/U==&Q@
M46W`H\$'V:6*WU$$(7T9DA%$!^Q3!JV33XW%"!:95:C=JG1`,OG4!(E)!4:$
M#7U`-'6>"U8$XGT`]&4$`A2?M]P'1LA<BS";112A5%$?XQ5``U2AN9C-`5A`
M!EC``6C`?9Q9_4R`KS',R<V9MS!8!G",!%B<$D+&X`B<_6F`D&Q`J61`K;00
M?'`*HJ1.&@*';1!`8]Q2`V*8S05)9#BA>MP*`53A"&+$N[W?!US9E_W=:S3`
M$`*5YDV$L6%0!E0?_D5@2HWAX8;PTJJDS@:E6<EI8D-T0)YET`:TX09MB/7H
MV@Y:B\#8(`(,42UV144$0"U&Q`$@(0;`8D4P84%,BT9`851)89,XGMDLH@,(
M6\*%8:U4Q\O-7P8PV`5XG?V]8D3,'T$$8QR2!P%$HP.TS^!\2?FYDP$H!'QD
M@`,8`*(,8H75'<PEB9!0A`6,1))$0!#6#IM,D#]Z0`;TS`9('&%,0'9X`-R!
MGOU]E@LRDP1,HG5$P*@P$TIMA0;HD2@QY$0FB078H`44T=AX&<PY#0=8$IH\
MFVTX6A%YP.F@$B[)B@\.`#>)QG$P#2A]Y`3)D`^2FU68%DB(3@6(5$C"_I'J
M?%9V%"7>O)G`I:$JLH;42.1,A=:(6-29%).1O")&R@H+^<<%#&17(B&\@`3Q
MY`1*#0LS;1S;<<"B*,`1ZM)(G@D+548O:D0P<@0Q4H0QH@0B4H0R0A4S6I\G
M/IX"Y,D#*`1$($`&Q,4$/$`%X,H!P&.F9&-!T"%$")PW;HE*P1\N74]5*.;!
M@(W!T.$VBD].4,`"N",'/`:)E"`]/MCN10<_-DE39(`!T)#,L=W&G=P"6%QN
M7L"[A5X(Z82V64`!\$D!5,!OS@MD(DM$^)<C)0"_6&(!;,!Z!%$"Q(2QE8H%
M!$8`T,\&Z!\K*D`%$,`"5$!R#F,%1&-4",WF_D@``@`3XE1`%E8&`T9`@_P(
MM`C-?":;!20`!:09%UY`^0WH=HK.`B!`!1A``MBG%AJ`154%7%8`ETE$7S"F
M*B)`<L"'K1'@!D2/>G:0VP2C!3!HOG7&(EX&`YQG&/FFR`S`3!"`!R9/U5'`
M@S+``Q%&9#X`J6Q`P6A`.T9`>IHG;E8``[#'1/BB$0KC7DY$7WK+7TY$8#X5
M,Y8*>`#`5$R'Z&P`AVCH!!C``2"$`B3`8QK(L<B&);).PH6I]4A?&W+)2G2A
M#X(FD!@``BS`+67(`1CHNV3`L?R&.\+DL8A,<<8FA.V>D%+D!XW$RQ&$AK),
M3F0`U3V`P<QGS'Q`_CN6WY^ADC?.7\PPT`686\@IBTB)SIRT$`7\2`%RC!A^
M)P-!ZJF9"Y8JP+"XA+.-ZG5V2P(@66W:QIQ@0()"T,#P3':(Z@70R@0`"D0P
M130=#`.,*F,JZ$#XFJ7@D0:L65P<9IU^%`(P0#LJ74%0"<]`A)".JM>DW)E%
M4`*$I*&(R040`%=NCJ9^QWQ2*@843%=DY@TVS`8"R@58P-\0"60,1#L&D0>T
M8P%8@$(YB$HMWY+BI9-J1)0B8T94*:)FK(#5G5`80(V>2U.XC5,4'9W:AP-8
M:B12W4BTHZ%@@&1\5&BL:39FP+O`TP<90`-(@.C<A\O1$*1V67NX36"0_L9\
M"DWR;(4"*,5,R$3(Q.J\8,"71,1F:@"/O*S(`1K.%&0)&<EW$D`A,6?H-4@(
M69R"&LFC1H`$8``5@MZ\#,MW1D2L$(Z#+L5C**#:XDL'J!\!P)AJAMX!>$VM
M<&7JL.Q\FJRECEW!4L0"#(ZCP8H#(>Y,:*J*'(<!;$#/A%"D&4G"]N(O$LO$
M&J%%6"Q&8*S&EJY^V1P7ZAM$Z!QXC(0$`)I"^!V=5B[AC`2FKFQV$&"'=E/,
MFDMNM,5'L&1!M*@/$LD`_-C)<9^.5:[9_)E1#*VL4LO1/BUD@!!"<,!JSDG2
M9FJ`%,!61$"?S(G(P<25M<5W/-NOZ01##,NK_N)*]G;`R7W`V4:`&79$V^H$
M?Q[,8S"*XQ6G^.Q3\YJ0ROF:#*VA`\A&B`HN1!#NHM8NY%+/F\7KF:&,F%5F
M^$)$Y+:C'"7LAKBML0%:8]YE1N0E10PCQ8;NE$H$Z9HN"Y=5W26``,1P39AA
M=!K,37!(OR;`5H2I@[P&9TBAAMC&_O`@`C2`0+".P7#AMT*0R\H$_Q&`S+P(
MGJ:&#QX`APJ%I-U'`DR?`?C7=RQ`3IRCPUFQ!7#`?8!Q^?$2!G`(L8D/!`71
MU.SM]7UK!W!``B!`KU(M'NL;9[2BAH@L9!Y,[%EQ`_"?F>G$[L('`W"(:A(5
MEJ$)C2HQ`TR0%>NI_AXK0``M@!5C@)=R<"1FQ[M1@(.BAB>?8V1.A"@+0!9:
M!5PRIB<WZ!KGD/CXV!UO\0UK,N<VJ5Z>,$>D<$2L<`L',UC-YE-YJ5"U17JX
MG#!K!$QV%9-B!`E/A`F#;B\GXS)?\U@]H&!&\T]M2'HX$C9?Q(XYL\3N,C67
ML"\7!#"',SL[%3&WL]`]\T4<H3DO(0I;,SSG<U1ILT5(GP:`VB?Z'>?T&$:,
M<_39Q`5B1`\Z51W'HKX%B+*`&@01]`9U;D,#%4`[E3Q;!#>WR)-*1,6F,T&L
MLSZ7=%"]\T1T1P$4``'PB+W]ZDR`T!)^-">&7$5H%%<XP`8`ZM)-LE/9_I\&
M)2Q4=%,`K'1+WXA%]10$?*QV)+(&>6&S(`"C'I5S:(!57S566_7K,5]6=[55
M?_2]>757D[1)E_4&\7-%,)!9=A_GV(;*KI"@1--"9K34UAH;K1!W/+3JX-A<
MJPY!0D2790<'*)EMD-IWP"\+'F-R""F:/#2X?)D$7**RD%T=`S1<3\W4^5AV
MC%J=TG4'P%AA:P!E@_8%>.]'=0MK>-X*&?0_TTEK-[3TH8EMT)A5%"!(M+95
MK)`$Z+1>?S9(P/;471%>PT=1)$8J)LD5$>1<^YABC,Q<@XN."5G9%0#J4/=*
M5S?JH$[3D01V7[=W6S=I4`1N?G=W@[=9GS>L_D4I15@NG0BHR#9>W0`%H,V$
MRY49F#AUK/@9X6`<HC3`H4RR`BQ`@,-D938%%#>`]RI`%T>`3'BOSB[R`PCI
M;T2$G:E.9Z2<R2V&`AQ'0O1E7H"KWX4IN*9<*Y:/2!!/@R-.<IXGF"#$]34`
M8YZGR,;3+&[&`/`2<"B&`D0:V]$O\;1X3#``TQ@SS29)`@QC/"X2V'5`@.M&
M(4?/0DR,>EB/QXHAL$+&4R`*`<(XY86WCO%9DR_9+"HD`23`(M?QMYIIC\@;
M@Q=R(Z(WG(L86J^W`"R'`?S->R_`,(($8])WE#3%E$"0V?1(':?J]971!/BT
MK3YJ-G;%5EAB^UB*_I]\UB2[8^1&!*\!:E<LTT;1J$3P&E<\$/$PH*KY8%/$
M#%3*;V2:BXY&$-X`>CO2Z9=8*%?0;BR'=T($@)WC>6T\YCYBTQJ&X]AT4.&J
ME1&-A`XCJ6$\AVR4^CHV[SXJ<ULLQGYL5.JTYRFWR';^V>&8B_D.``8#FTI5
M[FI$(L"<7IRG>XFAM$0(QADMTY\9"7PGFDOX^6Z7<)<`0-JN#'.*G-10"Z,W
M1?-2"U!/`(=@W_7&[`V2R&V'QHDNXF*4(,MJX@&$#JDGQ]OFQGDB`,<GVZT.
M1$=5`,,DK6MP?(LZWK1;1>7"(@>(A07`^YH^IGX6!'9Q_'Q&]@!*@`)0_AZ'
M'$HDPE`!V#P&Q'QR`"]I'&C1"\F"@1VCV#SO*"$N/68;;4QO!.//'(P`3K%4
MSTEN0/&;JSO8UV/"981:4_A`)+H)LP:?I-4Y!H6>#J]*N:Q"@`2UW`>Y)-IA
M/D!M!.AK$HY:>5JWZ$BP<^JE'XG>=,;+!&/S8OH(>B%(/&A$6'G&]RK'T)*M
M)F[(*TZLBXM:%6;"?D<L=T@W=<N6F,MC]GN9A<K!U+&9CPV@3::I&XKF_8A"
M$KUM2$;S+MBJ)@E8W%,N$JP&[,=R&E(N,L?H]1FP6BY>N)Q*C="<W)/`A;WT
M;QB[2ZWXMH<!.,"W5H;)S3?;!WF.%`2_?%,!_N2KF6^G2)RXF0OX!!6``Y0I
MXE*+RW)AA(SIX(<&4TQBA?.TR?U)WP/$@PL?-B#XL$##!X4?.A1HL,#`A(4?
M)CCX8('!APP*/C!0T.!`!P4#&U3X`$%"!0(-$D#X4,&`@P,6+"R8J!"F`P,8
M.!BXR8&`AXD-*%!\X"'!`@4..B!@L("!4`1%$5CXX"`!U@,=%VQ(ZM$#48H6
M&U(\H#/#!@(.%/ALL#2DA+,&,GS`0,!`@0()%4!%X$%#3`01.`Q(T.!OS[</
M.!00&@&!S`TW*5>V?!ES9LV;.7?V_!ET:-&A(R00*E8#`P,*,)P\8)*"`0D9
M$'1@8/$#`@P0#A@X_A`2I&^#&!0<:-!A='+ERYDW=[[Y0@+/'NK>W)`!<(<-
M&Q(2[,!ALL;P"CM45[B!`T'S&LQGZ/Z!`_:$V.&GU["!^H8.&L!_`.P_`^06
MPJ`!`!5B3RCZ-$!.@J(@>(\\GK2;J+\)__L`00R1TZ\^[>Y;J`,,D)N0LOB0
MNW`AZJQ#KC^-NJ/N/?P($@K#NNKR`(,$NT,/OLDNY"#'"%6LD48@:020O@,U
MH!'']'J*+\6T##POR.>LO!++++7<4J$&`)`@-P@Z(&"!#"`((`,&`K`I`0`$
M$J"#`P!H38`+&$@@@SP]<"K/N@AX`(,"++I@/"X-/111*RV0+M%&DV,@_CW-
M/%A`J`J.=!333*_LZ5)-/?T4U%"['`#.P2:`4R'C0"*@@P$,`#2`.`<XP(,Z
M&9BJ@H$06("""G(L8"H,)DM`(E&-/=:Y"PQ"5M0.!,S,@TB9G79:#PJE%MML
MM:VL@3L1BR""H!1:`*H%"I`K@3?CA(``"FPE<X$'<BN`W`@P7&"``.S=EM]^
MHYM.VILZ#8V#@3,+>")G*;PL6DD1]O1A"@T.K8.))[*8LXHIPYCA9ST+6.&(
M^T5V`@:>,AFJDU5.F>.1-^M6`P$(@*""`'P4M%M\L8(USI3RM3.CA1!P22$.
M'J@X@@%:=IEI1Y6=CE7*'AP-@PF0\G@S`R*>_J#`A1(0&0.+)&C-,@T8#?7K
MRUAK#B7-IA[-@8$2QNVS"KK^K(!G46JJ:6H9B("""2@(?'#!"2<\@*7[YC8C
M"`"`P(/>)%!@@`VZG0``"Q10]P`P%0#`S@,F&)T#!(@=?<P$)##])*L6?QW3
M?SOS@%4.M$NO*0N$`D\H9_7#C\/S?(2`J?"R\\_V)16RMN`/M*Z,ZXDFLYU#
M'K_K(`$*A$*/1NTR./NR[;I7WC+FS^N]8O"P/K]@'L_C8('6S(=/NV>W(^_V
MA<"#0"+F=S<_3A<8F.]8)"/__`X^O5N079XW/^IM3UK:L5MEHM4BVR'/`P7@
MW0<>`*;P[$=QL,L2_@.NA9G$B=`S@V.(`ZS2`0DT``+I&9SE.C"!"EC.`Q$8
MR`88H`$*,*!;#>!`!((8E0U`X&_(T2$*F<BE14U'@P\X@&HF<!<%=``R=_)`
M!>AE@0(D@`$%T`\8DQ*G`P1*.U,\``6`DA1:;6"*0W/>UNXVQP6`T2%AS,`%
MRD0`!7#`(TNA3AS!MS%R+>`O%5!CQ`J"2(D\#UP:(%.Q;J(U1(;1*F]1``%$
MM"MBY0:,!E@25J#B`0@8@`$'L-?JS&6U0%I$)JJAP`7(M#X*T`L#J[N3LYR"
M`*4QP`(:4.,%'C"`"6#OCF!*@%-$<D=[64"-=5R()!70%P\\0"(:,`@!_L!X
M``[LS3$4B./ZFL@E$G;FA.54YSK9B9FGS8Y5#I`7!J2#)TZ=)"72R6!=B.)#
M^`S@`Q)P2=X84)0Q;4``4MGC0#"PE>=1)GH+L2288(A/C'R`-7ST3_P68)4G
M7F:(##E`:B)0GA)^H`$2:4@'(!D!25Y&@PL`$P4:H$VA[`0"]HI<4TQ2D^\I
MA`$7@$"!A$D[H3#`AE'Y0`(T4-$+<`0!$%H(!3C"4B5*0`+RXD#B%G`!JH(G
M+5N)@$MV6A6C",6;(PVH-`\4%*1@`)L8,DT!ZI)5<-(N/1.0:CNQ=$[.I).O
M@14L"F7'&=IUH(,8,@B>,B``!#PV`A4(&@'2_H/-#B!2`0D5Z`?R%E6%T*4`
M"L&3!A1@.I\\]"81_2S\K.*`HH"K)@?))0$>>X`+>!,^A128`TQ'@/ML4@$G
MQ5.J-M!285[&DAX%9M<8@`'5U+9TZ8$C!6B+@-?DE"!I58@$)A"NVA)((C_U
M+&5HJA''/G:H)OE`4(#9`0<`BU`&>:YUO=*:]]8V`Z']P`78BB&.<'`"<35;
M!A7"1Y1D$"B#-91?-P-8!>M/`@ZXS01$QA`,7/C"&K'6LX;4(\ZTZ,$A_JAA
MXPDF;2XU`_>\L&05HD$`1^`H'1!`0`=ZV1:*D0`*8<T"+)6!T])Q(LF]RFLE
M<%'6Q/8E&QB)799E_AG-"86N%2C8`^1%&0:89*5J=8!+MV(9(6.$-@K136(I
MLJ?6//6I"K'`$>T%1Z->17!=NZ$#PBN=\=ZDO"K&`+@8DE!@8@`[%D``'$^R
M+ZOIAL8*.>8!)J/:B01&Q\0$TQ/%:)2[*BV@K@NQ<QBL&0<K."P)D'*T*G`8
M@UU@5M950`:Q2#;X.$;1_:V,!8[YWTT+]IV&C:*)Y0NIG1E@`RQ&\$DF8(%7
M)6``'5`D!K3FXP<,IC&BS0!D'I``QZ!V(A.H+@*>U-$A?P!<&GV(5X#X%V>S
M#@*:EMZ?-HD!<?)&;C<)#&]=\FR9<!FYK+U(1D[&R9ZPI4`(>)4H/=`7_IET
M`+N$ALQ[);`G()J&SAJ1#E1LV;5?H^?8?@YF`:I=4@)0."90R4U=.&`<C[SD
M``\P0']C5BX/7(#C"9`.-U7^30DTQ`.KTTF%;PV:3F<FG4BQ+@<DD"X/4,"Z
M1+O(J@&I$#--A#4=*!!D(F#*`OWM`=_CCVNMVX#;(N"*+%&W:%I2F0?8>B)V
MNDG>^*,_6%.D`4/*45HN+)0F:>`N&<#`!2Q`J)ZK<\2<R1&/5/1RH>!]=]TA
M&X\VD*,%"HL^(?(1V1:(>.PDZ2<7T+P`Y;,A)^DG(3A"CMY!=('R7*0HE>&`
MZ1EO^LM(?B'NX8#MS$.9SC.D.^Y9((ZZ@P"]_C]+[]OS474:/WLD09`A=0G1
M^D",>+M80%@Y7B#LU>,?#.1>0#@R#Y!`_.A!FZ?Q*@J0``E2L!N%_^_-^;D)
MF30`#6C`V,01J`/R&QY\W:?+:5X(-TN.=`Q,I2T:XBDN0``6H'2(YSXH`"$T
MH&0:2CDNP"<LHP!<;2&4A28LH"X(2M.`X@(=H`$([0,8S72(1R*((\#<97`@
M``(&(/72C[":S`5!XP)X#EON#%3R"ROVQ5!.+`8_9?TN(^@$8,L2BYX@H"4,
MP.X$10**J\!L0J(4`)K$0K(4(`&4Y2F\*`$$;>$&)R:*;2UJ+S04\#)$C3)0
M3>82P%XT<"$0Z@Q7_@X$17`@?JHD`JPL%&*H>I"P=`L/`XM\FH4G$@5%]M!1
M?M`R@LZ8+""QG@H"%``"8"U0JHT)]POM=J+KBD*R%J!;)*RK"D!9!D,!*,#=
MID*`]BS9DF,#2K%$"*"$U&XBU+!HWHYKWK`@JD-K'*,BZK#40D@0F277=M$7
M?Q$80X,0*R/H<LPN"J`"$*"[["5JGHT!!B"_>N6V*,!U#$`D#,#88$)S3J5D
M.LHQ(.O/*"`+O4K4\D8Y5N=:"H*2TBYH%H*@U.O5%H)KHNV@?$\A(D`!,H("
MF"*TF(T&@Y$7]=!1.L`2P60S/("W]K$SR$TS+"`^9"VU(J/*.*,!P)!+_@"%
MF`PK+PI`='3Q,B++,V`"T9R.;FXB`GQ#=Y2L`"#G)0P``7;(VHX"(#GMI`J1
M2>Y&LB2B`JR",4XB(2```\BEA\BERHXB`^3EAXI"`E(C`R9@*8]B-VIB`1P@
M*#$QYX").8B#`;@K`CR"`M-.9@J``/+&%5^-1J(G`:H)V.R1(`)@(`+,`V("
M6$QF'6<26WI14\R&(?Z1/!SC.SHCJS8CJNAI,T;J+SMC;1(%F!KF(`7@_2"P
M+D4CKCZ,DVZI4LBD,FXK`RQ@`#B`$3-@)AKC`KAH4EPJ>^R2.8:1,CXMQ(#D
M`E(,,ZQE.^YG>HZ$,1GB1/"C8)KG//"'(69S_COX$C4]I;`.T@@[1^(0X"C@
MQSCV8YF.@P+L!7L.@K>^)K,`)P(VHC@:CC:<PB!1J@`OP`$X0.8@(#(BPSSC
MKF@(H%V4S"E6K[34JP(<R]@6`#EM8U>DY51>PP'"PG02HA/!9`(2(.4*SM4>
M`,M,X]F&:R/`C@,J`)$T+3H&XR648HTN`NRJ0CS)TS[EQ6P0H`$FLE8J<"M(
M"T0]X)K^,Z`>2U>>K0&RZ)JHT+.0;BH""I&JHV%8R@.D;@*<\"84)@350BCV
M\:)&[D5):^R&T^=JDA@]4DF?%-=@4#/29$>#8B<\H+D^\9K$*4=(4*M\@D*W
M3"\#["YFSTJ71([(_@,)^6BKG(4`+&!,M`?8%F*SJN(J80)%A0;O.A,HPF+2
M?'2.,.+)W*TAQNA[4'2D$E,2/V`??\A::(4!L.,!`.<ON@?8)L6KK%$#\@;8
M&H(F2,@Q,\@K!`@34V3&UG-/!F*L%-`#+,#K3*/D&D-["N#0,L`!**6AX(B7
M-``"*.4F8$('D<PRE*4.^2C`@$KS!@`OR`E*-T,U;X(UFU5:-ZTX)86F$D``
M$FQYS!$^(A".CK4G0K`N`NS$R)11]H)6$DU-]RW:ANUYAFN[(`?6>@)";V(P
M&24HOJB:C'&U,*+D4NXZ8-!5,XNT7"TNR3,U#J":*F<#'L!<(."')@(#_@:@
MFE*NO&AG(Q2"A?Q5OW0#"5_B;D9T/0NCFF2NH!;BE/85YM+#LUCC`5+OXPJ@
MF@J``K!+8$JG.H25,J`)/XP1(Q3R("`P(2*@)*?569ET-9V4B3;``G82:8UV
M#_$R,Z@J0"@+H.PB4.R#-#5"&;4JM.R17*7#7%ML`_1+!4%D30TPM%AMCI;J
M/02*;>&(Q2;B7A4B*`X@0(`DR#@`([Z#5T<J`BV`2YMB(RAP4K<BI9Q%1`Q`
MRF"LO&*O-C@@`0N$=GBP`3ZU;,4LOX1"M3S@:@-JU30(K,2BAL:*]AJ"9?D"
MKOJ'`"3K.U+,9L_#=<3B(@!U(DHC4LQQK(@C_E4V52@T"FHYXU;.D'B+]PP!
M0&EA)QE3BM;$SF#F,P`$H`"2E#(&;4#:L4NZ3&`^5CEB)GH'P"*ZRO8$('H_
M+GC+4"`M8P)8PP%B)5X@T$SB!P$D*VY$T0#XRR?PEE$?H&P9$%#.520BP`)F
M!FUKMUW-\5W-8[,DC#@BRW:SYZ."8G+$LXZT!B,:Z@**+C<$F''/*`($@#@H
M,&;LA=EH[2^0,2<>=WD&X[;<C7*#`@%\YE.C+3<TP`'B9N5,-:<:@`#JXC9,
MD-F(Z0-1V!I=K&7AZGX;@!^I$=AB%S[^Y+W"`\DD0%H(4`4C8`-XJYB6Q"$0
M"4L9$1DI0CBG%451_K1BROB,S;B,>\X(L88\=7`B(!1%.7.O!";M`)6E$N`K
MEX<Y?-=:)A`*;8]6<(0`XNU\+R)]*8A,*<P#`NQ&*D`@_(-,<0)0)(+"[&(@
M&F0S.:!8JBZ#(8#,_*/A-H`"L,@_JBZ@D..2%6+O_(,"'L`J-``>G2[K4@^5
M$5%[)N+F9-DN.FA$!"HA('DG,X`"KL7%-&)2D4,#.HB8,V"6&2*K;,0D<H@A
MP.6&9-F4Q3B7<DI$J6Q2C8=(61F;MD<%TZ.DQ)A1-X#O^*=H5'`R+N`KV6P\
M_*DCWD,\J<P!\&.2"2*GTJ.1(QG<QOB0?U&2#`8H2JA>%8+*"D[@J/AC_K&)
MT83)=`"5IB(6NP[6&D$3[!#NL0;@.(H#T0P@+>6->T7MC@2N/;2W1P>ZP*1T
M6F@5)NJXB8A.J3!E:*!IC[4%E5F:I\/0=B?B-'^U'14P@^.1->(R3I1,50%5
MCSTWC4#6JM3J6#7"FQ*+T'J8,C1@`*AL`2AK`5Q"M<*,E;7WD*MU6HC.I01+
M`\XY4VH(`BRRI^.:G9C-8/:),A)ZK1!KF7+,;GB7T6`M`WQT`P+`-P(`3*(J
M?E@*H6J+(WHB(:RKHX=-W@8@IZCX()0+<A<B\,Y7:N7:LS\;M$$C7CH%(;%W
M(>8V<A#Q:!(L3JXL2!EMOWR4B/0N-L8""5EM_EX#Q*PP2FZLXI@?C7O'!;.=
M3GL7`(XY.Y%#6[F76[E-*7OX@P&'YGD=H@%6(X<^D7*.*FH8#>F0S@GCTCPF
ML##D)8.NB5?F]TZD\;:XID`HZYJ>)3`NQ=LN:BDSP*,1(R3>NZQ=FKG[V[\_
M6]F(AV:8E2"P:FSLK@(HK`(VQ'46W"[T2FX(,NWJXH;\PU+V:S88U<!CN=B&
M]*C&0\+3;C+4^2+0PRF+S.YRF;/Y^[];W,5?'%N^$\;1=\9KW,9O',=#I;-S
MG,=[_-:NQ\>;R*R#G,B+?*;9@@$>P"-Z<F.H<B&</#1XU3(4D,<8`B++4'L&
MHFDI(\-O0G.JJ:;"_F)@*J":&%&@77#'C5S-U]Q?L-$V82*G\91134,T]`_/
MUDB<*.SM-`,N0XL[*$-\;Z+H*@"2'8-;)Z)7"3V5DI=:7;H\F!7SPJ?"`K$R
MEL3XDJ,/IT,CM.32,V5["%QZ0/UB9#HT&!U+.AU:,$07X=HR2&1;2D/F3.<,
M93W6S]#4F08HZC@#H@;08TB,.(`EP,2YQW/I>@C<)H<IE.4MU(W,?&A,C+!_
MBJY,["*9+"T`'(#0EPXA@I;+<8-VU,((=_HDB&9/J/<7\5*2#`"K!>:WL]HB
M0MG=,T-K;$@TZ/U9*\,!%F3/K23!->4"[,7;-"/K.*,@XC@R.R.Y'24P_C5#
MA=2J,PX],VRX7PJJ[RJ>[R[>XBT@6OF*JBYC?E6/FXKB-2XK)2AE=/[O.I!0
M*1#.ZZ"QH-<06(`2/@+`(<6H9%JU-L2(I?P7Y\#E_^*#5@)=ET<"KAS#F.+$
MU<Y6H95N)JLU)>!N8UAE/QKO8HJN86<C1H)D/S1";U.$)ZR1\/R.2A)$;W%D
M,B[K:)2']PZ$^G["`$I9@US/Z<`0/-CC0(P$1H0B2((S/)P//N3^T42D1P0?
M2-8'[W!'\4J;M81EFH($,-)B0=1Y[ZHC3_3G^II,ZH0(/@1??_K>201?J\FF
M\BED^,K//=90Z_FC2O3'];;>+B(D/;+*[@6&_O'1/D[T+E*H@_@*WQT;[T2J
M8X%6;T3FP^QC#_PX7_@;Y=X7(IV**V;6!3$"(`"*0P/XJ+SR9@(&8`()\RH$
M0`#4$SY`)P3Q+[,"0&%%A+T<:XBB5S?`2/I%>I98W,OEW[:F/#$BD#8DB5=,
M:6@>@*X`8L&%#QT,7$CPX0,!#PD3>L@@X0"$#@48*L#PX0*$!08^;)#@8`"&
M"0\H?H@0`0*"!P\*9!#8L*&$`0@0,-#@H4"'#PXH-(0`H>&#"#&+&CV*-*G2
MI4R;.CUJ`:%1#PTF3"W`P0(!!@ND?J!JL*6#`T0C(!C+`8."#P<2/&CHX4`#
M!0(Z/)C`H<`#!!)X_B9H@*!#VP<<#CA0`&$#`@6*-7`PX""!@P\)#K2T8!0#
M`0<<!BAP0*"#AP4+YC),J)6!`@:CSW*P2=K#`\X%-)#D^3FP!8DNX2Y@X$#G
MA,T8=C\X@+&A@P7!-:A-&#H!@I<&6E;X0+K!@0X;!C"@<%'C<=;9%3R$C.!`
MPPX($FB@8-E@PPWJ/2#8,"%^<0$2/*SF>MH'%33P%0$G%0!84&8Y8$`&&@SP
MVP$![@:!2QE(I1,&D!F`000$-"!93(]%QMD!C!UP5@$8^,<`@`]`MD%#!)QE
MP`8%,220<0U>R-9*!*SXWP(>2.`65CIF\%222#$0HU,!G):35AI20"`$_D0=
MH($%"TS@@`<$;$!`5LBM]4$#%%#4)`4(LJ4!?1]P^8$"%W!`0`4)>`!!`Q($
M90`%"%7`0$8V^<24!P9@9E0%!@18U`6!/L;0A1YT4,$""LR&`087=+``1H]=
M0.9"#1V`I$<&=&!@G!TJ8(&&&Q@PP84C/9#324`YD.FF,!4E`8%PZ<33=0D!
MY=`!`RF);++*+JO4!0@<-98%C!;8@07/?C!`3([R%%0&@>GD`4G/-1@3E5]A
M=9>&&G3@6$4?4/`8DE9.NEU/'R"@P0-]&;I!`M>9:Q2^J'*`W048W.D!`XA^
M$!5#!VRP@$\@)93`B@;P]>8#](D&P9Y,<M`D_D$3>/`:!A0LD)`!.#TGTZ01
ML[S0GMCY!*BW"0T%9D(7)72!A`=[D+`%"G^`P;4)H60HP47'A*\&".2D])T&
M:@ETIPV96VL$!$(MJI89%)`05C]]O`&/'^@DYP<97"#!HQTIMV^-#_AD[`=[
M7B#D:.(5]67&-V*'P0,-;+`!!SS6?;=Y">,-`0?K0L!DX<PJR>133S;T&7`1
M5WGE``)$',```3B;D$A2V5NQSFJRZ2:<"@PP``$=?^"TAPAP^&>@;+G;5+^$
M,>3!!I$1C!3>"2$`[P(25*!`5@ED4./7G"[``4N@0A?@!`5,8"=M%F'00`0=
M@(;!`1Q<(,`%)'G)_@%*Y6L@O4`=')M0KS'EM%-/'6"TD06`2CB_R0EP@`0T
MRD&0@JJK9`5E"HF)T#Z@+X_<1P`)J*`$QA6RD_3E7M6S2D0*(($,J*<A-?H`
M`PQ0P01PP%[X&IJJ4C>@HPC,70JC``%2N#`+3*9@"\#,71)B+PD$8"<2>``&
M!I#",P4'.7`!C`)4!"<OI=!7-VO/`2AP/86$*RBL8A@#8O@N![Q*9QC1P,/>
M=<,*6BM&KXE)!"1@D@]`2B9`@>/;'H,MNQ4@A?2+H9=.8I4/-&B$3K.9((E'
MD"5FBDPZ*6']WH+'ANSJ(C_$4L:&P\<(PF51&5G`W^2GR,-IX))I3,`%_C;0
M@!G9B$$<*B!3*N>D`$7``!4@@`3,924VX0U.+ED4G5AF)D&.T@/>$4`AS?BF
MR<C)2Q,#5:^.N#0P1F"'3[%``W[#@`;0#RD02<@*%6"5(2F@`033$@.0M(`'
M*"`"'M!`4,K$J$HIH#\=\%4$',.5"CB@`Q%`S`0N<`$*>$!K%<",.9$4@0PH
MQH&!=$@#&#(!#&3@+<Q3`&)VH@%JNG*C''4*Z6+R@.MH(%7W"XV62J>M0#F@
M+XJAR$XNT*JU.!(U*$.576)U'3"YE">N^@"Q!FH7NKDS*/R"(1699B,:MDHJ
M$Q@E:NYTR!Z^*U#VP4!>'A`HDKR*(:VBP"@G_J`[HCW+4".93%Q&B9^&Y,4B
M$44(!P0PI*!(56@B9,A*QZBJ@B3G9^_20#"7UA"DE?"`:CV`^?C%,/,8Z'KA
M"AF@/)*M:<K1`'DA&`7.>2W*7NVKF"4(7!5PG0NL%))ONQE1H%;)KT(@BQ/8
MP%#X%J.4[)1#7GW3.1%BR0E`X&`)::H$"/8`"%0`22?KZ)(RN)3+)00#`N!`
M`#*`RRMI`&_FPDH"%B`1S30``I%A@(2(UJ=Y[F4ER<QKF#Y4``O(C``'!%@1
MC3NY7<'W*7B:KWWO6T#"-N1K!:B33PE%K9,V<+\%H$`$%QH1!MP'@_>SE`+"
M=!?!,"`!"D*`I1#[_IJNO$4"TQ&8A1$0%*/ZM*$F9(Q237A=\S1$*PJ@,'8P
MTP$%=.6AX+Q7!6ZC$@6GQ0"`6=AC5'.`&^_P`@;P+OWB0AH0&THU%;&`0>:J
MTNO>20-ONP@#$-2`MTS84MPYP(2-)B`.[<:[I<*<5"K@95*QY:%;%I):"\`5
ML$4`SE=\4YK+EEE$:D@[FSH`:18B0C*_-Y+>_#!1."S"KVHYQ;+9H$,*(./`
M8.>Z'-JSL429,11?&,W>=8Z7$;"P^\*R*<K]2@4\<.H-8"0#2+(`=R[@G'<!
M#8MRE,`$*#`2O"0DULY!M;1HAQ$+<,`#/MD`!9#$:@%ER2/)B35^E20!_J<^
M6RE`F[:UK\V4J$QE7=[<R7R`UB3D<F#<.PE>0M@%/()M8%H>X8X<RRTY;Z[;
M(U"*-^VX`[QX<V`G'2!8-^&"DR;M.R&$*XK00-;M^<3(W'+<M[<==QIV>1O@
M':AXO]>#DZ*TL^($:R?#;31ODA&\20S?M^,TT*:1`YSA\^%WQHLR\'._W-TD
MF_?]`GZ2"-A(K2$/-Z,D[A"<?X7;%V>Y0^R]KGE?W","GSC!/3Z?<3,$Z")7
M>KE!=AJ0>1OHTQXU4TJ-[;"OI^)B+[O9SX[?CZ+=[!APNI(>N/:XBQTE<J^[
MV;V>7"A-8._<.;;:)A#"^?B$4M[<)KQ03;O:_L*480#EP`0J;H$,`+X"'[EU
M1N`U0`Y`(`'`44WCE*)/Y4PJRTSY_'K.N5P`:\#1=F^]ZQGFE=?+'BYNG[WM
MF47VV^N^@'A7BG*)Z8`'9`"]&O$1\1S07#=EA$S0(0R6/D2`#"A@47#NH0!T
MC@"SZ`L^#HC`F,&L+"*?&B[P28X,51:V#H`5D4G!5[GDTEMJIF7W]+^VVNN/
M__SK?__\=TKOD_)[`^`@*2$@"P`!#Z`!8L,6_H)7QM,0!:`RAM$77*(`6.)E
M`D$`*I-]#:!0)Z-0$Z``&6!^RD(GTA83PU=[:H,`<'(V5%9@P?<6(%@21)-.
M9]00"*`9.[$^JZ4!_N+C`.'#`7,A,1A!%>S6?T>H+;&'A$;Q&D:X46V4%/3!
M0$FB*?>"7`4T4$035DO(A?WW?TCQ>P)@$PY@%1<"`1DX0J]R6<J712D#5EYF
M4);"`)!#&A<`0H#A(0D0`3:T$K)A`)RT+.#1?L)2%&1()SNA$Q%0$@-0`8Y'
M/2>3%],5`"$S1@Q@%20Q&QZ@%F]E54'&`0E``8\%=UW8A?='BMY46O-%:$?Q
M6,AB+Y;447A4;:=(B_7WA4?Q>ZD"'K(17.P4&F\2.@2`3,L7$Z?RAQ$0*.&S
M3@6`C#UT*@60?43Q+KYB`2.C6<MB+4E1-QJW&6?H$SJQ)U!#&=L%`0-`_@$[
ME``A`P$2@5UO0@`#P!";6!'*IQ8W(E^UV'_ZU114<3L0@&HHPAH-X2P)P(Q/
M9!44D!X)0"FZ@P"(Q'DH4C@7HS$U<1_WHF`-:3>&112;9RS49UEOX1`.<#N8
M$0&&%100T&(@1)`8T3,(\%!J=4.&01#>A8,%84N*41/K@D(-$&,H(FTCY1(F
MDAX$TY(OB8K3AU6003LUH0`[43XVX0'(YP#;4F1#R1-MH8#XJ)5E=XM&$8`.
ML0`TH7E$(3:L$A<5$```D#X````C="H4L"@)0$'^80$"`"@"41$<%@&A<T4!
M(``%0!\#8)3*DA/;M&*`Z$#5@57/(AS^""PK_@A0`86.)*<7+!%]X.$`02&/
MP3-"SV$FB+F5^F>*2S%1!5)5;X)(=JB)H;%5#+`3/903[01F>CA5;[43"6!0
MN#6!#6!&#/$\>4(R'1%!S[-BYK$!#%`^0(,`&H$R$8`05"*./^1-`A`C%4,L
MA8%J!(*;@M(!`Q`C5;&4($4W/C$4T=E0;[5OD^A2.!A&9Q,C'8-'QI->9?)/
M:[$!`<!^H:F?^-6510%VH:D8ID<R>W&%<2(L7I*`'1".P(*,U6(^@,E<3:)V
M><(E.2&"S0,VAN)J-:89&K6?]3>:U-9/"`!7M406`7(]3D,08",T","()E0!
M$$!B[C%9>6&:*VH?_NIV132!`-N32Y#B-(41$[G46R")$KET&T*S`6)X.U0$
MA2@Q?351%_KD)<"#%>YB`"CBHN(I3'8#`1K`I#SV9@7R%37"HRCB7#519/&)
M,F)SI!MTC1\JI_#5GS'QG_IYEUSA0D;1`:X96%12+0(5D$/R%THS3H316P`&
M,>J3$5\Z$;ISG`D02*-19G.Z>_K(%.M'3!XP$!<"8"GZ+!01B0ES'1C`$4Y'
MG-YBHTDS6?8Q2FH!=X[QHV]C&=)8/SL$`0!#ADCZ%@?W-AL@;3;*$Y>%*`-Q
MCH<D1SKA+M/!,UQJ27L22<`ZIG^4-,#2`1D01X[#IF=#,"AQ&^)HJ>'J_DK:
M09'E:JX4"5?BJJ[KFG;@MQ0("2AU`1QH9GZ@NJ)T0@$1,`"!5`!32#'(XR_"
M2B1VTA=M@9#28@`1,`&4-:L,(0'4*2+;\P">9``2(`$,2Q1)&BBE0:]J)0#Z
M<BI3,K'M.;!Z2!$,@6:`HE&04QBJ-1H-T+'>E*$&8B@=@))V(JA?!&H480'R
MV:T1\!@D,8FKQZY%:[1'B[2SAZG9%FV-B&J!IU;707C$1CL1<`$BF!!2%1/^
M$GCATA`=DAR@!K4=0`&_131(0K4JR(3+PQ".AWD2!6P>,1!/:X+$IC[$LWKC
MYVQ@^Q4"E1`0\6OK(0'&MA/)1K?W$TZ$XK=L_I,<'J!>I1)06?$NA:M0ZD5D
MW$&(2:NYF\NYG<M1(8I?ZO<T14&<3&&#30$JH>:Y1O$U).%FJPN[GGL!6-4B
M1K046>*$24(!%,`]N:MQ)K,B:F."1>$@L3M?2_MLX9*?#+.\4)&"2%$<QHL4
MMA&XTFN][,H!XY0!4Y<!JM&\.I.5RP(A$S9"2Y$P?N9GC984LW.]&P6Z[0N_
M\2N_MA<7`!83$S"Z3&@`1$H!^)$!CE<JJS>WU,LH`^!M9V0;9\(P(P$7HN(?
MKK6'X\<!O!LC/^1XIY:VSC:_3(&\&^S!'PS"UI:-1V$HAGDT7\I)_3H<6P*8
MNW$R"-@G<Q@3`_!&_GNAB5>T'&P1,7#!>8UX,]O#'`4!>!5Q%Z^B6S)%,'L:
MP@;DKDOLQ$\,Q8'(?$;A+T?1)U\S$+5Q+Q@A$*GC)9I!>4XGF`W@72=G&QVA
M9O=S6?TJ&T1Q(?NS`1?P)1VC-:R&)1WS-U$LD$VLQWWLQW_<&<T[4LN;`0-P
M``;0K]Q*&:,D$.:3?HZB%S/L;=U'9'.(QJ.D`#;1(6"I0U81I'Y6(1O0,23B
M`&*D&&#DQQW\QZO,RB'L9",(7JJ;$'IR;@-06??"R!A@B;13`&SC$6#3$`9,
M$"OX10QC(+#H300@+:^"`62XE.;R5J)\2U3EI^D!RU'\OJVLS=O<OJ@T_DYY
M4JA'@2:2)`%B0Z,"\8G6[!\H8K\#```!$`"LX60N61'(C!H&$#I$$4&?O!@X
M>!=485@;I#V^&\*JS,T'C="P.V[?F]!(F,T-#=$1+=$3[4H&3=$7+;\J<:X;
MK:8$C=$??10/#=(C#;MUVA#*-<$%13NN)B`5,'Y_BR1ELUR(1&P5T+^8,2><
MNB(98-,8H`$VO3\VG;D<-3\2\$87D+O]MM#/RQ1+K20B=S^B07L7;=$D;=6<
M:]()H5P6@"`0P-4+H!.">18WJ!X`LS,$YQV#PUZA\2()*Y)Z4I*9/`$$"9(<
M-5#9Y],78!;]<10S`3L!X*]/L0$`$#O[^A0%_N%),1%'PT)B$:UM5PW9QIO5
M'[#5C!%CF%$5WLD\J$A99DT_>5%P,^&+_<8E.L=/_I@MH[A1"3.8#@$<N9N`
MR6%O^"9'IQ$RPKH!%;%OZQ8\#]?;X-5Q.Y>MFL=Z$2W2D8W<ZSK96RT`!Q`1
ML56.!B``BDO&N[M#:4-P`8`B[00`&)$M0$0`SJVOF\$P@5U`7V.$"(I`?4(0
M4M87',9EP:2BR8QR%?`L"K8`WK(`&-,65Y8!#4##&88`C;@H^<$1Q0W159W<
M"VZIRWT:<+<E'H";\`@P#"``$&+6YD=H$V8>+J'+SGP2O^-%QC4!YMT0H$C"
MZ?1(7X$EG/1&SR&=_AX1``50``,0%`Q`%"NUHH)!DE_Z+!$D&%NU$`G3V!#]
MV`R.Y$7KX*BA.U1&`$*2+95R+L"Z/7YI*0(PW3).`'42&M%7`;$C6K&S``3(
MY,8U?$:(*L,[+"I6)A=S.Q7`I"?ZC!-')^?6(,%TUOB26Q,9)VY>(S4R0K9&
MU7R<Y(6^GTO^%0$R*>>6Z(Q.$),B&A87<157;=4FU9`N&HKNT<LRL6['*>]4
M%(HR<?Q+99'"/ZH1L0YA$,$43%"SYPL53*CYC'95Y`U]Y(:.ZQ^*Z!^*D`_0
M*A6P%_;;P"C4'@PP(ESA%R\R2AH0`)E[GQ4$C53A$U3V`&[!)AFS4-3^_AF0
MXIS!@>`-?=RY+NY(N.N_]1NV:A0C8Q3"[D`*RA0>*AM(\>U)`EVW]G)'41P`
MU2I?(5&G,5THRBB<"E/;2SO$,S_SAJUR9".E,C_#U&P88&\2'>[C3O'ZA^@<
ML#R8814W%CSWQ#/5PDX8,!'&`E-(/2?WI``4@!D2@-06`+0=0CQZLKW<8Q<*
M*H(3S*FZ5O&EJ(0[[_->6*!@>!J-MQH]*P$60"6H=#-^9=.\.2#LX4Y1*49`
M@4I8)'P*D"^#0R@+<)PJ?T&9^=\P12H0`%T_OX03;_9IWWJ(CFLVP@%S"!S<
MISL(V%1[QP`7\%"$X8^"\Q5`VP"3X=)[#U:(_O(6@M,`#6`!L^%3KC4;%O`1
MRZ*)%AM12:W83KAU!#V+!$%?M3<IF\[*"J[VH5]WB`Y0S:S++E]0Y_1.=&\;
M1L1=*]2G0H,KW9<!/7&.4<\2@4-&W\&[@6.U-`8]:3'43\%AJ[4V>Z'N5"R-
M%%&IQ<@!BH+N'H'N$T,Q)KS>C%(A%TXK$D_HHN_]HQ_TN!AQ1#$2,7(!I^9X
M3=)VZX)R(^,<&+&[_]N_YX,1P_40FH@?WM8A.%$!2+TB`$%APX<+'BY\F,#A
MPT*&#1TV;,#`@\,."QX\_+"!@(8/#2!\Z,!AXD*1!C@PD#`QY,0*"CHPE."`
M80(,'SQP>/E!I,*;_BH-C$1H@",'!!5T=GBY<F'/A4HQ/H4:5>I4JE6M7H5Z
M(0%6KEV]?@4;5NQ8LF7-GD6;5JU8!@.K!@!*8>U9N5PS$`#:T,-&C!,27$#@
M@<(!!0@V>%B00,&`"P4.8)B`0(%0!02,+I30=L,&!!<X+S@@X8,!!0PR2$:0
MH<-/AH\9;M#0H4`""(,+<^"LX,"%TZ`SS`4>O"M@X<6-'T>>7/ERYLT_,/"L
M8;-TZ;"MPX;KW#B%!5`3U'7H(<%&#P443FA@H7N'`1P<&'7@P4.#"1<8-)0@
M@,#^`!@J',0`@0\*J(FF#S)PB;6%!)A(@PGJ8P\I`EY"CP*7-L`@@@8Z_M#@
M-^T^)$LK$$<DL4033T21N0<*(*``%UMDT<489<PKQ;'NJG$IOC!2+Z,#%M(`
M@0A$^P"!#AHPBH($$#"@OOM@DFFAOS98``$$?C3@,`*LM'(UH`@8"`,&%'`)
MKPU^_"#(#AB8#0,.%IC-0QOG=(@X.N_$,T\]]^2S3ZH<8"`GABJZZ"G[0,+K
M`_4H:,"F`HZLH`,"%&I`@D.AG`D#!2CP((,?S?O@`(XZB%3!#QY88"0+$I#-
M@U8_J&"!##+PH(+'-/!@`@7\1%%$7G\%-EAAAR66*[\@N``#"R!`@-.LGH2`
M-@-40P#0`2`M#X(&"H@@@P(.PBS*#_Z"0(%H_@L84"%;F9W`2X8\J"R!`PBP
MX-5H(9A6`P,@6`#9`R)(@,ABF[-S8(,/1CAAA9GS`+(':96*`SDSJ'>I"S3`
MP`,-%.K`@HU_PT!.V!C"H(.&"SJH()(\M@G<AC:P(..6EZ(X)PXL\!!FCA9&
MSE>>?P8Z:*&')KIH@@4T.FFEEV:Z::<5]OEIJ:>FNFJL/-CL,*NWS@IIKK\&
M.^RB-5A``0<@<*"TG1_"P(`#WHX@1ZPV</N`OS#2H-&,$EA;J@P*!<N"`]RF
M"3%!&7+@[0,>.#SIJ,6&/'+)@QU,SH4P..`RARQ(#8/&+`@K@VDQH&"`FAP*
M4"<#P)M*4[%TS0"R_@'V4L@A!23``(/$FBYX<M]_!QY%#MK#2*/:&[)@UX50
M^H!9!6JBLMJ/))#L-P<:8'4A3V%ZLJ$`5ZOK300V[(#,:!]`0*(+#J@2=+(1
M@$#CQ"98M;33&YJ@^P$V*,"!\055`.AL`B:FK2IX!T1@`I7#'>^P;B$6(``#
M&K"8#5A(8X]20`7@E9X+':!\\6/(]BZ')N^]S0!+^8X'(L``#@A`2YS*(`;V
MQP'S/,8##I@`!B9$-]P,0(#X:Q:C"K`7&&HN@#/YH>.\ID`F-M&)8ED?5`QP
M/X98H$D-(.`"P/67(<*J`8EC``,(@""7'8B$O;M<`'3UD?*0Q"1=!!4$_G#7
MG>=00`!A3("L!&2!)RT@B0N90`0M(A)0/6`"##GB0CK#M,<]T9&/A.1#/("`
M0SY$`@G(4?(6DK:.U`4!;7L)HQX`@<V43`%E%.$''``XD@F(`P0HR*,R\D9'
M*00"]:%C`,$$&XP)Z`)T].-#*-"]A<2QDA](Y/`:5S0#1M*9SWQD11A0,I#H
M+E`\4EYY*(`YR!Q@/@_PE&FF6(&?G+(A=Y&`!+`H$@H(*G6*FM07,["`"-!P
M(9-J7GT&4`%;B0<""-KF5E9C@0H(H%ZLRY]#\&E(#AA%`96*@`$NT@$'#@V-
MT,1H1H&7@15*$`)]<XB#0AB_"SB@G@>*P-ED_H*!LPUD`GWC0`-D>E(/0$!0
M&Q"8!"R0*R2YZB/->TG,<!J!!W!,G3OE@&@,\@"`N6F)I'.(316%@0U$`"$R
M=8``.<!*HC52HU\%JT:%A($$_/%$K[2`!8984P5>-*QOA:LC.4#4,MKH;Z1<
M2ENW$E>^]M6O?RV+6P$[6,(&2S!E8\`"%N"LXCW`L4R5B@8T9Q,*/*"=!*&B
M5=R"GV7RU:N%!6UH\:2!?PFJ`Q`XP&8;<H%]04".<JLB,253KL#@D"NZ>XA)
M""M8T?;6MR/:2V8?V,4Z$3.I#\S`7+.JJ.Y)"G$;&*5KDR*!!]1$`Y7U#`0>
M<!`V5>`!#@"OOG`"_@&H?H`"(-7H9W^[7O8FIP)[Q0@"S-J8+S:`4Q,*U9FV
M.2T^-H0!8YW(BDK:*`5$($">8XRW+G"!25$``1++``7,(Q3YTE`^'H1K,]N[
M80X;Y[U0D>]#UI=.G:KRO)C$V`0,0%!B?@`#S#+2`T03I%=2@`+@%9'&+A!(
M#?S2C;\Q@$07XL=+O96W'49RDL,B*<N13);%=4@&$F#9#AR`/@'L[^7T]ASO
MSM@P!)B`!.IS@5UQP``.&$R/NS-)`1I``K+D8WKBJEXEU]G.5L$<8VTR@0,T
M>2%DSMK.!L<A;]*0G\TE@`1Z/$89IRDP4\PGF16U*PT(('8*\``#XK80_I-D
MQB9NZVQ&CWQG4I?Z(1V00&DB<KM08R!&+7H)OVSB/XO4AY4(<HQ1(B"7#=Q'
MRM5J6*,RG;X&7(`HV^)2\D2B@-]\T;/P-76TI8T15\$V*IFNJW/@Y>>OCGK:
MWP:W5"QB[>3`RZI\U7"XU;UN=J?%V^V&]V!KI=C$,D"#4$FJ@2?2+K),P+6N
M34E7,I!MU`WI>/@A-^3>'6^&Q_5,$#C>5@V#D5=^<5_I(@MUY059@1-\*0[H
MGQA56\L$TKGA)W]K>0BNUAQ50&\G&="R[JT!UW)D`A6(6P9>ZP&=;O<A1/VS
M95U%I';EJKI#_Z>+#T+SCWKOR1.P*LTE8+("_EC@`0+<@!Q?\I];AOII"T=Y
MV)_YX:<<P*QF9@`%:E<`+9J=;@0=XIF398`+1*L#`MCNCA@"=`>7E(4G+)(&
M5KD^LD6`M1N8P`/>+F&@:#?**Y:`!PE0["G2K0(.SO1N^O4UDXO=\\ZT$(C-
M"A*7%^`B!1A(!"+`(=FMAB/V7DB?\<N`/P(=`1S9"VD5J8$'?$<A8XH40A@7
MNPE<"RD>&*5##+F04X(*AQ'PHZTRD':"T'%K8/]\]IDH*?0>"+]1%>!>RJ,0
MU>L+S1/*T@>T**7&3(3V#@%Z:HNIK]@?AH_TFC<!(`/.,U-@(V2:@-#3'FVY
M##\JI,JB)PFHIP4P_@K7X9K.T[X(9"+,N;>E&`SA4I1OX8`)&")04;V8<+$`
M6(V!R(P+HJ&7>+^&`+JS(0@#B)`-V)]B:QY^X0C[2CR@PP`1')0"("7,N3E,
M>Z57>@E#T@JD4("3:$#KLYITD\`FC"9^80!`*3"OX[,!X)LB.8^$6)()TH`$
M&(@;0@":Z(#`.)6Z@CJ0^"]F:QX$4"S86!(6(JOTH:AZVD(%Z)L-J`PWLPD8
M`QTC^8`(T*`(L!*Y6"X,V#*KP3XG5$3?.;Y%]`H(=,1(E,1G2L1)M,1+/"!(
MQ,1-Y$3)J<1.!,50E!I-%,52-$6E^<135,553!A29,57A$5B2<58I,5:_L03
M5[3%7-3%7EFB7?3%7Z037`3&821&X9C%8D3&9!P+853&9G1&KCC&9Y3&:10Q
M:*/&:\1&JXC&;.1&9&3&;@3'8MS&<"3'7/S&<D1'6QS'=&1'53S'=H3'4US'
M>*3'37S'>L1'3)S'?.1'1;S'?@1()]S'@"1(L?O'@D3(L!O(A&1(=CO(AH3(
M=5O(B*1(4WO(BL3(4IO(C.3(#KO(C@1)#MO(D"1)T?K(DD3)T!K)E&3)OCK)
MEH1)S^K%F*3))'O)FL1)C%K)G.1)1[K)G@1*)]K)H"3*X/G)HD3*WQG*I&3*
ML#G*IH1*SIO)J*1*9WK*JL1*IUG*K.1*H[G*_JX$2XN:RK!D&HKJ@`G8-YVH
M@)K(@`?)H0<Y+UA1"`L8B`KBB`IPRPJ2#X)ZB8'+B(/(@`H8.0IP2Z]KF`:I
MG>1BFY&`&*BXB>[[LQR1CZJ0FPR`3*H@.#=9FX8AF:>0F:J0&*K8S,M\BMAH
M"(Z`#;=4B`M0.Q=[D"1:L(6H@-KIL8;8P(?!&5BIR[ATF'8A3+7KS<!LJ#JQ
M1K)L&AC,``"0"P"0%`0@``JH``0(`"$1@`1(``$PLSZD@`P8@`,PJ`4P@`'H
MC&O)PT=Y``$@E0RR0GQB"`2\K*?P``M@3?I9B*1S"!9:B)-ZBJS+$*BXO+KJ
M`'&1"@=8IK;XBLEZ_J[[B4_$>8H&.+B(P4"*^*GZ3#CXVTSRLH#BL\Z_Z<X8
M+(#%$)@"&(!B.AT)4$(+J,[O$$09Z@`,$(`#8(QM61(8E!<#$$0`^`Z:4!Z&
MV$KCS!/D?-$/``#6:ABY8`^%"`"%H+L5*Y)A:I3*,J^M:"$=$@E*>H`!@("6
M\(@_[#&7Z<_INPR/D4^*R1\$B`G3<"T&B(VSF8^;"2.>0)N-T;4WJX`P`AT-
MD1CZ`9C-RQWSVHAAVIFI.TLPI:%Z:H!-$YT+J-/D>I"%8)1Z08^U/(ASBQMU
MDHN44M-E<;$,O2$-H<L-F,U5.A*%V,#W4R?8R`P^HBI^TBZ-J12=8--M_NHU
MJ\JAAJ@`[9H``KT`^C"OFMM.D!B`8=*5IA"`U[N>Z:$C&!RCT0`7$T4>$F*/
MBUL`F?`W%ER(`<`5$>2````DQ"-.'Y4:Y#2`LA)!`A@`6;$)[/R```"O"=/.
M`V`=)=&)`4BU^O2(;;&0@C(]5!.8"TB)(S30'0,OW+$W,7.`7JNY+R*=_,%#
MHE`(TIF^K$.FO"$K#LB@;J&/!;!8":C3`!V(D\B`@TV5#["4R]/8MCA9#3`\
MFU!3%F*V]$,^AS4)!=B`!D`,YI.--[D`Q>N,%0K0##C4_]`T#>`]11,S!SV0
M!SNEC[*W:3(,68D6?XV5K0K9MNS8@Y4`B9G0_G'9U3#SKO+A'PN(`/08%%<I
M/OM!%U@9'P1X`'C%C-*P*@+!#"6\@``(LM^`@"0=C1]J@`$85P\(U@D0`)W@
M5IO@D>($UZ01UP`!`)VX/_E0UP"0J6MATF:A))#@"'EM(0?;),="&\7`&A43
M4!<S5/,RB@!]@"\ZB0RE3W.A%<5RE8C`@(N`.)"`@#'9*F3:``?H3P50/&0*
M0."U``KH$9V@#]"1B(SXKKR!E8X]@,2J)"0QBF*+$L%8IT:Q62TB$I>X#Y,"
MG0;($">)*:0]5*)5//11)X7@O>=(NL42")E@MG)1%`HP@`F*S@:@IU3AG/B(
MJ89(E7_*4`MP`#`1_I`(>,Z'4#$QPY$H;8`#&.#+4(`%^"]FG5ODJ3H+4(@$
M``#0,0"CP(V(^`_`S37"C8H>3=PY$=<B`8"[D"P"`%8D50AL38`&X,X7$Q6S
MB=)YK;2U9(Q1VH``\-VVB$*BY=&INP_[9`"T<8#5?4UD^B?$"!2=:]F.(#^Z
M/,('F*3=[5U+08S@50#Z>9-"B2E_5;^16(#L_4,Q*1^-.1W>M:H%8"GMB8\#
MZ%^;Y9?:X5Y5J@#1@.,%M*DD3JY#'3A4V<#T/9"+H`\-8L#W12:=2Q76Q#0,
M()L.V(!?$@P5$DP!_5^*2;6*X(PTGLEA':`(T!=U^HA52M>W$<$.YH`-_J19
MD5"4U,()!D,MY+L]VF@`Q1,)%V*(;2UAQ#UAHDEA"VA<!PB`?4I7A<#.\@B9
M`@@`B2@?`?!#S;V6TL&[4_D(W$4``$@MQRIBDIWAD7@/!5R3TR@QUT4,*4N`
MDSB2!-`MK9@@#B`,5NE@JW()!?@++]8DU[")/F.`!#@F!Q"-2Y((UWJO=:;0
M?YZ`D"6)!!@3"\#>AB&A/%YBZ_PDJQ*5F#H3^R$,USIC"5+?BY`(?"8H1H[?
M1[:Q/.H`K?!"4E:2(R2HJAJRFB)3"5ZL`M8`,7,(428(`GCF^?@(;>GI3R,G
M````2C)J`.`(8C;J!H`?]HB4!`@`5FF`I+:`_OWIY<&%"B8,YK&1SZ^^`+`6
MZ[`FZ[$NZ[,>:_E$:[0>N;-XT'?Q.JA(7N6@.<?T.J1HB@H5"YEF")O*%:\<
MRZX.&@S)G<(V[,-&[,16[,5F[+9&$=5;CC%T;!31G%JQB;B&&F`6[,T>&*3`
M;.31;,X>+$JNHMB@*MI\ZXF(T(;@D(=0#:X`"KUVB`UXZZEHS+2@HLRJT-A0
M[<YDFQ"Z+;N0;8QPL``P;C>K4!,6[=]IR\NY.HN%SLMI:P*;BIMYB(/%BO_0
M'H&Q"DOABHI1"];9T86P6:DP-NIF/HS8T=&="GCABFN";09(ZOG.GE]>;K\Z
M+<;9L:+:W;'=I`R"_N[+N)C*J@L-H!?:L"J6^J$.8*J&\@_6/-@'Z#'P;4_+
MR@@T2RH5BN#Z]*!<%12@!9T*<("#@.@,D`!MV9D*<@!:H:X6O;%=!=6&>JV0
MW2E#!)?:3(D;@["_=K'8H4M_K2F;,I=-J['=O8R_CI^;TZ'W4CU_2G`*QS0Y
M.D22=0!<&:61V*J4F+)#$CP,GDW1N+DF7YX6=P^T%%M4*ZH6=0@)F.\VGW(1
M"^S[SJ@<2B?O7:&_J20+H"X-V)3+L)2-6("7$(_5`%H$H9*<&/&QE3$&!*=5
MTATJ&0E`!UEP2N(PJXN=719#7(H%H!+WD.=>RYN8F+X'LL/%LA2F,B0X_OXB
MNC%$/N\UBX5TG9`(65EQ+6JG)^$H;:$`,K.Q_YBB%;>)(UR`O/&0M@`3CR"K
M*IM=U@):3<%#>'E-)33Q>;JY;5J(ZE(T2:?9EHW.K.N,ZAHR&\L,G?/!90G9
MX6P(`VCS^680^Y;SN.*`<D$;VGZ`76EN@A!@/(QNDI6THDKO71$S*TL`#UDS
MW@-$`YLU!W-J/&X>NDF;M<0+^G0Q[>((.C(S!Z`)$:<7N>"Y@U">#'V.)48,
M`[N`N)E6/$0(6\$>^O4?MYBF(3F(Z%N3ILCE7*Z(TSA8@`>77>F.'<O/7$V\
M?]J578'.71D2JQ)Z[#Y$GL,>G*^=56&<75GQ_B=U.6W)H5VI``&*8M3"W\@X
M%0D:[Z48@'5/Z@"8[#^+\W=_)M.X50G?*OVMI+"6\#['C'YG>(#O6`R>:=*1
ML<O;*>KRKDM.;\6+9)VCB9L;0"ZFHXJ(3P&6Y_Z$>61ZH$,"Y#4QL`Q!C)Q'
M"#[JF.FKE9RX\\M#)M:D$H;(Y=1%)C<18)W_]\V_G-20+Z&7_*+_PQNCX@(K
M&6*2`('XBYLIE'I)I^Y8\?LPL-N-SO*!%:WO`)W#M-@IX`N@*(PX`+(WZMEQ
M=[4/JQ7"WX/=*B6Y7,S*^7VWE%WQ=_5K"7Y'%>M+GN=AJGI1#`'6@,02EUTA
M)5UA-HT-(.4Y$SPL_BN&2'^`X)"@00(,#!1,D'#A@X(/'RQ,^,!@@X*"$3!<
MD.!A@0.*'R9@>+!@@0<'"Q@X_)#!@`</"A10V'#@9$H($R@X8(CAY86&"ATZ
MF#!!`4F''5@:X``A0P,*#2E4:'C19$X%&Q`H8*`AXH>>!*,J6/C!J0(-#3M&
MR.KAPL0###]4L."008<,$,AR0/!!($P-$%(ZI`!@,&'"#P`C=GA!;^+&CA]#
MCBQY,N7*EB]CSJQY,^?.GC^##BUZ-.G-'3ZT1.WAPX;4J%]W6.UP->V4+6O?
M!IPZ]VZCNE]_.-W;-6W9*4^K+JX:^'#<RFL'/PYXP^'E>V/;QKU<N.S=_L9?
M.R\>'C:'EERC*\\.WO=RY[/;0_>>^$&`PH,9?&]\(4'I_O[_`QB@@`,26*"!
M!R*8H(+^>9!`!@M:U@%R$#Z&P0($"#!``A;DIQ]C%((8HH@CDEBBB2>BF*)F
M':K8(HN/[=>BC#/26*.--^*8HXX[^K<8CS\"&:200Q)9I)%`QGBDDDLRV21@
M'$@()90=2!DEE59.6>6565ZY)99?>AFFEF-V22:79X)I9IIELHFFF&VNZ:::
M;\H))YUQXGFGGG/R:6>?=0*:IY85?.BDH8<B:F,'+RW`Z$M$/=JHHY!.2BFE
MDEJ*J:2:1MIIIIY>"BJGGU:ZJ:B>CDIJJJ.N_HKJJ9.V"NNKH9;J:JVRWDHK
MJ;K&&BNOK_JJ``+\)5JLL<<BFZRRRWK(K+//0ANMM--2F"2UUV*;K;;;9NLC
MM]^"&ZZXX_YH+;GGHINNNNO^YRV[[\(;K[SRFCNOO??BF^^S[NK;K[__`BQD
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MN^6PVY[[X[3KWOOAN/L>/."\"U\\WL`;GWS<Q"O??-K(.Q^]V,Q+7[W6T%N?
M_=34:]_]TMA['W[4"HM?OM?@FY_^S=RKW[[,Z+L?O\KLRU]_R?#;G__6Y.O?
M__J=^R^`,Z.?``O(,/P9,($$(Z`"&_@O!#HP@O=BH`0K2"\`6C"##J.@!COX
M-@QZ,(0!XZ`(2Z@M")HPA=0BH0I;N"\0NC"&ZF*A#&OH-QC:,(??HJ$._GNH
M)!3Z,(B#XY\0BP@M(!HQB3OBH1*;6",D.C&*,F*B%*MH(BA:,8N2(Z(6NR@P
M''HQC$ODHAC+>",LFC&-0".C&MN((C2Z,8Z@H:(<Z\@9.-HQCY>AHQ[[.!D\
M^C&0CN&C(`NY.C`:,I&C(:0B!0G(1@:2D9#LXR,GJ4=)6M*.E<QD'3')R3AN
M\I-N]*0HU1C*4J:1E*@LXRE7*495NM*+K71E!R#P`%OB\I:ZS"4O=^G+7@+S
ME\(,)C&':<QB(O.8RDPF,Y?IS&9"\YG2C"8UIVG-:A)S`8B,Y7_6@I%O7@"<
MX@PG.<=ISG*B\YSJ3"<[U^G.=L+SG?*,)SWG_FG/>N+SGOK,)S_WZ<]^LC,"
MV^3F?S#@``<\P`$5B$P$0*.!CTRH,A3@0$HF\"(>/10R&OD,!R@PF?.DY*$5
MV`!D,B`6S&04,1)`C$EM0]+*6#1!%A@H0?O#@0Q$H`$8>.EC6/(9MR2`IY71
M2DH40-$B(>"B'TCJ9\PR&0P>P`,,P`!D*-#0S#`5,2EU2`6J\P&#6B8!$2T0
M+`E:@;^8!0$KG<T#$-``#QB@`0CP*`6&=0$+,"`!1NU`7AM@`;XB``*RD8``
M))``!P16)0G84$HXP``$X(<BPM*`!A*P@`-LH%$6H(!>-0#8G$Q@L2F=:0(N
MX)(%($`N<UD-72"`_H`%<.`"$:D`3AK@5<,B``,E04!.*J#7#'``M8)]`$D[
M0I344D``?P&,;1%@T:1B8+$+X6QJ=]N`#D2WM+9I:P,R,!,'?2`"D"U/6QW0
M(`]`0+7)A0`#Y)H3LR3@/$Y)`%T^VP'86F"Y*A$6!"H@`*\R8`$36,!8>-L`
MW[Z$`PH@`%51@UBC)I2WBKWL6`DT2[/^I2`->A!<\".!#!``N"QY@`<R`!,%
M>.`!$[!)@RH0%`[X-25`I0!<\Y(!#2``.14P+0/8<H$.'*"RP"W`!@C0@<IJ
M(+H66$`'*G`4RC;X*!S@0%((L($,-.T!%\AL!?#3Y;-^9"@5D$T'2&RA_@F8
M-P(KN:D$&#!F!BSYH5:Q,I8_X!;$)(`"'4#`58!\XZB:%\L90$!L94+9J'+5
MPQ4H0)/].A&<4."M$<`Q!-;JD*0R(`(>X'-I-Q#4P)`D`A$(2HHGL.0#'#6\
M&P#RGHUC90^@.L<6.(!OT2L!L#HD`Q$1-0,T$FL-<(#1"2HK-\&,Z`AX]`-W
M28E/H_J`Q>:YH4*QR@<DP%FB+$"U=O[`IQ.@`0*,!+:YKD@!%G,:!VC@SFWI
M2@$"[(`.-*``1JW``0RP4-80F"$XWDO3--"`]/8W.`@`<T(6D-(4#TL!#E"M
MIU.2X[%$P.#ZUHM`MHWGTV@9`=\.,`,X\.P$_B3U`0;(+;A/@IQE?\"I&LCT
M`0)LRWM_H`#V!HQ;IBJ1C8\DHQ18Z<JIC8$&?,``7H6+7@F0%^,T^^?!20"8
MK8KKO6CS`!%@P(.L<F<F#YNF->T/F!&0`9<T.-(>B$`%FEU9#UA@X-*6@(HW
M$FF/3H##V^XV!S";8MDLX,>EA3.LA=P!(KNESTK!P)@/;&9B29G*>>$W8(3E
M@2ZC/=OX:8`$RI(2$S\^`6Q/<=GKP@`W2[7+?R4RQ?F#:,"4M@-!S;'='W#V
MQ6P%O1%(2IE3(O8(0*`A&L@[23)``32C-^U`3G54;6YP#4?@J!3`CZA)_0!K
MRY6G20GVT9F]FEAW_N`"M#Z,TW/B$%&79.I5OPJP#5#A`<UTZPJ2;<J%=574
M<-<EJT'Q8P,,$;CH&;4##RYOC:.`G%)4`W!`=,U52BP&?8V4-DV$61!%<#G$
M!`P+!@#6==550:1$VFW(1@0'2J2$!`#=![35`K2&-CD`3O#4?;D52;C7XPU+
M!F06`I#8H)U$9FW@!]A6!5@:?14@2>S'P$D59*&87#'93`W<=KF5O[$&B;F6
M55B75#V$5]G6`SP(<9D8`KP?7M&7!S@6;RD8=IF70T@`5EB%`WP@0\S?1[P6
M`F3$0TQ`7HA%9=&7+3V4`]R496$=9FQ$N&';2.QAHXR$I1D@&ZG?C.">_J#E
M"$7(78)T5$HD0*HERYYAP`24H8%X0`!,V25B8B;>%`<"1OH-(H^,G0,T&(Y,
M`,PI2'E4U/D9RP4X@`2H8H!48F4X(&(0VRK57F/X7MP]QEJ8B`6<%`4DHBSJ
M%V+PXB16!N'5Q"L:R%9\AE0M%M5QP/N-QDTYQEK<8F+P8F;$(F5L`"<&XB=2
MXB`=QD4IF(E86TIHV8HX!E,$769855$YXH(HW4_%!@8$6;Z1AE`XAH(M7F.4
MHS8&@"SBHP%J'3AZAD!LP,@5`(<(2P(\@)9YUP&8%VH90$@(0`70FQ6&%$ID
M``-0P`$<P%^X!:P=16HYQ`840`(LY`]JG`)T_H!,5-N][98!3!0"V.0$R`0"
M'``KTM>@0=9&Z.0&?*1&.L3N88!"RMT"#,`%$(`"&$!#N=8!:!M05J3JV:1"
M&(!*\L4#S)H5_F"000!(:IL]NE7,)8`!3,"B((`!>%8"'`"*B1>MV<9C&4`X
MC5R0626?Z<6F`26?/0:B4=GN281-9H!:LJ4$@"2-/9;&V=X!K.4&7,5;UAV1
M(59NH6-AI:2]4:5%)MME;.-D=&-B>*)!!HCJR80'&`0%_`4%/.22415.CAF:
M*1A<6<"LI5H"<-X!G`:?C614%8!QG*9!5$"V#5@IAN%LS@:-1=>R/4"D+42/
ME2"WF=H"4$!=;D!P_DG`!J244?)'5UT>T!D9D,E$;9[>!G`(FDG`2DF`0)4'
MJCD(K,5%D%FG3%0`!Z04!'3$US$:K)E4+4E`I<'%2I"G;'#`F$7:3I38`M@$
M7#2`*(;$\EE`FST&`=@DK>U>3VQ669@6!`A43&C`DD$$/D::LBW?0JRG4"@9
MH3264;&$612H!T2:ZJU(0%+&+*Z.()(F1P45@:T<LJE$:Q(::GB:9=&A2Q:`
MJ$'`A$B`;S6<1'A72^CFG9TD@76D!"P`[NE9@ZYG&;H$?0W$@U"`4Y!4!+"B
M7(2DJ&6`!2C`0G*``Q@`?A3E`BB=!7@5.QH`:AR`/8K:1K'&8G%$.EJ`_GBQ
M%D(>!8<FWP4L0`%40$<6@'[5DF-NFD.4EEXEP*@M1(D])?@YA$#0UU0=AD"(
M8LH97`,T@`9$G*B9HFZ<GJ@.A:C%W6+]G[\90"O^GX\^H'IR%D590%"48J4N
MZ*8:E5Y01%Y8UG45I&[0*&AZHV+@:(YV!D+JWE0U8A2R8@3(Q*C!F`"*56IE
MEG'4G7FIX4H<19J:GY3BFTI(ZP940$,=%`<,P"AB633.50-0A%41EQHNG`U*
M`(P9!`?\IRB>9IR"%9U>'GX4`&H0V@%DP#R.!1V2ZI(YUM11P+<A)+=90&9U
MHU`V@%9$5P?6Y`:\ZWYP:&8A6\<I@`480`9T_F1*5(``.L!4&<`&1$!S=MPM
M,01_[(=0KM3YK>KNX9AY&FIF04!WI=N@J>O[)42UJ>8#!%<%3,"D818K-M;J
ML09,..QU995G)JMDV"A!.BN`U%(TLL9*48"`A6EABL2/F<1ZED1,;.PH7MJ#
M=*/-(>I_IMB3K-0&S)8"/,!I8`0(Z@8$7"F)6:E"C-T"?!@P!H=(T!7?'ED#
MR&EC20`S^MYQ0"?\?55[G>#:2AOB_A49)FF2L@;D4M5PTJ%!$)51F(1'"1V]
MPEBF143E>51'IJZ#(2X$F"H#B&[E:=I#W%O9]JW'-0:)22Y<<`250*X$3,#*
M49WQOIL!RH4OHI>`_HGJ!B"J`-I&4/Q%!V@:Y[8M0%9&:"+&:'YMC7A`Y?F+
MN>K+9W+M0#)K^0X(*H+&1$%&2\0C9MRO4B7&_6I&//)O9,@O9J2J@A@'=N"O
M4DF(;3P&_P;P9K!O9(COC<*O@$B<:+Q58U``1ABC9TJC[UJ&47E&!WA?36Q5
M9+S5`PQP?T"`4(&&!Y1AJ&)&(T)&.'W8-2*&C"9&&WK&`T-&US+-!-N4J3%$
MA#X4C.)D!U@`;:V&!GP853$Q577`32!'!BAJ5RRO41P66V#D:L@63YD4C3GM
M:40Q!G#(0F7`K6T$?ISQ@V``!M!8%Z-&7,CP0V!`=@;'[Y6'+^H9!5QJ_IB>
MQD6HQ*WM!2<^7ANB'6TAAP8HJHJ!!&KXL6W\'DEQ@!"CG0X_L0=0EDI\Z!D#
MF]0M<23>&$[NA12[X%Z(A05$(DEU@!\S98.5X!6S8:KI[9C]V$,LBFQ1U**F
M)4:J!`;`X`2P)8SJV2C[<JY),AG'!@ZR<&7P\&-$\`4>*Q!/!JRUF952)P%L
M1`1,`&8-@`<2UP%P5JGFF9LIP'I>%4IB0,1])$FY!`0PY5`D1%/,,00PW;\-
M18.,VF_JY?)UY,(I0%2$Q,E.@$<&U4%)P``<U0%07E0YEV%Y``%$G'/=8P18
MZ5)YP%64+4GAYEP\7Y!U<X.>9+FU577NGC8W_L1<:+-NHJ6`L1<$VJ-3_!ZN
MTA<PUQU7;#,%%$`KBA4X)Q0[!IR=+30^B]=19I0#Q!=FX6=="<=<*53S6L5,
M1RE"&8!AX:!A+2EF7>D]JY4#W!D[DIW!Z6YUZF\U;BT`NV]7-*LT'R-*M,0"
MC)_>/@`!5!:K1L3/08`!"(O"A21/)=7#)>T'.,`%7`#0T>D!+%8!)-M==``!
MZ-4`J*E#L`2A&0!UGF^D&;9$HO!2+19:CJ2X+=5I1-49NRFL/2%@4P!C)\``
M7,5>3#:-W1R>`D5=B:K#<1Y@5P!J(_1)HME"`EU+^%0M+11%)*VUT=U$@.%*
M&1Q?UG&C<!M?7AI%_FD<L93%AX2J\F:E2JK68KFBQ%D%".N4;E;<SB%;=V56
M!PQ`12PE2BS*;+@D;HH@7!L9^'+CLJ*U6HM&!A!8DUF>53B7=ZD<`R3M8&NS
M%FK`C2$F;7]:>CJ$E@WV$P;5D1W579!DB34<7)&D!M0M]/T8!U#'0GD;)M?=
M_!W5PZ$:K:U$I$JM0N48:D;JD?5$1!`5K+%65,SVI=6VBM<C;<R5/>+57G3>
M6#1G^[WC7<BP6(G@K7Z`"/9=:CWV?Y:A6"W57"_5:@/%0B`;JH$X:B39`WS>
M@Q":#%-=CGF$>$>:"S+9BF.`4^'P1R14DN-8!@<I'I9U#Y_UA;E2@\C5_G".
M'V\IP`"8F*@>A<@)X*RF5GMMK(S=!&\EA4.PEP40-@H?P`.@&J-[%#T;=1JO
MZ:9165O)5E@(79X&W*Q)NK\.A-%=VFYN.@+H<VD'-N1"+K=1B0&XUD)LM+(-
M!)_I'CZJ%5<"]F`O0`.<]*8Y0)_G!6(Y[4!8Q:=;`!5+>JYR&XQ]H3XRH<9]
M.G]P@`",H@PGU4D<A`<L)%#PEFY"(&()QV$I:!@Z@)7I%4'PY9BO)VM.1$4"
M^["G,6H=Q[NZ.6\IY?]&A@<,1GT``,`+_+_?AVA&LWW7[TZEW!)[`'9IYY$%
M!V7MF&H&!P8<U<(^R8,,H'&@)H<'AR2;5DI<_F=1ZM;YIGE2/0AV412+9]]I
MC+PI(X=V:H!L?)U*P/S7I3Q)K9I*<%@I!L<%4)0&C'#*?1TF:WECN2!%[7R2
M`8;*>Q9JOM0&Z%;%']653=G,JT1+--B4+7R)F7*)M436<MC8<YAVGN3&G^34
MST::&_/,`UN#/8C13]EULK@&D!33.X3%;Q76SSS4>]:PI37"DX9`#`N__P=7
MFV2(E,1W,"V0)*2VL8N=W[E*3(C:>R9K+#-B6'[^U.(JT=\H_E5F=)R"0P8(
M]X_DHY(%#,!`>^!"I:5!-?[WH9E?")8'2.(%@-@#S&PKMH0'RD4MT;/AJP_Y
M"KYI)$67%T!PI1OA_L$<`?Q>`5A(H.*NG'I=&&+9!3PDEAF$0ICZZ0=^\3\&
MIE&5P8G@`[1;2MVI8%J;3:XE9W'OKCG[63%5Q_D/\8-_9M3<^/NLDW&6C&$R
M0##X$('"`@P?,FQ(T"'"A($%,WR`,`$!!P\5/V34N)%C1X\?0884.9)D29,G
M4:94N9)E2Y<A+R!X.9-F39LW<>;4N9-G3Y\U$4!@<'"!A@4;'"1(X##C@0]&
M/TB@D.&`@H4-%DB0\!!#U847JAK@4,'"3[-GT:95NW;CA01LX<:5.Y=N7;L_
M/73PX.'#W@X9._S5*/COWKYZ#QM6C#CQ7KYW(4>6/)ED3,J7,6?6O)ES_F?/
MGT%_=AN:=&G3IU&G5KV:M4O+K6''ECV;=FW;MT&.QKV;=V_,'1X$%SZ<>''C
MQY$G5[Z<>7/GSZ%'ESZ=>G7KU[$?7_#6=W?OW]=ZP#">?'GSY]&G5[^>?7OW
M[^''ES^??GW[]_'GUZ]>`WC__P$,\"0.+BC0P`,13%#!!1ELT,$'(8Q0P@DI
MK-#`#5C**S`.`MNPPPXX[#!$#T7\<$0034RQQ!5)W/"QVCPX44856T2111MK
MG/%&'7.D$<<?>032QR")'-+('3]T24@DF>RQR26=%$S`F2Z8$K4J5[H@@RTU
MV))++S/HTDLQOQP33#+#/%--,]DLDTLL:ZL`_LPTVZ3333OQ1%//->_<LTX_
M^^0S3T$!'?1/0A$]=,NR6-K``D$-#51122DUE"DK7</4-#A3XM0S3V4#5=/.
M1#5I`PQ!*W74DE1=%;-618+U,EE3H]75R&S]Z-30<KVU+5\_9:E7R(8EK5A@
MXSI6HUU31?8D99U5"UIHYZ*6U&@UHY99T;"MK-M7A37V-FN_[4E;5+DM-S=U
M)YM67-O(93>G<WF5UZ-X[;7)W7KAS?<N>IOU5R-\!7YIWX!K([C@E@!.MV"%
M%\XR7'X3CEBNAH,-[[$7<9+R`\$X#BGDC`PC^2.(+48)2\=&7I??DENFJ>2^
M-B:IY9EC_@#EE$U:_IDQ4]'-&"T/&D@`@0HZN#0D"%*"0`&^.%`J@0P@B&BD
M!_KCB.J,-GC@9)[9PA(!I9[>:`,*OJX7`J,C\&"KD9A&R8(#,.S`*@0RJ$!I
MD"BHH".D-%K`9;#3JG*#`MCFB(*@.=I6Z+,X6&`O"SJ@_`$)*L!@`@<BHJ"!
M"S`HX`*T+>!@@@>2=@!=#!RH@(,"(LC(@M@YP``""51WVP$,3(>`@\L]<&#S
M#=S&FNK?)7B@>`XTF&"KG0F/-2/)HYJ@`P@>V`""BBAPH+^WH?^IR@3XJL`#
M"CR((`().,"]K`L:F(J`"QRZ8(,*(-"@^ZP_0$J"BP3W`0QXK0,7L,`#_G;W
M@0HTP'RGXT`$(-`!"D"`<QZHP.Z0XH&)"&Y_'9!`W,(7O:\!S@,)X$`&'!"!
M#AP@@A"(X%B6Q3C.A!`D$UA``S+``0<P,`(,F``#+J"`#42@*QVHB.`>D`$#
M8(`"#\"``C(2-0PL((A6\\`#%/``#F!O@1F80$PT@(`-+,`"6GD`!+KW0;?8
MC@$6P)[Z+M#&!7!`9R)$"Y:HAT*R3*`!%G"`!1KP1`^@BH8\J9(%%@!$#_@0
M`A4X0`80@`$$7!&2&C`A%(F8``LL4)!]2<``<6>^OCC-`1RP@`(P8$((%-$`
M5)O``@N22@P,!6\IE(H"X)=*#AP@:X6TX\#Z_N>`C#BQ:E0$H@/ZACHZ<DV&
MF_$E1S10%@X($8L?8T#?/B#$%!K``T]#8@:0V``(-"`C&O":WA@@&`M@"`/B
MS$`'<)A"7BH/`<$YG09TV``ZHA("@C-G`QQ`00LPY9F_Q"-?9E>!,QID?0QX
M0`->5%"<7$""'S.A0S&D@*TMH`/RU(`W!R)("3!@G'SI@$"04K6,7*`_&6BC
M0^:XS<A]8`$!1:/?%O#*#SQ`H?KT0%9(VH`-"&2EOS2+X83Y`09H`((*N*!"
MSA@[LS4S6VHQ(@09H$,*-L"'%OAI!4@Z@`\@((P2>*3@+I`5<GX,`1)(@`;2
MF1%(2J`!'WQG71WP_H`"F/,#XN2IZG18@05$0*/8>^@#*,"`Y`VTJ$;U"9:6
M(@$Q*I8!&D6E`G[H`49)]"954@`$(K`0.4+@D4PK2@(B0`!+9@"UD90<:T=*
MLL$ZE8CE;*LX&4M%!41@`#/%'02Q>5K)9@"Q)-7H4K*ZUCHZUES]6XK3+B(!
M`RAT`MB[W0EC2#&T=(`L>\G`Z/BX`8M@0+,%$D]"Y%1`N5)`2AR@0'_(NRP*
MD!>?XK$@!B@:D?)ZX)W\%2#2.J`!"V[IOR#J)7.;^P$+4(`"='2O!BY@P0`W
M>+F<U5=?-JD7#&2`P0KH0$3(:\`<;OA^(^:+_I;YL<P])<7W,QP[%6P!_@QT
MX"`Z,]^N#H+B#^ML/$]IL'B`B>"=5.E\$_`J0BJ@`7QZU0)>W3$SM0L7"R1`
M`?PS#80ME&4M;YG+7?:RA:RF$I:FJ4ME)O.9S9QF-*]9S6UF,YM%9<D$6'C(
M7[;SG?&<9ST7J,>-HFIFZ"QD!.>%0X5&D:$1?6A%)YK1BW9THQN=,T%'SP-[
MMC2")IUI36^:TYWV]*=!'6I1CYK4I3:U9O!6PL;]62,4"8KI6"+53,4M6LR;
M`*JLQY&8(*`!'F-5E9(H$?:91$XX@4#(TL<UM"D074G;R(QE;1(-;B39',$`
MHQ8GDO:%1`*".39'<OUKB1RDD6$>230]4FV?_L37)-]N2XW[$FU119@D-'ZR
M2O`)$TF_)`)GDW:TY69ECD0MS!&`-6P`0#ZQ%I!X"3AV!@ZR`8%_H)04OX#7
M-MP7EL:(<D^!]WD1@I`P*9G=`@1Q_P;9\0U0=&I+W4O6*MV?E3]&P![00.7T
MTM(/6\U+']LXA&GL8'J7D[PG1-5W'5RZ`$>8HB+',+I,:1&@<V#F'N]+CS4P
M8ZY%6.)P4M\#0&=SF\.)`F5A<-9I#-_^W3SD9E,>23NZNX.(IZ48X)\IW58!
M>H_'YO0E;\P'4[J^TUTC2XU(`2T"4?S&C7B(MWG7LQG'#>1\(P1Z.;VW=%(,
MH&J1O.L?T]E[<0$+_C[K@"D=!SZ7\Z)+O=>UB^OGQ;Z!#0>XXQ[IVB(CZ``)
M6&#O+26PZ3E$/"U]>/./A[#&<T@R+7VL]K"_^2`U2\<"!C@O"@DQAK+^H@+V
MIW8<A7"E073"S2.DTI,G*\1CWH&WXIR_\/Z`*2MW38AF?P,C/W+V(\*!%`NO
MS%)/__J/#.\T`N].*&L**`/\*R(<)4:4S/6H3CP.HN<V(NN(AYP@[NH.HG+H
MJ.K*:4O$JS\$;$L>@ZZ>3P.$RFM@(P"F:P`\X``.8'X(X&@*H`"^Z&TVX@%>
M:6J*JXT"2HP20/?2JJXR8@(4H->`2`$8P*$60`$8A8^HR'E4Y[,8@+4"_NH`
MXD@"F`A+Q(EN#J!U,J+L%NRS$."DE(HJ&`4!'.``.(`!(D",#.`!ZDD!HN:A
MY.H'D4FC,H(`2*N;0DN2B@:!P.J:=L@!^((/*^(-%Z`"?A#L;D@"(@"+T@IU
M$"(!'HJP?&B8`FH!%J")NL(!L$2AP$J27*@!<*DA/'$",L`&20:'/(>)'*"R
M+H""-.H`'N``!`,-)8`(%:M[-I$!_D@!=*^'>FUZ(L`6#:"Z'*#*IL<!\,:A
M3*@!?F@!XD8"/FI[S,EI-A$!$HM^4G$`'6XH&`"WD)`"WE`F^J(`K)$2VZ@@
M(*"52.JM#F#9:DJ+"N`!#&(1)X!W'FH."\"D_KI0H<+H`0Q``^J1J#J":)HG
MD"A``I#0$9,Q`XJ0K#(BBU;IAQY`M=[0%L5)`3;1`=*04<YH:GY0JBPI.#8`
MH,9H;=2OGTI)<PX`K![@K1"@;0JO&*%J(+NPGJZI`LKQI!X@'#?``"Q@NL2)
MK`[``H(B`8+2;P#CLQ2``A2`(4^I`2)@ARB@"W$(&!]QB/@GJ)")O:@2**W0
MX>;H&Z,H*)P*E3P)`@C@))5JC'[2+:8,`O;J=K!HRI@Q:'Y0C#[GAB;@$7&I
MIO*'$E'0DD@1"P5"CN(G(_HI?YB*`;HF-@3``@A@`#3``':JAQ:H``X@@#KB
MC"0@A^P1@59I>U@'_@&J2YR(JBNRBJ0FKP&R9W2FAX*.K0`0\(.6@E$88)%^
MQP$$(Q;Q1@$0@%$Z"FN$20+@IPQI37`@P%%("X46B:8$:WLR(@(B8A,9A::4
MR@.JRPHE(#(3*3B0B18+L3M_IZ^PR:$":@K[*;$$`PMIRCHU(&[(HFHRX!'#
M2"T5B"H]2SN[I@-4BVB:LR-2J&N:4W7H)XOJ:C<KKJ^T$3F[1GNHDCE5<VZ&
M48':<0T_X!N90G+ZAH50J0%Z;3XS`@O)Z94"JDMPYZ0$%%U.:7L>Z"=5QYJV
MLR\2$SF5:L$$HFI`U(\THAA]AYRDL3]RBG<\TG:4JC"LX@*^<I&VQB`__K/?
MSF@#(!2+'FJDN+/&2(N(8BM_!$*?J#),>N@#RBXC;(<)X?!M$JN:Q&F%G`:0
MAJEV^$A#%\PS96=[*F`KBN+8!"(1P8KBUM"1"#&Y=,8:AV(K.$>Y^J*Z\,8Z
MD\<BPI%`'((-Q6D!4A&B-"(T2VETX,E"3XJU\/2SR$>!<*H"ENT\P70[(6C.
M;HUIEBI_A.*'),+*!(+!8#.O<*@]B[$A'`J*HN(@%&N`;,<CZ5!G*"`"E&R<
M(A,V!*"$!*`#!L"LP"J@=FOSW"].N28X#$2(4(F(#F`"4)$IFPR9?.B58%-2
M,\(3#02@9B<F#LAV..I+DRJ;-B"2(D`W*`ZB_I3R*.!Q:S)B1S\JC`8H.H="
M==X&?\"I3/]5J4R0*NA'>VBJD:YMOO#0!`F2`\C*J79G%_.F*.+G]1`V*L4T
M(_0F?^YS=UZ)J,@B<)0*`[3B@ICF)_-"<9Y&$?M*4@/I402B0;WUB[HFD%Q(
M<,"5P_2NC3ZFRL0B,?,F:W:S;X3HUL0I3Z<1(HUB@$P6=^!JIW93,%"(2B/`
M5-GPE6)K-VTT1[V'5:ML:HIB`C1@7D.SEFCJ6!-6*G9HC*C"I)`3&&>IDF)G
M:SV"`MY"$;,4*7+6I;*T1"6IC-(V:\$46>_34OMH(L=H=JCB+V*Q>3H@D>R&
M2A5BJ![`C<*KRCQ1_G!`ILH0(*TT@)?X5#K_M)2N:8JFJ&V[J5Y="IP4HFW?
MSTPY9R"3Z':^"*#0]9JH$7VDL61V3Y]8)ZV*%G4A4U,UX&TRH`$LR52;,HRB
M)G4KX%Y/UWJJ3'6+0G@`5DIJJ9VDHF--4&ZU,7^8PHV>*#3!XGFG@BE')Q<=
M$3)1L#4$(FOC:`(J+9T>2O;VADP)PW4\DKO8,`,0R:O^-XI@,VETR".1IO3>
MKX#_!VI!*WWTB<$<`@*R,[&0]8?@;0+0)H[0QG.^DRD_P"%*AZZ0%6T<8BM`
MF&0B0'HS;@A3^(H"ZKNX*RJ"IY3@BB8U2)S&:`H!R:?V\0H'ZD5ZR%'T_H\I
MD:+!',5UQBEK["Y3WZ]-*YB[V&=OM@W6V`O"4$]Y'(*]2):,6$J"7$HJMB*(
M3T6<'F.&#<XA3M+=MF+#9HE_K2>%&(4:9XF]RH[J"J0A%*C;YA6$AZHA@,,W
M7YAD'()_1RI,QH,J7<]ZEDV`?*BB_D=9.PISV&N!:#(JIK#!9EB(RN+64+CR
MMF+;SKC!8),[RV^E?&CE+(`!WFJ,DZ9T5BZ.J$AVLN+:&(`IW8:(LPYT+G&6
M+V`-O^@"0M.'N)/B1I`JSR:%\.Z%(<Z6V9:DHH+!R)0-]:<"P(IRT">I@N>,
M3FH->_-L`NP@^'>*^TH#]*Z<$$LO'J`AYI@[_KUYEV-X"(?B`K^0EB5(]^`)
MM(X/D`PN<[*"L4I'$FE*>,[G>H0JCNYUBARBAPP0@8"(>)@&./2IG"BJK@:J
MHBZ#`PB@,D=Z`$KZI"LSQ>YBRC3I)4[)USQ"DF!:,\Z35.T"DE3Z-'8IIST"
MIP4H-##VL\Q"$\OF(QQ@.V8Z)Z[5+)8Z)0J"Q7:BA!+I)>#-3E$"DC"K)MB2
MI+G:I+E:476"`P!@K,FZK,V:IUE"+ZK$P%J"0\QT9#1@\OB79H9.(V96(_+M
M(&>ZD-BZ).[M,$AFWUHE::3$?EA-9#PFJ5.BY.[EV11[(]1Z7>[:VCPF+_!K
MDPZ[(TJ.L3OB4?":_D`&XU0BVR1`Y",J;5WPR]IR)D9>!,BHS2+\NB2T3H#V
M+:]3@GE@XB0FNR,8X[2OKB:(#+;KC<9`0K2+^[#=NB8<P*R9FZRM.B?$NKF;
M.[--0HOT439GHD$WPLC4AR^0];G_!JU!HJEMXG<Z@+JYAM86.R2:2$I^^90S
M!*Q9XD+3S4X']&IFZB/(.UUE:,[F3+Q!`@'Q.F?4CW]",X"TA^I0AVQ?`IY`
M0G*F1FOVS=I:0KX_8J/)3R3@4R7.&R3\RR2:K-X,<K]3`KQ#0H=P]R.H+B06
M+"V66[K-VL3+&\:9&\!3H@!V2`((@,&NDL$EZRH,X&VZ8@S)B1#3L"H7_H"7
MMML""B"`#J"RA--M$(#!&^``OO8TQ0(!>"USM=$MWD9Z#T",2G1L!*/'%>(H
MH7("C,9WC,:;,6L!@D+'356R(!P!?!4PC"9[("`F%H(B3"C)&\QH:HPG.8IS
MM!PPE?PB>.U\9LF;5ZHJQNA;O5PX(2K)W_81$8",!F"64)-KPKPY$^`E;8B%
MEHC/!:.RE%*8,%7]%`"S$@*"9J>ORBG4W8A`*@#'J8Q\M@<R*?%S$.`-'4ER
MVI!NAND?!P`!".!SK[(LM]>IEN4`"%.9@Z<YM7PWC<97=3P7^VJ9&;,`3+4@
M[>8HHT@!XI$GB[H!@AP5APB2R,H`T-`C$G$`_ORFFXXR2!'@D5RPVX1S=IBP
M+_[(`(J:&1F<TKF\D8I0WL/<-X63+):"W"\HR<WIB;YU(R#R6[&0(G:S`;;\
MWJ_-S@4C`@R`<U[IWD])*1XC?A)`*,O8"F."EZ`\*0]@P[1\#9\2X'<I`1CT
M%<5\I\A=QD*];Y)\>PA1X^>5(\FJUS1GI4+=5"-,L09@;C)]ISQ^.W9/.`>`
M:IY<RA-@V4:=O833X#*]#9_&K"Z)W-$[76F\K&6\)J([[<?Z[/%[CL!.S9-W
MI=PB=;_S"YF08(=*@#B'L5KM<AGSHZZ'M=I)OV;R;#RGFR+GJYR("67MEQ-`
ME`3H[OOB::B&O`YZ_J8&*\*>,O04L6M<5G*,[&E>[V,$ASVIJ"'P"Y<.@'TF
M(HZ&:2@6276&%8&9XHMV,Q_?>R+/6RJR*=;?0O=@*A9U!BQ0KYTZR2V/@GX4
M:Y-"D[`N0)"5BD#H2H>^$&FB<O-<"*[N<^MPQS<7K)3(AW,$XG,A:FO3Z9-X
M*C$Q!/4H#JXZ:I,P?WW22J<T`FM,L)1P*'DV`"`4?%A0@4('@1\Z.,`@X0,#
M"1D8?/B@`<(%"@XZ,)@0`0-"#A<F,(#``(.'B0<B;)"`80.$!ALV:!"X8*+-
MB0L\2$QH0`*'!Q@<?$B0X8&'!10L+HAP8:*'!B2;?O!PP0*"#A,3?'B0_N%"
MA004)CCLD!,I!(\5)G`XH+:!AH(-@AX].;'H0)8),,2U8.'`A@,&%5R(0`$G
MUPP2&'204$'!4PX3&5"@L$'HA\D:,^BEX-A"!:88(C`("<&QA`47#@[LT`!F
MZ(D+-3C0,%BRA`TY%6!8L%O#1`4<9!=T`/F#YI<3+!RMO('!40T2&2?H4*'"
M!Y(<$`1M[('Q1`D4/"B8`#2!AIH+'%SPH-5"A.D3K-^<3]\!@/OX\^>O2;^_
M___S<:#?@/D5!^"!-Q''``?J39"`!13XYA`&#&@6`0(3;6"!`A2@!]T'%1!G
M@5@V37`!!!M,!,%Y'W2$P(@I>L`0`O$U,!`'_C8R4,$#(XYH$P,:/A09A1E,
MY=@%#F1PE(D:.7364118D$&2"?S$D$3)2=0`70G9V$`&I7E&H5X7#)8`!!)`
M.-%;VC%`'`80/,`!!B1.0&$''>DHGV-@6K>`CS4]`-Y1@QV%094-7-#`B">Y
MY!`%$ESP$`:>91"!`F).U`!(:3)@P4045$`62V"N*%J*'TR07`/$A4I<H!%=
MMZ-#.J7X(`44?@#3!SAN!9U"GFEUP0,10&AB@C$Y0-Q+&SRP@9>3B3>10J$=
M!1%_%5V4T4,0J`GB60NP6:2,$B!`*DDQ66`C?_/5M!-5$"P`U`,#6>K0!!9Q
M5.14#+R50%.938?3_E8A9I!`=6/E2`&/\54`;WH@3:`>!`-Q::FU%]Q*Y%7#
M-H`IKG5-<,`%IZ5J@43$1<:D95'JY(`%$DQ0DV<K:B!:=1?4I($%!TND6&L<
M@`E;L@Y4D'.HO>KFJ4\X>5"41CM]4/3)\1V$8V4.:6#C!!V"N*,#'G"@<4Y<
M?Z?<>#S>9F,&%!PLT(DY%81@@@02R.[<>-,G8-T#HIHW@!(TH)@!DY4K\$`(
M&$`A`I9A<``"T"%PP%,'0$!<2!3L:V($$E+`0$X16(J`8Y$AT``%BB)00*^*
M)8!`L87QJ\'C&.`D>>VI'A"NY&FE5@`"$&0'6)2S(W`5X1P=H$"3#71`_B]/
M"#C;[>/-26[!`L!O8#VHCW-0X0&5OUDG0P?DY:E\?26P00('1"J6`:8?E!)#
M["7^ET?`-TJQI^4_E(%G%:D`]32E``1PP`,&H$L'$I``!63```N``(JT9Q,!
M)J`!%3``AR3@@)JLZ`&Z:Y9#(O`["(AL.A``'ZH:<`#G*.9E(U)>=A``J0MD
M0#[%4U9P,.0L+W7`>%I)2$9TY[^=<(!P%8C3@EQ'(@P8H($"-&!D#I`D"$(@
M`X_+P+H\0+&;Y.1=KI.`G!AP``/8JW5LZ8A3,-B]J1C/`%CY`/Q@\D0:6N=@
M.5J@N:I3O\!%;"'PDP">ZO(X59%/`=I+W`PG_F.\XD!@=(BA0!DK(!$Y109U
M/P&5Y$YD/-%\``/`TX#-'(>`6/4%<CYC30-<5QP')"L"RN-0!7I5%@3DY#<+
M\(NN8G>=\BU@`Q!<G@%FY9P&(&`Z<8M``(P7E&/BZ9BQDP#[#.(Z5PKED>I+
MH0$%$BH+2`5!]N';?OY&3IOL39SX,5`YU\G.=OY')SQSY]P8),_+3,LR]535
M`^133X?T<YTA0E!W&O+/@DX$)*"2`)H`5!0*V,B@$/T/:S;$)7=&[9_VFHI\
M&/)/"%!R7P="'42;!]$,+"^B@,,=2NF&SOO<;:7G;*G?5DI3>89&0C2E2D%U
MVL_%.*R@GZKI?R80WD<`=:>B0FVG![B&5/I`JJA)A>A@9NK.H!8T:'H#J3PW
MP!2\:8"J]5R/5%4:5>.HDZ;A;.E+41I3=)ZUK'"-JUSG2M>ZVO6N>,VK7O?*
MU[Y*K:4N36I;Q0E6OQKVL(A-K&(7R]C&.O:Q44TK.M<:T8%.0`(QP^QE,QLS
MJ$+VLZ`-K6A'2]K2FO:S#-FL:C6K6:N>]K6PC:UL9TO;VMKVMKC-K6YWR]O>
M^O:WP`VN<(=+W.(:][C(3:YRE\O<YCKWN="-KG2G2]WJ6O>ZV,VN=K?+W>YZ
,][O@#:]XV1D0```[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
